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“The world is full of lies. Memory is 
fuzzy and unreliable. Words we say are 
often transformed and what ends up in 
the pages of history is an 
amalgamation of people’s perception 
of us through time. But science…man 
science is cool” 
Winston Churchill  
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Abstract 
 
Diet and lifestyle have changed dramatically in the last few decades, leading to an increase 
in prevalence of obesity, defined as a body mass index >30Kg/m2, dyslipidaemias (defined as 
abnormal lipid profiles) and type 2 diabetes (T2D). Together, these cardiometabolic traits 
and diseases, have contributed to the increased burden of cardiovascular disease, the 
leading cause of death in Western societies.  
Complex traits and diseases, such as cardiometabolic traits, arise as a result of the 
interaction between an individual’s predisposing genetic makeup and a permissive 
environment.  Since 2005, genome-wide association studies (GWAS) have been successfully 
applied to complex traits leading to the discovery of thousands of trait-associated variants. 
Nonetheless, much is still to be understood regarding the genetic architecture of these 
traits, as well as their underlying biology. This thesis aims to further explore the genetic 
architecture of cardiometabolic traits by using complementary approaches with greater 
genetic and phenotype resolution, ranging from studying clinically ascertained extreme 
phenotypes, deep molecular profiling, or sequence level data. 
In chapter 2, I investigated the genetic architecture of healthy human thinness (N=1,471) 
and contrasted it to that of severe early onset childhood obesity (N=1,456). I demonstrated 
that healthy human thinness, like severe obesity, is a heritable trait, with a polygenic 
component. I identified a novel BMI-associated locus at PKHD1, and found evidence of 
association at several loci that had only been discovered using large cohorts with >40,000 
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individuals demonstrating the power gains in studying clinically ascertained extreme 
phenotypes.  
In chapter 3, I coupled high-resolution nuclear magnetic resonance (NMR) measurements in 
healthy blood donors, with next-generation sequencing to establish the role of rare coding 
variation in circulating metabolic biomarker biology. In gene-based analysis, I identified 
ACSL1, MYCN, FBXO36 and B4GALNT3 as novel gene-trait associations (P<2.5x10-6).  I also 
found a novel link between loss-of-function mutations in the “regulation of the pyruvate 
dehydrogenase (PDH) complex” pathway and intermediate-density lipoprotein (IDL), low-
density lipoprotein (LDL) and circulating cholesterol measurements. In addition, I 
demonstrated that rare “protective” variation in lipoprotein metabolism genes was present 
in the lower tails of four measurements which are CVD risk factors in this healthy 
population, demonstrating a role for rare coding variation and the extremes of healthy 
phenotypes. 
In chapter 4, I performed a genome-wide association study of fructosamine, a measurement 
of total serum protein glycation which is useful to monitor rapid changes in glycaemic levels 
after treatment, as it reflects average glycaemia over 2-3 weeks. In contrast to HbA1c, which 
reflects average glucose concentration over the life-span of the erythrocyte (~3 months), 
fructosamine levels are not predicted to be influenced by factors affecting the erythrocyte. 
Surprisingly, I found that in this dataset fructosamine had low heritability (2% vs 20% for 
HbA1c), and was poorly correlated with HbA1c and other glycaemic traits.  Despite this, I 
found two loci previously associated with glycaemic or albumin traits, G6PC2 and FCGRT 
respectively (P<5x10-8), associated with fructosamine suggesting shared genetic influence.  
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Altogether my results demonstrate the utility of higher resolution genotype and phenotype 
data in further elucidating the genetic architecture of a range of cardiometabolic traits, and 
the power advantages of study designs that focus on individuals at the extremes of 
phenotype distribution. As large cohorts and national biobanks with sequencing and deep 
multi-dimensional phenotyping become more prevalent, we will be moving closer to 
understanding the multiple aetiological mechanisms leading to CVD, and subsequently 
improve diagnosis and treatment of these conditions. 
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1 Chapter 1: Introduction 
 
1.1 Complex traits 
 
Complex diseases and traits are phenotypes that, in contrast to simple Mendelian disorders, 
are not explained by the action of one single gene within any given person or family. 
Instead, complex diseases and traits arise from the action of independent genetic factors, 
environmental factors and gene-by-environment (GxE) interactions. The independent 
genetic factors often provide small contributions to the overall risk of a disease or to the 
variability of a continuous trait [1].   
Height and weight are two examples of human complex traits. Early studies looking at family 
resemblance suggest that these two traits have a strong genetic component and that there 
is no single major locus influencing these traits [2-4]. Welfare components such as 
nutritional quality and health also have a high impact on these traits [5, 6]. As such, 
individuals could have a strong genetic background of trait increasing alleles but never 
realize their genetic “potential” if not placed in a permissive environment. This is a key 
difference with traditional Mendelian disorders where a single mutation within a given 
family is considered necessary and/or sufficient to cause the phenotype.   
 
1.1.1 Cardiometabolic traits and impact on human health 
 
Cardiovascular diseases (CVDs) are a group of mostly complex diseases that affect the heart 
and blood vessels including: coronary heart disease (CHD), cerebrovascular disease, 
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peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein 
thrombosis and pulmonary embolism [7]. CVDs account for most deaths globally [7] and it is 
estimated that 90% of these diseases are preventable [8].  
In recent years, CVDs have been increasing in prevalence in developing countries [9-11] 
which makes them a continuing global public health priority in the years to come. Risk 
factors for cardiovascular disease include: family history [12], age [13], sex [13], tobacco use 
[14], physical inactivity [14],  diet (e.g high trans-fat intake [15], high salt intake [16]), heavy 
alcohol consumption [17], high blood pressure [18], diabetes [18] , obesity [19] and excess 
circulating lipids (hyperlipidaemia) [20].   
Many of these risk factors are not completely independent of each other. Obesity, defined 
as a body mass index (BMI) greater than 30Kg/m2, often co-occurs with type 2 diabetes 
(T2D) and/or hyperlipidaemia and confers a ~3 fold increase in risk for coronary heart 
disease in men younger than 65 even after adjusting for other risk factors [21]. The 
increased risk is also observed in women but with a smaller relative risk [22]. Besides CVD, 
obesity is a risk factor for other medical conditions such as hypertension, osteoarthritis and 
certain cancers [23]. Furthermore, obesity has an overall adverse impact in quality of life as 
on top of some secondary physical factors arising from obesity, there is a social 
stigmatization of the condition that can result in discriminatory behaviours towards obese 
individuals [24]. More details about obesity are described in Chapter 2.   
Diabetes is a group of  disorders characterised by excess levels of sugar in a person’s blood 
over a long period of time. Over 90% of the cases of diabetes are T2D cases [25].  T2D arises 
as a result of insufficient insulin production from pancreatic beta cells when an individual 
develops insulin resistance, a condition characterised by the cells’ inability to respond 
3 
 
properly to insulin. Obesity is considered one of the most important factors leading to T2D 
as it is tightly linked to development of insulin resistance [26]. Given diabetes is a lifelong 
condition, chronic mismanagement of the condition leads to early mortality, and 
particularly, cardiovascular death. This risk is exacerbated by medical complications linked 
to the condition such as renal complications [27]. More details about diabetes are described 
in Chapter 4. 
Hyperlipidaemia encompasses conditions such as hypercholesterolaemia (excess levels of 
cholesterol) and hypertriglyceridaemia (excess levels of triglycerides). Cumulative exposure 
to hyperlipidaemia in young adulthood is associated with an increased risk of CHD in a dose-
dependent fashion after adjusting for other cardiac risk factors [20]. Hyperlipidaemia can be 
divided into primary or secondary. Primary hyperlipidaemias are also called familial 
hyperlipidaemias and are characterised by genetic alterations leading to abnormally high 
levels of lipids [28].  Secondary hyperlipidaemias, also known as acquired hyperlipidaemias, 
arise from underlying disorders leading to alterations in lipid levels. T2D is one of the most 
common causes of acquired hyperlipidaemias [29].  More details about circulating lipids are 
described in Chapter 3. 
 
1.1.2 Heritability 
 
Heritability is defined as the proportion of variance of a trait that can be explained due to 
genetic factors. This measurement captures the resemblance between parent and offspring. 
So traits with high heritability have high resemblance between parents and offspring 
whereas traits with a low heritability have low resemblance [30]. Heritability can be divided 
into broad sense heritability and narrow sense heritability. Broad sense heritability (H2) 
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reflects all genetic contributions to a phenotype including additive (average effects of alleles 
at a locus), dominant (interaction between alternative alleles at a single locus) and epistatic 
effects (interactions between different loci) and it is defined as H2=Var(G)/Var(P), where 
Var(G) is the variance of genotypic effects and Var(P) is the variance of the phenotype .  
Most of the genetic variance in populations is thought to be driven by additive effects [31]. 
Therefore another widely used estimate of heritability is that of narrow sense heritability 
(h2) which is defined as h2=Var(A)/Var(P) where Var(A) is the additive variance component 
of the genetic variance.  
To estimate heritability, studies in human populations have mostly focused on related 
individuals. Traditionally studies calculated heritability looking at correlations amongst 
family members (e.g parent-offspring, full siblings, twins) [30] or adoption studies [32]. 
Amongst these studies, the most common study design is a twin study design that looks at 
phenotypic correlation between monozygotic (MZ) twin pairs and dizygotic (DZ) twin pairs 
[33]. The rationale behind these studies is that differences in trait correlation between 
monozygotic twin pairs compared to dizygotic twin pairs are driven primarily via genetic 
effects since twins tend to share the same environments. These studies are also particularly 
helpful to disentangle shared and unique environmental effects. Shared environmental 
effects can be extracted by subtracting the heritability estimate contribution from the 
observed twin phenotypic correlation (rMZ-h
2 in MZ twins where rMZ is phenotypic 
correlation in MZ twins and rDZ-(h
2/2) in DZ twins where rDZ is phenotypic correlation in DZ 
twins), i.e the percentage of the observed correlation that is not explained by genetic 
effects.  Unique environmental effects are obtained by quantifying the observed difference 
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in MZ twins (1-rMZ), i.e, the degree to which the observed correlation in MZ twins differs 
from 1.  
One important feature about heritability is that it is not constant in time or space. The 
heritability of foetal length, for example, increases during later developmental stages [34]. 
Changes in environmental factors within a population can also affect heritability estimates 
as in the case of intelligence measurements [35]. Changes in allele frequency during 
selection or introduction of new alleles in a population via migration can also alter a trait’s 
heritability in a given population.  
Heritability is an important parameter as the power of most studies to discover loci 
associated with a trait is positively correlated with the heritability of the trait [36]. For 
Mendelian disorders, heritability is straightforward as the disorder only manifests itself if 
you have alterations in one gene (or in very few cases a small number) and discovery of this 
gene, or genes, can be assessed in families with affected individuals by observing the 
patterns of co- inheritance of the disease and genetic markers (described in more detail in 
Section 1.1.3). For complex traits, heritability estimates can be taken into account when 
selecting a population in which to study the genetic basis of a particular trait. For example, 
BMI is a trait where heritability is higher during childhood [37] so if one wants to boost 
power for locus discovery, one might opt to choose a population where environment has a 
lesser impact on the variance of the trait. With the development of improved technologies 
for human molecular phenotyping at scale, population studies of traits such as high 
resolution measurements of circulating lipid and lipoprotein subclasses have become 
feasible in genetic studies.  As the overall heritability of these traits is higher compared to 
traditionally measured lipid traits in the clinic (e.g. large-density lipoprotein (LDL) 
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cholesterol or triglycerides (TG)) they can be used for lipid metabolism locus discovery with 
smaller sample sizes and to shed light on more detailed biological aspects of lipid 
metabolism [38] (more details in Chapter 3). 
More recently, with the advent of genome-wide array technologies (described in more 
detail in Section 1.2), new methods have been developed to estimate heritability using 
genome-wide genotype data [39-43]. These are routinely used to both estimate the 
heritability of traits, and the proportion of this heritability that can be explained by mostly 
common genetic variants. These methods will not be discussed in further detail in this 
thesis. 
1.1.3 Genetic studies of complex traits 
 
Genetic studies of Mendelian disorders used linkage and candidate gene approaches to find 
the underlying genes with mutations causal of the disease in question.  Linkage of two loci 
occurs when these are transmitted together from parent to offspring more often than 
expected by chance under random assortment. A collection of loci along a chromosome 
region that are often inherited together is called a haplotype. Using linkage information one 
can identify genetic markers that co-occur with a disease in family pedigrees. After 
identifying co-inherited genetic markers, one uses this information to narrow down the 
region where the causal gene likely lies by finding the smallest haplotype that is co-inherited 
in affected individuals (Figure 1.1). Before high-throughput sequencing approaches were 
possible, once this interval was identified, selection of plausible candidate genes within the 
region was done based on biological knowledge. Candidate genes were then sequenced in 
patients to find the mutations associated with the trait. One of the first success stories for 
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linkage studies was the identification of the cystic fibrosis gene [44, 45] where a three base 
pair deletion accounts for 70% of all cystic fibrosis cases observed. Other genes successfully 
identified via linkage analysis were the Duchenne muscular dystrophy (DMD) gene [46], the 
Fanconi’s anaemia gene [47] and the Huntington disease gene [48, 49]. 
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Figure 1.1: Principles of linkage analysis. A family pedigree is shown from a typical linkage analysis study for a Mendelian 
dominant disorder. Square (males) and circles (females) in black indicate affected individuals whereas symbols with no fill 
indicate unaffected individuals. Rectangles next to the symbols represent a fraction of a chromosome with the haplotype 
containing the associated gene where black filled sections represent the same specific alleles at marker polymorphisms. 
Letters A, B and C represent genetic markers and the red star is the unknown causal mutation.  
Applying the principles of linkage analysis to complex traits has been a more difficult task 
and has led to many false positive results [50, 51]. As mentioned previously, complex traits 
are often the result of the action of many independent genes, each one contributing to a 
small degree to disease development/trait variability [1]. Other factors that made linkage 
studies for complex disease and traits difficult were the variable degree of expressivity, 
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incomplete penetrance and variable age of onset affecting a trait/disease, making it hard to 
properly define phenotype or choose the right population to study [52].  When applying 
linkage analysis to complex phenotypes, these factors combined result in linked regions with 
very wide 95% confidence intervals (CI) making the prioritisation of genes extremely difficult 
as intervals could encompass hundreds of genes.  Sample sizes required to reduce the 
standard error in the positional estimate were prohibitively large (>1,600 families) and 
denser marker maps could only provide marginal benefits towards identifying plausible 
causal genes. This is important since most linkage studies at the time (1990-2000) were 
done using very small sample sizes [53]. Significance thresholds were also very lenient at the 
time which contributed to the generation of false positive results [54]. When using more 
stringent significance threshold, it was found that 66.3% of the linkage studies on complex 
traits as of December 2000 showed no significant linkage [55].  For these reasons, genetic 
association studies were proposed as a better suited technique to analyse complex traits 
[56].  
1.2 GWAS of complex traits 
 
Genome-wide association studies (GWAS) have been crucial to our understanding of 
complex traits. The shift from family studies to population based studies was in great part 
motivated by the common disease/common variant (CD/CV) hypothesis that states that 
common disease in the population is mostly influenced by common genetic variation in the 
population [57].  Given that allele frequency of disease associated alleles and prevalence of 
disease are strongly correlated, the CD/CV hypothesis would suggest that most of the 
common variation associated with disease would have low penetrance. To find these 
common variants with low penetrance one would need to test a wide number of variants 
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across the human genome. To this end, GWAS makes use of linkage disequilibrium (LD).  The 
phenomenon of LD occurs when in a population, alleles at a number of loci co-occur more 
than expected by chance. The human genome can then be divided into blocks of haplotypes 
with differing degrees of LD [58, 59]. Population phenomena such as migration, bottlenecks 
and genetic drift can alter the patterns of LD in the genome and as such, one expects 
differences in LD block size across different populations. African populations for example, 
tend to have smaller LD blocks than European ones mainly due to the more recent arrival of 
humans in Europe allowing less time for recombination events to take place [60]. Therefore, 
instead of attempting to test all variation across the genome, one could just test 
polymorphic sites in a population that capture the majority of variation within an LD block. 
The most common polymorphism in the genome are single nucleotide polymorphisms 
(SNPs), and these became the preferred variant to test in genetic studies as they could be 
accurately genotyped with ease. SNPs that capture variation within an LD block are called 
tagging SNPs or tag SNPs, as they “tag” or capture information on that particular LD block. In 
GWAS, testing the causal allele for a phenotype is very unlikely and therefore testing for 
polymorphisms in LD with the causal allele can lead to identification of genomic regions 
associated with a trait (Figure 1.2) [61]. In a case-control study, a GWAS tests if an allele is 
observed more than expected by chance in individuals with a disease compared to a set of 
controls. For a quantitative trait, in the most basic scenario, a GWAS tests if the presence of 
a certain allele is a statistically significant predictor of the outcome variable (i.e. the 
quantitative trait) under a linear regression. 
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Figure 1.2: Indirect association. In a GWAS more often than not, the tested allele is not the causal allele. GWAS takes 
advantage of LD to identify regions of the genome associated with a phenotype by using SNPs in high LD with the causal 
allele. Figure extracted from Bush W.S and Moore J.H (2012) [62]. 
 
The International HapMap project  was a major milestone for association studies as it 
provided the first comprehensive collection of SNPs covering the human genome [63]. By 
capturing variation at millions of sites within the human genome, the HapMap project 
allowed the examination of the correlation of SNPs in different populations and the 
identification of tag SNPs. One important insight gained from the HapMap project is that in 
European and Asian populations, one can capture >80% of common variation (MAF >= 0.05) 
across the genome using only a subset of SNPs between 500,000 and 1,000,000 [64]. Before 
the HapMap project, technologies to simultaneously assay a few thousand SNPs in the 
genome had already started being developed [65]. The first decade after the development 
of the first genotyping array saw an increase in number of sites tested ranging from a few 
thousand in the first array to more than a million in the latest versions in great part thanks 
to the HapMap project [66] and later projects such as the 1000 genomes project (see 
Sections 1.2.1.1). 
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It was soon after the development of genotyping arrays querying hundreds of thousands of 
sites that the first GWAS was published in 2005 [67].  This GWAS was a case-control study 
looking at age-related macular degeneration (ARMD) and found two SNPs that were 
significantly associated with the condition. Two years after, the Wellcome Trust Case 
Control Consortium (WTCCC) demonstrated that one can use shared controls in GWAS to 
find associations at multiple common diseases [68].  
1.2.1 Meta-analysis  
 
Similar to linkage analysis, one of the key limiting factors to detect signals in association 
studies is sample size [69]. Combining different studies for a trait under a meta-analysis 
framework provides multiple advantages for association studies. Firstly, combining studies 
increases sample size, therefore increasing power to detect association, especially at 
variants on the lower frequency allelic spectrum (minor allele frequency (MAF) 1-5%) which 
normally can only be detected if there is a large effect size which is rare in polygenic 
conditions. Secondly, it helps reduce false positives by testing for evidence of association at 
the same locus in multiple independent datasets. One major development that made meta-
analysis of several different studies possible was genotype imputation. 
One of the drawbacks of meta-analysis is that between-study heterogeneity can arise due to 
study specific factors such as different LD structure in populations, different environmental 
exposures or phenotype classification. Identifying sources of heterogeneity though, can 
reveal some interesting biological features underlying the association results [70].   
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1.2.1.1   Imputation 
 
Imputation consists of mathematically inferring the most likely genotype at a given position 
given information of SNPs surrounding the position (Figure 1.3) [71]. LD information from 
populations of interest is used to maximise accuracy of these predictions. This technique 
allows comparison of genotypes at the same position in two studies that might have used 
different genotyping arrays and therefore might not have typed exactly the same variants. 
Imputation normally requires a “reference panel” which is a set of SNPs for which we know 
LD information in a given population. Besides the HapMap project, another initiative that 
provided a key boost to the field was the 1000 genomes project (1000G) [72]. The goal of 
this project was to sequence the genome of ~1000 individuals from diverse ethnic 
backgrounds using sequencing technologies that were developed during the time of the 
study. When used as a reference panel for imputation, 1000G project provides haplotype 
information for several million of variants across the human genome. 
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Figure 1.3: Genotype imputation process. A) Genotype data from individuals is collected with missingness at certain sites. 
B) Testing association only at directly genotyped sites may not lead to a significant signal. C) Samples are phased and 
haplotypes are modelled as mosaics of the haplotypes present in a reference panel. D) A reference panel is used to impute 
missing variants. E) After imputation, sites with missingness for which the reference panel has information are 
mathematically inferred. F) Testing association on the imputed dataset might boost signal. Figure extracted from Marchini J 
and Howie B (2010) [73]. 
Advances in imputation technologies facilitated the collaboration amongst many research 
groups to study complex traits and led to the creation of several consortia to perform large 
scale GWAS. Examples of these consortia focused on cardiometabolic traits are presented in 
Table 1.1.   
 
Consortium  Traits of interest  First publication 
GIANT  anthropometric traits (e.g height, BMI) Willer et al (2009) [74] 
DIAGRAM type 2 diabetes Zeggini et al (2008) [75] 
MAGIC  glycaemic traits (e.g fasting glucose, 
fasting insulin, two hour glucose, 
glycated haemoglobin (HbA1c), amongst 
others) 
Prokopenko et al (2009) [76] 
GLGC lipid traits (e.g HDL cholesterol, LDL 
cholesterol) 
Willer et al (2008) [77] 
CARDIoGRAMplusC4D coronary artery disease and myocardial 
infarction 
CARDIoGRAMplusC4D (2013) 
[78] 
Table 1.1:Examples of large cardiometablic GWAS consortia. 
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1.2.2 Insights gained from GWAS of complex traits 
 
In the past 13 years since the publication of the first GWAS, this study design has become 
the standard in the field of human genetics to study complex traits. The CD/CV hypothesis 
received early support from GWAS with most trait-associated loci being indexed by common 
variants (median allele frequency of 40%) with small to modest effect sizes (median odds 
ratio (OR)=1.19) [79]. Furthermore most associations found as of July 2018, have been 
associations in non-coding regions (~94.7%) [79].   
For traits like height and BMI, there are now >3000 and >900 established loci respectively 
[80]. These loci explain ~24.6% of the variance in height  [80] and~6% of the variance in BMI 
[80] which leaves much room to identify additional loci in the future explaining some of the 
remaining heritability. However, heritability estimates using genome-wide imputed data 
suggest that much of the remaining heritability for both traits  can be explained by common 
variation with smaller effects than those discovered  so far and therefore the rest of the 
associated loci will be uncovered by just increasing sample size [41, 81].   This also appears 
to be the case for T2D where large-scale sequencing studies support the hypothesis that 
most of the genetic predisposition to T2D arises from common variation [82]. For other 
glycaemic traits, association studies have highlighted potential differences in genetic 
architecture for these traits. Beta cell function by homeostasis model assessment (HOMA-B) 
and insulin resistance by homeostasis model assessment (HOMA-IR), for example, are two 
traits with similar heritability estimates (26% and 27% respectively) and despite only slight 
differences in sample sizes (NHOMAB=36,466, NHOMAIR=37,037), GWAS found more significant 
associations with HOMA-B (>12 associations) than for HOMA-IR (two associations) 
suggesting differences in effect sizes, allele frequency of variants, number of loci or 
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environmental modification between these traits [83]. For lipid traits, more than 250 loci 
have already been identified associated with high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and/or triglycerides (TG) 
[84]. The genetic architecture of some of these traits like TG features a complementary role 
of common variation with small effects and rare variation with large effects affecting the 
trait as evidenced by the enrichment of rare variation (MAF<1%) found in known GWAS 
genes associated with elevated levels of TG [85]. 
 Overlap of genes found in linkage studies of Mendelian forms of disease and GWAS 
performed on related cardiometabolic traits has been commonly observed in the field 
suggesting that many genes responsible for severe phenotypes also play an important role 
in complex traits [86-88].  For example, in studies of T2D, rare variation influencing disease 
risk, appears to be enriched in genes implicated in Mendelian forms of diabetes or altered 
glucose metabolism [82] providing evidence for genetic overlap between the more common 
and rarer forms of disease. Similarly to T2D, GWAS for lipid traits have found associations 
with common variants near genes involved in Mendelian forms of dyslipidemia such as 
APOB, LDLR, APOE, PCSK9 , CETP, LIPC and LCAT amongst others[89].  
Furthermore, evidence for low-frequency variants with effects larger than those found in 
common variants but lower than those found in Mendelian disorders (so called “Goldilocks” 
alleles)[90] so far have not been found for most complex traits except lipid traits [91] (Figure 
1.4).    
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Figure 1.4: Results from single point association analysis in UK10K for 31 core traits shared between TwinsUK and 
ASLPAC cohorts. Minor allele frequency of variants is plotted on the X axis and effect sizes are plotted on the Y axis. Known 
associations are coloured in dark blue whereas novel associations are coloured in light blue with error bars being 
proportional to the standard error of the beta. Red and orange lines indicate 80% power at experiment-wide significance 
level (p < 4.62x10
-10
)  for the maximum theoretical sample size for the WGS sample and WGS+GWA, respectively. The 
notable absence of loci in the middle part of the figure suggests “Goldilocks” alleles are a rare occurrence. Figure extracted 
from UK10K Consortium (2015) [91]. 
 
Results from GWAS have also led to novel insights into the biological pathways involved in 
the development of complex diseases. For genes near BMI associated loci, an enrichment in 
pathways related to synaptic plasticity and glutamate receptor activity has been observed 
which has highlighted the key role of central appetite control in the aetiology of common 
obesity [92]. Analysis focusing on low-frequency and rare variants have also implicated 
pathways related to insulin action and adipocyte/lipid metabolism [93]. For related 
measures of adiposity such as waist-to-hip ratio (WHR), there has been evidence of 
significant sexual dimorphism and an enrichment of genes expressed in adipose tissue 
depots [94]. Results from GWAS show that, as expected, T2D can arise due to alterations in 
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pathways affecting pancreatic beta cell formation and function or via pathways involved 
with regulation of fasting glucose as well as obesity [95, 96]. Some associations have also 
highlighted the role of genes involved in circadian rhythm pathways in glucose metabolism 
and T2D development such as MTNR1B [76, 97] and CRY2 [83]. Interestingly, subsequent 
work found that these associations were season-dependent [98]. Other unanticipated 
enriched pathways that have been highlighted by these approaches include pathways 
related to the CREBBP-related transcription factor activity, cell cycle regulation and 
adipocytokine signalling [96]. Results also show an enrichment of pancreatic islet enhancer 
clusters in T2D and fasting glucose (FG) associated loci showcasing how integration of 
genetic information with knowledge of regulatory features can help identify processes 
affecting traits and aid in fine-mapping and finding causal variants [99]. Integrative 
approaches looking at mechanisms underlying insulin resistance have also revealed a pivotal 
role of storage capacity of peripheral adipose tissue in insulin-resistant cardiometabolic 
disease [100].  Loci identified via GWAS have also highlighted novel regulatory pathways 
involved in lipoprotein metabolism like in the case of SORT1, a locus harbouring variants 
associated with LDL-C and myocardial infraction (MI), which was shown to modulate hepatic 
VLDL secretion in mouse [101].  
Our increased understanding of the biology behind many of these traits through GWAS has 
also led to clinically relevant applications. One important genetic tool in this context is the 
genetic risk score (GRS). For any given complex trait, GRS are often constructed by summing 
the number of risk alleles present in an individual and usually weighing this sum by the 
effect size of each one of these risk alleles. In cases like CVD, GRS can now outperform 
traditional risk factors for risk prediction which makes incorporation of genetic testing in the 
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clinic a valuable addition [102]. GRS for coeliac disease also show improvements in risk 
prediction over traditional methods [103].  With the increasing prevalence of obesity in 
younger individuals, GRS scores for T1D can be used to discriminate between T1D and T2D 
diagnosis as the genetic overlap between these two traits is very low [104]. In cases like 
obesity, traditional risk factors such as family history and childhood obesity are still 
outperforming GRS for risk prediction [105]. Nevertheless, obesity GRS has been helpful in 
Mendelian randomisation approaches to identify phenotypes where obesity is causal, 
therefore clarifying the relationship between obesity and many of its co-morbidities (Figure 
1.5) [106].  
 
Figure 1.5: Inferences of causality of obesity derived from Mendelian randomisation studies. Only phenotypes with most 
consistent evidence are shown. Phenotypes in green are those for which there is a positive causal association of obesity 
whereas phenotypes in red are those with a negative causal association. Phenotypes in black are those where mendelian 
randomisation approaches have shown no causal role of obesity.  Figure extracted from Goodarzi, M.O (2018) [106]. 
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Mendelian randomisation analysis is a method that uses genetic instruments to assess the 
causality of a modifiable exposure on an outcome of interest [107-110] (Figure 1.6).  In 
addition to ascertaining the causal role of obesity on its co-morbidities, this approach has 
also been used to identify the causal relationship between additional traits and disease. For 
example, it has demonstrated that the influence of lipid measurements such as LDL-C and 
HDL-C on T2D [84] and CVDs [111-114] risk is dependent on the particular pathway involved. 
That is, only some pathways that reduce LDL-C have an impact on T2D incidence [84] and 
only some genetic mechanisms that increase HDL-C have an impact on CVD risk [110, 112]  
(more details presented in Chapter 3).  
 
Figure 1.6:Comparison of conventional clinical trial with a Mendelian randomisation (MR) study. In a conventional trial, 
trait reducing treatment (in this case statins and LDL-C) is randomly allocated in a population and comparing the treated 
and untreated group allows you to assess if the trait (LDL-C) has an impact on the outcome (CV event). In a MR study, we 
look at the random allocation of alleles in a population at birth and use associated genetic variants as an instrument to 
assess the impact of the trait on the outcome. Extracted from Bennet D.A et al (2017) [115]. 
 
GWAS has also helped identify potential drug targets. Even though common variation near a 
gene identified via GWAS can have a very small effect on the trait, targeting the gene itself 
might lead to potential clinical benefits (e.g common variation near HMGRC has a small 
effect on LDL-C but its targeting via statins [116] had been previously shown to successfully  
treat hypercholesterolaemia). Loss-of-function (LoF) variants in APOC3 have been associated 
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with a favourable lipid profile and reduced CVD risk suggesting the gene is a good candidate 
for lipid lowering drugs [117].  Another gene where protective LoF variants have been 
identified is SLC30A8, where carriers of rare protein-truncating variants have 65% reduced 
T2D risk highlighting this gene as a potential T2D drug target as well [118]. Not only can 
GWAS help identify drug targets, it can also influence treatment choice for certain 
conditions. For example, response to treatment of T2D via sulfonylureas can be influenced 
by variants near TCF7L2 [119]. Another example is response to fenofibrate, a lipid lowering 
medication, which can be influenced by variants near APOA1 [120]. 
Finally, another way GWAS could be used in the clinical setting is by identifying alleles that 
can influence accuracy of disease diagnostics. One notable example is potential 
improvement in T2D diagnosis using HbA1c in individuals with African American ancestry. 
HbA1c is a measurement of protein glycation reflecting average glucose concentration in 
the blood during the lifespan of an erythrocyte (~ 3 months). Usage of HbA1c as a T2D 
diagnostic tool can sometimes be hampered by the fact that HbA1c levels can be affected 
via conditions altering lifespan of eyrthrocytes independent of blood glucose levels (more 
details in Chapter 4).  A GWAS on HbA1c has identified a variant with high prevalence in 
individuals with African American ancestry (MAF=11%) near G6PD that affects HbA1c levels 
by shortening the life span of red blood cells. It is estimated that screening for this variant 
would avoid 650,000 false negative T2D diagnoses in African Americans in the US [121]. 
1.2.3 Open questions/ unresolved issues: 
 
Despite greater understanding of the genetic architecture of many traits, the proportion of 
heritability explained remains below 10-15% for most, and causal variants for associated loci 
are mostly unknown [122]. Early on, one possible explanation for this “missing heritability” 
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was that a substantial proportion of the heritability of complex traits can be explained by 
rare variants with large effects that aren’t captured by standard genotyping platforms [123]. 
This is also known as the common disease / rare variant (CD/RV) hypothesis in contrast to 
the CD/CV hypothesis. At the time of this thesis though, data does not support this 
hypothesis and accumulating evidence suggests that for traits like height and BMI, most of 
the heritability will be explained by common variation (see Section 1.2.2). Another model 
that attempts to explain gaps in knowledge and suggest future directions for association 
studies is the “omnigenic model” that argues that a large number of loci will affect a given 
trait through indirect effects in regulatory networks affecting a core number of genes that 
affect the disease directly [124].  To address the “missing heritability” problem, several 
approaches have been proposed. Larger imputation reference panels such as combined 
UK10K [91] and 1000G Phase III [72] or the haplotype reference consortium (HRC) [125] 
have greatly increased imputation accuracy, especially for low-frequency and rare variants 
achieving good correlations (r2 >0.6) between imputed genotype dosages and masked 
genotypes for variants with a MAF as low as 0.5% in UK10K and 0.1% in HRC [126, 127].  
Denser genotyping arrays enriched for low-frequency variants in coding regions are also 
powerful approaches since variants in these regions normally have a high phenotypic impact 
and are therefore under selective pressure [91, 128, 129]. Some arrays like the UK Biobank 
Axiom Array [130] combine the “exome component” with a “GWAS component” designed 
to enhance genome-wide imputation of common and low-frequency variants in a specific 
population. Another way to analyse rare coding variation is by doing whole-exome 
sequencing (WES) which uses target-enrichment methods to selectively capture exonic 
regions during library preparation before sequencing. As next-generation sequencing 
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technologies costs continue to decrease, whole-genome sequence (WGS) becomes a viable 
alternative that allows us to explore noncoding variation at a higher resolution. An 
important finding highlighting the relevance of honing in on low-frequency and rare coding 
variation is that variants identified via these approaches are better than common coding 
variants at identifying enriched gene sets associated with traits such as BMI suggesting that 
we are more likely to find causal variants with these approaches [93].  Sequencing studies 
have found multiple rare variants in candidate genes such as variants in PCSK9 associated 
with LDL-C [131],  variants in ABCA1, APOA1 and LCAT associated with low HDL-C [132] or 
variants in  ANGPTL4 associated with reduced TG and high HDL-C [133] suggesting an 
important role of rare variants in the genetic architecture of these traits. These approaches 
have also helped increase the number of known effector transcripts associated with T2D 
[82].  
Population-scale studies coupled with these approaches allow increases in power especially 
when it comes to the analysis of rare variants. Several of these cohorts have already started 
appearing in different countries such as UK Biobank (UKBB) which consists of 500,000 
deeply phenotyped UK individuals with genotype data currently available and sequencing 
data in the near future [134]; the All of Us Research Program which aims to recruit 
1,000,000 United States individuals that will have genotype and whole genome sequencing 
data [135] or the China Kadoorie Biobank which has a similar sample size as the UK Biobank 
(~510,000 individuals) and has also been deeply phenotyped  and  genotyped on a custom 
array for Asian populations [136]. The availability of individual level genotype and deep 
phenotyping in these large datasets provides several advantages. Firstly, having a very large 
dataset instead of meta-analysing various small studies is more convenient in terms of 
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dealing with between-study heterogeneity [137, 138], or sample overlap [139]. Secondly, it 
enables multi-trait analyses across multiple potentially correlated traits, which is more 
powerful than combining results from univariate analysis even when genetic correlation of 
the traits is weak [140, 141]. It also provides extra information on the covariance of these 
traits that would be missed when comparing summary statistics from different studies 
[142].  The availability of linked medical health records facilitates the study of pleiotropy (i.e 
the influence of one locus across multiple phenotypes) of genetic variants using methods 
such as phenome wide association studies (PheWAS) [143-145]. PheWAS are studies where 
a variant or subset of variants (normally previously linked to a trait of interest) are tested 
against a wide number of phenotypes simultaneously to examine the pleiotropic effects of 
these variants.   Availability of linked medical health records also allows inferences to be 
made regarding the causality of traits in certain diseases. Finally, we can also evaluate GxE 
interactions by collecting multiple environmental data for these individuals [146, 147]. 
Recent work in UK Biobank, has been able to find predicted LoF variation protective against 
diseases such as T2D, asthma and coronary artery disease in the UK population bolstering 
the case for usage of large-scale population studies with dense genome-wide genetic data 
to identify potential drug targets [148]. Sequencing data in these large cohorts will provide 
new opportunities to explore the impact of rare variation in the aetiology of complex traits.  
 
Another area of on-going improvement is that of diversity in studied populations. To date, 
most association studies have been performed in individuals of European ascent. But there 
are several advantages to be gained by increasing diversity. Firstly, effect sizes can vary 
between populations due to differing environmental factors which is crucial if one wants to 
use genetic information in the clinic to assess disease risk in non-European individuals. As 
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highlighted also by trans-ethnic HbA1c work [121], allele frequency also can differ widely 
between populations and some prevalent variants in a specific population are of particular 
value in the diagnostic setting. These differences in allele frequency also have aided in 
identifying associations of different cardiometabolic traits such as T2D and 
cardiomyopathies with variants that are rare or monomorphic in European populations 
[149-151]. Population isolates in particular are helpful to study rare variation as population 
events such as bottlenecks, genetic drift and endogamy can lead to an enrichment of rare 
alleles[152, 153]. Finally, the differing LD structure between populations can be helpful in 
fine-mapping efforts to identify causal variants [154-157]. 
Structural variations, such as CNVs, have also been currently underexplored but several links 
of structural variation to complex traits have been found such as autism [158], 
schizophrenia [159], severe childhood obesity [160, 161], asthma and obesity [162],several 
anthropometric traits[163] and T2D [164]. Currently array-based comparative genomic 
hybridisation (aCGH) is considered the gold standard for CNV detection [165] although 
platform-dependent differences in sensitivity have been a source for concern [166]. Usage 
of sequencing as a viable alternative has been explored [167, 168] and as WES and WGS 
becomes more prevalent, long-read sequencing technology improves and algorithms to 
analyse such data continue being developed [169, 170], the number of studies exploring 
structural variant association with complex traits will likely increase significantly.  
Improvement in measurement resolution for many quantitative traits is also a promising 
avenue moving forward. GWAS studies using over 500 metabolites measured on the 
Metabolon platform or  high resolution nuclear magnetic resonance (NMR) measurements 
of lipoprotein and lipid traits have found associations with effect sizes that are unusually 
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large for GWAS and enrichment of druggable targets in metabolomics loci [38, 171-173].  In 
addition to this, proteomics platforms such as OLINK have been helpful to identify variants 
regulating proteins that have been previously implicated in cardiovascular disease [174].  
1.3 Thesis aims 
 
In this thesis, the overarching aim is to gain further insights into the genetic architecture of 
different cardiometabolic traits through a combination of approaches with greater 
genotypic and phenotypic resolution. The main aim for each of the three results chapters in 
this thesis is described below:  
1. In chapter 2, the aim is to characterise the genetic architecture of persistent and 
healthy thinness and contrast it to that of severe early onset obesity in two clinically 
ascertained cohorts. 
2. In chapter 3, the aim is to gain novel insights into metabolic biomarker biology by 
analysing the contribution of rare variants to high resolution metabolic 
measurements.  
3. In chapter 4, the aim is to characterise the genetic architecture of fructosamine, a 
measurement of total serum protein glycation, and explore the influence of 
previously established glycaemic loci on the trait.  
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2 Chapter 2: The Genetic Architecture of Human Thinness 
 
2.1 Introduction 
 
Obesity, defined as a body mass index (BMI) greater than 30kg/m2, is one of the leading 
causes of preventable death worldwide [175]. In recent years, the prevalence of obesity has 
risen and this has been linked to an increasingly “obesogenic” environment (i.e an 
environment promoting the consumption of high calorie foods and reduced levels of 
physical activity [176]). However, within a given environment, there is considerable 
variation in body weight; some people are particularly susceptible to severe obesity, whilst 
others remain thin [177, 178].  Indeed BMI heritability estimates from multiple family, twin 
and adoption studies range from 40% to 70% which suggests that genetic factors play a 
major role in the development of obesity [179]. To date, most studies aimed at 
understanding the aetiology of obesity have focused on BMI as a continuous trait, and have 
identified more than >900 common and low-frequency obesity-susceptibility loci [80, 93, 
180-184]. Additionally, studies of people at one extreme of the distribution (severe obesity) 
have led to the identification of rare, penetrant genetic variants that affect key molecular 
and neural pathways involved in human energy homeostasis[185-192]. These findings have 
provided a rationale for targeting these pathways for therapeutic benefit. One such example 
is the development of drugs targeting MC4R [193] which harbours both, rare highly 
penetrant variation [194, 195] and downstream common variation with modest effect size 
[93, 196].  In contrast, little is known about the specific genetic characteristics of 
persistently thin individuals (thinness defined using WHO criteria BMI<18kg/m2).  
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A small number of previous studies have found that thinness appears to be a trait that is at 
least as stable and heritable as obesity [197-200]. A large study of 7,078 UK children and 
adolescents, found that the strongest predictor of child/adolescent thinness was parental 
weight status. The prevalence of thinness was highest (16.2%) when both parents were thin 
and progressively lower when both parents were normal weight, overweight or obese [201].  
There is also some evidence for gene dosage playing a role in both tails of the BMI 
distribution. A deletion in 16p11.2 has been shown to associate with a highly penetrant 
form of obesity, whereas its reciprocal duplication is associated with underweight status 
[202]. Another copy number variant in 20q13.3 is associated with less severe forms of 
obesity and thinness, with deletions observed in obese, and duplications observed in thin 
probands (defined in this particular study as BMI <= 23 kg/m2) [203]. 
Despite evidence for genetic factors contributing to the phenotypic variance at both tails of 
the BMI distribution, at the time of this study, GWAS approaches that had included thin 
individuals had either used them exclusively as controls to contrast with extreme obesity 
[204], and/or they had not ascertained for healthy thinness [205]. Understanding the 
mechanisms underlying thinness/resistance to obesity may highlight novel anti-obesity 
targets for future drug development [206]. To do this there are two possible study designs,  
each with its own advantages and disadvantages. One approach uses a population-based 
cohort, where data for participants at the tails of the distribution are extracted, and each is 
compared to the other in a case-control analysis. This approach was used effectively by 
Berndt et al 2013 [207] who analysed the top and bottom 5% of each cohort that 
contributed to the original GIANT BMI meta-analysis [208]. One of the biggest advantages of 
this approach is that it is less susceptible to age, sex and other environmental effects 
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influencing observations. The disadvantage is that, by their very definition, such population 
based cohorts often contain a limited number of people at the “extremes” (i.e. severe 
obesity and thinness) [207]. For example, in the full UK Biobank release (N= 487,411), there 
are only 626 individuals with a comparable level of obesity as those present in children from 
the Severe Childhood Onset Obesity Project (SCOOP) cohort (BMI standard deviation score 
>3, age of onset <10yr) which has been previously used to identify novel loci associated with 
obesity [160]. The second approach is particularly useful for complex disorders where 
environmental exposure can have a strong influence on the development of the condition 
(e.g. asthma, type 2 diabetes and obesity). Here, one maximises genetic load in the cases by 
carefully selecting affected individuals that are less likely to have been exposed to 
environmental risk factors. For example, one might select individuals with early age of onset 
for the condition which lessens the amount of time they would have been exposed to 
environmental factors [160, 209].  To complement this approach to the selection of cases, 
controls are also selected to increase the chances that they do not have the disease or are 
unlikely to develop the disease later in life [204]. This is normally done by selecting 
contrasting controls, or “super-controls”. The advantages of this approach as a way to 
increase power have been shown in multiple studies [210-212] including the previously 
mentioned study performed by our group using the SCOOP cohort uncovering new loci that 
had been missed by conventional BMI GWAS at the time [160].  One of the limitations of 
this approach is that it is more susceptible to differential effects of age, sex and other 
environmental factors between cases and controls.   
In this chapter, I describe a genetic study that used this case-“super control” design to begin 
to dissect the genetic architecture of healthy human thinness. To do this our group 
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collaborated with Professor Sadaf Farooqi’s group who recruited a new cohort of healthy 
thin individuals from the UK (STudy Into Lean and Thin Subjects, STILTS cohort; mean BMI = 
17.6 kg/m2) and who had previously recruited the SCOOP cohort.  My work focused on all 
analytical elements of the study.  
2.2 Chapter aims 
 
The overall aim of this chapter is to contrast the genetic architecture of persistent healthy 
thinness with that of severe early onset obesity. In this chapter I use genome-wide directly 
genotyped and imputed data from two clinically ascertained cohorts (STILTS and SCOOP) 
and two population cohorts (the UK household longitudinal study (UKHLS) and UK Biobank 
(UKBB)) to: 
I. Assess the heritability of persistent healthy thinness. 
II. Identify the contribution of established BMI loci at the extremes of the phenotype 
distribution. 
III. Discover novel loci associated with either tail of the BMI distribution. 
 
2.3 Methods 
2.3.1 Cohorts 
 
SCOOP, STILTS and UKHLS cohorts were used for the heritability, genetic correlation, genetic 
risk score and association analyses with established BMI loci, as well as, used as a discovery 
cohort in the genome-wide association study (GWAS). UK Biobank samples were used for 
genetic correlation analysis and in the replication stages of the GWAS. ALSPAC was used to 
for sensitivity analyses in SCOOP vs UKHLS comparisons (Figure 2.1). 
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Figure 2.1: Overview of cohorts and analyses.  
 
2.3.1.1 STudy Into Lean and Thin Subjects (STILTS)  
 
Recruitment was performed by Professor Sadaf Farooqi’s group at  the Wellcome Trust-MRC 
Institute of Metabolic Science (IMS). The aim was to recruit a new cohort of UK European 
ancestry individuals who were thin (defined as a body mass index < 18kg/m2) and well. After 
ethical committee approval (12/EE/0172), they worked with the NIHR Primary Care 
Research Network (PCRN) to collaborate with 601 GP practices in England. Each practice 
searched their electronic health records using the inclusion criteria (age 18-65 years, 
BMI<18 kg/m2) and exclusion criteria (medical conditions that could potentially affect 
weight (chronic renal, liver, gastrointestinal problems, metabolic and psychiatric disease, 
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known eating disorders). The case notes of each potential participant were reviewed by the 
GP or a senior nurse with clinical knowledge of the participant to exclude other potential 
causes of low body weight in discussion with the study team. Through this approach, 25,000 
individuals were identified who fitted the inclusion criteria in the study. These individuals 
were invited to participate in the study; approximately 12% (2,900) replied consenting to 
take part. The team obtained a detailed medical and medication history, screened for eating 
disorders using a questionnaire (SCOFF) that has been validated against more formal clinical 
assessment [213] and excluded those who exercised vigorously (>6 metabolic equivalents 
(METs); http://www.who.int/dietphysicalactivity/physical_activity_intensity/en/). Prof 
Farooqi’s group also excluded people who were thin only at a certain point in their lives 
(often as young adults), to focus on those who were persistently thin/always thin 
throughout life as this group would likely be enriched for genetic factors contributing to 
their thinness. The participants were asked this specific question to identify persistently thin 
individuals: “have you always been thin?” Only those who answered positively were 
included. Questionnaires were manually checked by senior clinical staff for these 
parameters and for reported ethnicity (non-European ancestry excluded). A small number of 
individuals (N=43) with a BMI of 19 kg/m2 were included as they had a strong family history 
of thinness. 74% of the STILTS cohort have a family history of persistent thinness, suggesting 
there is an enrichment for genetically driven thinness. DNA was extracted from salivary 
samples obtained from these individuals using the Oragene 500 kit according to 
manufacturer’s instructions.   
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2.3.1.2 Severe Childhood Onset Obesity Project (SCOOP) 
 
The Severe Childhood Onset Obesity Project (SCOOP, N~4,800) cohort [160] is a sub-cohort 
of the Genetics Of Obesity Study (GOOS, N~7,000) [214] comprised of those individuals of 
British self-reported European ancestry. As for GOOS, all SCOOP participants recruited into 
the cohort have a BMI standard deviation score (SDS) > 3 and onset of obesity before the 
age of 10 years. SCOOP individuals likely to have congenital leptin deficiency were excluded 
by measurement of serum leptin, and individuals with mutations in the melanocortin 4 
receptor gene (MC4R) (the most common genetic form of penetrant obesity) were excluded 
by prior Sanger sequencing.  The cohort has ethical committee approval (MREC 97/5/21). 
2.3.1.3  UK household longitudinal study (UKHLS) 
 
United Kingdom Household Longitudinal Study (UKHLS) also known as Understanding 
Society (https://www.understandingsociety.ac.uk)  is a longitudinal household study 
designed to capture economic, social and health information from 40.000 UK households 
(England, Scotland, Wales and Northern Ireland) representative of the UK population [215]. 
A subset of 10,484 individuals was selected for genome-wide array genotyping. Genetic and 
phenotype data was obtained through The Understanding Society Data Access Committee 
(DAC) application system. The United Kingdom Household Longitudinal Study has been 
approved by the University of Essex Ethics Committee and informed consent was obtained 
from every participant. This cohort was used as a control dataset with SCOOP and STILTS 
cases. UKHLS data is available for download in EGA with accession code EGAS00001001232. 
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2.3.1.4 UK Biobank (UKBB) 
 
This study includes approximately 488,377 participants with genetic data released (including 
~50,000 from the UKBiLEVE cohort [216]) of the total 502,648 individuals from UK BioBank 
(UKBB).  UKBB samples were genotyped on the UK Biobank Axiom array at the Affymetrix 
Research Services Laboratory in Santa Clara, California, USA. The full release was imputed to 
the Haplotype Reference Consortium (HRC) [127]. UKBiLEVE samples were genotyped on 
the UK BiLEVE array which is a previous version of the UK Biobank Axiom array sharing over 
95% of the markers. At the time of this study, 487,411 samples with directly genotyped and 
imputed data were available and data was downloaded using tools provided by UK Biobank. 
Extensive data from health and lifestyle questionnaires is available as well as linked clinical 
records. BMI, as well as other physical measurements were taken on attendance of 
recruitment centre. Severely obese participants in the available data were defined as those 
with BMI ≥ 40 kg/m2 (N=9,706) and thin individuals were defined as those with BMI ≤ 19 
kg/m2 (N=4,538). For sensitivity analyses, to more closely match thin individuals in UKBB to 
the STILTS cohort, I also used ICD10 clinical records as well as self-reported medical data to 
exclude individuals whose low BMI could be explained by a medical condition 
(Supplementary Tables 12-13 of Riveros-Mckay et al 2018 [217] (Appendix A)). This 
resulted in a subset of 2,518 thin individuals who met the same health criteria as those in 
the STILTS cohort. Given that it has been previously shown that type I error rate for variants 
with a low minor allele count (MAC) is inadequately controlled for in very unbalanced case-
control scenarios [218], I randomly subsampled 35,000 individuals from the original 487,411 
genotyped individuals and removed those with BMI≤19 or BMI ≥30, to generate an 
independent control set. The 25,856 participants remaining after BMI exclusions from the 
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tails, generated a non-extreme set of individuals kept as putative controls. The other 
452,411 genotyped samples were kept as the BMI dataset for downstream analyses (Table 
2.1). An interim release consisting of a subset 152,249 individuals from UKBB was released 
in May 2015. This interim release was imputed to a combined UK10K and 1000G Phase 3 
reference panel and contains several variants which are not currently present in the HRC 
panel, as such it was used in some of the analyses described. 
  
  
Thin 
(BMI ≤ 19) 
Obese 
(BMI ≥ 40) 
Controls 
(19 < BMI ≤ 
30) BMI Dataset 
Initial sample sets 4,538 9,706 35,000 452,411 
Final sample sets post 
QC 
3,532 7,526 20,720 
(BMI range 19-30) 
387,164 
Sex 
Male 719 (20%) 
2,468 
(33%) 
9,467 (46%) 178,029 (46%) 
Female 
2,813 
(80%) 
5,058 
(67%) 
11,253 (54%) 209,134 (54%) 
Table 2.1:Summary of UKBB sample sets 
2.3.1.5 Avon Longitudinal Study of Parents and Children  (ALSPAC) 
 
The Avon Longitudinal Study of Parents and Children (ALSPAC) [219, 220], also known as 
Children of the 90s, is a prospective population-based British birth cohort study.  Ethical 
approval for the study was obtained from the ALSPAC Ethics and Law Committee and the 
Local Research Ethics Committees. The study website contains details of all the data that is 
available through a fully searchable data dictionary 
(http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/). ALSPAC children 
were genotyped using the Illumina HumanHap550 quad chip genotyping platforms by 
23andme subcontracting the Wellcome  Sanger Institute (WSI), Cambridge, UK and the 
Laboratory Corporation of America, Burlington, NC, US. Genotypes were imputed against 
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the 1000G Phase 3 reference panel using IMPUTE V2.2.2 [221, 222]. In the current study, 
analysis was restricted to a subset of unrelated (identity-by-state < 0.05 [39]) children with 
genetic data and BMI measured between the age of 12 and 17 years (n=4,964, 48.5% male).  
The mean age of the children was 14 years and the mean BMI 20.5. 
 
2.3.2 Genotyping and quality control 
2.3.2.1 SCOOP, STILTS and UKHLS 
 
For the SCOOP cohort, DNA was extracted from whole blood as previously described [160]. 
For the STILTS cohort, DNA was extracted from saliva using the Oragene saliva DNA kits 
(online protocol) and quantified using Qubit. All samples from SCOOP, STILTS and UKHLS 
were typed across 30 SNPs on the Sequenom® platform (Sequenom® Inc. California, USA) 
for sample quality control by the Genotyping Facility at WSI. Of the 3,607 SCOOP and STILTS 
samples submitted for Sequenom genotyping, 3,280 passed quality controls filters which 
were i) degraded samples, ii) gender inference failure, iii) Sequenom failure or iv) low 
concentration (90.9% pass rate).  Of the 10,433 UKHLS samples, 9,965 passed Sequenom 
sample quality control (95.5% pass rate). Subsequently, UKHLS controls were genotyped on 
the Illumina HumanCoreExome-12v1-0 Beadchip. The 3,280 SCOOP and STILTS samples, and 
48 overlapping UKHLS samples (to test for possible array version effects) were genotyped on 
the Illumina HumanCoreExome-12v1-1 Beadchip by the Genotyping Facility at the WSI.  
Genotype calling was performed centrally for all batches at the WSI using GenCall. I 
excluded samples based on the following criteria: i) concordance against Sequenom 
genotypes <90%; ii) for each pair of sample duplicates, exclude one with highest 
missingness; iii) sex inferred from genetic data different from stated sex ; iv) sample call rate 
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<95%; v) sample autosome heterozygosity rate >3 SD from mean done separately for low 
(<1%) and high MAF(>1%) bins; vi) magnitude of intensity signal in both channels <90%; and 
vii) for each pair of related individuals (proportion of IBD (PI_HAT) >0.05), the individual 
with the lowest call rate was excluded.  I performed SNP QC using PLINK v1.07 [223]. Criteria 
for excluding SNPs was: i) Hardy-Weinberg equilibrium (HWE) p<1x10-6; ii) Call rate <95% for 
MAF≥5%, call rate <97% for 1% ≤MAF<5%, and call rate <99% for MAF <1%.  SMARTPCA 
v10210 [224] was used for principal component analysis (PCA). To verify the absence of 
array version effects I used PCA on the subset of shared controls genotyped on both 
versions of the array. Cutoffs for samples that diverged from the European cluster were 
chosen manually after inspecting the PCA plot. SNPs with discordant MAFs in the different 
versions of the array were excluded. After removal of non-European samples and 13 
samples due to cryptic relatedness, 1,456 SCOOP and 1,471 STILTS samples remained for 
analysis. For UKHLS, 82 samples were removed after applying a strict European filter and 
680 related samples were removed by Vanisha Mistry after applying a ‘3rd degree” kinship 
filter in KING [225]. A total of 9,203 samples remained, of which 6,460 had a BMI >19 and 
<30 (“non-extremes”).  
 
2.3.2.2 UK Biobank 
 
Sample QC was performed using all 487,411 samples using the sample QC file provided by 
UK Biobank. I used the following criteria to exclude samples: i) supplied and genetically 
inferred sex mismatches; ii) heterozygosity and missingness outliers; iii) not used in kinship 
estimation; iv) non-European British individuals; v) samples that withdrew consent and vi) 
for each pair of related individuals (KING kinship coefficient >=0.0442), I preferentially kept 
37 
 
cases (BMI ≥ 40 or BMI <=19), otherwise, I randomly selected one individual out of the pair.  
After sample QC, thirteen individuals with very extreme BMI values were also removed (BMI 
<14 or BMI >74). One of them had no genotype data, whereas the remaining twelve had 
underlying health conditions that could influence their BMI such as eating disorders, 
abnormal weight loss and COPD for eleven underweight individuals and hypothyroidism for 
one extremely obese individual. In the end, 7,526 obese (BMI ≥ 40), 3,532 thin (BMI ≤ 19) 
and 20,720 non-extreme controls (19 < BMI ≤ 30) remained for case-control analyses. In 
addition, 387,164 samples remained for analysis of BMI as a continuous trait. There was an 
overlap of 10,282 samples (~2.6% of the BMI dataset) with obese and thin cases (Figure 
2.2). The same procedure was performed on the interim release of 152,249 UKBB samples 
to produce a set of 2,799 obese, 1,212 thin, 8,193 controls and 127,672 individuals for the 
independent BMI dataset. All genome-wide association analyses on UKBB were also 
performed on this subset to query variants that are not currently available in the full UKBB 
release.  
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Figure 2.2: Summary of the UKBB sample sets after QC. Venn Diagram showing sample numbers and overlap between 
UKBB sample sets used in genetic correlation (BMI dataset) and GWAS replication (obese, controls, lean) analyses. 
 
2.3.3 Imputation and genome-wide association analyses 
 
2.3.3.1 SCOOP, STILTS and UKHLS association analysis 
 
Imputation and genome-wide association analyses for SCOOP, STILTS and UKHLS were 
performed by Vanisha Mistry. Genotypes from SCOOP, STILTS and UKHLS controls were 
phased together with SHAPEITv2, and subsequently imputed with IMPUTE2 [221, 222] to the 
merged UK10K and 1000G Phase 3 reference panel [126], containing ~91.3 million 
autosomal and chromosome X sites, from 6,285 samples. More than 98% of variants with 
MAF ≥0.5% had an imputation quality score of r2≥0.4, however variants with MAF <0.1% had 
a poor imputation quality with only 27% variants with r2≥0.4. First-pass single-variant 
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association tests were done for all variants irrespective of MAF, or imputation quality score 
(see below).  Analyses of 1,456 SCOOP, 1,471 STILTS and 6,460 controls (BMI range 19-30) of 
European ancestry were based on the frequentist association test, using the EM algorithm, 
as implemented in SNPTEST v2.5 [226], under an additive model and adjusting for six PCs 
and sex as covariates.  
2.3.3.2 UKBB BMI dataset single-variant association analysis 
 
For the BMI dataset, I used BOLT-LMM [227] to perform an association analysis with BMI 
using sex, age, 10 PCs and UKBB genotyping array as covariates.  
 
2.3.4 Heritability estimates and genetic correlation 
 
Summary statistics from the SCOOP vs. UKHLS, STILTS vs. UKHLS, UKBB obese vs controls, 
UKBB thin vs controls and UKBB BMI analyses were filtered and a subset of 1,197,969 of the 
1,217,312 HapMap3 SNPs was kept in each dataset since HapMap3 reference panel markers 
are common and normally well-imputed variants. Using LD score regression [228] I first 
calculated the heritability of severe childhood obesity (SCOOP vs UKHLS) and persistent 
thinness (STILTS vs UKHLS). For severe childhood obesity, I estimated a prevalence of 0.15% 
using the BMI centile equivalent to 3SDS in children [229]. In the case of persistent thinness 
(BMI<=19), I used a General Practice (GP) based cohort for our prevalence estimates: 
CALIBER [230].  The CALIBER database consists of 1,173,863 records derived from GP 
practices.  For the heritability analysis, I used a prevalence estimate of 2.8% for BMI<=19 
(Claudia Langenberg and Harry Hemingway, personal communication). I also used LD score 
regression to calculate the genetic correlation of SCOOP with STILTS, SCOOP with BMI and 
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STILTS with BMI. The genetic correlation between obesity and persistent thinness with 
anorexia was estimated using the summary statistics from SCOOP vs UKHLS and STILTS vs. 
UKHLS, and summary statistics available from the Genetic Consortium for Anorexia 
Nervosa (GCAN) in LD Hub [231].  The same analysis was repeated for UKBB obese vs 
controls and UKBB thin vs controls. Genetic correlation estimates for BMI vs Overweight, 
Obesity Class 1, Obesity Class 2 and Obesity Class 3 were also extracted from LD Hub 
(http://ldsc.broadinstitute.org/ldhub/). 
 
2.3.5 Comparison with established GIANT BMI associated loci 
 
I obtained the list of 97 established BMI associated loci from the latest publicly available 
data from the GIANT consortium at the time of this study [92]. I used this list as I wanted to 
focus on established common variation in Europeans with accurate effect sizes. In order to 
test whether there was evidence of enrichment of nominally significant signals with 
consistent direction of effect, I performed a binomial test using the subset of signals with 
nominal significance in the SCOOP vs UKHLS, and STILTS vs UKHLS analyses.  Variance 
explained was calculated using the rms package [232] v4.5.0 in R [233] and Nagelkerke’s R2 
is reported. Power calculations were performed using  Quanto [234].  
 
 
2.3.6 Analysis of potential age effects in SCOOP 
 
To investigate if differences in the observed OR from our SCOOP vs UKHLS analysis were 
influenced by age differences between cases (SCOOP, mean age ~ 11) and controls (UKHLS, 
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mean age ~52), I obtained BMI summary statistics from Nicholas Timpson and Laura Corbin 
for the ALSPAC cohort. To calculate ORs and SE from the ALSPAC BMI summary statistics I 
used genotype counts from SNPTEST output. I then used a z-test to test for significant 
differences between the OR calculated using genotype counts of SCOOP and ALSPAC against 
the SCOOP vs. UKHLS OR. 
 
2.3.7 Simulations under an additive model 
 
I created 10,000 simulations of 1 million individuals for the 97 GIANT BMI loci randomly 
sampling alleles based on the allele frequency from UKHLS using an R script. For each 
simulated genotype, phenotypes were simulated with DISSECT [235] using the effect size in 
GIANT and then removed all samples from the lower tail where the phenotype was <3SDS to 
better reproduce the actual BMI distribution. Afterwards I randomly sampled 1,471 
individuals from the bottom 1.6% and 1,456 from top 0.15% and compared against a 
random set of 6,460 controls from the equivalent percentiles to BMI 19-30 in UKHLS.  
Finally, for each of these loci, I calculated the absolute difference between our observed OR 
and the mean OR from the simulations and counted how many times an equal or larger 
absolute difference in the simulated data was observed and assigned a p-value. This was 
done separately for SCOOP vs UKHLS and STILTS vs UKHLS. The high accuracy of the 97 
GIANT BMI loci allowed me to assess significant differences between the observed and 
expected ORs. 
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2.3.8 Genetic Risk Score 
 
For this analysis, Vanisha Mistry calculated the GRS scores, Audrey Hendricks performed 
ordinal regression statistical analyses and I compared BMI category GRS scores with 
simulations. The R package GTX (https://CRAN.R-project.org/package=gtx) was used to 
transpose genotype probabilities into dosages, and a combined dosage score, weighted by 
the effect size from GIANT, for 97 BMI SNPs [92] was calculated and standardised.  An 
ordinal relationship between the genetic risk score and BMI category (i.e. thin, normal, or 
obese) was checked using ordinal logistic regression with the clm function in the ordinal R 
package. For each of the 10,000 simulations, a genetic risk score was created and an ordinal 
logistic regression was run. Audrey compared the observed test statistic testing whether the 
odds were the same by BMI category to the 10,000 simulation test statistics. Audrey 
calculated the p-value as the number of simulations with a test statistic larger than that 
observed in the real data. I also calculated a mean genetic risk score for each BMI category 
(obese, thin and controls) across the 10,000 simulations. I used a t-test to test whether the 
mean observed GRS score in each category was significantly different from the one 
estimated using the simulations.  
 
2.3.9 Discovery stage GWAS 
 
First pass single-variant association analyses results were used as discovery datasets for the 
GWAS. After association analysis performed by Vanisha Mistry, I removed variants with 
MAF<0.5%, an INFO score <0.4, and HWE p<1x10-6, as these highlighted regions of the 
genome that were problematic, including CNV regions with poor imputation quality. 
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Quantile-quantile plots indicated that the genomic inflation was well controlled for in 
SCOOP-UKHLS (λ=1.06) and STILTS-UKHLS (λ =1.04), and slightly higher for SCOOP-STILTS (λ 
=1.08). I used LD score regression [228] to correct for inflation not due to polygenicity. To 
identify distinct loci, I performed clumping as implemented in PLINK [223] using summary 
statistics from the association tests and LD information from the imputed data, clumping 
variants 250kb away from an index variant and with an r2>0.1.  In order to further identify a 
set of likely independent signals I performed conditional analysis of the lead SNPs in 
SNPTEST to take into account long-range LD. A total of 135 autosomal variants with p<1x10-5 
in any of the three case-control analyses were taken forward for replication in UKBB. All 
case-control results are reported with the lower BMI group as reference. 
 
2.3.10 UKBB association analysis 
 
I tested 72,355,667 SNPs for association under an additive model in SNPTEST using sex, age, 
10 PCs and UKBB genotyping array as covariates. Three comparisons were done: obese vs 
thin, obese vs controls and controls vs thin. Variants with an INFO score <0.4, HWE p<1x10-6 
were filtered out from the results. Inflation factors were calculated for variants with 
MAF>0.5%.  Inflation factors were calculated using HapMap3 reference panel markers. The 
LD score regression intercepts were 1.0074 in obese vs thin, 1.0057 in obese vs controls and 
1.009 in thin vs controls.  I used all thin individuals, regardless of health status, as a 
replication cohort to maximize power.  
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2.3.11 GIANT, EGG and SCOOP 2013 summary statistics 
 
Summary statistics for the GIANT Extremes obesity meta-analysis [207] were obtained from 
http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_fil
es. Summary statistics for EGG [236] were obtained from http://egg-
consortium.org/childhood-obesity.html. I used summary statistics from our group’s previous 
study of 1,509 early-onset obesity SCOOP cases compared to 5,380 publicly available 
WTCCC2 controls (SCOOP 2013) [160]. Data for the SCOOP cases is available to download 
from the European Genome-Phenome Archive (EGA) using accession number 
EGAD00010000594. The control samples are available to download using accession 
numbers EGAD00000000021 and EGAD00000000023. These replication studies are largely 
non-overlapping with our discovery datasets and each-other. When a lead variant was not 
available in a replication cohort, a proxy (r2≥ 0.8) was used in the meta-analysis. 
 
2.3.12 Replication meta-analysis 
 
I meta-analysed summary statistics for the 135 variants reaching p<1x10-5 in SCOOP vs 
STILTS, SCOOP vs UKHLS, and UKHLS vs STILTS with the corresponding results from UKBB 
and study specific replication cohorts. For obese vs. thin and obese vs. controls comparisons 
I used fixed-effects meta-analysis correcting for unknown sample overlap in replication 
cohorts using METACARPA [237]. For thin vs. controls I used a fixed-effects meta-analysis in 
METAL [238].  Heterogeneity was assessed using Cochran’s Q-test heterogeneity p-value in 
METAL. A signal was considered to replicate if it met all of the following criteria: i) consistent 
direction of effect; ii) p<0.05 in at least one replication cohort; and iii) the meta-analysis p-
value reached standard genome-wide significance (p<5x10-8). Application of a more 
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stringent p-value cutoff of p≤1.17x10-8 which would take into account the  additional 
variants on the lower allele frequency spectrum (and hence increased number of 
independent tests) [239] only affected one previously established signal (SULT1A1, 
rs3760091, p=2.65x10-8) in the obese vs. controls analysis that fell just above this threshold 
(Table 2.6).  rs4440960 was later removed from final results (SCOOP vs UKHLS and STILTS vs 
UKHLS) after close examination revealed it was present in a CNV region with poor 
imputation quality. 
 
2.3.13 Comparison of newly established candidate loci and UKBB independent BMI 
dataset 
 
To evaluate whether the number of associated signals in SCOOP vs STILTS, SCOOP vs UKHLS 
and UKHLS vs STILTS that were directionally consistent and nominally significant in the 
independent UKBB BMI analysis were more than expected by chance, I performed a 
binomial test (Table 2.9).  
2.3.14 Lookup of previously identified obesity-related signals in our discovery datasets 
 
I took all signals reaching genome-wide significance, or identified for the first time in the 
GIANT Extremes obesity meta-analysis [207], with either the tails of BMI or obesity classes, 
and in childhood obesity studies [160, 236] and performed look-up of those signals in all 
three of our discovery analyses (SCOOP vs STILTS, SCOOP vs UKHLS and UKHLS vs STILTS) 
(Supplementary Table 10 of Riveros-Mckay et al 2018 [217] (Appendix A)).    
 
 
46 
 
2.4 Results 
 
2.4.1 Discovery cohorts characteristics 
 
The discovery cohorts consisted of genotype data for 1,622 persistently thin healthy 
individuals (STILTS), 1,985 severe childhood onset obesity cases (SCOOP) and 10,433 
population based individuals (UKHLS) used as a common set of control. A summary of 
cohort characteristics is presented in Table 2.2.  I tested for significant differences between 
discovery cohorts that could affect interpretation of association results. Using a Fisher’s test 
I determined that there’s a significant sex difference (p<0.001) in STILTS vs SCOOP and 
UKHLS reflecting a low prevalence of thinness in men as defined by our BMI threshold. I also 
found significant differences in the ages of all cohorts using a t-test (p<0.001). This 
difference was partly by design in SCOOP since ascertainment based on young age was done 
deliberately to minimize time of exposure to Western obesogenic environments. After 
sample and variant quality control, I retained 1,471 thin individuals, 1,456 obese individuals, 
6,460 control individuals in the BMI range 19-30 kg/m2 (non-extremes). 
 
 STILTS (thin) SCOOP (obese) UKHLS (controls) 
N total 1622 1985 10433 
  Female Male Female Male Female Male 
N 1325 (81.69%)* 297 (18.31%)* 1083 (54.56%) 902 (45.44%) 5837 (55.95%) 4596 
(44.05%) 
Age** 36.64 ± 14.33 
(mean ± SD) 
35.17 ± 14.50 
(mean ± SD) 
10.74 ± 7.44 
(mean ± SD) 
10.93 ± 7.09 
(mean ± SD) 
52.02 ± 16.73 
(mean ± SD) 
52.67 ± 17.31 
(mean ± SD) 
BMI 17.56 ± 0.93 
(mean ± SD) 
17.56 ± 1.06 
(mean ± SD) 
33.66 ± 9.47 
(mean ± SD) 
34.41 ± 10.61 
(mean ± SD) 
26.98 ± 7.94 
(mean ± SD) 
26.86 ± 7.83 
(mean ± SD) 
BMI sds 
(children) 
  3.70 ± 0.83 
 (mean ± SD) 
3.83 ± 0.87 
(mean ± SD) 
    
Table 2.2:Summary of discovery sample sets before QC. *Significantly different in STILTS compared to SCOOP and UKHLS 
p<0.001. **Significantly different across all cohorts p<0.001. 
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2.4.2 Heritability of persistent thinness and severe early onset obesity 
 
In my first analysis I contrasted the heritability of thinness to that of severe early onset 
childhood obesity. To this end genotypes for SCOOP, STILTS and UKHLS were imputed 
together to a combined UK10K+1000G reference panel by Vanisha Mistry and logistic 
regression results from SNPTEST for SCOOP vs UKHLS and STILTS vs UKHLS were used. I used 
LD score regression to estimate heritability explained by common variation (MAF >5%) using 
a subset of 1,197,969 HapMap3 markers (Methods 2.3.4). Using prevalence estimates 
previously described (Methods 2.3.4), I estimated that common variation accounted for 
32.33% (95% CI 23.75%-40.91%) of the phenotypic variance on the liability scale in severe 
early onset obesity, and 28.07% (95% CI 13.80%-42.34%) in persistent thinness, suggesting 
both traits are similarly heritable.  
 
2.4.3 Contribution of known BMI associated loci to thinness and severe early onset 
obesity  
 
To investigate the role of common variant European BMI-associated loci in persistent 
thinness vs severe early onset obesity, I focused on the 97 loci from GIANT [92] available at 
the start of this study.  Three-way association analyses were performed by Vanisha Mistry: 
SCCOP vs. STILTS, SCOOP vs UKHLS, UKHLS vs. STILTS (Methods 2.3.3.1). After quality 
control, 41,266,535 variants remained for association analyses in the three cohorts: SCOOP 
vs STILTS, SCOOP vs UKHLS and UKHLS vs STILTS.  
Of these 97 established BMI associated loci, I found that 40 were nominally significant 
(p<0.05) in SCOOP vs UKHLS and 15 in UKHLS vs STILTS (Table 2.3, Supplementary Table 2 of  
Riveros-Mckay et al 2018 [217] (Appendix A)). Direction of effect was consistent for all of 
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these loci, which was more than expected by chance (binomial p=9.09x10-13 and binomial 
p=3.05x10-5, respectively). Overall, the proportion of phenotypic variance explained by the 
97 established BMI associated loci was 10.67% in SCOOP vs UKHLS, and 4.33% in STILTS vs 
UKHLS (Methods 2.3.5). However, evaluation of association results in thin (STILTS) and 
obese (SCOOP) individuals, compared to the same controls (UKHLS), highlighted that the 
results are not a mirror image of each other (Figure 2.3).   
 
 
rsID Gene GIANT SCOOP vs. UKHLS UKHLS vs. STILTS 
EA EAF Beta P value EAF OR P value EAF OR P value 
rs1558902 FTO A 0.41 0.08 7.5X10
-153
 0.41 1.42 1.25X10
-17
 0.38 1.17 2.78X10
-4
 
rs6567160 MC4R C 0.23 0.05 3.93X10
-53
 0.24 1.30 7.91X10
-9
 0.22 1.25 1.38X10
-5
 
rs13021737 TMEM18 G 0.82 0.06 1.11X10
-50
 0.83 1.35 3.89X10
-7
 0.82 1.21 4.44X10
-4
 
rs10938397 GNPDA2 G 0.43 0.04 3.21X10
-38
 0.44 1.18 4.50X10
-5
 0.42 1.08 6.24X10
-2
 
rs543874 SEC16B G 0.19 0.04 2.62X10
-35
 0.21 1.20 2.22X10
-4
 0.20 1.17 3.11X10
-3
 
rs2207139 TFAP2B G 0.17 0.04 4.13X10
-29
 0.17 1.17 2.70X10
-3
 0.16 1.11 6.21X10
-2
 
rs11030104 BDNF A 0.79 0.04 5.56X10
-28
 0.79 1.14 1.27X10
-2
 0.79 1.12 2.43X10
-2
 
rs3101336 NEGR1 C 0.61 0.03 2.66X10
-26
 0.60 1.19 3.66X10
-5
 0.59 1.05 2.07X10
-1
 
rs7138803 BCDIN3D A 0.38 0.03 8.15X10
-24
 0.37 1.21 4.68X10
-6
 0.36 1.03 4.47X10
-1
 
rs10182181 ADCY3 G 0.46 0.03 8.78X10
-24
 0.49 1.20 9.30X10
-6
 0.48 1.18 6.81X10
-5
 
rs3888190 ATP2A1 A 0.40 0.03 3.14X10
-23
 0.40 1.12 3.87X10
-3
 0.39 1.03 4.34X10
-1
 
rs1516725 ETV5 C 0.87 0.04 1.89X10
-22
 0.86 1.15 1.89X10
-2
 0.85 1.18 5.03X10
-3
 
rs12446632 GPRC5B G 0.86 0.04 1.48X10
-18
 0.85 1.09 1.24X10
-1
 0.85 1.19 2.20X10
-3
 
rs16951275 MAP2K5 T 0.78 0.03 1.91X10
-17
 0.77 1.13 1.43X10
-2
 0.77 1.05 2.80X10
-1
 
rs3817334 MTCH2 T 0.40 0.02 5.15X10
-17
 0.41 1.09 3.52X10
-2
 0.40 1.09 3.29X10
-2
 
rs12566985 FPGT-TNNI3K G 0.44 0.02 3.28X10
-15
 0.43 1.20 1.04X10
-5
 0.42 1.03 3.96X10
-1
 
rs3810291 ZC3H4 A 0.66 0.02 4.81X10
-15
 0.67 1.13 4.69X10
-3
 0.66 1.07 1.15X10
-1
 
rs7141420 NRXN3 T 0.52 0.02 1.23X10
-14
 0.51 1.11 1.11X10
-2
 0.50 1.00 9.48X10
-1
 
rs13078960 CADM2 G 0.19 0.03 1.74X10
-14
 0.20 0.99 9.08X10
-1
 0.20 1.19 9.49X10
-4
 
rs17024393 GNAT2 C 0.04 0.06 7.03X10
-14
 0.02 1.56 1.26X10
-4
 0.02 1.09 5.20X10
-1
 
rs13107325 SLC39A8 T 0.07 0.04 1.83X10
-12
 0.08 1.28 4.84X10
-4
 0.07 1.20 2.89X10
-2
 
rs17405819 HNF4G T 0.70 0.02 2.07X10
-11
 0.70 1.12 1.19X10
-2
 0.69 1.08 6.30X10
-2
 
rs2365389 FHIT C 0.58 0.02 1.63X10
-10
 0.59 1.09 3.94X10
-2
 0.58 1.06 1.80X10
-1
 
rs205262 C6orf106 G 0.27 0.02 1.75X10
-10
 0.26 1.16 1.14X10
-3
 0.26 1.05 3.12X10
-1
 
rs2820292 NAV1 C 0.55 0.02 1.83X10
-10
 0.56 1.03 4.74X10
-1
 0.56 1.09 3.47X10
-2
 
rs9641123 CALCR C 0.42 0.01 2.08X10
-10
 0.41 1.09 3.19X10
-2
 0.40 1.03 4.09X10
-1
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rsID Gene GIANT SCOOP vs. UKHLS UKHLS vs. STILTS 
EA EAF Beta P value EAF OR P value EAF OR P value 
rs12016871 MTIF3 T 0.20 0.03 2.29X10
-10
 0.17 1.15 7.09X10
-3
 0.17 0.96 4.84X10
-1
 
rs16851483 RASA2 T 0.06 0.04 3.55X10
-10
 0.06 1.20 2.17X10
-2
 0.06 1.17 8.83X10
-2
 
rs1928295 TLR4 T 0.54 0.01 7.91X10
-10
 0.56 1.10 2.00X10
-2
 0.56 0.99 8.13X10
-1
 
rs2650492 SBK1 A 0.30 0.02 1.92X10
-9
 0.29 1.17 2.93X10
-4
 0.29 1.05 2.42X10
-1
 
rs12940622 RPTOR G 0.57 0.01 2.49X10
-9
 0.55 1.12 7.20X10
-3
 0.55 1.06 1.28X10
-1
 
rs11847697 PRKD1 T 0.04 0.04 3.99X10
-9
 0.04 1.25 1.72X10
-2
 0.04 1.24 5.05X10
-2
 
rs4740619 C9orf93 T 0.54 0.01 4.56X10
-9
 0.54 1.05 2.10X10
-1
 0.54 1.12 5.88X10
-3
 
rs11191560 NT5C2 C 0.08 0.03 8.45X10
-9
 0.07 1.23 4.23X10
-3
 0.07 1.00 9.98X10
-1
 
rs1000940 RABEP1 G 0.32 0.01 1.28X10
-8
 0.30 1.11 1.47X10
-2
 0.29 1.06 2.04X10
-1
 
rs2836754 ETS2 C 0.61 0.01 1.61X10
-8
 0.65 1.05 2.42X10
-1
 0.64 1.12 1.03X10
-2
 
rs9400239 FOXO3 C 0.68 0.01 1.61X10
-8
 0.70 1.11 1.84X10
-2
 0.70 1.09 4.31X10
-2
 
rs29941 KCTD15 G 0.66 0.01 2.41X10
-8
 0.67 1.13 5.77X10
-3
 0.66 1.02 5.56X10
-1
 
rs9374842 LOC285762 T 0.74 0.01 2.67X10
-8
 0.77 1.16 3.41X10
-3
 0.76 1.05 2.53X10
-1
 
rs6477694 EPB41L4B C 0.36 0.01 2.67X10
-8
 0.35 1.10 2.73X10
-2
 0.34 1.04 3.53X10
-1
 
rs7899106 GRID1 G 0.05 0.04 2.96X10
-8
 0.05 1.24 1.48X10
-2
 0.05 0.94 5.90X10
-1
 
rs2245368 PMS2L11 C 0.18 0.03 3.19X10
-8
 0.16 1.22 2.73X10
-4
 0.16 0.98 7.82X10
-1
 
rs17203016 CREB1 G 0.19 0.02 3.41X10
-8
 0.20 1.13 1.32X10
-2
 0.20 0.98 7.28X10
-1
 
rs17724992 PGPEP1 A 0.74 0.01 3.42X10
-8
 0.74 1.15 2.99X10
-3
 0.73 1.04 3.90X10
-1
 
rs9540493 MIR548X2 A 0.45 0.01 4.97X10
-8
 0.45 1.12 9.92X10
-3
 0.44 1.00 9.28X10
-1
 
Table 2.3: BMI-associated loci that were nominally significant in either. SCOOP vs UKHLS or UKHLS vs STILTS.EA= Effect 
allele (BMI increasing allele); EAF = Effect allele frequency. Only loci that are nominally significant (p<0.05) in at least one 
comparison are shown. Nominally significant loci (p<0.05) are highlighted in bold for each comparison 
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Figure 2.3: Odds ratio comparison for the 97 BMI associated loci. Odds ratios for SCOOP vs UKHLS (x-axis) and UKHLS vs 
STILTS (y-axis) comparisons are shown for the 97 known BMI loci from GIANT.  Colours of data points represent nominal 
significance in both analyses (red), only SCOOP vs. UKHLS (green), only STILTS vs UKHLS (blue) or in neither analysis 
(purple). Error bars represent 95% confidence intervals for the odds ratios for SCOOP vs UKHLS (x-axis) and for UKHLS vs 
STILTS (y-axis). A subset of data points with larger separation from the red diagonal line (x=y) are labelled. 
 
Notably, a striking difference was observed in association results in the FTO locus where the 
lead intronic obesity risk variant, rs1558902, showed a moderate effect size and modest 
evidence of association in controls compared to thin individuals (UKHLS vs 
STILTS)(p=0.00027, OR=1.17, 95% CI [1.08,1.28], EAF=0.39), despite having a large effect and 
being associated at genome-wide significance levels in obese compared to control 
individuals (SCOOP vs UKHLS) (p=1.25x10-17, OR=1.43, 95% CI [1.32,1.55], EAF=0.41) (Figure 
2.3, Table 2.3). GNAT2 also showed a larger effect and significance in the analysis of SCOOP 
vs UKHLS (p=1.26x10-4, OR=1.57, 95% CI [1.25, 1.97], EAF=0.03), than in UKHLS vs STILTS 
(p=0.52, OR=1.10, 95% CI [0.82, 1.47], EAF=0.02)  (Figure 2.3, Table 2.3). This discrepancy in 
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association strength and effect size was also seen at the opposite end of the BMI spectrum 
in CADM2 where the lead SNP, rs13078960, showed evidence of association in UKHLS vs 
STILTS (p= 9.48x10-4, OR=1.2, 95% CI [1.08, 1.33], EAF=0.20) but no association in SCOOP vs 
UKHLS (p>0.05). In contrast to results at the FTO and CADM2 loci, for MC4R the results are 
more comparable, with genome-wide significant association in SCOOP vs UKHLS (rs6567160, 
p=7.91x10-9, OR=1.31, 95% CI [1.19, 1.43], EAF=0.25) and highly significant association 
results in UKHLS vs STILTS(p=1.38x10-5, OR=1.26, 95% CI [1.13, 1.39], EAF=0.23). One 
possible explanation for these observed differences is that they arose as a result of 
randomly sampling a small subset of individuals at the two extremes of the distribution 
and/or by the different degree of extremeness of the phenotype. To formally test if these 
results were significantly different from those expected under a model where loci act 
additively across the BMI distribution, I simulated 10,000 different populations of 1 million 
individuals with genotypes for the 97 established BMI loci using allele frequencies in UKHLS, 
and then simulated a phenotype using the effect sizes in GIANT (Methods 2.3.7). These 
simulations detected fourteen loci with nominally significant deviation from an additive 
model, however none remained significant after correction for the number of tests 
(p=0.05/97*2 = ~0.0002, Table 2.4). However, CADM2 was nominally significant in both 
SCOOP vs UKHLS and STILTS vs UKHLS analyses, with slightly lower OR detected in SCOOP vs 
UKHLS compared to simulated data, and slightly higher OR detected in UKHLS vs STILTS 
compared to simulated data (Table 2.4). Since both SCOOP and STILTS are significantly 
younger than UKHLS, I used summary statistics from the ALSPAC cohort which consists of 
4,964 children aged 13-16 to test if the OR differences observed in SCOOP vs UKHLS were 
due to age effects. For the 97 GIANT loci overall there were no significant differences (z-test, 
p>0.05) except for rs2245368 (PMS2L11 locus, z-test p=3.81x105, Supplementary Table 4 of 
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Riveros-Mckay et al 2018 [217] (Appendix A)). In combination, these results suggest that 
the observed differences in ORs and p-values could have arisen because our severe obese 
cases are much more extreme (i.e. deviate more from the mean) than the healthy thin 
individuals. Results also suggest our obese and thin sample sizes gave us limited power to 
detect significant differences compared to the additive model given the wide confidence 
intervals observed in simulations.  
SCOOP 
Gene p-val observed OR mean simulation OR 
QPCTL 0.0471 1.02 1.14 
FPGT-TNNI3K 0.0161 1.21 1.09 
CADM2 0.0177 0.99 1.12 
STXBP6 0.0379 0.99 1.09 
HSD17B12 0.0113 0.96 1.08 
ZBTB10 0.0166 0.95 1.14 
STILTS 
Gene p-val observed OR mean simulation OR 
MC4R 0.0137 1.26 1.12 
ADCY3 0.0059 1.19 1.06 
CADM2 0.0148 1.20 1.06 
LINGO2 0.0436 0.96 1.05 
TCF7L2 0.0337 0.96 1.05 
C9orf93 0.0398 1.12 1.04 
SCARB2 0.0473 0.95 1.06 
ETS2 0.0479 1.12 1.03 
CLIP1 0.0311 0.93 1.06 
Table 2.4: Nominally significant loci for non-additive effect in extremes. 
In addition to analysing established BMI loci on an individual basis, I also looked at genetic 
risk scores (GRS) generated from the 97 BMI associated loci from GIANT [92] to analyse the 
contribution of these loci as a whole. To this end, Vanisha Mistry generated weighted GRS 
scores and Audrey Hendricks ran an ordinal logistic regression testing the association of the 
GRS scores on BMI category (i.e. thin (STILTS), normal (UKHLS), obese (SCOOP)). As 
expected, the standardised BMI genetic risk score was strongly associated with BMI 
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category (weighted score p=8.59x10-133). The effect of a one standard deviation increase in 
the standardised BMI genetic risk score was significantly larger for obese vs. (thin & normal) 
than for (obese & normal) vs. thin (p=7.48x10-11) with odds ratio and 95% confidence 
intervals of 1.94 (1.83, 2.07) and 1.50 (1.42, 1.59), respectively. However, using the 
simulations described above (Methods 2.3.7), confirmed that the larger OR for obese vs. 
(thin & normal) was not significantly different (p=0.41) than what we would expect given an 
additive genetic model, and the different degrees of “extremeness” in our thin and obese 
cases. A BMI genetic score excluding the FTO variant produced similar results (data not 
shown). I also tested whether the mean GRS in each BMI category was significantly different 
from that predicted via simulations and found no significant difference (Figure 2.4). As a 
sanity check, I also compared controls against simulations and no significant difference was 
observed (p=0.18). 
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Figure 2.4: Mean GRS for SCOOP, STILTS and UKHLS compared to simulations. Histogram represents mean GRS scores for 
each BMI category across 10,000 simulations. Vertical red line highlights the observed value in real data. 
 
 
2.4.4 Genetic correlation between persistent thinness, severe early onset childhood 
obesity and BMI 
 
Given the observed differences in association results from thin (STILTS) and obese (SCOOP) 
individuals, compared to the same set of control individuals (UKHLS), I next explored the 
genetic correlation of severe early onset obesity, persistent thinness and BMI using LD score 
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regression (Methods 2.3.4). For this, I used summary statistics from the SCOOP vs UKHLS, 
STILTS vs UKHLS and BMI data from participants in UK Biobank (UKBB). As expected from 
the association results, the genetic correlation of severe early onset obesity and BMI was 
high (r=0.86, 95% CI [0.74, 0.98], p=1.86x10-43). I also detected weaker negative correlation 
between persistent thinness and BMI (r=-0.63, 95% CI [-0.44,-0.82], p=3.54x10-11), and 
between persistent thinness and severe obesity (r=-0.49, 95% CI [-0.17,-0.82], p=0.003). In 
contrast with previously described obesity classes, severe early onset obesity and persistent 
thinness were not completely correlated with BMI (Figure 2.5). As an inverse genetic 
correlation between BMI, obesity and anorexia nervosa (a disorder that is characterised by 
thinness and complex behavioural manifestations) has been reported [228], I also tested for 
genetic correlation with anorexia nervosa, and found that neither severe early onset 
obesity, nor persistent thinness, were significantly correlated with anorexia nervosa  
(r=-0.05, 95% CI [-0.15,0.05], p=0.33 and r=0.13, 95% CI [-0.02,0.28], p=0.09,  respectively).   
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Figure 2.5: Genetic correlation of traits and BMI. Genetic correlation estimates and 95% CI for severe early-onset 
childhood obesity (SCOOP), healthy persistent thinness (STILTS), Obesity Class 3, Obesity Class 2, Obesity Class 1 and 
Overweight.  Dotted lines represent complete genetic correlation. 
 
2.4.5 Discovery of novel association signals for persistent thinness and severe early 
onset obesity 
 
After the initial association analysis, I sought evidence for novel signals associated with 
either end of the BMI distribution (persistent thinness or severe early onset obesity; 
Methods 2.3.9). In all three analyses, in addition to loci mapping to established BMI and 
obesity loci, I identified PIGZ and C3orf38, two novel loci in the thin vs control analysis, that 
reached conventional genome-wide significance (GWS) (p≤5x10-8) (Table 2.5, Figure 2.6).  
However, an additional 125 SNPs, in 118 distinct loci, reached the arbitrary threshold of 
 p ≤10-5 in at least one analysis, for which I sought replication to assess if promising signals 
are true signals or likely false-positives that could have arisen by confounding effects such as 
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genotyping batch effects (Supplementary Tables 5-7 of Riveros-Mckay et al 2018 [217] 
(Appendix A) ). 
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Figure 2.6: Miami plot of SCOOP vs. UKHLS and STILTS vs. UKHLS. Miami plot produced in EasyStrata [23], Red=SCOOP vs. UKHLS; Blue=STILTS vs. UKHLS. Red lines indicate genome-wide significance threshold at 
p=5x10
-8
. Orange lines indicate discovery significance threshold at p=1x10
-5
.  Black labels highlight known BMI/obesity loci that were taken forward for replication and yellow peaks indicate those that met genome-
wide significance after replication. Grey labels highlight novel loci that did not replicate. 
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Obese vs. thin 
rsID Nearest gene EA NEA OR  (95% CI) P value EAF Obese EAF Thin 
rs9930333 FTO G T 1.70(1.52,1.90) 2.30X10
-20
 49.59% 37.46% 
rs2168711 MC4R C T 1.66(1.45,1.89) 8.29X10
-14
 28.90% 19.95% 
rs6748821 TMEM18 G A 1.65(1.42,1.91) 9.45X10
-11
 86.69% 79.84% 
rs506589 SEC16B C T 1.46(1.27,1.67) 5.42X10
-8
 23.98% 18.07% 
rs6738433 ADCY3-DNAJC27 C G 1.43(1.28,1.60) 1.71X10-
10
 47.31% 43.92% 
rs62107261 FAM150B T C 2.37(1.75,3.20) 2.07X10
-8
 96.37% 93.38% 
Obese vs. controls 
rsID Nearest gene EA NEA OR  (95% CI) P value EAF Obese EAF Controls 
rs9928094 FTO G A 1.44(1.33,1.57) 1.42X10
-18
 49.50% 41.32% 
rs35614134 MC4R AC A 1.31(1.20,1.44) 6.27X10
-9
 29.01% 23.69% 
rs66906321 TMEM18 C T 1.40(1.24,1.57) 2.35X10
-8
 85.78% 81.35% 
Controls vs. thin 
rsID Nearest gene EA NEA OR  (95% CI) P value EAF Controls EAF Thin 
rs117638949 PIGZ T A 3.5 (2.27,5.4) 1.50X10
-8
 99.50% 98.55% 
rs75937976 C3orf38 G C 2.95 (2.02,4.32) 2.43X10
-8
 99.20% 98.25% 
Table 2.5: Genome-wide significant loci in discovery analysis. EA= Effect allele (BMI increasing allele); EAF = Effect allele 
frequency. 
As our obese and thin cases (SCOOP and STILTS) lie at the very extreme tails of the BMI 
distribution, there are few comparable replication datasets. I therefore used the UKBB 
dataset and selected individuals at the top (BMI>=40, N=7,526) and bottom end of the 
distribution (BMI≤19, N=3,532) to more closely match the BMI criteria of our clinically 
ascertained thin and obese individuals. I used 20,720 samples from the rest of the UKBB 
cohort as a control set (Methods 2.3.2.2, Figure 2.2).  As previously mentioned (Methods 
2.3.2.2), I used all thin individuals regardless of health status in this analysis. However, using 
ICD10 codes and self-reported illness data (Supplementary Tables 12-13 of Riveros-Mckay 
et al 2018 [217] (Appendix A)) to remove individuals who had a relevant medical diagnosis 
before date of attendance at UKBB recruitment centre, yielded materially equivalent results 
(Figure 2.7), so I have elected to keep the original results with all thin participants as my 
primary analysis. In cases where lead variants or proxies (r2>0.8) were not, at the time of 
this study, available in the full UKBB genetic release I used results from the interim release 
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using 2,799 individuals with BMI>=40, 1,212 with BMI<=19 and 8,193 controls (Methods 
2.3.2.2). There was a significant negative genetic correlation for the obese replication 
cohort with anorexia nervosa (r= -0.24, 95% CI [-0.37,-0.11], p=0.01) and a positive genetic 
correlation for the thin replication cohort (r=0.49, 95% CI [0.22-0.76] p=0.0003). The positive 
genetic correlation for the thin replication cohort was still observed after using ICD10 codes 
and self-reported illness data to clean the phenotype (r=0.62, 95% CI [0.30,0.92], p=0.0001).  
  
Figure 2.7: Quantile-quantile plots for UKBB case-control analysis with different exclusion criteria for thin individuals. Q-
Q plot using all thin individuals as cases (Full UKBB) and removing individuals based on ICD10 and self-reported data 
(ICD10+self-reported filter). Correlation for –log10 p-values is shown (r=0.7462). 
 
To further increase power, I took advantage of publicly available summary statistics from 
the GIANT Extremes obesity meta-analysis [207], the EGG childhood obesity study [236], 
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and our group’s previous study on non-overlapping SCOOP participants (SCOOP 2013) [160], 
as additional replication datasets. For SCOOP vs. STILTS I used the GIANT BMI tails meta-
analysis results [207] (up to 7,962 cases/8,106 controls from the upper/lower 5th 
percentiles of the BMI trait distribution). For SCOOP vs. UKHLS I used the GIANT obesity 
class III summary statistics [207] (up to 2,896 cases with BMI ≥40kg/m2 vs 47,468 controls 
with BMI <25 kg/m2), the EGG childhood obesity study [236] (children with BMI ≥95th 
percentile of BMI vs 8,318 children with BMI <50th percentile of BMI) and SCOOP 2013 
[160]. Fixed effect meta-analyses yielded genome-wide significant signals at well-known 
BMI associated loci in both the obese vs. thin, and obese vs. control analyses, and both the 
PIGZ and C3orf38 loci identified at the discovery stage failed to replicate when combined 
with additional data (Table 2.6, Supplementary Tables 5-7 of Riveros-Mckay et al 2018 
[217] (Appendix A). However, the SNRPC locus described here (rs75398113), though not 
independent from the previously described SNRPC/C6orf106 locus (rs205262, r2= 0.29) [92], 
appears to be driving the previously reported association at this locus (rs205262 
conditioned on rs75398113, pconditioned=0.7, Table 2.7). Both SNPs are eQTLs for C6or106 and 
UHRF1BP1 in multiple tissues including brain and colon tissues on GTEx however neither of 
these are obvious biological candidates linked to energy homeostasis.
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Obese vs.  thin           Discovery cohort Replication cohorts Combined analysis 
rsID Nearest  
gene 
Chr Position (bp) EA NEA OR   
(95% CI) 
P value EAF Ob EAF Th Cohort OR  
 (95% CI) 
P value EAF Ob EAF Th OR  
 (95% CI) 
P value HetPVal 
rs9930333 FTO 16 53799977 G T 1.70 
(1.52,1.90) 
2.30X10
-20
 49.59% 37.46% UKBB 1.46 
(1.38,1.55) 
3.60X10
-36
 48.26% 38.93% 1.48 
(1.42,1.54) 
8.52X10
-76
 3.34X10
-2
 
          GIANT 1.43 
(1.34,1.54) 
8.10X10
-25
      
rs2168711 MC4R 18 57848531 C T 1.66 
(1.45,1.89) 
8.29X10
-14
 28.90% 19.95% UKBB 1.23 
(1.15,1.32) 
2.19X10
-9
 26.75% 22.90% 1.27 
(1.21,1.33) 
2.02X10
-21
 1.12X10
-4
 
          GIANT 1.20 
(1.10,1.30) 
1.80X10
-5
      
rs6748821 TMEM18
a
 2 629601 G A 1.65 
(1.42,1.91) 
9.45X10
-11
 86.69% 79.84% UKBB 1.27 
(1.18,1.37) 
1.31X10
-9
 85.00% 81.69% 1.32 
(1.24,1.39) 
7.76X10
-21
 2.81X10
-3
 
          GIANT 1.26 
(1.14,1.39) 
9.90X10
-6
      
rs506589 SEC16B 1 177894287 C T 1.46 
(1.27,1.67) 
5.42X10
-8
 23.98% 18.07% UKBB 1.25 
(1.17,1.35) 
5.44X10
-10
 23.11% 19.16% 1.28 
(1.21,1.35) 
3.14X10
-20
 1.21X10
-1
 
          GIANT 1.25 
(1.14,1.37) 
2.70X10
-6
      
rs6738433 ADCY7
b
 2 25159501 C G 1.43 
(1.28,1.60) 
1.71X10
-10
 47.31% 43.92% UKBB 1.21 
(1.14,1.28) 
2.74X10
-10
 50.70% 45.96% 1.19 
(1.14,1.24) 
3.19X10
-17
 6.25X10
-3
 
          GIANT 1.10 
(1.03,1.17) 
5.70X10
-3
      
rs7132908 FAIM2 12 50263148 A G 1.31 
(1.17,1.47) 
2.26X10
-6
 42.45% 36.27% UKBB 1.18 
(1.11,1.25) 
5.43X10
-8
 41.11% 37.39% 1.20 
(1.15,1.26) 
1.93X10
-16
 2.52X10
-1
 
          GIANT 1.20 
(1.10,1.30) 
6.60X10
-6
      
rs62107261 FAM150B 2 422144 T C 2.37 
(1.75,3.20) 
2.07X10
-8
 96.37% 93.38% UKBB 1.54 
(1.35,1.76) 
3.57X10
-10
 96.28% 94.36% 1.65 
(1.46,1.87) 
1.15X10
-15
 1.07X10
-2
 
rs12507026 GNPDA2
c
 4 45181334 T A 1.30 
(1.17,1.46) 
3.69X10
-6
 47.29% 40.92% UKBB 1.14 
(1.08,1.21) 
8.76X10
-6
 45.30% 41.98% 1.18 
(1.13,1.23) 
5.53X10
-15
 4.06X10
-2
 
          GIANT 1.20 
(1.12,1.28) 
3.10X10
-7
      
rs75398113 SNRPC 6 34728071 C A 1.53 
(1.27,1.85) 
8.91X10
-6
 11.95% 8.04% UKBB 1.24 
(1.12,1.37) 
2.07X10
-5
 10.47% 8.52% 1.30 
(1.19,1.42) 
5.19X10
-9
 5.56X10
-2
 
rs13135092 SLC39A8 4 103198082 G A 1.58 
(1.30,1.93) 
4.70X10
-6
 10.50% 7.24% UKBB 1.25 
(1.12,1.39) 
5.57X10
-5
 9.24% 7.52% 1.32 
(1.20,1.45) 
1.06X10
-8
 3.59X10
-2
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Obese vs. controls        Discovery cohort  Replication cohorts  Combined analysis  
rsID Nearest  
gene 
Chr Position (bp) EA NEA OR  
 (95% CI) 
P value EAF Ob EAF Co Cohort OR  
 (95% CI) 
P value EAF Ob EAF Co OR 
  (95% CI) 
P value HetPVal 
rs9928094 FTO 16 53799905 G A 1.44 
(1.33,1.57) 
1.42X10
-18
 49.50% 41.32% UKBB 1.30 
(1.25,1.35) 
2.74X10
-41
 48.34% 41.91% 1.32 
(1.29,1.36) 
 5.94X10
-101
 4.41X10
-5
 
             SCOOP 2013 1.46 
(1.34,1.60) 
4.88X10
-17
        
             EGG 1.21 
(1.15,1.28) 
7.20X10
-13
        
             GIANT 1.43 
(1.34,1.54) 
6.60X10
-25
        
rs35614134 MC4R
d
 18 57832856 AC A 1.31 
(1.20,1.44) 
6.27X10
-9
 29.01% 23.69% UKBB 1.22 
(1.16,1.27) 
1.25X10
-18
 26.72% 23.15%  1.23 
(1.20,1.27) 
 1.57X10
-43
 3.55X10
-1
 
             SCOOP 2013 1.32 
(1.19,1.46) 
1.22X10
-7
        
             EGG 1.22 
(1.15,1.30) 
1.27X10
-10
        
             GIANT 1.20 
(1.10,1.30) 
1.70X10
-5
        
rs66906321 TMEM18
e
 2 630070 C T 1.40 
(1.24,1.57) 
2.35X10
-8
 85.78% 81.35% UKBB 1.17 
(1.11,1.24) 
3.44X10
-9
 84.44% 82.20%  1.25 
(1.21,1.29) 
 9.72X10
-35
 1.33X10
-2
 
             SCOOP 2013 1.39 
(1.24,1.57) 
6.65X10
-8
        
             EGG 1.28 
(1.19,1.37) 
5.15X10
-12
        
             GIANT 1.27 
(1.15,1.40) 
3.40X10
-6
        
rs7132908 FAIM2
f
 12 50263148 A G 1.22 
(1.12,1.32) 
3.27X10
-6
 42.45% 37.82% UKBB 1.15 
(1.10,1.19) 
5.37X10
-12
 41.11% 37.71%  1.17 
(1.14,1.21) 
 2.38X10
-31
 4.86X10
-1
 
             SCOOP 2013 1.23 
(1.12,1.35) 
8.89X10
-6
        
             EGG 1.18 
(1.11,1.25) 
1.24X10
-8
        
             GIANT 1.20 
(1.10,1.30) 
6.60X10
-6
        
rs2384060 ADCY3
g
 2 25135438 G A 1.23 
(1.13,1.34) 
1.53X10
-6
 43.52% 38.90% UKBB 1.11 
(1.07,1.15) 
4.89X10
-8
 47.67% 44.93%  1.14 
(1.11,1.17) 
 9.39X10
-23
 1.13X10
-1
 
             SCOOP 2013 1.09 
(1.00,1.19) 
5.01XX10
-2
        
64 
 
Obese vs. controls      Discovery cohort Replication cohorts Combined analysis 
rsID Nearest  
gene 
Chr Position (bp) EA NEA OR  
 (95% CI) 
P value EAF Ob EAF Co Cohort OR  
 (95% CI) 
P value EAF Ob EAF Co OR 
  (95% CI) 
P value HetPVal 
             EGG 1.18 
(1.12,1.24) 
1.02X10
-9
        
             GIANT 1.12 
(1.04,1.19) 
1.60X10
-3
        
rs11209947 NEGR1
h
 1 72808551 A T 1.30 
(1.17,1.44) 
8.51X10
-7
 76.58% 72.18% UKBB 1.11 
(1.05,1.16) 
4.53X10
-5
 81.18% 79.76% 1.17 
(1.13,1.21) 
5.17X10
-20
 7.26X10
-5
 
             SCOOP 2013 1.46 
(1.30,1.63) 
2.21X10
-10
        
             EGG 1.13 
(1.06,1.22) 
4.60X10
-4
        
             GIANT 1.22 
(1.11,1.35) 
5.60X10
-5
        
rs12735657 SEC16B
i
 1 177809133 C T 1.24 
(1.13,1.37) 
9.72X10
-6
 24.26% 20.46% UKBB 1.12 
(1.07,1.17) 
1.48X10
-6
 22.87% 20.94% 1.15 
(1.12,1.19) 
 7.26X10
-19
 1.79X10
-1
 
             SCOOP 2013 1.20 
(1.07,1.33) 
1.18X10
-3
        
             EGG 1.14 
(1.06,1.21) 
1.52X10
-4
        
             GIANT 1.22 
(1.11,1.34) 
1.80X10
-5
        
rs13104545 GNPDA2 4 45184907 A G 1.27 
(1.15,1.40) 
1.61X10
-6
 27.41% 23.45% UKBB 1.07 
(1.02,1.11) 
5.35X10
-3
 24.36% 23.26%  1.13 
(1.09,1.17) 
 1.47X10
-11
 9.39X10
-5
 
             EGG 1.13 
(1.04,1.22) 
3.39X10
-3
        
             GIANT 1.34 
(1.20,1.49) 
1.20X10
-7
        
rs112446794 CEP120
j
 5 122665465 T C 1.23 
(1.13,1.35) 
2.08X10
-6
 33.15% 28.69% UKBB 1.07 
(1.02,1.11) 
2.55X10
-3
 29.47% 28.21%  1.09 
(1.06,1.13) 
 3.45X10
-10
 3.33X10
-2
 
             SCOOP 2013 1.08 
(0.98,1.19) 
1.38X10
-1
        
             EGG 1.12 
(1.06,1.18) 
1.22X10
-4
        
                    GIANT 1.05 
(0.97,1.13) 
2.40X10
-1
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Obese vs control 
 
     Discovery cohort Replication cohorts Combined analysis 
rsid Nearest  
gene 
Chr Position (bp) EA NEA OR  
 (95% CI) 
P value EAF Ob EAF Co Cohort OR  
 (95% CI) 
P value EAF Ob EAF Co OR 
  (95% CI) 
P value HetPVal 
rs3760091 SULT1A1 16 28620800 C G 1.24 
(1.14,1.35) 
1.56X10
-6
 64.89% 60.23% UKBB  1.09 
(1.04,1.14) 
1.19X10
-4
 63.49% 61.44% 1.12 
(1.07,1.16) 
2.65X10
-8
 8.49X10
-3
 
Table 2.6: GWAS results for SNPs meeting p<5x10-8 in all three analyses. EA= Effect allele (BMI increasing allele); NEA= Non-effect allele; OR = Odds ratio; 95% CI = 95% confidence interval 
for the odds ratio; EAF = effect allele frequency. Positions mapped to hg19, Build 37. a rs12995480 used as proxy in GIANT. b rs2384054 used as proxy in GIANT. c rs12641981 used as proxy in 
GIANT. d rs663129 used as proxy in GIANT, EGG and SCOOP 2013. e rs13007080 used as proxy in GIANT, EGG and SCOOP 2013. f rs7138803 used as proxy in SCOOP 2013. g rs6722587 used as 
proxy in GIANT, EGG and SCOOP 2013. h rs4132288 used as proxy in GIANT, EGG and SCOOP 2013. I rs1460940 used as proxy in GIANT, EGG and SCOOP 2013. j rs1366333 used as proxy in 
GIANT, EGG and SCOOP 2013. 
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SNPID p-value OR conditioned p-value conditioned OR conditioned 
on 
rs75398113* 5.44X10
-6
 1.53 2.94X10
-4
 1.5 rs205262** 
rs205262** 5.59X10
-3
 1.19 7.09X10
-1
 1.03 rs75398113* 
Table 2.7: Reciprocal conditional analysis of rs75398113 (SNRPC)  and rs205262 (C6orf106) in  SCOOP vs STILTS analysis. 
r2=0.29. p-values and ORs are shown without any LD correction applied. *Top signal in this study. **Previously established 
locus. 
 
This is also the case for the CEP120 locus (rs112446794) in the obese vs. controls analysis 
where reciprocal conditional analysis reveals the locus described here is driving the 
association observed at the reported locus (rs4308481 conditioned on rs112446794, 
pconditioned=0.08,Table 2.8). 
 
SNPID p-value OR conditioned p-value conditioned OR conditioned on 
rs112446794* 1.94X10
-6
 1.23 6.39X10
-3
 1.16 rs4308481** 
rs4308481** 1.89X10
-5
 1.2 7.82X10
-2
 1.1 rs112446794* 
Table 2.8: Reciprocal analysis of rs112446794 (CEP120) and rs4308481 (PRDM6-CEP120) in SCOOP vs UKHLS analysis. 
r2=0.36. p-values and ORs are shown without any LD correction applied. . *Top signal in this study. **Previously 
established locus 
Finally, I used the independent BMI dataset from UKBB (Methods 2.3.2.2) to investigate 
whether any of the loci meeting our arbitrary p ≤10-5 in discovery efforts, were 
independently associated with BMI as a continuous trait.  This identified a novel BMI-
associated locus near PKHD1 (SCOOP vs. STILTS p=5.99x10-6, SCOOP vs. UKHLS p=2.13x10-6, 
BMI p=2.3x10-13, Table 2.9).  Furthermore, there was an excess of nominally significant and 
directionally consistent signals in variants taken for replication in the obese vs. thin, and 
obese vs. controls analyses, after removing known signals and PKHD1, when comparing 
against a GWAS performed on the BMI dataset from UKBB (binomial p=4.88x10-4, and 
binomial p=9.77x10-3, respectively, Methods, Table 2.9).  
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Despite the smaller sample size, the SCOOP vs STILTS comparison had increased power to 
detect some loci, including the locus FAM150B (Table 2.6), which did not meet our p<10-5 
threshold to be taken forward for replication in SCOOP vs UKHLS analysis (p=2.36x10-4).   
SCOOP vs. STILTS 
SNP 
 
Nearest Gene 
 
Effect 
 
Other 
 
EAF  
UKBB 
 
Beta 
UKBB 
 
SE 
UKBB 
 
P value 
UKBB 
 
Binomial 
P value 
rs654240 CCND1 T C 0.41 0.05 0.01 1.50X10
-5
 4.88X10
-4
 
rs4447506 PIK3C3 G A 0.39 0.05 0.01 1.50X10
-6
  
rs2425853* CDH22 C G 0.69 0.06 0.01 8.30X10
-7
  
rs2836760 LOC400867 T G 0.09 0.05 0.02 8.70X10
-3
  
rs6711131** BAZ2B A G 0.63 0.06 0.02 1.80X10
-3
  
rs375252497** SEMA3B AAATAAT 
AATAAT 
A 0.67 0.10 0.02 1.80X10
-6
  
rs11792928 LMX1B T C 0.29 0.03 0.01 1.10X10
-2
  
rs516579 MTCL1 G T 0.80 0.03 0.01 2.30X10
-2
  
rs73145387 ABI3BP C G 0.97 0.07 0.03 2.90X10
-2
  
rs11185396 LOC100129138 C T 0.10 0.04 0.02 2.60X10
-2
  
rs599291 SLC44A5 T C 0.45 0.02 0.01 2.50X10
-2
  
rs2784243*** PKHD1 T C 0.58 0.07 0.01 2.70X10
-11
  
SCOOP vs. UKHLS 
SNP 
 
Nearest Gene 
 
Effect 
 
Other 
 
EAF 
 UKBB 
 
Beta 
UKBB 
 
SE 
UKBB 
 
P value 
UKBB 
 
Binomial 
P value 
rs144435735 LINC00682 A G 0.02 0.09 0.04 1.20X10
-2
 9.77X10
-3
 
rs8096590 LINC01541 A G 0.31 0.04 0.01 7.90X10
-4
  
rs10944524 MIR4643 T C 0.15 0.03 0.02 2.80X10
-2
  
rs115474151 SLC7A14 A T 0.01 0.18 0.09 3.70X10
-2
  
rs11563327 HOXA1 C T 0.71 0.02 0.01 4.30X10
-2
  
rs1571570 PBX3 C G 0.07 0.05 0.02 1.90X10
-2
  
rs5873242** RANBP17 A T 0.32 0.08 0.02 7.80X10
-5
  
rs75809547**** PTBP2 C T 0.01 -0.15 0.06 1.30X10
-2
  
rs898708 PNOC C T 0.69 0.02 0.01 3.30X10
-2
  
rs2237402 POU6F2 G A 0.66 0.05 0.01 1.20X10
-6
  
rs10456655*** PKHD1 G C 0.17 0.10 0.01 2.30X10
-13
  
UKHLS vs. STILTS 
SNP 
 
Nearest Gene 
 
Effect 
 
Other 
 
EAF 
 UKBB 
 
Beta 
UKBB 
 
SE 
UKBB 
 
P value 
UKBB 
 
Binomial 
P value 
rs514529 LRP5 T A 0.53 0.03 0.01 5.10X10
-3
 3.75X10
-1
 
rs138251346 LOC101929452 A G 0.99 0.13 0.07 3.50X10
-2
  
rs553440779**** KCNJ3 T C 0.01 -0.16 0.07 2.20X10
-2
  
Table 2.9: Consistency of the direction of effect in candidate loci meeting p<1x10-5 in the discovery stages with BMI 
dataset GWAS. *Proxy for rs10546790. **Interim release used in UKBB for these signals. N=127,672. ***Novel signal – 
excluded from enrichment test. ****Opposite direction of effect. Effect=Effect allele (BMI increasing allele); Other=Other 
allele; Beta UKBB=Beta in UKBB BMI GWAS; SE UKBB=SE in UKBB BMI GWAS, P value UKBB=P value in UKBB BMI GWAS. 
Binomial P value=P value for binomial test). 
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2.5 Discussion 
 
In this chapter, I and others performed the largest, at the time of completion, GWAS on 
healthy individuals with persistent thinness, and provided the first insights into the genetic 
architecture of this trait. I first show, using genome-wide data, that persistent healthy 
thinness is a heritable trait (h2=28.07%) with a comparable heritability estimate to that of 
severe childhood obesity (h2=32.33%). I also show a negative and incomplete genetic 
correlation between persistent healthy thinness and severe childhood obesity (r=-0.49, 95% 
CI [-0.17,-0.82], p=0.003). The incomplete genetic overlap between the two clinically 
ascertained traits is highlighted by the fact that some established BMI loci are more strongly 
associated  at one end of the clinical BMI distribution compared to the other (e.g. FTO and 
CADM2), while others, appear to exert effects across the entire BMI spectrum (e.g. MC4R 
[184, 240, 241]). However, further exploration by simulation demonstrated some of these 
differences are likely to be due to the different degrees of “extremeness” of the two clinical 
cohorts (i.e. the difference in mean BMI between controls and obese individuals is larger 
than that of controls and thin individuals) and not due to a deviation from additive effects of 
the tested loci on BMI. It is worth noting that CADM2 was not detected even at nominal 
significance in the previous SCOOP effort (p=0.41, OR=1.04 [160]), nor is it detected in the 
EGG study of childhood obesity (p=0.06, OR=1.06 [236]) which suggests that in this case the 
departure from expected OR (Table 2.4) may reflect a true finding. Variants in CADM2 have 
also been associated with habitual physical activity [242]. GRS results also showed that 
overall genetic effects of the established loci do not deviate significantly from an additive 
model. This is in contrast with earlier studies which suggested larger effects at the higher 
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end of the BMI distribution [243, 244] but in agreement with more recent observations 
contrasting the bottom 5% and top 5% of the BMI tails where associated loci were also 
consistent with additive effects [207]. This is also in contrast with a previous study on 
height, where a deviation from additivity was found, but only for short individuals in the 
bottom 1.5% of the distribution [245], which suggests that analysis focused just on the most 
extreme individuals may be warranted.  
 Focusing on the 97 BMI associated loci [92] studied here, I show that the percentage of 
phenotypic variance explained by these loci is lower in persistently thin (4.33%) compared 
to obese individuals (10.67%) which is higher than previous estimates for BMI (~2.7% 
variance) using the same loci [92] and for severe obesity  based on a subset of 32 loci  (5.5% 
of the variance) [207]. Even though I partially addressed the possibility of age influencing 
these results by using data from the ASLPAC cohort, one cannot exclude the possibility that 
different effects of age and sex in our discovery cohorts (Table 2.2), and gene-by-
environment interactions, could be influencing some of the results observed.  For example, 
gene-by-environment interactions and age effects have been previously reported at the FTO 
locus [246-249] where a larger effect is detected in younger adults.  
 In studying thin individuals there are often concerns regarding the prevalence of eating 
disorders, notably anorexia nervosa, amongst participants. Prof Farooqi’s group sought to 
carefully exclude eating disorders at two phases of recruitment (by medical history and by 
questionnaire). Additionally, in this work I demonstrate that in our cohort of healthy thin 
individuals, anorexia nervosa is unlikely to be a confounder as the two traits do not exhibit 
significant genetic correlation (r=0.13, 95% CI [-0.02,0.28], p=0.09).   This was not the case 
for the UKBB replication cohort where a positive genetic correlation was observed (r= 0.49 
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95% CI [0.22-0.76] p=0.0003). The positive genetic correlation with anorexia was still 
observed after removing individuals with medical conditions that could explain their low 
BMI (r=0.62, 95% CI [0.30,0.92], p=0.0001). These results highlight the importance of the 
careful phenotyping performed in the recruitment phase and the utility of the STILTS cohort 
as a resource to study healthy and persistent thinness. 
In the genome-wide association analyses amongst the signals I took forward for replication, 
in addition to detecting established BMI-associated loci, I find a novel BMI-association at 
PKHD1 in the UKBB BMI dataset (rs10456655, beta=0.10, p=2.3x10-13, Table 2.9), where a 
proxy for this variant (rs2579994, r2=1 in 1000G Phase 3 CEU) has been previously nominally 
associated with waist and hip circumference (p=5.60x10-5 and p=4.40x10-4 respectively) 
[250].  In addition, I found associations at loci that had only recently been established at the 
time of this study, using very large sample sizes. FAM150B, was only suggestively associated 
at discovery stage in Tachmazidou et al (2017) [251] (N=47,476, p=2.57×10−5) whereas it 
reached genome-wide significance when contrasting SCOOP vs STILTS (N=2,927, 
 p=2.07x10-8, Table 2.6). Also, PRDM6-CEP120 [180] was discovered in a Japanese study with 
a sample size of 173,430 and had not been previously reported in a European population. In 
this study, a signal near the locus (rs112446794, r2=0.36) showed suggestive evidence of 
association in SCOOP vs UKHLS (p=2.08x10-6, Table 2.6) with a significantly smaller sample 
size. Conditional analysis revealed the lead SNP in this study drives the association of the 
previously established signal (Table 2.8).  CEP120 codes for centrosomal protein 120 and 
variants near this locus have been previously associated with height [252] and waist 
circumference in East Asians [253]. Missense variants in the gene itself have been associated 
with rare ciliopathies [254, 255].  Lastly, amongst the signals taken forward for replication 
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from our case-control analyses, and after removing known and newly established loci, an 
enrichment of directionally consistent and nominal associations in the analysis of BMI as a 
continuous trait is observed, suggesting that some of these results may warrant additional 
investigation, in particular in similarly ascertained thin and obese cohorts. One such 
example is rs4447506, near PIK3C3, which was not only nominally significant and consistent 
in the independent UKBB BMI analysis (p=1.5x10-6, Table 2.9), but also in the Locke et al. 
(2015) [92] BMI results (p= 0.01), and in the GIANT BMI tails analysis I used as replication 
(Supplementary Table 5 of Riveros-Mckay et al 2018 [217] (Appendix A)).  Despite not 
reaching genome-wide significance in our discovery cohorts, directionally consistent 
suggestive associations were observed at a number of loci previously associated with BMI 
tails and with different obesity classes [207] (Supplementary Table 10 of Riveros-Mckay et 
al 2018 [217] (Appendix A)).  One important limitation of this study design is that most 
replication cohorts are population derived and not clinically ascertained cohorts like our 
discovery dataset which could be a source for phenotype heterogeneity and subsequently 
reduced power to replicate signals.  
It is also worth noting that these clinically ascertained extremes display evidence of 
incomplete genetic correlation with BMI, in contrast to previously described obesity classes 
(Figure 2.5) which supports the hypothesis that additional loci might be uncovered by 
focusing on these clinical extremes. Altogether, these results highlight some power 
advantages of using clinically ascertained extremes of the phenotype distribution to detect 
associations. However, a consequence of their very specific clinical ascertainment is that the 
conclusions we draw here cannot be straightforwardly extrapolated to the general 
population. 
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In summary, analyses performed in this chapter suggest that further genetic studies focused 
on persistently thin individuals are warranted. The STILTS cohort is an excellent resource in 
which to conduct such additional genetic exploration. Further genetic and phenotypic 
studies focused on persistently thin individuals may provide new insights into the 
mechanisms regulating human energy balance, and may uncover potential anti-obesity drug 
targets. 
2.6 Future directions 
 
Some outstanding questions remain from the work presented in this chapter, which could 
be addressed with some additional analyses.  Namely, the possibility remains that the 
observed ORs in the UKHLS vs STILTS analysis could have been influenced by the significant 
age difference between the two cohorts. An analysis using only a subset of UKHLS samples 
with a similar age distribution to those in STILTS could provide a better estimate to explore 
differences in effect sizes on the tails of the BMI distribution.  
Additionally, it would be of interest to assess the genetic correlation of extreme obesity and 
healthy persistent thinness with additional diseases and traits.  These analyses would be 
feasible using summary statistics for >500 traits from UK Biobank participants recently made 
available (http://www.nealelab.is/uk-biobank/).  
Lastly, for future studies it would be of interest to explore multiple BMI cutoffs for obesity in 
adults from UK Biobank and calculate genetic correlation with SCOOP to find the optimal 
BMI cutoff for future replication studies in adults when pursuing findings originating from 
the SCOOP cohort. 
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3 Chapter 3: The Role of Rare Variation in Circulating Metabolic 
Biomarkers 
3.1 Introduction 
 
Metabolic measurements reflect an individual’s endogenous biochemical processes and 
environmental exposures [256, 257]. Many circulating lipids, lipoproteins and metabolites 
have been previously implicated in the development of cardiovascular disease (CVD) [258-
261] or used as biomarkers for disease diagnosis or prognosis [262, 263].  High circulating 
levels of total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol, for example, 
have been associated with increased risk of coronary heart disease (CHD)[264]. On the other 
hand, circulating levels of high-density lipoprotein (HDL) cholesterol have been regarded as 
protective factors against CHD [265]. Despite the observed association between low HDL 
levels and increased CHD risk, a causal role for HDL levels was more unclear before genetic 
studies, due to potential confounding by other CHD risk factors correlated with low HDL, like 
increased plasma triglycerides (TG) [266].  
In the diagnostic setting, metabolites like creatinine and  branched chain amino acids 
(valine, leucine and isoleucine) are helpful biomarkers for diseases such a kidney disease 
[267] , or hyperinsulinism [268-270]. Understanding the genetic influence on circulating 
levels of these metabolic biomarkers can help us gain insight into the biological processes 
regulating these traits, lead to improve aetiological understanding of CVD and identify novel 
potential therapeutic drug targets. Notable examples of candidate drug targets identified via 
genetic approaches are LDLR [271, 272], APOB [273, 274] and PCSK9 [275, 276]. 
Mipomersen, a commercially available APOB inhibitor, has already shown association with 
reduction in cardiovascular events in patients with hypercholesterolaemia [277] and two 
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PCSK9 inhibitors: alirocumab and evolocumab have been shown to reduce risk of myocardial 
infranction (MI) and stroke in clinical trials [278]. 
Genome-wide association studies (GWAS) focusing on traditionally measured lipid traits 
have greatly expanded our knowledge of lipid biology and to date 250 loci have been 
robustly associated with total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C), and/or triglycerides (TG) [84, 116, 279-285]. 
Through these studies it has been found that most loci identified in European populations 
contribute to the genetic architecture of lipid traits across global populations [116], that 
there are metabolic links between blood lipids and type 2 diabetes, blood pressure, waist-
hip-ratio and BMI [280], and more recently that  some mechanisms of lowering LDL-C 
increase type 2 diabetes  (T2D) risk [84].   Mendelian randomisation (MR) approaches have 
also used information gained through GWAS to examine the causal link between low HDL 
levels and CVD where findings suggest that low HDL levels are not causal for CVD since many 
studies report no association between CVD and genetically lowered levels of HDL [110-114].  
These MR approaches have also been used to identify a potential causal link between 
increased plasma urate levels and CVD [286], although other studies measuring serum urate 
levels have not found that link [287]. 
In addition to this, more detailed metabolic profiling using high resolution nuclear magnetic 
resonance (NMR) measurements, has proven helpful to find additional lipid and small 
molecule metabolism-associated loci with smaller sample sizes, and to assess pleiotropic 
effects of previously established loci [38, 173, 288]. An example of this, is a novel link 
between the LPA locus and very-low-density lipoprotein (VLDL) metabolism (measured by 
using high resolution NMR), with effect sizes twice as large as those found for traditionally 
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measured lipid traits like LDL-C and TC, suggesting these measurements are better at 
capturing the underlying biological processes in lipid metabolism than traditionally 
measured lipid traits. In this same study,  by constructing a genetic risk score using variants 
associated with Lp(a) levels and using a Mendelian randomisation approach the authors 
were able to demonstrate a causal link between increased Lp(a) levels and overall 
lipoprotein metabolism [173]. 
Despite the increased usage of exome arrays which have been used at scale to capture low-
frequency and rare coding variation contributing to lipid and amino acid metabolism [84, 
282-284, 288, 289], large-scale sequencing studies have the added value of assessing rare 
variation at single nucleotide resolution across the whole genome, or exome, including the 
detection of private variants which could have large effects on protein function.  These 
approaches enabled, for example, the discovery of inactivating variants in key proteins 
which are models for drug target antagonism such as ANGPTL4, where carriers of a 
missense E40K variant and other inactivating variants had reduced risk of CHD [290, 291]. 
Notwithstanding the progress made in recent years in understanding the genetic aetiology 
of a number of traditional lipid traits, at the time of this analysis, there were no studies 
coupling NMR measurements with sequencing data to explore the role of rare genetic 
variants in the metabolism of high resolution lipid, lipoprotein and metabolite traits.  In this 
chapter, I address this gap in knowledge by examining the contribution of rare variation 
(MAF <1%) to 226 serum metabolic measurements in the INTERVAL cohort which consist of 
healthy blood donors residing in the UK. This project was done in collaboration with Dr 
Adam Butterworth’s group at the University of Cambridge. My work involved QCing of 
sequencing and phenotype data as well as all analytical aspects of the study.  
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3.2 Chapter aims 
 
The overall aim of this chapter is to explore how coupling next generation sequencing (NGS) 
and high resolution metabolic measurements can help us gain new insights into metabolic 
biomarker biology through rare variant analyses. To do this, I took advantage of the 
INTERVAL cohort, which is comprised of healthy blood donors who have been deeply 
phenotyped and who also have genome-wide array data. In my project I used data from a 
subset of 7,142 participants with NMR measurements and NGS data to: 
I. Identify novel loci, genes and/or gene sets associated with metabolic biomarkers. 
II. Identify effector transcripts at established GWAS loci for traditionally measured lipid 
traits.  
III. Assess the contribution of genes known to be involved in lipoprotein metabolism to 
the tails of the phenotype distribution of lipoprotein and glyceride traits in a healthy 
population.  
 
3.3 Methods 
3.3.1 Participants  
 
The INTERVAL cohort consists of 47,393  predominantly healthy blood donors in the UK 
[292]. This study was the result of a collaboration between the Universities of Cambridge 
and Oxford and the NHS Blood and Transplant Unit. The study was set up to determine the 
optimum intervals between donations for men and women without affecting the overall 
health of blood donors. Individuals were asked to fill an online general questionnaire every 
six months containing basic lifestyle and health-related information. At the time of this 
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study, a different set of biomarker assays were performed on blood samples collected on 
the first visit and those collected on the 2 year follow-up visit. All individuals have been 
genotyped using the Affymetrix UK Biobank Axiom Array and imputed using a combined 
UK10K-1000G Phase III imputation panel [293]. A subset of 4,502 individuals was selected 
for whole-exome sequencing (WES) [294] and another subset of 3,762 was selected for 
whole-genome sequencing (WGS). There was an overlap of 54 individuals in both datasets.  
 
3.3.2 Sequencing and genotype calling  
 
WES and WGS were performed at the Wellcome Sanger Institute (WSI) sequencing facility, 
with read alignment and genotype calling performed by the Human Genetics Informatics 
(HGI) group at Sanger. For WES sheared DNA was prepared for Illumina paired-end 
sequencing and enriched for target regions using Agilent’s SureSelect Human All Exon V5 
capture technology (Agilent Technologies; Santa Clara, California, USA). The exome capture 
library preparation was sequenced using the Illumina HiSeq 2000 platform as paired-end 75 
bp reads. Reads were aligned to the GRCh37 human reference genome using BWA (v0.5.10) 
[295]. GATK HaplotypeCaller v3.4 [296] was used for variant calling and recalibration. For 
WGS sheared DNA was prepared for Illumina paired-end sequencing. Sequencing was 
performed using the Illumina HiSeq X platform as paired-end 75 bp reads. Reads were 
aligned to the GRCh38 human reference genome using mostly BWA (v.0.7.12) although a 
subset of samples was aligned with v.0.7.13 or v.0.7.15. GATK HaplotypeCaller v3.5 was 
used for variant calling and recalibration. I extracted coordinates from the VCF files that 
mapped to regions targeted in the WES. I then used custom scripts to transform coordinates 
of variants to GRCh37 human reference.  
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3.3.3 Sample QC  
 
I performed sample QC for WES using the same filters Tarjinder Singh used on a previous 
release of the INTERVAL WES dataset [294]. Sample QC for WGS was performed by Kousik 
Kundu, Klaudia Walter and I. For WES data I filtered out samples based on the following 
criteria: i) withdrawn consent; ii) estimated contamination >3% according to the software 
VerifyBamID [297]; iii) sex inferred from genetic data different from sex supplied ; iv) non-
European samples after manual inspection of clustering in 1000G principal components 
analysis (PCA) and choosing cutoffs on the first 2 PCs; v) heterozygosity outliers (samples +/- 
3 SD away from the mean number of heterozygous counts); vi) non-reference homozygosity 
outliers (samples +/- 3 SD away from the mean number of non-reference homozygous 
counts); vii) outlier Ti/TV rates (transition to transversion ratio +/- 3 SD away from the mean 
ratio); viii) excess singletons (number of singleton variants >3 SD from the cohort mean). 
After quality control 4,070 WES samples were kept for downstream analyses. For WGS data 
we filtered out samples based on the following criteria: i) estimated contamination >2% 
according to software VerifyBamID; ii) non-reference discordance (NRD) with genotype data 
on the same samples >4%; iii) European population outliers from PCA (PC1>0 and minimum 
PC2); iv) heterozygosity outliers (samples +/- 3 SD away from the mean number of 
heterozygous counts); v) number of third-degree relatives (proportion IBD (PI_HAT) >0.125) 
> 18, vi) overlap with WES. After quality control 3,670 WGS samples were kept for further 
analyses. 
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3.3.4 Variant QC  
 
For variants with MAF>1% I used the following thresholds to exclude variants: i) VQSR: 
99.90% tranche for WES and 99% tranche for WGS; ii) missingness >3%; iii) HWE p<1x10-5. 
For variants with MAF≤1% the following thresholds were used: i) VQSR: 99.90% tranche for 
WES, 99% tranche for WGS SNPs and 90% tranche for WGS indels; ii) GQ: <20 for SNPs and 
<60 for indels; iii) DP <2; iv) AB>15 & <80 for heterozygous variants. After genotype-level QC 
(GQ,DP,AB) only variants with <3% missingness were kept. 1,716,946 variants were kept in 
the final WES release and 1,724,250 in the final WGS release. 
 
3.3.5 Phenotype QC 
 
A total of 230 metabolic biomarkers were produced by the serum NMR metabolomics 
platform (Nightingale Health Ltd.) [298] on 46,097 blood samples from the INTERVAL cohort 
collected on the first visit. Phenotyping was performed by Antti J. Kangas (Nightingale 
Health Ltd.). I performed phenotype QC on the raw phenotypes. Glucose, lactose, pyruvate 
and acetate were excluded initially due to unreliable measurements according to platform 
provider. Conjugated linoleic acid and conjugated linoleic acid to total fatty acid ratio were 
set to missing for 3,585 samples showing signs of peroxidation. Creatinine levels were set to 
missing for 1,993 samples with isopropyl alcohol signals. Glutamine levels were set to 
missing for 347 samples that showed signs of glutamine to glutamate degradation. Samples 
with more than 30% missingness or identified as EDTA plasma were removed.  After this 
step, for each pair of related samples (PI_HAT>0.125) I kept only one, preferentially keeping 
samples with the lowest missingness in WES or lowest NRD in WGS. Phenotypes were rank-
based inverse normalised for all individuals. Clare Oliver-Williams assessed which technical 
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covariates influenced phenotype levels and determined centre, processing duration and 
month of donation were possible sources of batch effects.  I then separately performed 
linear regression for WES and WGS adjusting for age, gender, centre, processing duration, 
month of donation and 10 PCs.  Residuals from both WES and WGS linear regressions were 
used as the outcome variables in all subsequent analyses. After this final step I kept 3,741 
samples in the WES dataset and 3,420 samples in the WGS dataset for downstream 
analyses.  
3.3.6 Single point analyses 
 
Power calculations to define MAF threshold for single point analyses were done using 
Quanto [234]. I used the WES data as a discovery dataset and performed association 
analyses using SNPTEST v2.5.2 [226] under an additive model. Variants were taken forward 
for validation if p < 1x10-5. I then performed association analyses using SNPTEST on the WGS 
data which was used as a validation dataset. Results were subsequently meta-analysed 
using a fixed-effects model in METAL [238]. Genome-wide significance threshold was 
calculated as: 0.05/ (276,563*19)=9.52x10-9, where 276,563 is the number of tested variants 
with MAF>0.1%  and 19 is the number of PCs explaining >95% of the variance of 226 
metabolic biomarkers , an approach previously used in similar studies using the same NMR 
platform [38, 173]. A signal was considered to replicate if after meta-analysis it met the 
following criteria: i) it met the defined genome-wide significance threshold (9.52x10-9); and 
ii) it was nominally significant (p<0.05) in the validation dataset (WGS). After this step, to 
define loci, I performed clumping using PLINK [223] based on the lowest p for each variant 
on any trait-association using an r2 =0.2 and a window size of 1Mb.  
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3.3.7 Gene-based analyses  
 
I annotated coding variant consequences with VEP [50] using Ensembl gene set version 75 
for the hg19/GRCh37 human genome assembly. Loss-of–function (LoF) variants were 
annotated with a VEP plugin: LOFTEE (https://github.com/konradjk/loftee). This plugin uses 
distance to end of transcript and other in-frame splice sites, non-canonical splice site 
information and size of introns to remove LoF that are less likely to have a damaging impact 
on protein structure. I downloaded M-CAP scores and extracted all missense variants with 
AC>=1 in the WES or WGS datasets [51].  Two different nested tests were used to group rare 
variants into testable gene units: predicted to be high confidence LoF by LOFTEE in any 
transcript of the gene, and the same LoF variants plus rare (MAF <1%) missense variants, 
mapping to any transcript of the gene, predicted to be likely deleterious by M-CAP (M-CAP 
score >0.025) (MCAP+LoF).  M-CAP uses a machine learning algorithm integrating multiple 
annotations (e.g base-pair conservation, amino acid conservation, chemical properties of 
substituted amino acid, etc) to predict the pathogenicity of rare (MAF <1%) missense 
variants. 
I performed rare-variant aggregation tests as implemented in the SKAT-O R package [52, 
53]. For the LoF tests, I performed a burden test (rho=1) whereas for the MCAP+LoF tests I 
used the optimal unified approach (method=”optimal.adj”).  Genes were taken forward for 
validation if p<5x10-3. 
To increase power in my analyses I also implemented a strategy to incorporate information 
from the multiple phenotypes measured in our dataset, by adjusting for correlated 
phenotypes, which has been shown to increase power in single point association analyses 
[30].  To minimise chances of a false positive association I only adjusted for phenotypes as 
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covariates at the validation stage ensuring evidence of association in discovery stage was 
present without adjustment for covariates. In order for a metabolic biomarker to be 
selected as a covariate in the validation stage, the following conditions had to be met: i) no 
evidence of genetic correlation (p>0.05) with outcome using publicly available summary 
statistics from Kettunen et al. (2016) [25]; ii) phenotypic correlation in our dataset >10%; iii) 
not belonging to same metabolic biomarker supergroup as outcome (Table 3.1). This 
approach resulted in 99 eligible NMR traits for which other traits could be used as 
covariates. METASKAT [54] was used to perform meta-analysis using the same parameters 
as in discovery.  A signal was considered to replicate if: i) it met the Bonferroni corrected 
gene-level significance threshold (p < 1.32x10-7); ii) >2 variants were tested; iii) it was 
nominally significant in the unadjusted test for WGS (i.e without adjusting for correlated 
traits).  The Bonferroni corrected gene-level significance threshold was chosen after 
adjusting the standard gene-level significance threshold (2.5x10-6) for 19 PCs. To test if a 
single variant was driving an observed association, I performed leave-one-out analysis for all 
variants contributing to the test. An association was considered to be driven by a single 
variant if, after removing it, the test resulted in a non-significant association (p>0.05). 
Traits   Description Supergroup Single 
point 
tests 
Gene 
tests 
Gene-set 
tests 
Enrichment 
near GWAS 
signals tests 
Tails 
tests 
XXL-VLDL-P Concentration of chylomicrons and 
extremely large VLDL particles 
Lipid and 
lipoprotein 
X X X  X 
XXL-VLDL-L Total lipids in chylomicrons and extremely 
large VLDL 
Lipid and 
lipoprotein 
X X X  X 
XXL-VLDL-PL Phospholipids in chylomicrons and 
extremely large VLDL 
Lipid and 
lipoprotein 
X X X  X 
XXL-VLDL-C Total cholesterol in chylomicrons and 
extremely large VLDL 
Lipid and 
lipoprotein 
X X X X X 
XXL-VLDL-CE Cholesterol esters in chylomicrons and 
extremely large VLDL 
Lipid and 
lipoprotein 
X X X X X 
XXL-VLDL-FC Free cholesterol in chylomicrons and 
extremely large VLDL 
Lipid and 
lipoprotein 
X X X X X 
XXL-VLDL-TG Triglycerides in chylomicrons and 
extremely large VLDL 
Lipid and 
lipoprotein 
X X X X X 
XL-VLDL-P Concentration of very large VLDL particles Lipid and 
lipoprotein 
X X X  X 
XL-VLDL-L Total lipids in very large VLDL Lipid and 
lipoprotein 
X X X  X 
XL-VLDL-PL Phospholipids in very large VLDL Lipid and 
lipoprotein 
X X X  X 
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Traits   Description Supergroup Single 
point 
tests 
Gene 
tests 
Gene-set 
tests 
Enrichment 
near GWAS 
signals tests 
Tails 
tests 
XL-VLDL-C Total cholesterol in very large VLDL Lipid and 
lipoprotein 
X X X X X 
XL-VLDL-CE Cholesterol esters in very large VLDL Lipid and 
lipoprotein 
X X X X X 
XL-VLDL-FC Free cholesterol in very large VLDL Lipid and 
lipoprotein 
X X X X X 
XL-VLDL-TG Triglycerides in very large VLDL Lipid and 
lipoprotein 
X X X X X 
L-VLDL-P Concentration of large VLDL particles Lipid and 
lipoprotein 
X X X  X 
L-VLDL-L Total lipids in large VLDL Lipid and 
lipoprotein 
X X X  X 
L-VLDL-PL Phospholipids in large VLDL Lipid and 
lipoprotein 
X X X  X 
L-VLDL-C Total cholesterol in large VLDL Lipid and 
lipoprotein 
X X X X X 
L-VLDL-CE Cholesterol esters in large VLDL Lipid and 
lipoprotein 
X X X X X 
L-VLDL-FC Free cholesterol in large VLDL Lipid and 
lipoprotein 
X X X X X 
L-VLDL-TG Triglycerides in large VLDL Lipid and 
lipoprotein 
X X X X X 
M-VLDL-P Concentration of medium VLDL particles Lipid and 
lipoprotein 
X X X  X 
M-VLDL-L Total lipids in medium VLDL Lipid and 
lipoprotein 
X X X  X 
M-VLDL-PL Phospholipids in medium VLDL Lipid and 
lipoprotein 
X X X  X 
M-VLDL-C Total cholesterol in medium VLDL Lipid and 
lipoprotein 
X X X X X 
M-VLDL-CE Cholesterol esters in medium VLDL Lipid and 
lipoprotein 
X X X X X 
M-VLDL-FC Free cholesterol in medium VLDL Lipid and 
lipoprotein 
X X X X X 
M-VLDL-TG Triglycerides in medium VLDL Lipid and 
lipoprotein 
X X X X X 
S-VLDL-P Concentration of small VLDL particles Lipid and 
lipoprotein 
X X X  X 
S-VLDL-L Total lipids in small VLDL Lipid and 
lipoprotein 
X X X  X 
S-VLDL-PL Phospholipids in small VLDL Lipid and 
lipoprotein 
X X X  X 
S-VLDL-C Total cholesterol in small VLDL Lipid and 
lipoprotein 
X X X X X 
S-VLDL-CE Cholesterol esters in small VLDL Lipid and 
lipoprotein 
X X X X X 
S-VLDL-FC Free cholesterol in small VLDL Lipid and 
lipoprotein 
X X X X X 
S-VLDL-TG Triglycerides in small VLDL Lipid and 
lipoprotein 
X X X X X 
XS-VLDL-P Concentration of very small VLDL particles Lipid and 
lipoprotein 
X X X  X 
XS-VLDL-L Total lipids in very small VLDL Lipid and 
lipoprotein 
X X X  X 
XS-VLDL-PL Phospholipids in very small VLDL Lipid and 
lipoprotein 
X X X  X 
XS-VLDL-C Total cholesterol in very small VLDL Lipid and 
lipoprotein 
X X X X X 
XS-VLDL-CE Cholesterol esters in very small VLDL Lipid and 
lipoprotein 
X X X X X 
XS-VLDL-FC Free cholesterol in very small VLDL Lipid and 
lipoprotein 
X X X X X 
XS-VLDL-TG Triglycerides in very small VLDL Lipid and 
lipoprotein 
X X X X X 
IDL-P Concentration of IDL particles Lipid and 
lipoprotein 
X X X   
IDL-L Total lipids in IDL Lipid and 
lipoprotein 
X X X   
IDL-PL Phospholipids in IDL Lipid and 
lipoprotein 
X X X   
IDL-C Total cholesterol in IDL Lipid and 
lipoprotein 
X X X X  
IDL-CE Cholesterol esters in IDL Lipid and X X X X  
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Traits   Description Supergroup Single 
point 
tests 
Gene 
tests 
Gene-set 
tests 
Enrichment 
near GWAS 
signals tests 
Tails 
tests 
lipoprotein 
IDL-FC Free cholesterol in IDL Lipid and 
lipoprotein 
X X X X  
IDL-TG Triglycerides in IDL Lipid and 
lipoprotein 
X X X X  
L-LDL-P Concentration of large LDL particles Lipid and 
lipoprotein 
X X X X X 
L-LDL-L Total lipids in large LDL Lipid and 
lipoprotein 
X X X X X 
L-LDL-PL Phospholipids in large LDL Lipid and 
lipoprotein 
X X X X X 
L-LDL-C Total cholesterol in large LDL Lipid and 
lipoprotein 
X X X X X 
L-LDL-CE Cholesterol esters in large LDL Lipid and 
lipoprotein 
X X X X X 
L-LDL-FC Free cholesterol in large LDL Lipid and 
lipoprotein 
X X X X X 
L-LDL-TG Triglycerides in large LDL Lipid and 
lipoprotein 
X X X X X 
M-LDL-P Concentration of medium LDL particles Lipid and 
lipoprotein 
X X X X X 
M-LDL-L Total lipids in medium LDL Lipid and 
lipoprotein 
X X X X X 
M-LDL-PL Phospholipids in medium LDL Lipid and 
lipoprotein 
X X X X X 
M-LDL-C Total cholesterol in medium LDL Lipid and 
lipoprotein 
X X X X X 
M-LDL-CE Cholesterol esters in medium LDL Lipid and 
lipoprotein 
X X X X X 
M-LDL-FC Free cholesterol in medium LDL Lipid and 
lipoprotein 
X X X X X 
M-LDL-TG Triglycerides in medium LDL Lipid and 
lipoprotein 
X X X X X 
S-LDL-P Concentration of small LDL particles Lipid and 
lipoprotein 
X X X X X 
S-LDL-L Total lipids in small LDL Lipid and 
lipoprotein 
X X X X X 
S-LDL-PL Phospholipids in small LDL Lipid and 
lipoprotein 
X X X X X 
S-LDL-C Total cholesterol in small LDL Lipid and 
lipoprotein 
X X X X X 
S-LDL-CE Cholesterol esters in small LDL Lipid and 
lipoprotein 
X X X X X 
S-LDL-FC Free cholesterol in small LDL Lipid and 
lipoprotein 
X X X X X 
S-LDL-TG Triglycerides in small LDL Lipid and 
lipoprotein 
X X X X X 
XL-HDL-P Concentration of very large HDL particles Lipid and 
lipoprotein 
X X X X X 
XL-HDL-L Total lipids in very large HDL Lipid and 
lipoprotein 
X X X X X 
XL-HDL-PL Phospholipids in very large HDL Lipid and 
lipoprotein 
X X X X X 
XL-HDL-C Total cholesterol in very large HDL Lipid and 
lipoprotein 
X X X X X 
XL-HDL-CE Cholesterol esters in very large HDL Lipid and 
lipoprotein 
X X X X X 
XL-HDL-FC Free cholesterol in very large HDL Lipid and 
lipoprotein 
X X X X X 
XL-HDL-TG Triglycerides in very large HDL Lipid and 
lipoprotein 
X X X X X 
L-HDL-P Concentration of large HDL particles Lipid and 
lipoprotein 
X X X X X 
L-HDL-L Total lipids in large HDL Lipid and 
lipoprotein 
X X X X X 
L-HDL-PL Phospholipids in large HDL Lipid and 
lipoprotein 
X X X X X 
L-HDL-C Total cholesterol in large HDL Lipid and 
lipoprotein 
X X X X X 
L-HDL-CE Cholesterol esters in large HDL Lipid and 
lipoprotein 
X X X X X 
L-HDL-FC Free cholesterol in large HDL Lipid and 
lipoprotein 
X X X X X 
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Traits   Description Supergroup Single 
point 
tests 
Gene 
tests 
Gene-set 
tests 
Enrichment 
near GWAS 
signals tests 
Tails 
tests 
L-HDL-TG Triglycerides in large HDL Lipid and 
lipoprotein 
X X X X X 
M-HDL-P Concentration of medium HDL particles Lipid and 
lipoprotein 
X X X X X 
M-HDL-L Total lipids in medium HDL Lipid and 
lipoprotein 
X X X X X 
M-HDL-PL Phospholipids in medium HDL Lipid and 
lipoprotein 
X X X X X 
M-HDL-C Total cholesterol in medium HDL Lipid and 
lipoprotein 
X X X X X 
M-HDL-CE Cholesterol esters in medium HDL Lipid and 
lipoprotein 
X X X X X 
M-HDL-FC Free cholesterol in medium HDL Lipid and 
lipoprotein 
X X X X X 
M-HDL-TG Triglycerides in medium HDL Lipid and 
lipoprotein 
X X X X X 
S-HDL-P Concentration of small HDL particles Lipid and 
lipoprotein 
X X X X X 
S-HDL-L Total lipids in small HDL Lipid and 
lipoprotein 
X X X X X 
S-HDL-PL Phospholipids in small HDL Lipid and 
lipoprotein 
X X X X X 
S-HDL-C Total cholesterol in small HDL Lipid and 
lipoprotein 
X X X X X 
S-HDL-CE Cholesterol esters in small HDL Lipid and 
lipoprotein 
X X X X X 
S-HDL-FC Free cholesterol in small HDL Lipid and 
lipoprotein 
X X X X X 
S-HDL-TG Triglycerides in small HDL Lipid and 
lipoprotein 
X X X X X 
XXL-VLDL-PL_% Phospholipids to total lipds ratio in 
chylomicrons and extremely large VLDL 
Lipid and 
lipoprotein 
X X X   
XXL-VLDL-C_% Total cholesterol to total lipids ratio in 
chylomicrons and extremely large VLDL 
Lipid and 
lipoprotein 
X X X X  
XXL-VLDL-CE_% Cholesterol esters to total lipids ratio in 
chylomicrons and extremely large VLDL 
Lipid and 
lipoprotein 
X X X X  
XXL-VLDL-FC_% Free cholesterol to total lipids ratio in 
chylomicrons and extremely large VLDL 
Lipid and 
lipoprotein 
X X X X  
XXL-VLDL-TG_% Triglycerides to total lipids ratio in 
chylomicrons and extremely large VLDL 
Lipid and 
lipoprotein 
X X X X  
XL-VLDL-PL_% Phospholipids to total lipds ratio in very 
large VLDL 
Lipid and 
lipoprotein 
X X X   
XL-VLDL-C_% Total cholesterol to total lipids ratio in very 
large VLDL 
Lipid and 
lipoprotein 
X X X X  
XL-VLDL-CE_% Cholesterol esters to total lipids ratio in 
very large VLDL 
Lipid and 
lipoprotein 
X X X X  
XL-VLDL-FC_% Free cholesterol to total lipids ratio in very 
large VLDL 
Lipid and 
lipoprotein 
X X X X  
XL-VLDL-TG_% Triglycerides to total lipids ratio in very 
large VLDL 
Lipid and 
lipoprotein 
X X X X  
L-VLDL-PL_% Phospholipids to total lipds ratio in large 
VLDL 
Lipid and 
lipoprotein 
X X X   
L-VLDL-C_% Total cholesterol to total lipids ratio in 
large VLDL 
Lipid and 
lipoprotein 
X X X X  
L-VLDL-CE_% Cholesterol esters to total lipids ratio in 
large VLDL 
Lipid and 
lipoprotein 
X X X X  
L-VLDL-FC_% Free cholesterol to total lipids ratio in large 
VLDL 
Lipid and 
lipoprotein 
X X X X  
L-VLDL-TG_% Triglycerides to total lipids ratio in large 
VLDL 
Lipid and 
lipoprotein 
X X X X  
M-VLDL-PL_% Phospholipids to total lipds ratio in 
medium VLDL 
Lipid and 
lipoprotein 
X X X   
M-VLDL-C_% Total cholesterol to total lipids ratio in 
medium VLDL 
Lipid and 
lipoprotein 
X X X X  
M-VLDL-CE_% Cholesterol esters to total lipids ratio in 
medium VLDL 
Lipid and 
lipoprotein 
X X X X  
M-VLDL-FC_% Free cholesterol to total lipids ratio in 
medium VLDL 
Lipid and 
lipoprotein 
X X X X  
M-VLDL-TG_% Triglycerides to total lipids ratio in medium 
VLDL 
Lipid and 
lipoprotein 
X X X X  
S-VLDL-PL_% Phospholipids to total lipds ratio in small 
VLDL 
Lipid and 
lipoprotein 
X X X   
S-VLDL-C_% Total cholesterol to total lipids ratio in Lipid and X X X X  
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Traits   Description Supergroup Single 
point 
tests 
Gene 
tests 
Gene-set 
tests 
Enrichment 
near GWAS 
signals tests 
Tails 
tests 
small VLDL lipoprotein 
S-VLDL-CE_% Cholesterol esters to total lipids ratio in 
small VLDL 
Lipid and 
lipoprotein 
X X X X  
S-VLDL-FC_% Free cholesterol to total lipids ratio in 
small VLDL 
Lipid and 
lipoprotein 
X X X X  
S-VLDL-TG_% Triglycerides to total lipids ratio in small 
VLDL 
Lipid and 
lipoprotein 
X X X X  
XS-VLDL-PL_% Phospholipids to total lipds ratio in very 
small VLDL 
Lipid and 
lipoprotein 
X X X   
XS-VLDL-C_% Total cholesterol to total lipids ratio in very 
small VLDL 
Lipid and 
lipoprotein 
X X X X  
XS-VLDL-CE_% Cholesterol esters to total lipids ratio in 
very small VLDL 
Lipid and 
lipoprotein 
X X X X  
XS-VLDL-FC_% Free cholesterol to total lipids ratio in very 
small VLDL 
Lipid and 
lipoprotein 
X X X X  
XS-VLDL-TG_% Triglycerides to total lipids ratio very small 
VLDL 
Lipid and 
lipoprotein 
X X X X  
IDL-PL_% Phospholipids to total lipds ratio in IDL Lipid and 
lipoprotein 
X X X   
IDL-C_% Total cholesterol to total lipids ratio in IDL Lipid and 
lipoprotein 
X X X X  
IDL-CE_% Cholesterol esters to total lipids ratio in 
IDL 
Lipid and 
lipoprotein 
X X X X  
IDL-FC_% Free cholesterol to total lipids ratio in IDL Lipid and 
lipoprotein 
X X X X  
IDL-TG_% Triglycerides to total lipids ratio in IDL Lipid and 
lipoprotein 
X X X X  
L-LDL-PL_% Phospholipids to total lipds ratio in large 
LDL 
Lipid and 
lipoprotein 
X X X X  
L-LDL-C_% Total cholesterol to total lipids ratio in 
large LDL 
Lipid and 
lipoprotein 
X X X X  
L-LDL-CE_% Cholesterol esters to total lipids ratio in 
large LDL 
Lipid and 
lipoprotein 
X X X X  
L-LDL-FC_% Free cholesterol to total lipids ratio in large 
LDL 
Lipid and 
lipoprotein 
X X X X  
L-LDL-TG_% Triglycerides to total lipids ratio in large 
LDL 
Lipid and 
lipoprotein 
X X X X  
M-LDL-PL_% Phospholipids to total lipds ratio in 
medium LDL 
Lipid and 
lipoprotein 
X X X X  
M-LDL-C_% Total cholesterol to total lipids ratio in 
medium LDL 
Lipid and 
lipoprotein 
X X X X  
M-LDL-CE_% Cholesterol esters to total lipids ratio in 
medium LDL 
Lipid and 
lipoprotein 
X X X X  
M-LDL-FC_% Free cholesterol to total lipids ratio in 
medium LDL 
Lipid and 
lipoprotein 
X X X X  
M-LDL-TG_% Triglycerides to total lipids ratio in medium 
LDL 
Lipid and 
lipoprotein 
X X X X  
S-LDL-PL_% Phospholipids to total lipds ratio in small 
LDL 
Lipid and 
lipoprotein 
X X X X  
S-LDL-C_% Total cholesterol to total lipids ratio in 
small LDL 
Lipid and 
lipoprotein 
X X X X  
S-LDL-CE_% Cholesterol esters to total lipids ratio in 
small LDL 
Lipid and 
lipoprotein 
X X X X  
S-LDL-FC_% Free cholesterol to total lipids ratio in 
small LDL 
Lipid and 
lipoprotein 
X X X X  
S-LDL-TG_% Triglycerides to total lipids ratio in small 
LDL 
Lipid and 
lipoprotein 
X X X X  
XL-HDL-PL_% Phospholipids to total lipds ratio in  very 
large HDL 
Lipid and 
lipoprotein 
X X X X  
XL-HDL-C_% Total cholesterol to total lipids ratio in very 
large HDL 
Lipid and 
lipoprotein 
X X X X  
XL-HDL-CE_% Cholesterol esters to total lipids ratio in 
very large HDL 
Lipid and 
lipoprotein 
X X X X  
XL-HDL-FC_% Free cholesterol to total lipids ratio in  very 
large HDL 
Lipid and 
lipoprotein 
X X X X  
XL-HDL-TG_% Triglycerides to total lipids ratio in very 
large HDL 
Lipid and 
lipoprotein 
X X X X  
L-HDL-PL_% Phospholipids to total lipds ratio in large 
HDL 
Lipid and 
lipoprotein 
X X X X  
L-HDL-C_% Total cholesterol to total lipids ratio in 
large HDL 
Lipid and 
lipoprotein 
X X X X  
L-HDL-CE_% Cholesterol esters to total lipids ratio in 
large HDL 
Lipid and 
lipoprotein 
X X X X  
87 
 
Traits   Description Supergroup Single 
point 
tests 
Gene 
tests 
Gene-set 
tests 
Enrichment 
near GWAS 
signals tests 
Tails 
tests 
L-HDL-FC_% Free cholesterol to total lipids ratio in large 
HDL 
Lipid and 
lipoprotein 
X X X X  
L-HDL-TG_% Triglycerides to total lipids ratio in large 
HDL 
Lipid and 
lipoprotein 
X X X X  
M-HDL-PL_% Phospholipids to total lipds ratio in 
medium HDL 
Lipid and 
lipoprotein 
X X X X  
M-HDL-C_% Total cholesterol to total lipids ratio in 
medium HDL 
Lipid and 
lipoprotein 
X X X X  
M-HDL-CE_% Cholesterol esters to total lipids ratio in 
medium HDL 
Lipid and 
lipoprotein 
X X X X  
M-HDL-FC_% Free cholesterol to total lipids ratio in 
medium HDL 
Lipid and 
lipoprotein 
X X X X  
M-HDL-TG_% Triglycerides to total lipids ratio in medium 
HDL 
Lipid and 
lipoprotein 
X X X X  
S-HDL-PL_% Phospholipids to total lipds ratio in small 
HDL 
Lipid and 
lipoprotein 
X X X X  
S-HDL-C_% Total cholesterol to total lipids ratio in 
small HDL 
Lipid and 
lipoprotein 
X X X X  
S-HDL-CE_% Cholesterol esters to total lipids ratio in 
small HDL 
Lipid and 
lipoprotein 
X X X X  
S-HDL-FC_% Free cholesterol to total lipids ratio in 
small HDL 
Lipid and 
lipoprotein 
X X X X  
S-HDL-TG_% Triglycerides to total lipids ratio in small 
HDL 
Lipid and 
lipoprotein 
X X X X  
VLDL-D Mean diameter for VLDL particles Lipid and 
lipoprotein 
X X X   
LDL-D Mean diameter for LDL particles Lipid and 
lipoprotein 
X X X X X 
HDL-D Mean diameter for HDL particles Lipid and 
lipoprotein 
X X X X X 
Serum-C Serum total cholesterol Lipid and 
lipoprotein 
X X X X X 
VLDL-C Total cholesterol in VLDL Lipid and 
lipoprotein 
X X X X X 
Remnant-C Remnant cholesterol (non‐HDL, non‐LDL-
cholesterol) 
Lipid and 
lipoprotein 
X X X X X 
LDL-C Total cholesterol in LDL Lipid and 
lipoprotein 
X X X X X 
HDL-C Total cholesterol in HDL Lipid and 
lipoprotein 
X X X X X 
HDL2-C Total cholesterol in HDL2 Lipid and 
lipoprotein 
X X X X X 
HDL3-C Total cholesterol in HDL3 Lipid and 
lipoprotein 
X X X X X 
EstC Esterified cholesterol Lipid and 
lipoprotein 
X X X X X 
FreeC Free cholesterol Lipid and 
lipoprotein 
X X X X X 
Serum-TG Serum total triglycerides Lipid and 
lipoprotein 
X X X X X 
VLDL-TG Triglycerides in VLDL Lipid and 
lipoprotein 
X X X X X 
LDL‐TG Triglycerides in LDL Lipid and 
lipoprotein 
X X X X X 
HDL‐TG Triglycerides in HDL Lipid and 
lipoprotein 
X X X X X 
DAG Diacylglycerol Lipid and 
lipoprotein 
X X X   
DAG/TG Ratio of diacylglycerol to triglycerides Lipid and 
lipoprotein 
X X X X  
TotPG Total phosphoglycerides Lipid and 
lipoprotein 
X X X   
TG/PG Ratio of triglycerides to phosphoglycerides Lipid and 
lipoprotein 
X X X X  
PC Phosphatidylcholine and other cholines Lipid and 
lipoprotein 
X X X   
SM Sphingomyelins Lipid and 
lipoprotein 
X X X   
TotCho Total cholines Lipid and 
lipoprotein 
X X X   
ApoA1 Apolipoprotein A-‐I * Lipid and 
lipoprotein 
X X X   
ApoB Apolipoprotein B * Lipid and X X X   
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Traits   Description Supergroup Single 
point 
tests 
Gene 
tests 
Gene-set 
tests 
Enrichment 
near GWAS 
signals tests 
Tails 
tests 
lipoprotein 
ApoB/ApoA1 Ratio of apolipoprotein B to 
apolipoprotein A-‐I 
Lipid and 
lipoprotein 
X X X   
TotFA Total fatty acids Lipid and 
lipoprotein 
X X X   
FALen Estimated description of fatty acid chain 
length, not actual carbon number 
Lipid and 
lipoprotein 
X X X   
UnsatDeg Estimated degree of unsaturation Lipid and 
lipoprotein 
X X X   
DHA 22:6, docosahexaenoic acid Lipid and 
lipoprotein 
X X X   
LA 18:2, linoleic acid Lipid and 
lipoprotein 
X X X   
CLA Conjugated linoleic acid Lipid and 
lipoprotein 
X X X   
FAw3 Omega-‐3 fatty acids Lipid and 
lipoprotein 
X X X   
FAw6 Omega-‐6 fatty acids Lipid and 
lipoprotein 
X X X   
PUFA Polyunsaturated fatty acids Lipid and 
lipoprotein 
X X X   
MUFA Monounsaturated fatty acids; 16:1, 18:1 Lipid and 
lipoprotein 
X X X   
SFA Saturated fatty acids Lipid and 
lipoprotein 
X X X   
DHA/FA Ratio of 22:6 docosahexaenoic acid to total 
fatty acids 
Lipid and 
lipoprotein 
X X X   
LA/FA Ratio of 18:2 linoleic acid to total fatty 
acids 
Lipid and 
lipoprotein 
X X X   
CLA/FA Ratio of conjugated linoleic acid to total 
fatty acids 
Lipid and 
lipoprotein 
X X X   
FAw3/FA Ratio of omega-‐3 fatty acids to total fatty 
acids 
Lipid and 
lipoprotein 
X X X   
FAw6/FA Ratio of omega-‐6 fatty acids to total fatty 
acids 
Lipid and 
lipoprotein 
X X X   
PUFA/FA Ratio of polyunsaturated fatty acids to 
total fatty acids 
Lipid and 
lipoprotein 
X X X   
MUFA/FA Ratio of monounsaturated fatty acids to 
total fatty acids 
Lipid and 
lipoprotein 
X X X   
SFA/FA Ratio of saturated fatty acids to total fatty 
acids 
Lipid and 
lipoprotein 
X X X   
Ala Alanine Aminoacid X X X   
Gln Glutamine Aminoacid X X X   
Gly Glycine Aminoacid X X X   
His Histidine Aminoacid X X X   
Ile Isoleucine Aminoacid X X X   
Leu Leucine Aminoacid X X X   
Val Valine Aminoacid X X X   
Phe Phenylalanine Aminoacid X X X   
Tyr Tyrosine Aminoacid X X X   
AcAce Acetoacetate Ketone 
bodies 
X X X   
Crea Creatinine Fluid balance X X X   
Alb Albumin Fluid balance X X X   
Gp Glycoprotein acetyls, mainly a1-acid 
glycoprotein 
Inflammation X X X   
Table 3.1: List of traits and analyses where they were used 
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3.3.8 Gene-set analyses  
 
To perform gene set analysis I obtained a curated gene-disease list from DisGeNET [299, 
300] and gene lists of metabolic pathways from KEGG [301-303] and Reactome [304, 305]. 
The gene-disease list obtained from DisGeNET, combines expert curated gene-disease 
associations from the following databases: a) CTD (Comparative Toxicogenomics Database); 
b) UNIPROT; c) ORPHANET (an online rare disease and orphan drug data base);  d) 
PSYGENET (Psychiatric disorders Gene association NETwork); and e) HPO (Human 
Phenotype Ontology). I limited analysis to gene sets with more than three genes resulting in 
7,150 total gene sets to test. Finally, I extracted loss-of-function variants from genes in the 
gene sets and ran SKAT-O (method=”optimal.adj”) for each of the traits. Similarly to the 
gene-based analysis, I used WES data as discovery, and took signals forward for validation in 
WGS if p < 0.01. Covariate selection for correlated traits was performed as described in the 
gene-based analyses (Methods 3.3.7).  The gene-set-wide significance threshold was 
calculated by first estimating the effective number of gene sets tested given the high 
overlap amongst them. Using PCA I estimated that 1094 PCs explain > 95% of the variance in 
gene sets. The significance threshold was therefore calculated as: 0.05/(1094*19)=2.41x10-6 
where 19 corresponds to the effective number of phenotypes tested as described above. A 
signal was considered to replicate if after meta-analysis: i) it met the defined gene-set-wide 
significance threshold (pmeta < 2.41x10
-6); ii) >2 variants were tested; iii) it was nominally 
significant (pvalidation<0.05) in the unadjusted test for WGS (i.e without adjusting for 
correlated traits).  
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3.3.9 Genes near GWAS signals 
 
GWAS catalog data files (release 27-09-2017) were downloaded from 
https://www.ebi.ac.uk/gwas/docs/file-downloads [79].  I focused on GWAS loci associated 
with HDL cholesterol, LDL cholesterol, total cholesterol and triglycerides. I extracted all 
reported genes for GWAS loci that were associated at genome-wide significance (p<5x10-8) 
excluding cases where the “REPORTED GENE” value was: i) NR (not reported); ii) intergenic; 
iii) APO(APOE) cluster; iv) HLA-area (Table 3.2). For this analysis, I ran SKAT-O using the 
optimal unified approach (method=”optimal.adj”) on the four gene sets (HDLC reported, 
LDLC reported, TC reported, TG reported, Table 3.2). The list of genes known to be involved 
in conditions leading to abnormal lipid levels was created extracting relevant genes from the 
DisGeNET and Reactome gene lists. Afterwards, I conducted a manual review of the 
published literature to remove genes where functional work in mouse or human has 
revealed a direct role of the gene in HDL metabolism (Table 3.2). The search terms used 
were “[gene name] loss of function HDL” and “[gene name] knockout HDL”.  Significance 
threshold (p < 0.005) was determined by correcting for 10 PCs explaining >95% of the 
variance of the traits used in this analysis.  
HDLC 
reported* 
HDLC 
reported 
(known 
removed)** 
LDLC 
reported* 
TC 
reported* 
TG 
reported* 
Known genes 
ABCA1 ACAD11 ABCG5 ABCA1 AFF1 ABCA1 
ABCA8 ADH5 ABCG8 ABCB11 AKR1C4 ABCA8 
AC016735.2 ALDH1A2 ABO ABCG5 ALDH2 AC016735.2 
ACAD11 ANGPTL1 ACAD11 ABCG8 ANGPTL3 ANGPTL4 
ADH5 ATG7 ANGPTL3 ABO ANGPTL4 ANGPTL8 
ALDH1A2 CITED2 APOA1 ADAMTS3 APOA1 APOA1 
ANGPTL1 CMIP APOB ANGPTL3 APOA5 APOA5 
ANGPTL4 COBLL1 APOC1 APOA1 APOB APOB 
ANGPTL8 COPB1 APOE APOB APOC1 APOC3 
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HDLC 
reported* 
HDLC 
reported 
(known 
removed)** 
LDLC 
reported* 
TC 
reported* 
TG 
reported* 
Known genes 
APOA1 CPS1 BRAP APOE APOE APOE 
APOA5 DAGLB BRCA2 ASAP3 BAI3 ARL15 
APOB FADS1 CELSR2 BRAP LMBRD1 C12orf51 
APOC3 FAM13A CETP C6orf106 CAPN3 C6orf106 
APOE GPAM CILP2 CELSR2 CCR6 CD300LG 
ARL15 GSK3B CMTM6 CETP CEP68 CD36 
ATG7 HAS1 CSNK1G3 CILP2 CETP CETP 
C12orf51 IKZF1 CYP7A1 CMTM6 CILP2 FTO 
C6orf106 KAT5 DLG4 CSNK1G3 CITED2 GALNT2 
CD300LG LACTB DNAH11 CYP7A1 COBLL1 HNF4A 
CD36 LRP4 EHBP1 DLG4 CTF1 IGHVII-33-1 
CETP LRRC29 FAM117B DNAH11 CYP26A1 IRS1 
CITED2 MADD FN1 DOCK7 DNAH17 KLF14 
CMIP MC4R FRK ERGIC3 DOCK7 LCAT 
COBLL1 MLXIPL GATA6 EVI5 ERGIC3 LILRA3 
COPB1 MVK GPAM FAM117B FADS1 LIPC 
CPS1 MYL2 HFE FN1 FRMD5 LIPG 
DAGLB OR4C46 HLA FRK FTO LOC100996634 
FADS1 PDE3A HLA-C GCKR GALNT2 LOC55908 
FAM13A PEPD HMGCR GPAM GCKR LPA 
FTO PGS1 HNF1A GPR146 GPR85 LPL 
GALNT2 RBM5 HPR HBS1L HLA LRP1 
GPAM RSPO3 IDOL HFE INSR MSL2L1 
GSK3B SBNO1 INSIG2 HLA IRS1 PABPC4 
HAS1 SEMA3C IRF2BP2 HLA-C JMJD1C PLTP 
HNF4A SETD2 LDLR HMGCR KLHL8 PPP1R3B 
IGHVII-33-1 SLC39A8 LDLRAP1 HNF1A LIPC PRKAG3 
IKZF1 SNX13 LOC84931 HNF4A LPA RMI2 
IRS1 STAB1 LPA HPR LPL RP-11-115 
KAT5 STARD3 LRPAP1 IDOL LRP1 SCARB1 
KLF14 TMEM176A MAFB INSIG2 LRPAP1 SIK3 
LACTB TRPS1 MIR148A IRF2BP2 MAP3K1 TRIB1 
LCAT UBASH3B MOSC1 KCNK17 MAU2 TTC39B 
LILRA3 ZNF648 MTHFD2L LDLR MET UBE2L3 
LIPC  MTMR3 LDLRAP1 MIR148A VEGFA 
LIPG  MYLIP LIPC MLXIPL ZNF664 
LOC100996634  NCAN LIPG MPP3   
LOC55908  NPC1L1 LPA MSL2L1   
LPA  OSBPL7 LRPAP1 NAT2   
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HDLC 
reported* 
HDLC 
reported 
(known 
removed)** 
LDLC 
reported* 
TC 
reported* 
TG 
reported* 
Known genes 
LPL  PCSK9 MAFB PDXDC1   
LRP1  PFAS MAMSTR PEPD   
LRP4  PLEC1 MARCH8  PINX1   
LRRC29  PPARA MIR148A PLA2G6   
MADD  PPARG MOSC1 PLTP   
MC4R  PPP1R3B MTHFD2L PROX1   
MLXIPL  SMARCA4 MYLIP RSPO3   
MSL2L1  SNX5 NAT2 SIK3   
MVK  SORT1 NCAN TIMD4   
MYL2  SOX17 NPC1L1 TM4SF5   
OR4C46  SPTLC3 OSBPL7 TP53BP1   
PABPC4  ST3GAL4 PCSK9 TRIB1   
PDE3A  TIMD4 PHLDB1 TYW1B   
PEPD  TOP1 PLEC1 VEGFA   
PGS1  TRIB1 PPARA ZNF664   
PLTP  VLDLR PPARG    
PPP1R3B  ZNF274 PPP1R3B    
PRKAG3   PXK    
RBM5   RAB3GAP1    
RMI2   RAF1    
RP-11-115   RP11-115    
J16.1   J16.1    
RSPO3   SAMM50    
SBNO1   SNX5    
SCARB1   SORT1    
SEMA3C   SOX17    
SETD2   SPTY2D1    
SIK3   ST3GAL4    
SLC39A8   TIMD4    
SNX13   TMEM57    
STAB1   TOP1    
STARD3   TRIB1    
TMEM176A   TRPS1    
TRIB1   TTC39B    
TRPS1   UBASH3B    
TTC39B   UGT1A1    
UBASH3B   VLDLR    
UBE2L3       
VEGFA       
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HDLC 
reported* 
HDLC 
reported 
(known 
removed)** 
LDLC 
reported* 
TC 
reported* 
TG 
reported* 
Known genes 
ZNF648       
ZNF664       
Table 3.2: Gene sets used for enrichment of genes near GWAS signals analyses. HDL reported -Genes reported associated 
with "HDL cholesterol" unambiguously ; HDLC reported (known removed) - Genes reported associated with "HDL 
cholesterol" unambiguously but with known genes involved in HDL metabolism or lipid abnormalities removed; LDLC 
reported - Genes reported associated with "LDL cholesterol" unambiguously; TC reported - Genes reported associated with 
"Cholesterol, total" unambiguously; TG reported - Genes reported associated with "Triglycerides" unambiguously; Known 
genes - Genes removed for sensitivity analysis that are known to be involved in lipid abnormalities or HDL metabolism 
based on literature review; *Gene sets used in analyses running SKAT-O on gene sets.; **Gene sets used in sensitivity 
analyses. 
 
3.3.10 Analysis of tails of phenotype distribution  
 
For this analysis, I used all lipoprotein and lipid traits but excluded derived measures (lipid 
ratios) resulting in 106 traits (Table 3.1). I focused on likely deleterious missense and loss-of-
function variation in lipid metabolism and disease gene sets (Table 3.3) with an allele count 
<10 in each dataset. I chose an arbitrary cutoff of 10 individuals with the highest and lowest 
values for the traits to define tails for all 106 traits.   
Gene Set Source 
Abnormality_of_lipid_metabolism DisGeneNet 
Dyslipidaemias DisGeneNet 
HDL_assembly Reactome 
HDL_clearance Reactome 
HDL_remodeling Reactome 
Hyperlipidaemia DisGeneNet 
Hypertriglyceridaemia_CTD DisGeneNet 
Hypertriglyceridaemia_HPO DisGeneNet 
LDL_clearance Reactome 
LDL_remodeling Reactome 
Triglyceride_biosynthesis Reactome 
Triglyceride_catabolism Reactome 
Triglyceride_metabolism Reactome 
VLDL_assembly Reactome 
VLDL_clearance Reactome 
Table 3.3: List of gene sets used for tails analyses. 
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Given the high phenotypic correlation of these traits, there was a high overlap of individuals 
at the tails of the distributions so I removed traits that shared >=8 individuals with any other 
trait reducing the number of tested traits to 50. For each trait, total deleterious allele count 
from each gene set for upper and lower tails was obtained and an empirical p was 
calculated by performing 10,000 permutations extracting 10 random individuals from the 
phenotype distribution and counting the number of deleterious alleles from the gene set. 
The significance threshold (p = 0.00037) was chosen by correcting for 9 PCs explaining >95% 
of the traits variance and 15 pathways. Meta-analysis was done using Stouffer’s method 
[306] as implemented in the metap package [307] in R. 
3.4 Results 
3.4.1 Single point analyses 
 
I first explored whether I could recapitulate known associations with NMR traits, as well as, 
potentially identify novel associations with rarer variants not previously tested in GWAS 
arrays. To this end, I performed single-point association analysis for 226 NMR metabolic 
biomarkers using WES data from 3,741 healthy blood donors from the INTERVAL cohort as a 
discovery dataset (Methods 3.3.6).  Power calculations showed very limited power to detect 
associations for variants on the rare allele frequency spectrum with this sample size 
(power=4.6% to find an association with p<1x10-5 -threshold to take forward for validation- 
with beta=1 and variant with MAF=0.1%). I therefore focused on variants with MAF>=0.1%. 
After association analyses for all traits I took forward for validation 494 variants associated 
with at least one trait with p<1x10-5.   I performed validation using whole-genome sequence 
(WGS) data from 3,401 independent individuals from the same cohort. After meta-analysis, 
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34 unique loci were associated with at least one trait (Table 3.4). All of these associations 
had already been previously described [38, 173, 308]. 
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Rsid Gene most severe consequence top trait EA NEA discov p validation p meta-p beta se EAF n assoc traits 
rs1047891 CPS1 missense_variant (Thr1412Asn) Gly a c 1.48x10
-68
 4.47x10
-54
 2.09x10
-125
 0.42 0.02 32.47% 1 
rs1077834 LIPC,ALDH1A2 intron_variant L-HDL-TG t c 2.52x10
-16
 6.90x10
-21
 1.11x10
-35
 -0.25 0.02 21.41% 35 
rs11076176 CETP intron_variant M-HDL-TG t g 5.82x10
-7
 6.62x10
-6
 1.65x10
-11
 -0.15 0.02 16.92% 6 
rs11591147 PCSK9 missense_variant (Arg46Leu) IDL-FC t g 7.31x10
-12
 2.20x10
-5
 2.96x10
-15
 -0.48 0.06 1.73% 45 
rs116843064 ANGPTL4 missense_variant (Glu40Lys) S-VLDL-TG a g 7.81x10
-7
 2.67x10
-6
 9.11x10
-12
 -0.40 0.06 1.89% 17 
rs1184865 DOCK7 intron_variant M-HDL-TG a g 6.59x10
-6
 5.66x10
-5
 1.45x10
-9
 -0.10 0.02 36.13% 1 
rs12191266 SLC16A10 intron_variant Tyr t c 4.68x10
-6
 2.42x10
-5
 4.48x10
-10
 -0.15 0.02 14.43% 1 
rs1260326 GCKR missense_variant (Leu446Pro) MUFA t c 1.20x10
-6
 5.31x10
-6
 2.61x10
-11
 0.12 0.02 39.85% 17 
rs138326449 APOC3 splice_donor_variant (2
nd
 exon) S-VLDL-TG a g 7.91x10
-6
 8.80x10
-6
 2.90x10
-10
 -1.10 0.17 0.23% 6 
rs17231506 CETP upstream_gene_variant HDL2-C t c 6.73x10
-17
 4.65x10
-18
 1.35x10
-33
 0.21 0.02 31.83% 38 
rs174476 RAB3IL1 intron_variant UnsatDeg t c 2.05x10
-9
 1.48x10
-5
 1.95x10
-13
 0.12 0.02 41.71% 1 
rs174547 FADS1,FADS2 intron_variant UnsatDeg t c 1.03x10
-41
 5.96x10
-38
 9.02x10
-80
 0.33 0.02 33.71% 8 
rs174602 FADS2 non_coding_transcript_exon_variant UnsatDeg t c 1.21x10
-11
 5.64x10
-7
 4.97x10
-17
 0.17 0.02 20.16% 2 
rs1912826 KLKB1 intron_variant His a g 7.80x10
-11
 5.54x10
-9
 2.04x10
-18
 0.15 0.02 48.89% 2 
rs2072560 APOA5 intron_variant XS-VLDL-TG_% t c 1.15x10
-8
 2.06x10
-7
 1.07x10
-14
 0.27 0.04 5.90% 30 
rs2228671 LDLR non_coding_transcript_exon_variant IDL-FC t c 2.04x10
-7
 6.27x10
-7
 5.55x10
-13
 -0.18 0.03 12.26% 38 
rs2295601 ELOVL2 synonymous_variant DHA/FA a g 1.54x10
-10
 6.61x10
-9
 4.69x10
-18
 -0.17 0.02 22.90% 2 
rs2575876 ABCA1 intron_variant HDL3-C a g 1.92x10
-6
 8.30x10
-8
 8.12x10
-13
 -0.14 0.02 24.65% 1 
rs2657879 GLS2 3_prime_UTR_variant Gln a g 1.16x10
-11
 1.72x10
-15
 1.50x10
-25
 0.23 0.02 18.07% 1 
rs283813 PVRL2 intron_variant S-LDL-C_% a t 3.08x10
-8
 1.20x10
-5
 2.20x10
-12
 -0.23 0.03 6.90% 22 
rs28399637 BCAM intron_variant S-LDL-CE_% a g 4.95x10
-9
 8.59x10
-7
 2.02x10
-14
 0.14 0.02 31.77% 25 
rs28399654 BCAM missense_variant (Val196Ile) S-LDL-C_% a g 1.38x10
-11
 8.80x10
-8
 8.29x10
-18
 -0.40 0.05 3.37% 34 
rs328 LPL stop_gained (Ser474Ter) TG/PG c g 1.08x10
-8
 1.44x10
-7
 7.00x10
-15
 0.22 0.03 10.09% 19 
rs3798220 LPA missense_variant (Ile1891Met) XL-VLDL-CE t c 3.04x10
-6
 4.55x10
-13
 6.15x10
-17
 0.55 0.07 1.76% 16 
rs386606006 APOB synonymous_variant ApoB a g 9.37x10
-6
 2.97x10
-6
 1.17x10
-10
 0.11 0.02 48.80% 1 
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Rsid Gene most severe consequence top trait EA NEA discov p validation p meta-p beta se EAF n assoc traits 
rs429358 APOE missense_variant (Cys130Arg) S-LDL-PL_% t c 9.37x10
-17
 1.20x10
-17
 4.69x10
-33
 0.27 0.02 15.07% 61 
rs435306 PLTP intron_variant L-HDL-PL_% t g 4.90x10
-7
 4.17x10
-7
 8.84x10
-13
 0.14 0.02 25.50% 1 
rs4804573 KANK2 3_prime_UTR_variant S-LDL-PL_% a g 1.49x10
-7
 6.26x10
-5
 4.66x10
-11
 0.11 0.02 47.05% 9 
rs5880 CETP missense_variant (Ala390Pro) HDL-C c g 7.97x10
-7
 3.05x10
-8
 1.17x10
-13
 -0.28 0.04 4.87% 8 
rs61937878 HAL missense_variant (Val549Met) His t c 7.41x10
-14
 3.75x10
-8
 2.01x10
-20
 0.95 0.10 0.66% 1 
rs693672 FADS3 intron_variant UnsatDeg t c 1.44x10
-10
 1.36x10
-9
 8.97x10
-19
 -0.19 0.02 16.76% 1 
rs7412 APOE missense_variant (Arg176Cys) S-LDL-CE_% t c 8.55x10
-63
 1.82x10
-58
 5.97x10
-124
 -0.71 0.03 7.80% 89 
rs76075198 CEACAM19 synonymous_variant S-LDL-CE_% t c 6.76x10
-7
 5.25x10
-8
 1.72x10
-13
 -0.41 0.06 2.20% 10 
rs7679 PCIF1 3_prime_UTR_variant L-HDL-PL_% t c 5.43x10
-18
 1.14x10
-19
 2.23x10
-36
 -0.27 0.02 18.05% 19 
Table 3.4: Single point association analyses results. Most severe consequence=most severe consequence predicted by VEP on CANONICAL transcript. top trait=trait with the lowest p-value. 
EA=effect allele. NEA=non-effect allele discov p=p-value for top trait in discovery cohort (WES). validation p=p-value for top trait in validation cohort (WGS). meta-p= p-value for top trait. 
beta=beta for top trait after meta-analysis. se=se for top trait after meta-analysis. EAF=effect allele frequency. n assoc traits=number of associated traits. 
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3.4.2 Gene-based analyses 
 
I next sought to discover new gene-trait associations using rare-variant aggregate tests. 
After running association tests using two nested approaches to group rare variants (LoF and 
MCAP+LoF, Methods 3.3.7), genes were taken forward for validation if they reached the 
arbitrary threshold of p <5x10-3 (Supplementary Tables 1-2 of Riveros-Mckay et al (in 
preparation, Appendix B)). A burden test was used when testing only LoF whereas the 
optimal unified approach was used when adding predicted deleterious missense variants 
(MCAP+LoF). This is because I expected most high confidence LoF variants to influence a 
trait with the same direction of effect and therefore the burden test should be better 
powered than the optimal unified approach to detect an association.  When including 
missense variants one could expect different directions of effect and therefore the optimal 
unified approach should be better powered. As previously suggested, to boost discovery 
power I adjusted for correlated metabolic biomarkers [309, 310]. However, to minimise the 
possible collider bias this could incur, I only did this at the validation stage. This was to 
ensure there was at least suggestive evidence for association in the discovery stage without 
adjusting for any metabolite (Methods 3.3.7). After meta-analysis, five genes (APOB, APOC3, 
PCSK9, PAH, HAL) associated with 92 different traits with p < 1.32x10-7, which is the 
stringent significance threshold after correcting for the effective number of tested 
phenotypes (Table 3.5, Methods 3.3.7). All five genes have been previously associated with 
their respective traits [38, 308, 311]. As expected, I found that there was a significant 
increase in the strength of association signal  for traits for which I used other correlated 
traits as covariates when compared to the unadjusted tests [309, 310], with the most 
notable example being a >30 order of magnitude increase in association strength for PAH 
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and phenylalanine (Table 3.5). In total, 32 of the 92 known gene-trait associations met the 
stringent significance threshold (p<1.32x10-7) only after adjusting for correlated traits 
(Supplementary Tables 1-2 of Riveros-Mckay et al (in preparation, Appendix B)). 
LoF 
Gene Top trait p-value 
(covs) 
p-value (raw) N WES N WGS N overlap N traits 
associated 
Driven by 
single 
variant? 
APOB  IDL-TG 3.20x10
-13
 1.72x10
-10
 6 5 0 45 (57) No 
APOC3 XS-VLDL-TG 6.10x10
-13
 3.58x10
-12
 3 2 2 46 (56) No 
PAH Phe 5.82x10
-11
 8.25x10
-3
 4 3 1 1 (1) Yes 
MCAP+LoF 
Gene Top trait p-value 
(covs) 
p-value (raw) N WES N WGS N overlap N traits 
associated 
Driven by 
single 
variant? 
PAH Phe 8.33x10
-63
 1.67x10
-28
 39 41 18 1 (1) No 
HAL His NA 3.72x10
-42
 48 37 22 1 (1) No 
APOC3 XS-VLDL-TG 5.46x10
-11
 2.15x10
-10
 6 6 3 26 (40) No 
PCSK9 IDL-FC 2.39x10
-10
 1.11x10
-7
 15 17 3 29 (34) No 
ACSL1 IDL-P 1.82x10
-7
 1.76x10
-4
 4 6 2 0 (1) Yes 
MYCN M-VLDL-L 6.20x10
-7
 3.97x10
-6
 8 8 3 0 (5) No 
ALDH1L1 Gly NA 4.56x10
-7
 39 38 19 0 (1) No 
SCARB1 XL-HDL-FC NA 6.93x10
-7
 25 18 10 0 (6) No 
FBXO36 IDL-CE_% NA 1.98x10
-6
 5 2 1 0 (1) Yes 
B4GALNT3 L-VLDL-FC_% NA 7.59x10
-7
 28 22 13 0 (1) No 
LIPC  XXL-VLDL-C_% NA 9.03x10
-7
 28 29 11 0 (2) No 
Table 3.5:Genes significantly associated (p<2.5x10-6) with at least one trait in gene-based analyses focusing on  loss-of-
function (LoF) or predicted deleterious missense by M-CAP plus loss-of-function (MCAP+LoF). Genes that meet gene-level 
significance after adjusting for multiple phenotypes (p<1.32x10
-7
) are highlighted in bold. Top trait: trait with the smallest 
p-value after meta-analysis adjusting for correlated metabolites. p-value (covs): p-value of meta-analysis after adjusting for 
correlated metabolites for top trait. If NA, this analysis was not performed for this trait due to no metabolic biomarkers 
meeting the criteria to be included as covariates in meta-analysis. p-value (raw): p-value of meta-analysis without adjusting 
for correlated metabolites for top trait. N WES: number of tested variants in WES. N WGS: number of tested variants in 
WGS. N overlap: number of variants present in both WES and WGS. N traits associated: number of traits that meet gene-
level significance after adjusting for multiple phenotypes (p<1.32x10
-7
), traits meeting standard gene-level significance 
(2.5x10
-6
) in parenthesis. Driven by single variant?: Yes if after conditioning on top associated variant the meta-analysis 
association disappears (p>0.05). IDL-TG: Triglycerides in IDL.  XS-VLDL-TG: Triglycerides in very small VLDL. Phe: 
Phenylalanine. His: Histidine. IDL-FC: Free cholesterol in IDL. IDL-P: Concentration of IDL particles.  M-VLDL-L: Total lipids in 
medium VLDL. Gly:Glycine. XL-HDL-FC: Free cholesterol in very large HDL. IDL-CE_%: Cholesterol esters to total lipids ratio 
in IDL. L-VLDL-FC%: Free cholesterol to total lipids ratio in large VLDL. XXL-VLDL-C_%: Total cholesterol to total lipids ratio in 
extremely large VLDL. 
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In addition to established genes, I found 15 gene-trait associations in seven genes meeting 
standard gene-level significance before adjusting for multiple traits (p< 2.5x10-6) which also 
had nominal evidence of association in the validation cohort (p< 0.05).  Nine of these were 
gene-trait associations in three established genes (ALDH1L1, SCARB1, LIPC, Table 3.5), 
suggesting that other results achieving this significance threshold may warrant being 
prioritised for additional follow-up to establish their validity. In particular amongst the 
remaining four genes, the association between IDL particle concentration (IDL-P) and ACSL1 
(p = 1.82x10-7), as well as, the associations of multiple very-low-density lipoprotein (VLDL) 
traits to MYCN (min p = 6.20x10-7) merit further exploration as both genes have been 
previously linked to lipid metabolism in mouse studies [312-314]. 
3.4.3 Gene set analyses 
 
 To find links between predicted loss-of-function rare variants and metabolic biomarker 
biology, I next explored associations of these variants in 7,150 gene sets.  To this end, I used 
two biological pathway databases (Reactome, KEGG) and one database that contains expert 
curated disease associated genes  (DisGeNET) (Methods3.3.8). Gene set analysis yielded 163 
gene-set-trait associations with 14 unique gene sets (Supplementary Table 4 of Riveros-
Mckay et al (in preparation, Appendix B)). Given that 143 gene-set-trait associations were 
with 13 gene sets that included two genes with a well-established role in lipid biology (APOB 
and APOC3), I repeated the test removing variants in these genes. After removal, there is 
residual evidence of association (p<0.05) in 102 of 143 gene-set-trait signals representing 12 
of 13 gene sets. Of the 163 gene-set-trait associations, the remaining 20 gene-set-trait 
associations (in gene sets not containing either APOB or APOC3) represent associations of 
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various lipoprotein related metabolic biomarkers with the “regulation of pyruvate 
dehydrogenase (PDH) complex” pathway in REACTOME (R-HSA-204174, min p= 7.85x10-7, 
trait=phospholipids in intermediate density lipoproteins (IDL-PL),  Table 3.6). These 
associations encompassed 12 LoF variants in WES and four in WGS (Figure 3.1). Upon 
further inspection, I found that most variants in this pathway were contributing to the 
association suggesting the signal was not driven by a single gene, in addition they all have 
the same direction of effect (i.e. the rho(ρ) value in the SKAT-O test was one in both the 
WES and the WGS analyses). Two variants were of particular interest as they were present 
in both WES and WGS datasets, rs113309941 in Pyruvate Dehydrogenase Complex 
Component X (PDHX), and rs201013643 in Pyruvate Dehydrogenase Phosphatase 
Regulatory Subunit (PDPR).  In PDHX, rs113309941 leads to a premature stop mutation 
(Gln248Ter), it has an allele count (AC) of one in each of WES and WGS, and is very rare in 
gnomAD1. rs201013643 in PDRP also leads to a premature stop (Arg714Ter) and is present 
in a single heterozygous individual in the WES dataset and two heterozygous in the WGS. 
This variant is also rare in  gnomAD2.  The five individuals with these two variants had higher 
than average values (upper percentile range from 44.1% to 0.03%) for measurements that 
are CVD risk factors such as cholesterol in intermediate-density lipoproteins (IDL-C) and low-
density lipoproteins (LDL-C) suggesting these variants may have a deleterious impact on lipid 
metabolism and cardiovascular risk. Notably, one of the carriers of the PDHX Gln248Ter 
variant was in the top 0.03% for LDL-C in INTERVAL  (4.086 mmol/l) and had no predicted 
deleterious missense mutations in known hypercholesterolaemia genes PCSK9, APOB or 
LDLR suggesting this novel protein truncating variant may be contributing to  their high LDL-
                                                          
1
 AC (all gnomAD)=3, allele number (AN) (all gnomAD)=246,116, AC (Non-Finnish European (NFE))=2  
AN (NFE)=116,604. 
2
 AC (all gnomAD)=141, AN (all gnomAD)=275,988, AC (NFE) =8, AN (NFE)=126,382. 
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C levels. The other carrier was in the top 19.3% percentile of the cohort. None of the genes 
in this pathway have been previously associated to these traits and therefore this study links 
these genes collectively to intermediate and low density lipoprotein metabolism and 
circulating cholesterol for the first time. 
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Gene set id Trait WES p N WES WGS p N WGS Meta-p  Description Source 
R-HSA-204174 IDL-PL 0.005939 12 0.000503 4 7.85x10-7 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 M-LDL-PL 0.002671 12 0.000594 4 1.01x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 EstC 0.004754 12 0.001175 4 1.09x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 IDL-P 0.003992 12 0.000593 4 1.17x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 L-LDL-P 0.004822 12 0.000258 4 1.20x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 L-LDL-PL 0.004853 12 0.000423 4 1.21x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 IDL-L 0.004313 12 0.000574 4 1.21x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 SerumC 0.005999 12 0.001071 4 1.24x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 L-LDL-L 0.005082 12 0.000275 4 1.35x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 IDL-C 0.00475 12 0.001019 4 1.40x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 L-LDL-FC 0.00681 12 0.0003 4 1.46x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 L-LDL-C 0.006489 12 0.000275 4 1.87x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 M-LDL-P 0.006409 12 0.000132 4 1.96x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 L-LDL-CE 0.006486 12 0.000277 4 2.01x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 S-LDL-L 0.006413 12 0.000115 4 2.13x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 S-LDL-P 0.005994 12 0.000113 4 2.13x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 M-LDL-L 0.006416 12 0.000164 4 2.13x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 LDL-C 0.007809 12 0.000177 4 2.17x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 ApoB 0.00504 12 0.000803 4 2.20x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
R-HSA-204174 IDL-FC 0.009798 12 0.000399 4 2.22x10-6 Regulation of pyruvate dehydrogenase (PDH) complex Reactome 
Table 3.6: Gene set analyses results. WES p = p-value in WES dataset. N WES = number of variants tested in WES dataset. WGS p = p-value in WGS dataset. N WGS = number of variants 
tested in WGS dataset. Meta-p = Meta-analysis p-value after removing APO genes from gene sets (APOB and APOC3). 
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Gene Consequence AC
Pyruvate dehydrogenase (PDH) complex
DLAT Splice acceptor (2nd exon) WES=1
DLD Frameshift (Val212SerfsTer32) WES=1
PDHA2 Stop gain (Tyr28Ter) WES=1
PDHA2 Frameshift (Val297GlnfsTer14) WES=1
PDHA2 Stop gain (Gln78Ter) WES=1
PDHA2 Frameshift (Lys83IlefsTer20) WES=1
PDHA2 Stop gain (Tyr80Ter) WES=1
PDHX Splice donor (2nd exon) WES=1
PDHX Stop gain (Gln248Ter) WES=1
WGS=1
Pyruvate dehydrogenase phosphatase (PDP)
PDP2 Frameshift (Asn33IlefsTer5) WES=1
PDP2 Stop gain (Gln352Ter) WES=1
PDPR Stop gain (Trp402Ter) WES=1
PDPR Stop gain (Arg714Ter) WES=1
WGS=2
Pyruvate dehydrogenase kinase (PDK)_
PDK1 Stop gain (Arg66Ter*) WGS=1
a)                                                                                                       b)
 
Figure 3.1: Loss-of-function (LoF) variants in regulation of pyruvate dehydrogenase (PDH) complex pathway. a) Figure adapted from REACTOME pathway browser 
(https://reactome.org/PathwayBrowser/) [315]. Highlighted in red are protein complexes that carry LoF variants in INTERVAL WES or WGS. b) List of genes, consequences and allele count 
(AC) of LoF variants in the different protein complexes in the pathway. 
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3.4.4 Enrichment of rare variant associations in genes near established GWAS signals in 
lipoprotein related metabolic biomarkers 
 
Next, I conducted analyses to investigate whether genes near GWAS index variants 
associated with traditional lipid traits (HDL-C, LDL-C, TC and TG) were enriched for rare 
variant associations computationally predicted to affect protein sequence and function with 
high resolution lipoprotein measurements, which could suggest enrichment of effector 
transcripts (i.e. transcripts/genes likely to be causal of the original association) in the gene 
set. Given that this was a hypothesis driven approach using established signals, to boost 
discovery power I pooled together both WES and WGS data into a single dataset of 7,179 
individuals. First, I extracted from the GWAS catalog (release 27-09-2017) the “reported 
genes” near signals that have been associated with HDL-C, LDL-C, TC or TG and created four 
gene sets (Table 3.2). I only focused on genes that were reported unambiguously (i.e where 
only one gene is reported) since for associations where more than one gene is reported, it is 
possible that only one will be the effector gene and rare variants from the non-effector 
genes will only add noise to the analysis and therefore reduce power. I grouped rare coding 
variants in the gene set using two nested approaches (LoF and MCAP+LoF) and ran SKAT-O 
on the gene sets for 157 lipoprotein and lipid traits.  Using this approach I found 
associations (p < 0.005, correcting for effective number of tests, Methods 3.3.9) for genes 
near HDL GWAS signals with 18 HDL-related traits (Table 3.7), the strongest association 
being with esterified cholesterol in extra-large HDL (XL-HDL-CE, p=2.83x10-5, MCAP+LoF). 
Associations (p < 0.005, Methods 3.3.9) in two extra-large HDL cholesterol related traits 
remained after removing variants in genes known to be involved in conditions leading to 
abnormal lipid levels or genes where functional work has shown an effect on HDL-C (Table 
3.7) suggesting there is a contribution to the phenotypic variance of these traits by rare 
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coding variants in genes, near GWAS signals, without a known role in HDL metabolism, 
which may represent novel effector transcripts.   
 
Trait GWAS signal 
gene set 
LoF p-value MCAP+LoF p-
value 
LoF p-value 
(known 
removed) 
MCAP+LoF p-
value (known 
removed) 
HDL2-C HDL-C 9.03x10-3 4.72x10-3 4.73x10-1 1.41x10-1 
HDL-D HDL-C 6.29x10-3 2.55x10-3 6.88x10-1 3.46x10-1 
L-HDL-C_% HDL-C 1.49x10-3 6.04x10-2 4.45x10-1 8.78x10-1 
L-HDL-FC_% HDL-C 1.67x10-4 5.40x10-4 1.40x10-1 3.52x10-1 
L-HDL-FC HDL-C 9.21x10-3 3.14x10-3 3.95x10-1 2.63x10-1 
L-HDL-TG_% HDL-C 2.27x10-3 1.30x10-1 3.40x10-1 7.25x10-1 
M-HDL-TG_% HDL-C 6.76x10-4 1.18x10-3 9.98x10-2 7.19x10-1 
S-HDL-TG_% HDL-C 4.68x10-3 4.37x10-3 4.37x10-1 7.76x10-1 
S-HDL-TG HDL-C 1.61x10-3 5.47x10-3 3.47x10-1 3.73x10-1 
XL-HDL-CE HDL-C 2.86x10-2 2.83x10-5 1.00 3.69x10-4 
XL-HDL-C HDL-C 1.85x10-2 4.43x10-5 8.48x10-1 9.03x10-4 
XL-HDL-FC HDL-C 6.41x10-3 2.44x10-4 7.43x10-1 1.11x10-2 
XL-HDL-L HDL-C 1.14x10-2 1.75x10-4 7.00x10-1 7.07x10-3 
XL-HDL-P HDL-C 1.17x10-2 1.91x10-4 6.92x10-1 7.56x10-3 
XL-HDL-PL HDL-C 8.07x10-3 9.94x10-4 5.12x10-1 1.11x10-1 
Table 3.7:Significant results (p<0.005) in SKAT-O analysis on gene sets built from lists of genes near established GWAS 
loci. LoF p-value: SKAT-O results for analysis focusing on loss-of-function variants in gene set. MCAP+LoF p-value: SKAT-O 
results for analysis focusing on rare missense variants (MAF <1%) predicted to be likely deleterious  (M-CAP score >0.025) 
and  loss-of-function variants in gene set. LoF p-value (known removed) = SKAT-O results for LoF approach after removing 
genes known to be involved in lipoprotein metabolism. MCAP+LoF p-value (known removed) = SKAT-O results for 
MCAP+LoF approach after removing genes known to be involved in lipoprotein metabolism. 
 
3.4.5 Enrichment of rare variation in tails of the phenotypic distribution of lipoprotein 
and glyceride related traits 
 
Finally, I aimed to investigate whether individuals at the extreme tail of the phenotype 
distribution for 106 lipoprotein and lipid traits harboured rare coding variants likely to be 
contributing to their phenotype.  I used the WES dataset as a discovery dataset and the 
WGS dataset as validation. An arbitrary cutoff of 10 individuals at each tail was used to 
define the tails for all of the 106 traits (Methods 3.3.10). After meta-analysis, I found an 
enrichment of predicted deleterious rare variation (p < 0.00037, Methods 3.3.10, Table 3.8, 
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Supplementary Table 9 of Riveros-Mckay et al (in preparation, Appendix B)) in 
hyperlipidaemia related genes on the lower tail of cholesterol in small VLDL (S-VLDL-C), 
esterified cholesterol in small VLDL (S-VLDL-CE) and concentration of extra small VLDL 
particles (XS-VLDL-P), and rare variation on HDL remodelling related genes on the lower tail 
of concentration of small HDL particles (S-HDL-P).  I still observed nominal evidence of 
association in the WES and WGS datasets for the S-VLDL-C and XS-VLDL-P results using a 
0.5% percentile cut-off for the tails but no evidence of association was found when using a 
1% percentile cut-off (Supplementary Table 10 of Riveros-Mckay et al (in preparation, 
Appendix B)).   This is likely due to the fact that by extending the number of individuals 
taken from the tails, we are decreasing the average distance to the mean and diluting signal 
coming from true extreme values.  
Upper tails 
Trait WES P WGS P Meta-P Gene Set 
S-VLDL-FC 3.3x10
-2
 2.37x10
-2
 3.45x10
-3
 Hypertriglyceridemia_HPO 
XS-VLDL-C 3.3x10
-2
 2.37x10
-2
 3.45x10
-3
 Hypertriglyceridemia_HPO 
     
Lower tails 
Trait WES P WGS P Meta-P Gene Set 
S-VLDL-C 5.8x10
-3
 2.31x10
-3
 7.61x10
-5
 Hyperlipidaemia 
XS-VLDL-P 1.85x10
-2
 7x10
-4
 9.42x10
-5
 Hyperlipidaemia 
S-VLDL-CE 5.8x10
-3
 6.75x10
-3
  2.07x10
-4
 Hyperlipidaemia 
S-HDL-P 2.72x10
-3
 1.84x10
-2
 2.89x10
-4
 HDL_remodeling 
S-HDL-P 4.10x10
-2
 3.92x10
-2
 8.x24x10
-3
 Hypertriglyceridemia_CTD 
Table 3.8:Gene sets where there is a nominally significant enrichment of rare variation in the tails of a lipid or 
lipoprotein measurement (p<0.05) in both WES and WGS. Highlighted in bold are gene sets that are significant after meta-
analysis using Stouffer’s method [306] and after adjusting for multiple traits (p<=0.00037).  WES P: permutation p in WES. 
WGS P: permutation p in WGS. Meta-P: p after meta-analysis using Stouffer’s method. S-VLDL-FC: Free cholesterol in small 
VLDL. XS-VLDL-C : Cholesterol in very small VLDL. S-VLDL-C: Cholesterol in small VLDL. XS-VLDL-P: Concentration of very 
small VLDL particles. S-VLDL-CE: Cholesterol esters in small VLDL. S-HDL-P: Concentration of small HDL particles.  
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3.5 Discussion 
 
Exploring rare coding variation provides an opportunity to gain insights into biological 
processes regulating the circulating levels of metabolic biomarkers. Here I took advantage of 
the combination of sequencing data and high-resolution NMR measurements to elucidate 
how this variation influences multiple metabolic measurements in a healthy cohort of UK 
blood donors.  
To identify variants, genes and gene sets associated with metabolic biomarkers, I used a 
two-stage approach using WES data in discovery (Ndiscovery=3,741), and WGS data for 
validation (Nvalidation=3,401).  I first performed single-point association analysis to assess 
whether I was able to recapitulate established associations with metabolic biomarkers, and 
potentially identify novel associated rare variants. This yielded associations at 34 previously 
established loci. The lack of novel findings was expected given the smaller sample size 
compared to similar studies using the same NMR platform (INTERVAL N=7,142, Kettunen et 
al. (2016) [173] N=24,925) and the limited power to detect associations with rare variants. 
As an example, for 7,142 individuals, I only had 2.5% power to detect a significant 
association (p<9.51x10-9 in a combined analysis, Methods 3.3.6) with an effect size of 1 for 
variants with MAF 0.1%. This study was part of a collaboration with Dr Adam Butterworth’s 
group in the University of Cambridge. As such, array based genotype data for the full 
INTERVAL cohort was analysed by them and will form part of a large-scale meta-analysis 
collaborative effort. For this reason, I did not explore these results further. 
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 Rare-variant aggregation tests were used to identify genes harbouring multiple rare coding 
variants associated with metabolic biomarkers. To gain power at the validation stage I 
adjusted analyses for correlated traits, an approach previously described for single-point 
analysis [310]. This yielded significant power gains, namely at the known PAH association 
with phenylalanine levels, where adjusting for 71 phenotypically correlated traits resulted in 
a greater than 30-fold magnitude change in the statistical evidence of association after 
meta-analysis. This approach therefore can benefit similar studies with multiple phenotypes 
measured in the same individuals. And, in future efforts, use of association data from these 
traits in the INTERVAL cohort, instead of publicly available summary statistics, to determine 
which traits are not genetically correlated could also be used to increase power for many of 
the measurements that had no publicly available summary statistics, including all derived 
lipid ratios. Overall, this approach yielded 4,114 gene-trait associations taken forward for 
validation (pdiscovery<5x10
-3).  After meta-analysis besides recapitulating previous associations 
in eight known genes (APOB, APOC3, PAH, HAL, PCSK9, ALDH1L1, SCARB1 and LIPC, Table 
3.5), this method also identified four genes (ACSL1, MYCN, B4GALNT3, FBXO36) that met 
standard gene-level significance (p<2.5x10-6, Table 3.5) in at least one gene-trait association 
test. Of these, ACSL1 and MYCN have been previously linked to lipid metabolism [312-314], 
suggesting that among the gene-level significant findings there may be additional true 
positives which will merit additional follow-up. 
ACSL1, which encodes long-chain-fatty-acid—CoA ligase 1, is the predominant isoform of 
ACSL in the liver. The gene was associated with concentration of IDL particles in this study (p 
= 6.20x10-7), and its deficiency in the liver has been shown to reduce synthesis of 
triglycerides and beta oxidation, and alter the fatty acid composition of major phospholipids 
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[316]. An intronic variant (rs60780116) in ACSL1 has been associated with T2D [317] and 
elevated expression of ACSL1 has been shown to be an independent risk factor for acute 
myocardial infraction [318]. 
MYCN encodes N-myc proto-oncogene protein and its amplification can lead to 
tumorigenesis [319, 320]. Previous animal studies have shown that inhibition of MYCN can 
lead to accumulation of intracellular lipid droplets in tumour cells [314]. Here I find 
association between MYCN and concentration of lipids, phospholipids and triglycerides in 
medium VLDL, total particle concentration of medium VLDL and triglycerides in small VLDL 
(min p = 6.20x10-7, Table 3.5, Supplementary Table 2 of Riveros-Mckay et al (in 
preparation, Appendix B)).  
The other two genes do not have any obvious link to lipid metabolism. B4GALNT3 encodes 
beta-1,4-N-acetyl-galactosaminyl transferase 3. This protein mediates the N,N'-
diacetyllactosediamine formation on gastric mucosa [321]. Mouse knockouts have been 
associated with abnormal tail movements, abnormal retinal pigmentation and increased 
circulating alkaline phosphatase levels [322] and variants near the gene have been 
associated with height and hip circumference adjusted for BMI in human GWAS [94, 323].   
FBXO36  is a member of the F-box protein family. F-box proteins are known to be involved in 
protein ubiquitination [324]. Replication of these signals in additional studies would 
represent a novel link between these genes and lipid metabolism.  
In gene set analysis, the “regulation of pyruvate dehydrogenase (PDH) complex” pathway 
was newly associated with 20 traits, mostly related to IDL and LDL lipoproteins. None of the 
genes in this pathway have been previously linked to any of these phenotypes, and this data 
suggests the signal arises from a cumulative effect of predicted loss-of-function variants in 
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different genes in the pathway (Figure 3.1), which represents a novel link between this 
pathway and lipoprotein metabolism. Of note, a carrier of a rare stop gain mutation 
(Gln248Ter) in PDHX had very high levels of LDL-C (4.086 mmol/l, top 0.03% of full INTERVAL 
cohort) with no other rare mutation in genes known to harbour rare mutations causative of   
hypercholesterolaemia (PCSK9, APOB, LDLR). The other carrier of this variant had slightly 
increased LDL-C levels but within normal clinical range (1.823 mmol/l, top 19.3% of the full 
INTERVAL cohort). Since we lack information on medication, specifically, lipid lowering 
medication, the degree to which this variant influences the observed LDL-C levels is difficult 
to assess. The PDH complex has been shown to be crucial for metabolic flexibility, i.e. the 
capacity to adjust fuel oxidation based on nutrient availability, which itself has been shown 
to play a role in cardiovascular disease [325].  
In analyses aiming at identifying effector transcripts at established GWAS loci associated 
with traditional lipid measurements (HDL-C, LDL-C, TC and TG), I established that reported 
genes mapping near HDL-C associated loci were enriched for rare coding variants associated 
with multiple HDL-related measurements. The results remained significant (p<0.005) after 
removing genes known to be directly involved in HDL metabolism, suggesting rare coding 
variants in this gene set contribute to variation in these traits, and that this gene set is 
potentially enriched for additional effector transcripts, though common variants in the same 
haplotype as these rare variants could also account for some of the signal we observe. One 
of the major limitations of this approach is that most of the times, the reported gene is the 
closest gene and we may miss the true causal gene if the GWAS signal is regulating a more 
distant gene. It is also important to note that an enrichment of rare variant associations 
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near reported genes does not necessarily mean that they solely explain the GWAS non-
coding association and other genes might also be contributing to the signal.  
Finally, I showed that one can detect enrichment of rare variation in genes involved in 
lipoprotein metabolism in phenotypic extremes of some of these NMR measurements. 
Specifically, I showed enrichment of rare variants in hyperlipidaemia related genes in 
individuals with very low levels of cholesterol and esterified cholesterol in small VLDL, total 
small VLDL particle concentration, and enrichment of rare variants in HDL remodelling genes 
in individuals with very low levels of small HDL particles. Given that high levels of small HDL 
particles have been previously associated with higher incidence of ischemic stroke (IS) [326] 
some of these variants could have protective effects. These results are in agreement with 
previous work on LDL-C  [285] and HDL-C [327] that show that common polygenic signals 
seem to have a higher impact on the higher extremes of lipid traits whereas there is 
evidence for a  higher prevalence of rare variation on the lower extremes [327]. This is also 
expected since the INTERVAL cohort consists predominantly of healthy blood donors and 
therefore the distribution of many of these traits might be truncated and depleted of 
individuals with rare “damaging” variants. Another factor that could contribute to the 
observed results is that each trait will have a different distribution and given the fact I am 
choosing an arbitrary number of participants at the top and bottom of the distribution, 
these participants will not represent equivalent “extremes”.  
A major limitation of rare variant association analyses to date is that, despite the advances 
in computational methods predicting the pathogenicity of rare variants, many of these 
predicted deleterious variants appear to exert little to no effect as evidenced by the non-
significant associations with known positive controls where one should be well powered to 
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detect association if most of these variants were sufficiently deleterious. Some reported 
gene-based associations may be due to a few population specific variants, making those 
findings hard to replicate. As an example, a study using the same NMR platform and 
performing gene-based analysis using exome-chip data found a significant association of 
LIPG with many HDL subclass traits (min p=3.8x10-17, all protein-truncating and missense 
variants, Nvariants=5 in a Finnish population [288] whereas in this study the same gene was 
only nominally significant in triglycerides in medium HDL (p=0.049) querying 19 missense 
and LoF variants predicted to be deleterious. Power in our study was ~ 82% to find an 
association at p < 0.001 if 50% of the variants included in the test were causal and had the 
same direction and maximum beta is 1.1, this dropped to ~75% power if 20% of those 
variants had opposite directions of effect. Upon further inspection, the burden in the 
original study is mostly driven by one LoF variant (rs200435657, p=4x10-6), and one 
missense variant (rs201922257, p=8.6x10-9) that are almost monomorphic in Non-Finnish 
Europeans (gnomAD AC=1 and 7 respectively, AN= 126,228 and 126,712) but have an 
increased AC in Finnish populations (gnomAD AC=43 and 44 respectively, AN= 25,782 and 
25,784).  Another missense variant contributing to the association (rs77960347, p=4.8x10-6) 
is low frequency in NFE (INTERVAL MAF=1.6%) and therefore was not included in our 
analysis, but it is worth noting that this variant is predicted to be tolerated by SIFT and only 
possible damaging by PolyPhen.   Another study using the same platform but focusing on 
amino acids [289] found a burden of rare variants in BCAT2 (p=7.4x10-7, all protein-
truncating and missense variants, Nvariants=3) affecting valine levels where one of the two 
variants driving the association (rs199999090, p=5.36x10-4) was monomorphic in our data 
and the other variant (rs117048185, p=4.12x10-4) was also similarly associated in my dataset 
(p=3.x89x10-3) but was not predicted to be deleterious by MCAP (or other similar algorithms 
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like PolyPhen and SIFT) and therefore was not included in the burden test that included 
eight variants (pburden=0.76).  Other examples of non-significant associations from 
traditionally measured lipid traits include a PNPLA5 association with LDL-C [328] and a 
TEAD2 association with HDL-C [284]. In the case of PNPLA5 we tested 10 predicted 
deleterious variants and found no association p=0.59. However, the reported association 
with PNPLA5, was driven by an African American signal [283]. In the case of TEAD2 the SNP 
driving the signal, rs142665148, is monomorphic in the European population and was found 
in a Chinese population, although unlike LIPG, BCAT2 and PNPLA5, this gene is not a known 
effector transcript and might represent a false positive.  
Further work on the INTERVAL cohort incorporating proteomics data could help better 
understand the potential functional consequences of rare coding variation and help bridge 
the gap between the rare variant analyses associations presented in this chapter and the 
observed consequences to circulating metabolic biomarkers.Altogether, my results showed 
that focusing on rare variation and deep metabolic phenotyping provides new insights into 
circulating metabolic biomarker biology.  This argues for the expansion of deeper molecular 
phenotyping as part of large cohort sequencing efforts to gain further understanding on the 
role of rare coding variation on circulating metabolic biomarkers which may potentially lead 
to novel drug target discovery and/or provide additional genetic validation for specific 
targets. 
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4 Chapter 4: The heritability of fructosamine and its genetic 
relationship to HbA1c. 
4.1 Introduction 
 
Hyperglycaemia (high blood glucose) is the defining characteristic of diabetes. Normal 
fasting glucose (FG) levels in the blood range between 4.0 to 5.4 mmol/L (72-99 mg/dL), 
while post-prandial levels range up to 7.8 mmol/L (140 mg/dL) two hours after eating (2hr 
glucose) [329]. The most common tests to diagnose diabetes are fasting glucose (FG) and 
2hr glucose after an oral glucose tolerance test (OGTT) (Fig 4.1). Both tests require a fasting 
period between 8 and 12 hours. OGTT involves taking a blood sample after the fasting 
period and then patients are given a very sweet drink containing 75g of glucose. Another 
blood sample is taken after two hours and this sample is the one used for diagnosis (2hr 
glucose post-OGTT). In some cases, blood samples are also taken at regular intervals 
between the intake of the sugar drink and the 2hr blood sample. Concordance between FG 
and 2hr glucose is not complete [330] and interestingly, individuals diagnosed using both 
criteria have higher cardiovascular disease risk than those only diagnosed using FG [331], 
and cardiovascular and all-cause mortality are increased in individuals diagnosed using 2hr 
glucose when compared to individuals diagnosed using FG [332]. 
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Figure 4.1: Diagnosis of type 2 diabetes. Blood glucose levels are shown for unaffected individuals (red line) and 
individuals with diabetes (green line) over a time course of 5 hours after glucose challenge. Fasting glucose (FG) test only 
measures glucose at the first time point. OGTT measures the first time point and the 2hr mark. Extracted from: 
https://themedicalbiochemistrypage.org/diabetes.php 
  
Timely diagnosis of diabetes is important as uncontrolled high blood glucose levels can lead 
to clinical complications such as retinopathy, kidney failure or heart disease [25]. 
Undiagnosed diabetes can lead to damage to tissues due to hyperglycaemia which occurs 
over time without individuals displaying any marked symptoms. The degree of 
hyperglycaemia, reflecting the amount of damage to either insulin secretion or insulin 
response mechanisms (Fig 4.2), has an impact on the action course for treatment of the 
condition. Individuals with elevated glucose levels, but below the established threshold for 
diabetes diagnosis (FG=5.5 to 6.9 mmol/l  (100 to 125 mg/dl), 2hr glucose=7.8 to 11.0 
mmol/l (140 to 199 mg/dl)), are referred to as having prediabetes and can often manage 
their glucose levels by a combination of weight loss, physical activity and in rare cases oral 
glucose reducing medication [333]. When insulin secretion systems are severely damaged, 
individuals require insulin injections. This is the case for type 1 diabetes patients, who suffer 
from complete destruction of their beta-cells due to autoimmunity. For T2D cases there are 
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a host of oral treatments (e.g. metformin, sulphonylureas, thiazolidinediones (TZDs), 
dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose transporterase (SLGT-2) 
inhibitors) [334-336] but eventually many patients require insulin treatment.  
 
Figure 4.2: Aetiology of T2D. Interplay between genetic and environmental factors determines an individual’s susceptibility 
to T2D. T2D arises from impaired beta-cell function and insulin resistance which occurs primarily in muscle, fat and liver 
tissues (i.e. insulin target organs). Under normal beta-cell function, in the setting of insulin resistance, insulin production is 
increased to increase the uptake of glucose by these tissues and glucose levels in the blood are kept within normal ranges. 
If this fails, glucose levels increase in the blood leading to impaired glucose tolerance (IGT). Individuals with untreated IGT 
have a high risk of developing T2D and cardiovascular disease. Image provided by Inês Barroso. 
 
Another measure of glucose levels in the blood is glycated haemoglobin (HbA1c), which is 
the proportion of haemoglobin in the blood that has been glycated, and reflects average 
glucose levels over the life-span of an erythrocyte (~3 months). HbA1c is widely used to 
assess glycaemic control in patients with diabetes [337, 338].  As a diagnostic tool, HbA1c 
has a lower sensitivity than FG, but its negative predictive value is high, suggesting that low 
HbA1c levels provide strong evidence to discard a diabetes diagnosis [339]. However, HbA1c 
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levels as a diagnostic tool can be influenced by conditions that affect the lifespan of 
erythrocytes such as sickle cell trait and anaemia [340, 341], or by ethnic differences [342] 
(Figure 4.3).  For example, ethnic minorities in the US such as Hispanics, Asians, American 
Indians and blacks have on average higher HbA1c levels than whites after adjusting for 
factors affecting glycaemia. This could affect the utility of HbA1c for T2D diagnosis, 
especially in populations of different ancestry  [343]. Twin studies have estimated that 
heritability for HbA1c is high ranging from 62% to 75% [344, 345]. Multiple GWAS of HbA1c 
have looked into the genetic component of this trait, with a total of 60 loci identified to date 
[121, 346-350]. Lookups of association results of HbA1c-associated loci, with publicly 
available summary statistics for additional glycaemic (FG, 2h glucose and fasting insulin) and 
blood cell traits, in addition to conditional analyses adjusting for glycaemic traits (FG, 2hr 
glucose) or blood cell traits (haemoglobin levels, mean corpuscular volume, mean 
corpuscular haemoglobin)  classified these loci as those mostly influencing HbA1c through 
glycaemic, erythrocytic, or unclassifiable pathways [121]. Understanding the pathway 
through which these variants affect HbA1c levels is important as it may influence their effect 
on T2D risk, diagnosis and treatment.  For example, in a recent study from the MAGIC 
investigators [121] the authors described a missense variant in G6PD that lowers HbA1c 
levels through non-glycaemic pathways. This means that the lower HbA1c levels in G6PD 
variant carriers no longer reflect ambient glycaemia and therefore individuals with this 
variant could remain undiagnosed for T2D if this information were not taken into account 
and if they were screened by a single HbA1c measurement (see Chapter 1, Section 1.2.2). 
Understanding HbA1c genetics, which is studied in healthy non diabetic individuals to avoid 
confounding by diabetes and its treatment, could therefore help improve T2D diagnosis in 
populations of different ancestry.  
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Figure 4.3: Advantages and disadvantages of HbA1c as a diagnostic tool. 
 
Fructosamine is a measurement of glycation of total serum proteins. Since the most 
abundant serum protein is albumin, fructosamine normally reflects glycation of albumin 
[351]. In contrast to HbA1c, fructosamine measures short-term glycaemic control (from two 
to three weeks) and has been suggested as a useful marker for monitoring quick changes in 
glycaemic levels after treatment in individuals with diabetes [352]. As it is independent of 
haemoglobin, fructosamine levels are not affected by blood disorders and therefore is less 
likely to be influenced by erythrocytic traits, making it a viable alternative to HbA1c in the 
presence of anaemia or other blood disorders to monitor glycaemic levels [353]. Despite its 
potential advantages, it is not widely used as a measure of glucose control and has not been 
as standardised as HbA1c [354]. This lack of standardisation is problematic if fructosamine is 
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to be implemented as a diagnostic tool as accurate cutoffs need to be defined making sure 
variability within and between different labs is due to individual differences and are not 
assay or laboratory dependent. Nevertheless, studies have found association of 
fructosamine levels with diabetes incidence [355], retinopathy and chronic kidney disease 
[356], independently of baseline fasting glucose and HbA1c. Furthermore, there is a high 
correlation of fructosamine levels with HbA1c levels in patients with diabetes (r=0.7-0.8; 
[356-359]). The discordance in individuals between HbA1c levels and those levels predicted 
by its regression on fructosamine has been termed “glycation gap (GG)” [360]. Differences 
in FG and HbA1c as T2D diagnostic tools can be influenced by the GG as shown in a study 
where individuals were classified into three groups based on GG tertiles: low, medium and 
high glycators. Individuals diagnosed with diabetes by FG/2hr glucose and diagnosed as 
normoglycaemic by HbA1c had a significant depletion of individuals in the upper tertile of 
the GG suggesting individuals with low propensity for haemoglobin glycation are less likely 
to be diagnosed as diabetic by HbA1c criteria. In fact, the optimal HbA1c cutoff (i.e, the 
value misclassifying fewest patients) for low glycators was lower than that of high glycators 
(5.75% vs 6.25%) and had reduced sensitivity (54% vs 70%) [361]. To date, only one small 
study has looked at heritability of fructosamine in twins (40 monozygotic and 46 dizygotic) 
concluding it was not significantly inherited although a model including additive genetic 
effects and unique environmental influences could not be excluded [362]. A recent 
fructosamine GWAS performed on 8,951 mostly normoglycaemic white individuals 
(Ndiscovery=7,647, Nreplication=1,304) found one single replicating association near RCN3 
(rs34459162, p=5.3x10-9) after meta-analysis. This study did not examine the heritability of 
fructosamine and there was no significant evidence of genetic correlation with FG or HbA1c 
although there was some evidence of association for three established FG and/or HbA1c loci 
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(TCF7L2, GCK and SLC2A2) [363]. Elucidating non-glycaemic genetic influences of 
measurements used in T2D diagnosis, such as HbA1c and fructosamine, can help improve 
the diagnostic accuracy of these tests as well as provide insights into the different 
mechanisms by which these traits increase risk of diabetes comorbidities such as 
cardiovascular disease or chronic kidney disease independently of other glycaemic traits.  
In this chapter, I performed a fructosamine GWAS to gain further insights into the genetic 
influences on fructosamine levels, and explore its genetic relationship with HbA1c and other 
glycaemic traits.  
 
 
4.2 Chapter aims 
 
The overall aim of this chapter is to explore the genetic basis of fructosamine. I use genome-
wide genetic data available on up to ~19M SNPs on 24,586 individuals from the INTERVAL 
cohort to: 
I. Assess the heritability of fructosamine. 
II. Find novel loci associated with fructosamine. 
III. Explore the genetic correlation of fructosamine with other glycaemic traits. 
IV. Explore the effects of established glycaemic loci on fructosamine. 
 
4.3 Methods 
 
4.3.1 Participants 
 
Work in this chapter was done using the INTERVAL cohort which consists of 47,394  
predominantly healthy blood donors in the UK (more details in Chapter 3 Methods 3.3.1). 
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4.3.2 Genotyping, variant quality control and imputation  
 
Genotyping, variant quality control and imputation on the INTERVAL cohort were performed 
by collaborators and full details can be found in Astle et al 2017 [293]. INTERVAL 
participants (Ntotal=48,813) were genotyped in ten batches on the UK Biobank Affymetrix 
Axiom Array. Standard QC procedures were implemented by Affymetrix during the genotype 
calling pipeline. Samples were excluded if signal intensity was poor (dish QC <0.82) or if call 
rate was low (<97%). Variants were excluded if a) call rate was low (<95%), b) there were 
more than three genotype clusters, c) cluster statistics (Fisher’s linear discriminant, 
heterozygous cluster strength, homozygote ratio offset) indicated poor quality or d) they 
were complicated multi-allelic variants . Extra QC steps were performed by Tao Jiang and 
Heather Elding. Variants from a batch were failed if: a) fewer than ten minor allele 
homozygotes were called, b) the cluster plot contained at least one sample with an intensity 
at least twice as far from the origin as the next most extreme sample, c) the outlying 
sample(s) had an extreme polar angle (< 15° or > 75°) in the direction of the minor allele. 
Next, duplicate and non-European samples were excluded. Non-Europeans were defined 
based on PC1 and PC2 score thresholds defined after visual inspection of a PCA with 1000G 
major ancestry populations. Within batch variant QC was then performed discarding 
variants based on deviation from HWE ( p < 5x10-6)  and a low call rate (<97%). If variants 
failed any of these last two filters or any of the Affymetrix filters in four out of ten batches, 
variants were discarded across all batches. After merging all batches, sample contamination 
was estimated using a contamination estimate based on allele frequency and probeset 
intensity [297]. Samples were excluded if this estimate was >10% or >3% if the sample also 
had more than ten first- or second-degree relatives (PI_HAT > 0.1875).  Samples were then 
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excluded if they were heterozygosity outliers (>3 SD from mean), they had missing 
phenotypic sex or if supplied sex mismatched genetically inferred sex. Variants were 
removed if they had a MAF range >0.05 across all batches, if they were monomorphic in one 
or more batches and MAF > 0.01 in another batch, or if they had differing minor allele 
between batches (for variants with max MAF <0.475).  An extra 69 across-batch duplicates 
were removed after merging batches. A global HWE filter (p < 5x10-6) and a stringent call 
rate filter (>99% on non-failed batches and >75% globally) were applied to select variants 
used for imputation.  Dataset was phased using SHAPEIT3 [364] and then imputed to a 
combined UK10K-1000G Phase III imputation reference panel using the Sanger Imputation 
Server [127].  
4.3.3 Phenotyping 
 
Phenotyping was performed by Star-SHL lab (http://www.star-shl.nl/). Fructosamine was 
measured using a colorimetric assay (Roche/Hitachi MODULAR P analyser system) and 
HbA1c was measured using a high performance liquid chromatography assay (Tosoh 
Automated Glycohemoglobin Analyser HLC-723G8 system) using serum collected on the 2 
year follow-up visit.  Fructosamine and HbA1c measurements as well as questionnaire data, 
technical variables and blood cell trait measurements were provided by the data 
administrator (University of Cambridge).  I performed phenotype quality control in R to 
prepare the data for association analysis. 
4.3.4 Association analysis, heritability and genetic correlation  
 
Residuals obtained after phenotype quality control (Results 4.4.1) for fructosamine and 
HbA1c were used in this analysis. BOLT-LMM [227] was used to run genome-wide 
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association analysis on 19,100,024 variants with MAF > 0.1% and INFO score >0.4. LD score 
regression [42] was used to establish the heritability and genetic correlation of both traits. 
LD score regression was also used to compute genetic correlation of fructosamine and 
HbA1c with blood cell traits.  A subset of 1,142,170 of the 1,217,312 HapMap3 SNPs with 
non-missing betas was kept in each dataset to perform these analyses. HbA1c summary 
statistics for European individuals from Wheeler et al 2017 [121] were obtained from the 
MAGIC consortium website (https://www.magicinvestigators.org/downloads/). Blood cell 
traits summary statistics were downloaded from http://www.bloodcellgenetics.org/. 
Genetic correlation analyses with glycaemic traits and albumin was performed using LD Hub 
[231].  
 
4.3.5 Fructosamine discovery GWAS 
 
LD score regression results showed no signs of inflation so no genomic correction was 
performed (LD intercept=1.01). I performed clumping as implemented in PLINK [223] to 
establish unique loci. Variants were clumped if they were 250kb away from the lead signal 
and if r2>0.1. Conditional analysis was also used to identify distinct signals within a locus 
after clumping. To compare effect sizes of the lead variant near RCN3 (rs34459162) found in 
a previous study [363], I reran normalisation on fructosamine matching the transformation 
done in that study and correcting for sex, donation centre, height, weight, processing date, 
number of donations and attendance date. SNPTEST v2.5.2 was used to rerun association 
analysis under an additive model and used for reciprocal conditional analyses. To estimate 
the significance of the difference in effect sizes I used a Z-test.  SNPTEST v2.5.2 was also 
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used to test for association of the lead signal near RCN3 in this study with serum albumin 
levels.   
4.3.6 Lookup of established glycaemic loci  
 
A list of established glycaemic loci was obtained from Eleanor Wheeler. This list was curated 
by Eleanor Wheeler and Gaëlle Marenne and last updated in March 2018. I first removed 
from the list chromosome X variants, variants monomorphic in the European population, 
and one variant not present in the INTERVAL data. To extract index variants per locus, I 
extracted LD information from European individuals in 1000G  using LDlink 
(https://ldlink.nci.nih.gov/) [365]. For variants that were not biallelic in 1000G, I calculated 
LD in the INTERVAL dataset. For each pair of variants with r2 > 0.1, I kept variants that had 
the lowest p-value in any of the association analysis with fasting glucose, 2 hr glucose, 
fasting insulin or HbA1c performed in European individuals in the latest trans-ethnic MAGIC 
unpublished analyses. Association data was provided by Ji Chen. The full list of index SNPs is 
presented in Table 4.1. Significance threshold for association was established by dividing 
0.05 by the number of loci tested (0.05/142 = 3.5x10-4). To assess if there was an 
enrichment of directionally consistent and nominally significant signals in fructosamine that 
have been previously associated with glycaemic traits I performed a binomial test. Of the set 
of variants previously associated with glycaemic traits that were nominally significant in 
fructosamine, signals near USP4 and ANK1 were removed in this test since their association 
status with HbA1c is through non-glycaemic pathways and I chose to focus only on those 
influencing HbA1c through glycaemic pathways [121].  I also removed rs9727115 and 
rs150781447 as these were only associated with proinsulin levels adjusted for fasting 
glucose and late-phase proinsulin levels and the expected relationship between directions 
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of effect of a variant affecting proinsulin and fructosamine is not obvious. Direction of effect 
was determined using the HbA1c raising allele as reference (i.e we expect HbA1c raising 
variants to also raise fructosamine). If the variant was not associated with HbA1c, I used FG 
as reference and for rs9884482, which was not associated with HbA1c or FG, I used FI.  
 
snp chr pos gene trait 
rs340874 1 214159256 PROX1-AS1 FG [83], FG_adjBMI [366] 
rs1886686 1 67390468 WDR78 FG_adjBMI * 
rs2820436 1 219640680 LYPLAL1 FI [367], FI_adjBMI [367] 
rs141203811 1 229772141 URB2 FI_adjBMI [368] 
rs2375278 1 25529038 SYF2 HbA1c [121] 
rs267738 1 150940625 CERS2 HbA1c [121], HbA1c_adjBMI * 
rs6684514 1 156255456 TMEM79 HbA1c [346] 
rs857725 1 158607935 SPTA1 HbA1c_adjBMI * 
rs9727115 1 99177253 SNX7 Proinsulin_adjFG [369] 
rs1260326 2 27730940 GCKR 2hG_adjBMI [370], FG_adjBMI [367], FI_adjBMI [367] 
rs895636 2 45188353 SIX3 FG [371], FG_adjBMI [372] 
rs1371614 2 27152874 DPYSL5 FG_adjBMI [366], FG_BMI30 [366] 
rs3736594 2 27995781 MRPL33 FG_adjBMI [366] 
rs35720761 2 43519977 THADA FG_adjBMI *, HbA1c_adjBMI * 
rs138726309 2 169763262 G6PC2 FG_adjBMI [368] 
rs2232323 2 169764141 G6PC2 FG_adjBMI *, HbA1c_adjBMI * 
rs146779637 2 169764368 G6PC2 FG_adjBMI *, HbA1c_adjBMI * 
rs552976 2 169791438 ABCB11 FG_adjBMI [367], HbA1c [367] 
rs733331 2 173546313 RAPGEF4-AS1 FG_adjBMI [372] 
rs1530559 2 135755629 MAP3K19 FI [367], FI_adjBMI [367] 
rs10195252 2 165513091 COBLL1 FI [367], FI_adjBMI [367] 
rs1983210 2 220421417 OBSL1 FI_adjBMI * 
rs2943645 2 227099180 LOC646736 FI_adjBMI [367] 
rs17509001 2 24021231 ATAD2B HbA1c [121] 
rs12621844 2 48414735 FOXN2 HbA1c [121] 
rs3755157 2 169792171 ABCB11 HbA1c [346] 
rs17256082 2 175292364 SCRN3 HbA1c [121] 
rs11708067 3 123065778 ADCY5 2hG_adjBMI [367], FG [83], FG_adjBMI [366], HbA1c [121] 
rs7651090 3 185513392 IGF2BP2 2hG_adjBMI [367], FG [367], FG_adjBMI [367] 
rs17036328 3 12390484 PPARG FI_adjBMI [367] 
rs7616006 3 12267648 SYN2 HbA1c [121] 
rs9818758 3 49382925 USP4 HbA1c [121] 
rs8192675 3 170724883 SLC2A2 HbA1c [121] 
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snp chr pos gene trait 
rs4894799 3 171795540 FNDC3B HbA1c [121] 
rs35726701 3 49740895 RNF123 HbA1c_adjBMI * 
rs9884482 4 106081636 TET2 FI [367], FI_adjBMI [367] 
rs3822072 4 89741269 FAM13A FI_adjBMI [367] 
rs6822892 4 157734675 PDGFC FI_adjBMI [367] 
rs17046216 4 166255704 MSMO1 FI_adjBMI [378], HOMA-IR [378] 
rs13134327 4 144659795 FREM3 HbA1c [121] 
rs2237051 4 110901198 EGF HbA1c_adjBMI * 
rs1019503 5 96254817 ERAP2 2hG [367], 2hG_adjBMI [367] 
rs146886108 5 14751305 ANKH FG_adjBMI * 
rs7708285 5 76425867 ZBED3-AS1 FG_adjBMI [367] 
rs7713317 5 95716722 PCSK1 FG_adjBMI [367] 
rs4865796 5 53272664 ARL15 FI [367], FI_adjBMI [367] 
rs6450057 5 51647364 PELO FI_adjBMI [373] 
rs459193 5 55806751 LOC101928448 FI_adjBMI [367] 
rs31244 5 75594743 SV2C HbA1c_adjBMI * 
rs35658696 5 102338811 PAM Insulinogenic index [374] 
rs10305492 6 39046794 GLP1R FG [375], FG_adjBMI [368] 
rs17762454 6 7213200 RREB1 FG_adjBMI [367] 
rs35742417 6 7247344 RREB1 FG_adjBMI [368], HbA1c_adjBMI * 
rs2745353 6 127452935 RSPO3 FI [367], FI_adjBMI [367] 
rs6912327 6 34764922 UHRF1BP1 FI_adjBMI [367] 
rs7756992 6 20679709 CDKAL1 HbA1c [121] 
rs1800562 6 26093141 HFE HbA1c [367], HbA1c_adjBMI * 
rs11964178 6 109562035 LOC100996634 HbA1c [121] 
rs9399137 6 135419018 HBS1L HbA1c [346] 
rs592423 6 139840693 LOC645434 HbA1c [121] 
rs1799945 6 26091179 HFE HbA1c_adjBMI * 
rs1799884 7 44229068 GCK 1hG [376], 2hG [376], FG [376], HbA1c [350] 
rs2191349 7 15064309 AGMO FG [83], FG_adjBMI [366], HbA1c [121] 
rs6943153 7 50791579 GRB10 FG [367], FG_adjBMI [367] 
rs6947345 7 101071933 COL26A1 FG [377] 
rs194524 7 89861832 STEAP2 FG_adjBMI * 
rs1167800 7 75176196 HIP1 FI [367], FI_adjBMI [367] 
rs35332062 7 73012042 MLXIPL HbA1c_adjBMI * 
rs11558471 8 118185733 SLC30A8 FG [367], FG_adjBMI [366], HbA1c [121], Proinsulin [369] 
rs4841132 8 9183596 LOC157273 FG_adjBMI [366], FG_BMI30 [366], 
 FI_adjBMI [366], FI_BMI30 [366] 
rs4737009 8 41630405 ANK1 HbA1c [367] 
rs6980507 8 42383084 SLC20A2 HbA1c [121] 
rs34664882 8 41543675 ANK1 HbA1c_adjBMI * 
rs7034200 9 4289050 GLIS3 FG [83], FG_adjBMI [366] 
rs10811661 9 22134094 CDKN2B-AS1 FG [367], FG_adjBMI [366] 
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snp chr pos gene trait 
rs16913693 9 111680359 IKBKAP FG [367], FG_adjBMI [367] 
rs651007 9 136153875 ABO FG [375] 
rs3829109 9 139256766 DNLZ FG [367], FG_adjBMI [367] 
rs7040409 9 91503236 C9orf47 HbA1c [121] 
rs1467311 9 110536932 KLF4 HbA1c [121] 
rs11557154 9 34107505 DCAF12 HbA1c_adjBMI * 
rs3824420 9 712766 KANK1 Proinsulin AUC 0-30 [374] 
rs7903146 10 114758349 TCF7L2 2hG [367], 2hG_adjBMI [367], FG [83],  
FG_adjBMI [366], FI [367], FI_adjBMI [366],  
HbA1c [367], Proinsulin [369] 
rs701865 10 95381773 PDE6C FG_adjBMI * 
rs11195502 10 113039667 ADRA2A FG_adjBMI [367] 
rs7077836 10 132751498 MIR378C FI_adjBMI [378], HOMA-IR [378] 
rs16926246 10 71093392 HK1 HbA1c [350] 
rs906220 10 71060610 HK1 HbA1c_adjBMI * 
rs11605924 11 45873091 CRY2 FG [83], FG_adjBMI [366] 
rs11603334 11 72432985 ARAP1 FG [367], FG_adjBMI [366], FG_BMI30 [366],  
HbA1c [121], Proinsulin [369] 
rs1387153 11 92673828 MTNR1B FG_adjBMI [367], HbA1c [367] 
rs3782123 11 205198 BET1L HbA1c [121] 
rs2237896 11 2858440 KCNQ1 HbA1c [121] 
rs174577 11 61604814 FADS2 HbA1c [121] 
rs11224302 11 100456604 ARHGAP42 HbA1c [121] 
rs415895 11 9769562 SWAP70 HbA1c_adjBMI * 
rs117706710 11 10508903 AMPD3 HbA1c_adjBMI * 
rs643788 11 118967758 DPAGT1 HbA1c_adjBMI * 
rs10501320 11 47293799 MADD Proinsulin [369] 
rs10838687 11 47312892 MADD Proinsulin [369] 
rs17331697 12 97868906 RMST FG [377] 
rs10747083 12 133041618 FBRSL1 FG [367], FG_adjBMI [367] 
rs2657879 12 56865338 GLS2 FG_adjBMI [367] 
rs145878042 12 48143315 RAPGEF3 FI_adjBMI * 
rs860598 12 102898446 IGF1 FI_adjBMI [367] 
rs2110073 12 7075882 PHB2 HbA1c [121] 
rs2408955 12 48499131 SENP1 HbA1c [121] 
rs3184504 12 111884608 SH2B3 HbA1c_adjBMI * 
rs2650000 12 121388962 HNF1A-AS1 Insulinogenic index [374] 
rs150781447 12 65224220 TBC1D30 Proinsulin AUC 30-120 [374] 
rs11619319 13 28487599 PDX1-AS1 FG [367], FG_adjBMI [367], HbA1c [121] 
rs576674 13 33554302 KL FG [367], FG_adjBMI [367], HbA1c [121] 
rs282587 13 113351662 ATP11A HbA1c [121] 
rs9604573 13 114542858 GAS6, GAS6-AS1 HbA1c [121] 
rs3783347 14 100839261 WARS FG [367], FG_adjBMI [367] 
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snp chr pos gene trait 
rs229587 14 65263300 SPTB HbA1c_adjBMI * 
rs4502156 15 62383155 C2CD4A 2hG_adjBMI [367], FG_adjBMI [367],  
Proinsulin [369] 
rs2018860 15 99258710 IGF1R FG_adjBMI [372] 
rs1549318 15 71109147 LARP6 Proinsulin [369] 
rs11248914 16 293562 ITFG3 HbA1c [121] 
rs1558902 16 53803574 FTO HbA1c [121] 
rs4783565 16 68750190 CDH3 HbA1c [121] 
rs837763 16 88853729 PIEZO1 HbA1c [121] 
rs3747481 16 30666367 PRR14 HbA1c_adjBMI * 
rs201226914 16 88798919 PIEZO1, LOC100289580 HbA1c_adjBMI * 
rs72839768 17 7129898 DVL2 2hG_adjBMI * 
rs61741902 17 2282779 SGSM2 Fasting proinsulin [374] 
rs9914988 17 27183104 ERAL1 HbA1c [121] 
rs12602486 17 42241929 C17orf53 HbA1c [346] 
rs2073285 17 76117361 TMC6 HbA1c [121] 
rs1046896 17 80685533 FN3KRP HbA1c [367] 
rs2748427 17 76121864 TMC6 HbA1c_adjBMI * 
rs7225887 17 80904844 B3GNTL1 HbA1c_adjBMI * 
rs4790333 17 2262703 SGSM2 Proinsulin [369] 
rs1800437 19 46181392 GIPR 2hG_adjBMI * 
rs731839 19 33899065 PEPD FI [367], FI_adjBMI [367] 
rs11667918 19 17232499 MYO9B HbA1c [346] 
rs17533903 19 17256523 MYO9B HbA1c [121] 
rs35413309 19 33167837 RGS9BP HbA1c_adjBMI * 
rs6113722 20 22557099 LINC00261 FG [367], FG_adjBMI [367] 
rs17265513 20 39832628 ZHX3 FG_adjBMI [368] 
rs855791 22 37462936 TMPRSS6 HbA1c [367], HbA1c_adjBMI * 
Table 4.1: Index variants for established glycaemic loci per trait. 1hG= 1 hr Glucose. 2hG_adjBMI= 2 hr glucose adjusted 
for BMI. FG=Fasting glucose. FG_adjBMI=Fasting glucose adjusted for BMI. FI=Fasting insulin. FI_adjBMI=Fasting insulin 
adjusted for BMI. HbA1c=Glycated haemoglobin. HbA1c_adjBMI=Glycated haemoglobin adjusted for BMI. HOMA-IR= 
Insulin resistance homeostasis model assessment. Proinsulin AUC 0-30= Early phase proinsulin. Proinsulin AUC 30-120= 
Late phase proinsulin. Proinsulin_adjFG=Proinsulin adjusted for fasting glucose. Sources=Publication where the index SNP 
in the table was first associated with its respective trait. *MAGIC unpublished: based on European results from meta-
analysis of data genotyped on the ExomeChip array. 
4.4 Results 
 
4.4.1 Phenotype quality control 
 
Biological measurements can be susceptible to technical variation. To prepare the data for 
association analysis I performed quality control to assess if there were any effects of 
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technical variables on the fructosamine and HbA1c measurements. Fructosamine was 
measured on 28,310 individuals of the INTERVAL cohort and HbA1c was measured on 5,811 
individuals out of which 5,420 had both measurements.  
First, I inspected if measured values were concordant with what is expected based on 
available literature on the subject. Median fructosamine levels were high (294 µmol/L) 
compared to the normal expected range in healthy individuals (202-285 µmol/L ) [379]. In 
contrast, HbA1c median levels were within range (median=35 mmol/mol, expected 
value=31-42 mmol/mol) [380]. Correlation between fructosamine and HbA1c was  lower 
than expected (r=0.11 (this study) vs r=0.61[360], Fig 4.4). 
 
Figure 4.4: Correlation between fructosamine and HbA1c levels. r=correlation between fructosamine and HbA1c. 
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Next, I performed linear regression to determine which biometric and technical variables 
were significantly associated with fructosamine and HbA1c measurements. I  determined 
sex, donation centre, use of glucose medication, height, weight, processing date and 
number of donations were significantly associated with both; while age, number of low 
haemoglobin deferrals, use of lipid lowering medication and use of blood pressure 
medication were associated with HbA1c exclusively and attendance date with fructosamine 
(Table 4.2).  Individuals that reported use of glucose medication were subsequently 
removed. 
 
 
Variable Fructosamine HbA1c 
Age  X 
Sex X X 
Height X X 
Weight X X 
Attendance date X  
Processing date X X 
Donation centre X X 
Number of donations X X 
Number of low haemoglobin 
deferrals 
 X 
Use of glucose medication X X 
Use of lipid medication  X 
Use of blood pressure 
medication 
 X 
Table 4.2: Variables significantly associated with fructosamine and HbA1c. An X marks variables significantly associated 
(p<0.05 in linear regression).    
 
After adjusting for relevant biometric and technical variables, residuals were extracted and 
inverse rank normalised. Correlation between fructosamine and HbA1c remained 
unchanged after adjusting for covariates (Fig 4.5).  
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Figure 4.5: Correlation between normalised fructosamine and HbA1c levels after adjusting for biometric and technical 
variables. r=correlation between fructosamine and HbA1c. 
 
 
4.4.2 Heritability of fructosamine and genetic correlation results 
 
After inverse rank normalisation, 24,586 individuals with fructosamine measurements and 
5,153 with HbA1c measurements were mapped to the genetic data. I used this data to run 
genetic association analyses with BOLT-LMM. LD score regression was used on association 
results to estimate common SNP (MAF>5%) heritability for both traits. The heritability 
estimate for fructosamine was very low (2% (95% CI -2%-5%)) which is in contrast to that for 
HbA1c (17% (95% CI 0%-35%)). No evidence of genetic correlation was observed between 
the two traits (Genetic correlation (RG)=0.40, SE=0.63, p=0.52).  Using LD Hub, I estimated 
genetic correlation with other glycaemic traits. Fructosamine was not significantly 
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correlated with any other glycaemic trait (p>0.05, Table 4.3). HbA1c was significantly 
correlated with T2D (RG=0.47, p=0.01) and FG (RG=0.45, p=3.6x10-3, Table 4.3). There was 
also significant and almost complete genetic correlation between HbA1c in this study and 
HbA1c results from previous MAGIC efforts [121] (RG=0.88, SE=0.20, p=1.34x10-5) 
supporting the reliability of HbA1c measurements in this study. I also calculated genetic 
correlation between fructosamine and serum albumin and found no evidence of genetic 
correlation. Finally, given the established role of HbA1c-associated variants with some blood 
cell traits [121],  I also calculated  genetic correlation with twelve blood cell traits (Table 
4.3). I found a positive genetic correlation of HbA1c with mean corpuscular haemoglobin 
concentration (MCHC, RG=0.37, SE=0.14, p=6.1x10-3), mean corpuscular volume (MCV, 
RG=0.21, SE=0.11,p=0.04) and mean corpuscular haemoglobin (MCH,RG=0.28, SE=0.11, 
p=0.01) and a negative  genetic correlation with red cell distribution width (RDW, RG=-0.24, 
SE=0.11, p=0.04). 
Trait Fructosamine  HbA1c  
RG SE P RG SE p 
T2D -0.04 0.19 0.88 0.47 0.18 0.01 
FG_adjBMI 0.60 0.35 0.09 0.45 0.15 3.6x10-3 
FI_adjBMI -0.43 0.32 0.17 -0.15 0.17 0.36 
Fasting proinsulin -0.10 0.37 0.78 -0.01 0.30 0.98 
2hG_adjBMI -0.76 0.49 0.12 0.05 0.28 0.87 
Albumin 0.49 0.49 0.32 0.18 0.30 0.55 
HCT 0.52 0.29 0.07 0.13 0.11 0.25 
HGP 0.45 0.26 0.08 0.22 0.12 0.07 
HLR 0.30 0.22 0.18 0.15 0.11 0.18 
HLR% 0.23 0.20 0.24 0.17 0.11 0.14 
IRF 0.30 0.24 0.21 0.01 0.12 0.90 
MCHC -0.18 0.21 0.41 0.37 0.14 6.1x10-3 
MCH -0.03 0.14 0.83 0.28 0.11 0.01 
MCV 0.04 0.14 0.75 0.21 0.11 0.04 
RBC 0.35 0.21 0.09 -0.07 0.11 0.54 
RDW -0.18 0.16 0.27 -0.24 0.11 0.04 
RET 0.25 0.19 0.20 0.19 0.12 0.10 
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Trait Fructosamine  HbA1c  
RG SE P RG SE p 
RET% 0.18 0.17 0.30 0.21 0.12 0.07 
Table 4.3: Genetic correlation results for fructosamine and HbA1c.RG=genetic correlation. SE=standard error. P=p-value 
FG_adjBMI=Fasting glucose adjusted by BMI, FI_adjBMI=Fasting insulin adjusted by BMI, 2hG_adjBMI=2hr glucose adjusted 
by BMI. HCT=Haematocrit. HGB=Haemoglobin concentration. HLR=High light scatter reticulocyte count. HLR%=High light 
scatter percentage of red cells. IRF=Immature fraction of reticulocytes. MCHC=Mean corpuscular haemoglobin 
concentration. MCH=Mean corpuscular haemoglobin. MCV=Mean corpuscular volume. RBC=Red blood cell count. 
RDW=Red cell distribution width. RET=Reticulocyte count. RET%=Reticulocyte fraction of red cells. Highlighted in yellow, 
significant genetic correlation estimates. Genetic correlation analyses with glycaemic traits and albumin was performed 
using LD Hub [231]. Blood cell traits summary statistics for genetic correlation obtained from Astle et al 2017 [291]. 
 
4.4.3 Discovery of novel loci associated with fructosamine 
 
Fructosamine association analysis yielded two associated loci at genome-wide significance 
(p<5x10-8). The first association signal was rs853777 near G6PC2 (beta=0.06, p=1.7x10-10). 
This locus is also associated with HbA1c and FG [83]. The lead SNP in Dupuis et al 2010 [83] 
is rs560887 (r2 with rs853777=0.63) with an effect size of 0.032 (%) for HbA1c and 0.075 
(mmol/L) for FG. The effect size for rs853777 on the untransformed fructosamine values 
was 2.54 µmol/L. The second association signal was rs111476047 near RCN3 (beta=0.09, 
p=4.8x10-14). This locus was also previously associated with fructosamine in Loomis et al 
2018 [363]. The lead signal in their study, rs34459162, is in moderate LD with my index 
variant (rs111476047 r2= 0.28), and has the same direction of effect. To compare effect 
sizes, I repeated the association analysis for rs34459162 transforming the fructosamine 
measurements using natural log transformation as done in the previous study instead of 
inverse rank normalisation. The effect size was smaller in this study but the difference was 
not significant (betaINTERVAL=0.015, betareported=0.02, pdiff=0.24).  Reciprocal conditional 
analysis suggested that the lead signal found in this study was more tightly linked to the true 
causal variant than the previously reported signal (Table 4.4).  
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rsid p-value beta conditioned p-value conditioned beta conditioned on 
rs111476047*+ 2.19x10
-11
 0.014 3.42x10
-6
 0.011 rs34459162** 
rs34459162**+ 2.08x10
-7
 0.015 5.35x10
-2
 0.007 rs111476047* 
rs111476047* 5.23x10
-14
 0.087 8.90x10
-9
 0.074 rs739347*** 
rs739347*** 7.61x10
-8
 0.079 2.09x10
-2
 0.038 rs111476047* 
rs111476047* 5.23x10
-14
 0.087 1.51x10
-12
 0.083 rs34010237**** 
rs34010237**** 1.75x10
-4
 0.047 6.24x10
-3
 0.034 rs111476047* 
Table 4.4: Reciprocal conditional analysis of lead variant near RCN3. r
2
=0.28.+Analysis was performed using log 
transformed fructosamine values. *Lead signal in this study. **Lead signal in Loomis et al 2018[363]. ***Lead signal for 
albumin GWAS in Franceschini et al (2012) [381]. ****Lead signal for albumin GWAS in Kanai et al 2018[382]. Numbers 
might differ slightly from main text due to difference in software use for association analysis (Methods 4.3.5). 
Two additional SNPs mapping near the RCN3 locus, rs739347 (r2=0.25  with rs111476047) 
and rs34010237 (r2=0.02 with rs111476047), have been previously associated with serum 
albumin levels in European [381] and Japanese individuals [382], respectively. Both 
rs739347 and rs34010237 variants were significantly associated with fructosamine levels in 
this study (p=6.9x10-8 and p=2.2x10-4, respectively) though reciprocal conditional analyses 
showed the rs739347 signal was heavily attenuated after conditioning on the lead signal in 
this study suggesting this association was mostly driven by the lead signal in this study 
(Table 4.4). Finally, to assess the effect of my index variant (rs111476047) on serum albumin 
levels, I used NMR measurements available from the first visit (Chapter 3 Methods 3.3.1 ), 
and found a significant and directionally consistent association with albumin levels in these 
data (beta=0.02, p=6.2x10-3). 
 
  
4.4.4  Evaluation of the effects of established glycaemic loci on fructosamine levels 
 
 
Finally, I explored the influence of established glycaemic loci on fructosamine levels. For this 
analysis I used a list curated by Eleanor Wheeler and Gaëlle Marenne (Table 4.1). In total, 
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142 unique SNPs associated with at least one glycaemic trait were extracted.  I found 
significant associations (Bonferroni-corrected p < 3.5x10-4, Methods 4.3.6, Table 4.5) in four 
loci: ADCY5, GCK, G6PC2 and MTNR1B.  
rsid Gene Chr Pos EA NEA EAF B SE P 
rs11708067 ADCY5 3 123065778 A G 0.76 0.04 0.01 1.5x10-4 
rs730497 GCK 7 44223721 T C 0.18 0.04 0.01 1.4x10-4 
rs1387153 MTNR1B 11 92673828 T C 0.29 0.04 0.01 1.9x10-4 
rs552976 G6PC2* 2 169791438 G A 0.64 0.06 0.01 8.3x10-9 
Table 4.5: Associations of established glycaemic loci on fructosamine. Chr=chromosome. Pos = position in GRCH37. 
EA=Effect allele. NEA=Non-effect allele. EAF=Effect allele frequency. B=effect size SE=standard error of effect. P=p-value. 
*Nearest gene is ABCB11, but G6PC2 is known to be the effector transcript at the locus [368]. 
I also found an enrichment of nominally significant and directionally consistent glycaemic 
signals in the fructosamine association results suggesting that these loci also have an effect 
on fructosamine (binomial p=5.6x10-3, Table 4.6).  
 
rsid Chr Pos EA-FR EAF B SE P Gene Trait EA-T 
rs10811661 9 22134094 T 0.83 0.04 0.01 1.9x10
-3
 CDKN2B-AS1 HbA1c T 
rs11603334 11 72432985 G 0.85 0.03 0.01 7.9x10
-3
 ARAP1 HbA1c G 
rs11708067 3 123065778 A 0.76 0.04 0.01 1.5x10
-4
 ADCY5 HbA1c A 
rs1387153 11 92673828 T 0.29 0.04 0.01 1.4x10
-4
 MTNR1B HbA1c T 
rs17265513 20 39832628 C 0.19 0.03 0.01 1.0x10
-2
 ZHX3 FG C 
rs1799884 7 44229068 T 0.18 0.04 0.01 1.4x10
-5
 GCK HbA1c T 
rs2232323 2 169764141 A 0.99 0.13 0.06 2.3x10
-2
 G6PC2 HbA1c A 
rs3829109 9 139256766 G 0.73 0.02 0.01 3.3x10
-2
 DNLZ HbA1c G 
rs552976 2 169791438 G 0.64 0.06 0.01 8.3x10
-9
 ABCB11 HbA1c G 
rs7651090 3 185513392 G 0.32 0.03 0.01 1.2x10
-3
 IGF2BP2 HbA1c G 
rs7708285 5 76425867 G 0.31 0.02 0.01 2.2x10
-2
 ZBED3-AS1 HbA1c G 
rs9884482 4 106081636 C 0.37 0.02 0.01 2.4x10
-2
 TET2 FI C 
Table 4.6: Nominally significant and directionally consistent established glycaemic loci. Table legend: Chr=chromosome. 
Pos=position in GRCH37. EA-FR=effect allele in fructosamine. B=effect size in fructosamine. SE=standard error of effect size 
in fructosamine. P=p-value in fructosamine. Gene=nearest gene. Trait=Trait where the association of the SNP was 
previously reported. EA-T=Effect allele of the associated trait. Binomial p=5.6x10
-3
. 
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4.5 Discussion 
 
In this chapter, as is standard for studies of glycaemic measures, I examined the genetic 
influences on fructosamine levels in a healthy population where one can explore these 
influences in a non-diabetic setting where measures are unaffected by disease and its 
treatment. Specifically, I sought to quantify the heritability of fructosamine, identify loci 
affecting the trait and explore its genetic relationship with other glycaemic traits. Overall, 
my results show that, in contrast with HbA1c, the heritability for fructosamine is low, 
despite some evidence for shared genetic aetiology. Results also highlight a variant 
potentially regulating fructosamine levels through pathways that also regulate circulating 
albumin.  
Firstly I established that, in agreement with previous twin studies [362], fructosamine 
appears to be a lowly heritable trait (2% (95% CI -2%-5%)) suggesting most of the variation 
of the trait in this population is due to environmental factors which is not surprising given 
the fact that this is a trait normally used to measure short term changes in glycaemia after 
treatment . Fructosamine also does not show evidence of significant genetic correlation 
with other glycaemic traits including HbA1c (p>0.05) which is somewhat surprising given the 
fact that both traits normally have a high phenotypic correlation (~0.61[360]) and reflect 
similar biological processes, namely, the glycation of serum proteins.  This lack of genetic 
correlation was also observed in Loomis et al 2018 [363]. The HbA1c heritability estimate in 
this study (17% (95% CI 0%-35%) was higher than those reported in LD Hub (7% (95% CI 4%-
9%))[231] and the one obtained using summary statistics from the latest published MAGIC 
effort [121] (6% (95% CI 5%-8%)) but this difference was not statistically significant due to 
the wide confidence intervals in this study. It is likely though, that the estimate from this 
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study is inflated and the actual heritability estimate is closer to the one obtained from the 
MAGIC HbA1c data as this dataset has a much larger sample size (>20 times as large) and 
therefore is better powered to obtain a more accurate estimate. HbA1c was genetically 
correlated with both glycaemic traits (FG and T2D) and erythrocytic traits (MCHC, MCH, 
MCV and RDW), which is consistent with what is known about the biology of HbA1c [121]. 
Despite the low heritability, I was able to detect two loci associated with fructosamine levels 
at genome-wide significance (p<5x10-8).  The first locus was rs853777, near G6PC2. G6PC2 
codes for Glucose-6-Phosphatase Catalytic Subunit 2 and it is a well-established locus in 
HbA1c and fasting glucose metabolism [83]. This protein is produced specifically in islet beta 
cells and is involved in regulation of insulin secretion [383].  A mouse  knockout of this gene  
exhibits mild metabolic phenotypes (reduction of blood glucose with no impact on 
cholesterol, glycerol, insulin and glucagon concentrations or body weight)  and enhanced 
islet responsiveness to blood glucose levels[384, 385], making it a feasible therapeutic 
target given that no deleterious consequences were observed after the knockout. 
Interestingly, this locus was only nominally associated with fructosamine levels in Loomis et 
al 2018 [363] (rs1402837, p=0.016, r2 with rs853777=0.17). This therefore represents a 
novel association of this locus with fructosamine levels.  
The other associated SNP was rs111476047 located downstream of RCN3. RCN3 codes for 
Reticulocalbin 3, which is an EF-hand calcium-binding protein of poorly understood function 
[386]. This locus was previously associated with fructosamine levels and conditional analysis 
shows that the locus found in this study is possible more tightly linked to the true causal 
variant (Table 4.4).  There was no expression information for the lead signal in GTEx but 
rs113886122, the second strongest SNP in this locus  (p=7.3x10-14 , r2 with 
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rs111476047=0.62) is an eQTL for FCGRT in tibial nerve, subcutaneous adipose, transverse 
colon, skin and transformed fibroblasts tissues [387]. FCGRT codes for Fc Fragment of IgG 
Receptor and Transporter which plays a role in maintenance of albumin levels protecting it 
from degradation [388]. In addition to this, mouse studies have shown that hepatic levels of 
this protein regulate albumin homeostasis and susceptibility to liver injury [389].  These 
results combined with the suggestive evidence of association with albumin levels  
(p=6.2x10-3) suggest that the locus found in this study could influence fructosamine levels 
through pathways that also regulate albumin. 
Finally, lookups of previously established glycaemic loci suggest that factors affecting other 
glycaemic traits such as HbA1c, fasting glucose and fasting insulin also influence 
fructosamine levels reflecting a shared genetic aetiology for these traits. As sample sizes 
increase, it is likely some of these signals will reach genome-wide significance.  
The results in this chapter need further exploration given a few limitations. Firstly, 
fructosamine levels were unusually high (median=294 µmol/L) compared to established 
reference ranges (202-285 µmol/L). Secondly, the correlation of fructosamine levels and 
HbA1c was unexpectedly low (r=0.1) and this discrepancy appears to not be driven by 
unreliability of HbA1c measurements as these fell within expected ranges and were 
supported by genetic correlation results. Phenotype quality control did not address either of 
these issues which suggests that there might be other factors influencing these observations 
such as machine calibration issues. Nevertheless, fructosamine measurements seem reliable 
enough to produce biologically plausible association results. 
Future studies on the genetic architecture of fructosamine will shed more light into the 
different glycaemic and non-glycaemic mechanisms that can affect fructosamine levels, and 
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potentially identify mechanisms that affect risk of comorbidities independently of  other 
glycaemic traits such as fasting glucose and HbA1c. Furthermore, increasing the number of 
individuals with both HbA1c and fructosamine measured could help identify variants 
associated with protein glycation by examining the genetic influences of the glycation gap. 
Screening for these variants could be potentially useful in the clinic when testing for T2D 
using HbA1c as a diagnostic tool.  
4.6 Future directions 
 
While working on this analysis, the first GWAS on fructosamine levels was published [363]. 
This presents an opportunity to use summary statistics from that study for meta-analysis 
with my data. To my knowledge, ARIC and CARDIA, the cohorts used in this previous study, 
are the only cohorts with available fructosamine and genetic data therefore the only other 
dataset that can be combined with mine.  
To further explore the influence of established glycaemic loci on fructosamine levels, I will 
build a GRS score for T2D, FG, albumin and HbA1c and test them on the fructosamine 
dataset for association. In addition to this, I can also explore whether there is an enrichment 
of rare variant associations in known glycaemic loci using the WES and WGS data in the 
INTERVAL cohort (NWES+WGS=5,874). 
Another possible avenue to explore is to perform multi-trait analysis with fructosamine and 
HbA1c, or T2D, to identify pleiotropic effects or to boost power in identification of loci 
affecting fructosamine levels exclusively. This can be achieved using a method that uses 
summary statistics as input such as MTAG [390] so I can combine summary statistics from 
this study with data from the MAGIC and DIAGRAM consortia.  
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5 Conclusions and future directions 
 
Genetic studies of complex traits have advanced our understanding of complex disease by 
revealing the polygenic architecture of most of these traits, uncovering biological 
mechanisms contributing to phenotypic variance, and in some cases highlighting novel 
potential therapeutic targets.  Most of these advances have been through the exploration of 
common variation in the population through array-based genotyping. As the field has 
moved forward, there has been an increasing interest in understanding the contribution of 
rare variation to common genetic traits and diseases, facilitated by improved imputation 
reference panels [127, 152, 392], and decreasing costs of sequencing. Parallel to this, the 
range of studied phenotypes has continued to expand by including higher resolution 
measurements (high dimensional molecular phenotypes), focusing on extremes of the 
phenotype distribution, and measuring various correlated traits in the same individuals to 
gain novel insights into the pathophysiology of disease.  
In this thesis, I have provided further knowledge on the genetic architecture of a distinct 
number of cardiometabolic traits (Chapters 2, 3 and 4) by combining a variety of approaches 
with diverse genotypic and phenotypic resolution. These ranged from analysis of rare coding 
variation (Chapter 3) to common variants (Chapters 2 and 4), as well as, different degrees of 
phenotypic resolution, including biomarkers of cardiovascular disease obtained from NMR 
measurements (Chapter 3), extremes of continuous phenotypes (BMI) clinically ascertained 
(Chapter 2), and exploration of a glycaemic biomarker hitherto little explored (Chapter 4). 
 I and others first explored the genetic architecture of persistently thin and healthy 
individuals using a clinically ascertained cohort: STILTS (Chapter 2). This allowed me to 
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establish the heritability of healthy thinness for the first time and show that this estimate is 
similar to that of early onset severe obesity.  I and others also performed a GWAS of 
persistent healthy thinness vs. severe obesity with a total sample size of 2,927. We were 
able to find evidence of association in loci that had only just been discovered at the time of 
this work, using large cohorts with >40,000 individuals highlighting the added value of a 
clinical extreme approach. Finally, results from this study also showed that thinness falls on 
the lower end of the polygenic BMI spectrum, although incomplete genetic correlation with 
BMI suggests it is plausible additional loci influencing thinness might be found by focusing 
on clinically ascertained persistent and healthy thinness, and further investigating  the rarer 
allele frequency spectrum. The work from this chapter provides a valuable resource for 
future studies into body mass index, where further studies on similarly ascertained clinical 
extremes can be combined with these datasets to increase power to detect novel loci 
and/or investigate non-additive effects of established loci at the extremes of the 
distribution. Loci exerting their effect mostly through the lower tail of the BMI distribution 
might highlight protective variation aiding the search for anti-obesity therapeutic targets.  
In the next two chapters I studied the genetics of circulating biomarkers in a population of 
healthy blood donors (INTERVAL). In Chapter 3, I studied the influence of rare variation on 
226 serum lipoproteins, lipids and amino acids measured on a subset of this population with 
WES and/or WGS data (Ntotal=7,142). Gene-based analyses recapitulated established 
associations in lipoprotein metabolism genes (APOB, APOC3, PCSK9, SCARB1 and LIPC) and 
amino acid metabolism genes (HAL, PAH, ALDH1L1) and highlighted four genes (ACSL1, 
MYCN, FBXO36 and B4GALNT3) potentially involved in lipoprotein metabolism that merit 
further replication in additional studies using similar high resolution measurements. 
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Expanding the analysis to gene sets, I found a novel association of rare loss-of-function 
variants in the regulation of pyruvate dehydrogenase (PDH) complex pathway with 
intermediate and low density lipoprotein metabolism. Finally, focusing on genes near GWAS 
signals for traditionally measured lipid traits, after removing loci where the effector 
transcript is known, I found an enrichment of rare variant associations in genes near HDL-C 
GWAS signals in esterified and total cholesterol in extra-large HDL suggesting this gene set is 
enriched for effector transcripts. Exploring the tails of the distribution of these 
measurements, I also found an enrichment of predicted deleterious variants in lipoprotein 
disorder and metabolism gene sets at the lower tails of four lipoprotein measurements. This 
finding demonstrates that rare “protective” variation with strong effects is a significant 
contributor to lipoprotein levels in a healthy population. Overall, I showed that the 
increased genotypic resolution gained by using sequencing data allowed us to unveil the 
contribution of rare variation to the extremes of the distribution of circulating biomarkers, 
the identification of a novel pathway influencing  these measurements, and to highlight the 
enrichment of effector transcripts near HDL GWAS signals, all findings which had not been 
addressed in previous work using array-based genotyping platforms on larger sample sizes 
on the same NMR platform (e.g Kettunen et al. (2016) [173] N=24,925). 
In my last project, I performed the largest GWAS to date on fructosamine levels on 24,586 
individuals from the INTERVAL cohort (Chapter 4). Here I characterised the heritability of 
the trait and found it to be very low (~2%), which is consistent with what would be expected 
from a trait measuring short term changes in glycaemia. In addition to this, I discovered one 
novel locus (G6PC2) associated with fructosamine that has been previously linked to other 
glycaemic traits [367], and another locus (RCN3) that had been previously linked to 
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fructosamine through non-glycaemic pathways [363]. I also found some shared genetic 
aetiology between fructosamine and other glycaemic traits such as glycated haemoglobin, 
fasting glucose and fasting insulin (binomial p=5.6x10-3 for enrichment of nominally 
significant signals with consistent direction of effect) but no evidence of genome-wide 
genetic correlation (p>0.05 for all estimates).  Fructosamine, as a glycaemic trait, has been 
understudied and only very recently the first genetic study was published [363]. Future work 
on this dataset will aim to provide more clarity into the genetic relationship of this trait with 
T2D, its comorbidities and other glycaemic traits. 
Altogether, the different approaches used in this thesis shed light on specific components of 
the genetic architecture of the studied cardiometabolic traits. Varying levels of genotypic 
resolution allowed me to explore the impact of variation across the allele frequency 
spectrum to the genetic architecture of these traits. Contribution of common variation was 
assessed via genome-wide imputed data (Chapters 2 and 4) whereas contribution of rare 
variation was assessed via sequencing data (Chapter 3). I also tested various levels of 
phenotypic detail to capture different aspects of cardiometabolic trait biology (more on this 
on Section 5.1). The diverse study designs employed in this thesis showcase the utility of 
combining datasets with different degrees of genotypic and phenotypic resolution to gain 
novel biological insights.  
 
5.1 Expanding the range of phenotypic measurements 
 
Cardiovascular disease can be impacted by a wide diversity of risk factors. Understanding 
the genetic bases of each can help us better recognise the causality networks leading to 
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disease and the heterogeneity in presentation of symptoms, comorbidities and outcomes.   
The choice of phenotype to focus on will lead to a different snapshot of these complex 
networks of interactions. In this thesis I have explored different resolutions of phenotypes 
from anthropometric measurements (extremes of BMI distribution), to measurement of a 
relatively unexplored glycaemic trait (fructosamine), to high resolution circulating biomarker 
measurements (NMR data). Each of these projects allowed me to understand different 
biological aspects of these traits tightly linked to cardiovascular disease.  
As demonstrated in previous efforts [38, 173, 288] and this thesis, higher resolution 
measurements of many circulating lipid, lipoprotein and amino acids can provide novel 
metabolic insights as many of these measurements are better at capturing underlying 
biology. Having a single large cohort with these measurements provides a huge advantage in 
avoiding between-study heterogeneity not due to biological variables.  In future, coupling 
high resolution measurements with sequence data and electronic health records (EHR) has 
the potential benefit of assessing in-silico effects of protein inactivation on circulating 
biomarker metabolism and unexpected (positive or negative) medical side-effects. This can 
be achieved by testing the effect of loss-of-function variants (mimicking drug targeting) on 
different circulating biomarkers and medical conditions through mediation analysis.   
Population cohorts such as the UK Biobank (and other large cohorts that may accrue 
relevant data) will provide a unique opportunity to explore these types of questions as they 
accrue sequencing data and high resolution NMR measurements [393, 394]. 
In parallel with the development of large national biobanks, studies of carefully selected 
clinical cases can add a powerful dimension to the study of the genetic architecture of 
common traits.  In particular carefully ascertained individuals on the extremes of the 
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phenotype distribution, especially as sample sizes increase and the genetic resolution 
increases to sequence based studies, may reveal additional rare variants of larger effect 
exerting effects on these traits and highlight possible new therapeutics. Studies in height 
and lipid traits have shown a higher polygenic component in the upper tail of the 
distribution and have suggested a role for rare variation in the lower tail [245, 327]. It is 
possible then, that WES data on the STILTS cohort might generate further insights into the 
genetic causes of persistent and healthy thinness.  
 
     
5.2 Assessing pleiotropy in complex disease  
 
Deep phenotyping (i.e, the simultaneous measurement of multiple detailed phenotypes) 
also allows exploration of biological questions involving multiple correlated traits. The 
correlation structure of phenotypes can aid genetic studies in two ways: increase power to 
detect associations by capturing noise due to environmental variation and identification of 
shared genetic effects between traits (pleiotropy). The former was discussed in Chapter 3 
and the latter is a feature of complex traits whose better understanding is key for the future 
of precision medicine.  
Pleiotropy occurs when a single gene affects more than one trait simultaneously. One way 
to assess pleiotropy is by testing a single variant against a wide number of phenotypes 
simultaneously in a phenome-wide association study (PheWAS) [144]. Another way to test 
for pleiotropy that does not pinpoint the associated loci but gives an overall sense of genetic 
relationship between two traits is through genome-wide genetic correlation analyses [228, 
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395]. Through these approaches, it has been shown that pleiotropic effects in the human 
phenome are pervasive.  
Studies of pleiotropy can reveal unknown molecular links between seemingly unrelated 
phenotypes such as multiple sclerosis and schizophrenia [396] or childhood obesity and 
ulcerative colitis [228]. Given that in complex disease, a risk factor can be regulated by 
several different genetic variants representing different pathways, understanding how these 
variants impact disease risk could potentially add a new dimension to patient risk 
stratification beyond the sole measurement of the risk factor. For lipid and glycaemic traits 
in particular, there has been an increasing amount of evidence showing how cardiovascular 
disease and T2D risk changes depending on the pathway through which risk factors are 
increased or decreased, for example, only some HDL-C raising genetic mechanisms have an 
effect  on CVD risk [110](see Chapter 1 Section 1.2.2).  My findings in Chapter 3 were 
consistent with what has been previously reported in literature [38, 311] of pleiotropic 
effects of genes such as APOB, APOC3 and PCSK9 that have been previously associated with 
traditionally measured lipid traits on multiple detailed measurements of lipoprotein 
metabolism. In Chapter 4, I show that similarly to what has been previously shown for 
HbA1c [121, 350], fructosamine levels can be increased via glycaemic or non-glycaemic 
pathways.  
Further pleiotropic studies on CVD risk factors are warranted to get a clearer picture on the 
influence of these traits on cardiovascular disease and T2D risk and potentially identify 
optimal drug targets (e.g targets without a detrimental impact on another trait).  
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5.3 Exploring the contribution of rare variation to cardiometabolic traits  
 
Rare variant analyses are currently underpowered to detect associations at gene-wide 
significance (2.5x10-6) with sample sizes similar to the ones in many current studies (~10,000 
samples), especially in case-control studies [397]. It is therefore not surprising that gene-
based tests in Chapter 3 did not yield novel associations that remained significant after 
correcting for multiple traits. As mentioned in the discussion of the aforementioned chapter 
(see Chapter 3 Discussion 3.5), pathogenicity scores are an important tool to help prioritise 
variants but still, these are not perfect. Integration of information from human interactome 
networks and techniques such as deep mutational scanning in the future, will potentially 
lead to improvement in prediction of deleteriousness of protein coding variants [398, 399]. 
In the end, the balance between stringency of filters used in variant selection for the 
analysis and the number of variants included in it determines the outcome of the test. Since 
this information is usually not known a priori, it is not uncommon to use various sets of 
filters in gene-based tests to maximise power [91, 288, 400]. Since high confidence loss-of-
function variants are rare, an approach that has been used before with success is testing 
gene sets instead of individual genes [401]. This approach was also successful in my own 
data. The downside to this approach is that it is harder to pinpoint causal genes.  
As whole-genome sequencing becomes more prevalent, it will become an even bigger 
challenge to develop scores to prioritise variants to be included in rare variant aggregation 
tests as consequences of non-coding variation are less well understood than those in coding 
variation where one can more easily interpret the impact on the affected protein sequence. 
Attempts at scoring non-coding variants have been shown to fail to differentiate neutral 
variation from highly deleterious variation [402]. Generation of epigenomic maps for 
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distinct cell types such as the ENCODE [403], ROADMAP EPIGENOME [404] and BLUEPRINT 
projects [405] will provide additional data to functionally categorise non-coding variation 
and refine these functional scoring algorithms that mostly rely on machine-learning 
approaches. Previous efforts to improve annotation of non-coding variants also include 
usage of expression data from the GTEx consortium to generate an algorithm that predicts 
regulatory effects of rare variants [406].  Another technique that should allow for 
improvements in identification of regulatory elements is massively parallel reporter assays 
[407]. These assays allow testing for activity of thousands of regulatory elements in a single 
experiment making it ideal for this endeavour.   
On-going improvement of pathogenicity scores for coding and non-coding variation will not 
only aid in the discovery of novel gene-trait associations but will also be crucial when 
incorporating sequencing data from patients in the clinic by differentiating likely causal 
mutations for a given phenotype from neutral variation, therefore influencing provision of 
diagnosis and in time influencing  treatment choice.  
5.4 Concluding remarks 
 
The field of complex disease genetics has been undergoing a major transformation with 
increasing sample sizes, establishment of large deeply phenotyped cohorts and decreasing 
costs of sequencing. GWAS studies have helped us get a better understanding of complex 
disease but there are still many gaps in the knowledge of the biological underpinnings of a 
wide number of traits. During my PhD I have addressed some of these gaps by focusing on 
understudied phenotypes, in particular, risk factors for T2D and cardiovascular disease and 
using a combination of imputed and sequencing data to study them. I provided the first 
evaluation of the genetic architecture of persistent and healthy thinness, insights into the 
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contribution of rare variants to circulating biomarkers levels and novel findings regarding 
the genetic architecture of fructosamine regulation. Nevertheless, many questions still 
remain that can only be addressed by increasing sample sizes (preferably with sequencing 
data), expanding studies to include more samples of non-European origin, exploring other 
forms of genetic variation that are currently understudied (e.g. structural variation), 
expanding the number of phenotypes tested and functional follow-up of associated loci. 
Some of the outstanding questions in the field include but are not limited to:  
 How many independent loci influence these risk factors? 
 What are the causal variants in associated loci? 
 What is the contribution of structural variation to trait heritability?  
 What proportion of these loci are shared between risk factors? 
 Can we identify protective rare variation in genes not highlighted in association 
studies that only occurs in the tails of the phenotype distribution?  
 Which genes represent ideal drug targets? 
 What is the biological consequence of associated non-coding loci? 
 How do genetic variants associated with disease or trait mechanistically impact 
pathophysiology/ physiology? 
Answering these questions is necessary if one aims to be able to use genetic data in 
standard clinical practice. Precision medicine will rely on these on-going advancements in 
the field to improve quality of patient care.  
151 
 
References 
 
1. Lander, E.S. and N.J. Schork, Genetic dissection of complex traits. Science, 1994. 265(5181): 
p. 2037-48. 
2. Livshits, G., Growth and development of bodyweight, height and head circumference during 
the first two years of life: quantitative genetic aspects. Ann Hum Biol, 1986. 13(4): p. 387-96. 
3. Mueller, W.H., Parent-child correlations for stature and weight among school aged children: 
A review of 24 studies. Hum Biol, 1976. 48(2): p. 379-97. 
4. Rao, D.C., et al., Analysis of family resemblance. V. Height and weight in northeastern Brazil. 
Am J Hum Genet, 1975. 27(4): p. 509-20. 
5. Bogin, B. and L. Rios, Rapid morphological change in living humans: implications for modern 
human origins. Comp Biochem Physiol A Mol Integr Physiol, 2003. 136(1): p. 71-84. 
6. Singhal, A., et al., Early nutrition and leptin concentrations in later life. Am J Clin Nutr, 2002. 
75(6): p. 993-9. 
7. World Health Organization. Cardiovascular diseases (CVDs). [online] 2018  27 Jul. 2018]; 
Available from: http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-
(cvds). 
8. McGill, H.C., Jr., C.A. McMahan, and S.S. Gidding, Preventing heart disease in the 21st 
century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) 
study. Circulation, 2008. 117(9): p. 1216-27. 
9. Gersh, B.J., et al., Novel therapeutic concepts: the epidemic of cardiovascular disease in the 
developing world: global implications. Eur Heart J, 2010. 31(6): p. 642-8. 
10. Teo, K.K. and H. Dokainish, The Emerging Epidemic of Cardiovascular Risk Factors and 
Atherosclerotic Disease in Developing Countries. Can J Cardiol, 2017. 33(3): p. 358-365. 
11. Gaziano, T.A., et al., Growing epidemic of coronary heart disease in low- and middle-income 
countries. Curr Probl Cardiol, 2010. 35(2): p. 72-115. 
12. Kathiresan, S. and D. Srivastava, Genetics of human cardiovascular disease. Cell, 2012. 
148(6): p. 1242-57. 
13. Finegold, J.A., P. Asaria, and D.P. Francis, Mortality from ischaemic heart disease by country, 
region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol, 
2013. 168(2): p. 934-45. 
14. Borrell, L.N., The effects of smoking and physical inactivity on advancing mortality in U.S. 
adults. Ann Epidemiol, 2014. 24(6): p. 484-7. 
15. de Souza, R.J., et al., Intake of saturated and trans unsaturated fatty acids and risk of all 
cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-
analysis of observational studies. BMJ, 2015. 351: p. h3978. 
16. Baldo, M.P., S.L. Rodrigues, and J.G. Mill, High salt intake as a multifaceted cardiovascular 
disease: new support from cellular and molecular evidence. Heart Fail Rev, 2015. 20(4): p. 
461-74. 
17. Fernandez-Sola, J., Cardiovascular risks and benefits of moderate and heavy alcohol 
consumption. Nat Rev Cardiol, 2015. 12(10): p. 576-87. 
18. O'Donnell, M.J., et al., Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 
countries (the INTERSTROKE study): a case-control study. Lancet, 2010. 376(9735): p. 112-23. 
19. Eckel, R.H., Obesity and heart disease: a statement for healthcare professionals from the 
Nutrition Committee, American Heart Association. Circulation, 1997. 96(9): p. 3248-50. 
20. Navar-Boggan, A.M., et al., Hyperlipidemia in early adulthood increases long-term risk of 
coronary heart disease. Circulation, 2015. 131(5): p. 451-8. 
21. Rimm, E.B., et al., Body size and fat distribution as predictors of coronary heart disease 
among middle-aged and older US men. Am J Epidemiol, 1995. 141(12): p. 1117-27. 
152 
 
22. Evans, M.F. and J. Frank, Body weight and mortality among women. Can Fam Physician, 
1997. 43: p. 455. 
23. Khaodhiar, L., K.C. McCowen, and G.L. Blackburn, Obesity and its comorbid conditions. Clin 
Cornerstone, 1999. 2(3): p. 17-31. 
24. Taylor, V.H., et al., The impact of obesity on quality of life. Best Pract Res Clin Endocrinol 
Metab, 2013. 27(2): p. 139-46. 
25. World Health Organization. Diabetes mellitus [online]. 2018  27 Jul. 2018]; Available from: 
http://www.who.int/mediacentre/factsheets/fs138/en/. 
26. Al-Goblan, A.S., M.A. Al-Alfi, and M.Z. Khan, Mechanism linking diabetes mellitus and 
obesity. Diabetes Metab Syndr Obes, 2014. 7: p. 587-91. 
27. Tancredi, M., et al., Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med, 
2015. 373(18): p. 1720-32. 
28. Teramoto, T., et al., Primary hyperlipidemia. J Atheroscler Thromb, 2008. 15(2): p. 49-51. 
29. Chait, A. and J.D. Brunzell, Acquired hyperlipidemia (secondary dyslipoproteinemias). 
Endocrinol Metab Clin North Am, 1990. 19(2): p. 259-78. 
30. Wray, N. and P. Visscher, Estimating trait heritability. Nature Education, 2008. 1(1): p. 29. 
31. Hill, W.G., M.E. Goddard, and P.M. Visscher, Data and theory point to mainly additive genetic 
variance for complex traits. PLoS Genet, 2008. 4(2): p. e1000008. 
32. Plomin, R. and D. Daniels, Why are children in the same family so different from one 
another? Int J Epidemiol, 2011. 40(3): p. 563-82. 
33. Boomsma, D., A. Busjahn, and L. Peltonen, Classical twin studies and beyond. Nat Rev Genet, 
2002. 3(11): p. 872-82. 
34. Mook-Kanamori, D.O., et al., Heritability estimates of body size in fetal life and early 
childhood. PLoS One, 2012. 7(7): p. e39901. 
35. Sauce, B. and L.D. Matzel, The paradox of intelligence: Heritability and malleability coexist in 
hidden gene-environment interplay. Psychol Bull, 2018. 144(1): p. 26-47. 
36. Burton, P.R., M.D. Tobin, and J.L. Hopper, Key concepts in genetic epidemiology. Lancet, 
2005. 366(9489): p. 941-51. 
37. Elks, C.E., et al., Variability in the heritability of body mass index: a systematic review and 
meta-regression. Front Endocrinol (Lausanne), 2012. 3: p. 29. 
38. Kettunen, J., et al., Genome-wide association study identifies multiple loci influencing human 
serum metabolite levels. Nat Genet, 2012. 44(3): p. 269-76. 
39. Yang, J., et al., GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet, 2011. 
88(1): p. 76-82. 
40. Speed, D., et al., Reevaluation of SNP heritability in complex human traits. Nat Genet, 2017. 
49(7): p. 986-992. 
41. Yang, J., et al., Genetic variance estimation with imputed variants finds negligible missing 
heritability for human height and body mass index. Nat Genet, 2015. 47(10): p. 1114-20. 
42. Bulik-Sullivan, B.K., et al., LD Score regression distinguishes confounding from polygenicity in 
genome-wide association studies. Nat Genet, 2015. 47(3): p. 291-5. 
43. Loh, P.R., et al., Contrasting genetic architectures of schizophrenia and other complex 
diseases using fast variance-components analysis. Nat Genet, 2015. 47(12): p. 1385-92. 
44. Kerem, B., et al., Identification of the cystic fibrosis gene: genetic analysis. Science, 1989. 
245(4922): p. 1073-80. 
45. Riordan, J.R., et al., Identification of the cystic fibrosis gene: cloning and characterization of 
complementary DNA. Science, 1989. 245(4922): p. 1066-73. 
46. Koenig, M., et al., Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and 
preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 
1987. 50(3): p. 509-17. 
47. Strathdee, C.A., et al., Cloning of cDNAs for Fanconi's anaemia by functional 
complementation. Nature, 1992. 356(6372): p. 763-7. 
153 
 
48. A novel gene containing a trinucleotide repeat that is expanded and unstable on 
Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. 
Cell, 1993. 72(6): p. 971-83. 
49. Gusella, J.F., et al., A polymorphic DNA marker genetically linked to Huntington's disease. 
Nature, 1983. 306(5940): p. 234-8. 
50. Hutchison, K.E., et al., Population stratification in the candidate gene study: fatal threat or 
red herring? Psychol Bull, 2004. 130(1): p. 66-79. 
51. Todorov, A.A. and D.C. Rao, Trade-off between false positives and false negatives in the 
linkage analysis of complex traits. Genet Epidemiol, 1997. 14(5): p. 453-64. 
52. Tabor, H.K., N.J. Risch, and R.M. Myers, Candidate-gene approaches for studying complex 
genetic traits: practical considerations. Nat Rev Genet, 2002. 3(5): p. 391-7. 
53. Roberts, S.B., et al., Replication of linkage studies of complex traits: an examination of 
variation in location estimates. Am J Hum Genet, 1999. 65(3): p. 876-84. 
54. Lander, E. and L. Kruglyak, Genetic dissection of complex traits: guidelines for interpreting 
and reporting linkage results. Nat Genet, 1995. 11(3): p. 241-7. 
55. Altmuller, J., et al., Genomewide scans of complex human diseases: true linkage is hard to 
find. Am J Hum Genet, 2001. 69(5): p. 936-50. 
56. Risch, N. and K. Merikangas, The future of genetic studies of complex human diseases. 
Science, 1996. 273(5281): p. 1516-7. 
57. Reich, D.E. and E.S. Lander, On the allelic spectrum of human disease. Trends Genet, 2001. 
17(9): p. 502-10. 
58. Daly, M.J., et al., High-resolution haplotype structure in the human genome. Nat Genet, 
2001. 29(2): p. 229-32. 
59. Goldstein, D.B., Islands of linkage disequilibrium. Nat Genet, 2001. 29(2): p. 109-11. 
60. Gabriel, S.B., et al., The structure of haplotype blocks in the human genome. Science, 2002. 
296(5576): p. 2225-9. 
61. Shifman, S., et al., Linkage disequilibrium patterns of the human genome across populations. 
Hum Mol Genet, 2003. 12(7): p. 771-6. 
62. Bush, W.S. and J.H. Moore, Chapter 11: Genome-wide association studies. PLoS Comput Biol, 
2012. 8(12): p. e1002822. 
63. International HapMap, C., The International HapMap Project. Nature, 2003. 426(6968): p. 
789-96. 
64. Li, M., C. Li, and W. Guan, Evaluation of coverage variation of SNP chips for genome-wide 
association studies. Eur J Hum Genet, 2008. 16(5): p. 635-43. 
65. Wang, D.G., et al., Large-scale identification, mapping, and genotyping of single-nucleotide 
polymorphisms in the human genome. Science, 1998. 280(5366): p. 1077-82. 
66. LaFramboise, T., Single nucleotide polymorphism arrays: a decade of biological, 
computational and technological advances. Nucleic Acids Res, 2009. 37(13): p. 4181-93. 
67. Haines, J.L., et al., Complement factor H variant increases the risk of age-related macular 
degeneration. Science, 2005. 308(5720): p. 419-21. 
68. Wellcome Trust Case Control, C., Genome-wide association study of 14,000 cases of seven 
common diseases and 3,000 shared controls. Nature, 2007. 447(7145): p. 661-78. 
69. Ioannidis, J.P., Genetic associations: false or true? Trends Mol Med, 2003. 9(4): p. 135-8. 
70. Ioannidis, J.P., N.A. Patsopoulos, and E. Evangelou, Heterogeneity in meta-analyses of 
genome-wide association investigations. PLoS One, 2007. 2(9): p. e841. 
71. Stephens, M., N.J. Smith, and P. Donnelly, A new statistical method for haplotype 
reconstruction from population data. Am J Hum Genet, 2001. 68(4): p. 978-89. 
72. Genomes Project, C., et al., A map of human genome variation from population-scale 
sequencing. Nature, 2010. 467(7319): p. 1061-73. 
73. Marchini, J. and B. Howie, Genotype imputation for genome-wide association studies. Nat 
Rev Genet, 2010. 11(7): p. 499-511. 
154 
 
74. Willer, C.J., et al., Six new loci associated with body mass index highlight a neuronal influence 
on body weight regulation. Nat Genet, 2009. 41(1): p. 25-34. 
75. Zeggini, E., et al., Meta-analysis of genome-wide association data and large-scale replication 
identifies additional susceptibility loci for type 2 diabetes. Nat Genet, 2008. 40(5): p. 638-45. 
76. Prokopenko, I., et al., Variants in MTNR1B influence fasting glucose levels. Nat Genet, 2009. 
41(1): p. 77-81. 
77. Willer, C.J., et al., Newly identified loci that influence lipid concentrations and risk of coronary 
artery disease. Nat Genet, 2008. 40(2): p. 161-9. 
78. Consortium, C.A.D., et al., Large-scale association analysis identifies new risk loci for 
coronary artery disease. Nat Genet, 2013. 45(1): p. 25-33. 
79. MacArthur, J., et al., The new NHGRI-EBI Catalog of published genome-wide association 
studies (GWAS Catalog). Nucleic Acids Res, 2017. 45(D1): p. D896-D901. 
80. Yengo, L., et al., Meta-analysis of genome-wide association studies for height and body mass 
index in approximately 700000 individuals of European ancestry. Hum Mol Genet, 2018. 
81. Yang, J., et al., Common SNPs explain a large proportion of the heritability for human height. 
Nat Genet, 2010. 42(7): p. 565-9. 
82. Fuchsberger, C., et al., The genetic architecture of type 2 diabetes. Nature, 2016. 536(7614): 
p. 41-47. 
83. Dupuis, J., et al., New genetic loci implicated in fasting glucose homeostasis and their impact 
on type 2 diabetes risk. Nat Genet, 2010. 42(2): p. 105-16. 
84. Liu, D.J., et al., Exome-wide association study of plasma lipids in >300,000 individuals. Nat 
Genet, 2017. 49(12): p. 1758-1766. 
85. Johansen, C.T., et al., Excess of rare variants in genes identified by genome-wide association 
study of hypertriglyceridemia. Nat Genet, 2010. 42(8): p. 684-7. 
86. Chong, J.X., et al., The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and 
Opportunities. Am J Hum Genet, 2015. 97(2): p. 199-215. 
87. LeMaire, S.A., et al., Genome-wide association study identifies a susceptibility locus for 
thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1. Nat Genet, 2011. 
43(10): p. 996-1000. 
88. Newton-Cheh, C., et al., Common variants at ten loci influence QT interval duration in the 
QTGEN Study. Nat Genet, 2009. 41(4): p. 399-406. 
89. Hegele, R.A., Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet, 
2009. 10(2): p. 109-21. 
90. Antonarakis, S.E., et al., Mendelian disorders and multifactorial traits: the big divide or one 
for all? Nat Rev Genet, 2010. 11(5): p. 380-4. 
91. Consortium, U.K., et al., The UK10K project identifies rare variants in health and disease. 
Nature, 2015. 526(7571): p. 82-90. 
92. Locke, A.E., et al., Genetic studies of body mass index yield new insights for obesity biology. 
Nature, 2015. 518(7538): p. 197-206. 
93. Turcot, V., et al., Protein-altering variants associated with body mass index implicate 
pathways that control energy intake and expenditure in obesity. Nat Genet, 2018. 50(1): p. 
26-41. 
94. Shungin, D., et al., New genetic loci link adipose and insulin biology to body fat distribution. 
Nature, 2015. 518(7538): p. 187-196. 
95. Frayling, T.M., Genome-wide association studies provide new insights into type 2 diabetes 
aetiology. Nat Rev Genet, 2007. 8(9): p. 657-62. 
96. Morris, A.P., et al., Large-scale association analysis provides insights into the genetic 
architecture and pathophysiology of type 2 diabetes. Nat Genet, 2012. 44(9): p. 981-90. 
97. Lyssenko, V., et al., Common variant in MTNR1B associated with increased risk of type 2 
diabetes and impaired early insulin secretion. Nat Genet, 2009. 41(1): p. 82-8. 
155 
 
98. Renstrom, F., et al., Season-dependent associations of circadian rhythm-regulating loci 
(CRY1, CRY2 and MTNR1B) and glucose homeostasis: the GLACIER Study. Diabetologia, 2015. 
58(5): p. 997-1005. 
99. Pasquali, L., et al., Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-
associated variants. Nat Genet, 2014. 46(2): p. 136-143. 
100. Lotta, L.A., et al., Integrative genomic analysis implicates limited peripheral adipose storage 
capacity in the pathogenesis of human insulin resistance. Nat Genet, 2017. 49(1): p. 17-26. 
101. Musunuru, K., et al., From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol 
locus. Nature, 2010. 466(7307): p. 714-9. 
102. Knowles, J.W. and E.A. Ashley, Cardiovascular disease: The rise of the genetic risk score. PLoS 
Med, 2018. 15(3): p. e1002546. 
103. Romanos, J., et al., Improving coeliac disease risk prediction by testing non-HLA variants 
additional to HLA variants. Gut, 2014. 63(3): p. 415-22. 
104. Sharp, S.A., et al., Clinical and research uses of genetic risk scores in type 1 diabetes. Curr 
Opin Genet Dev, 2018. 50: p. 96-102. 
105. Loos, R.J.F. and A. Janssens, Predicting Polygenic Obesity Using Genetic Information. Cell 
Metab, 2017. 25(3): p. 535-543. 
106. Goodarzi, M.O., Genetics of obesity: what genetic association studies have taught us about 
the biology of obesity and its complications. Lancet Diabetes Endocrinol, 2018. 6(3): p. 223-
236. 
107. Afzal, S., et al., Genetically low vitamin D concentrations and increased mortality: Mendelian 
randomisation analysis in three large cohorts. BMJ, 2014. 349: p. g6330. 
108. Cho, Y., et al., Alcohol intake and cardiovascular risk factors: A Mendelian randomisation 
study. Sci Rep, 2015. 5: p. 18422. 
109. Hagg, S., et al., Adiposity as a cause of cardiovascular disease: a Mendelian randomization 
study. Int J Epidemiol, 2015. 44(2): p. 578-86. 
110. Voight, B.F., et al., Plasma HDL cholesterol and risk of myocardial infarction: a mendelian 
randomisation study. Lancet, 2012. 380(9841): p. 572-80. 
111. Haase, C.L., et al., LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian 
randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab, 2012. 
97(2): p. E248-56. 
112. Agerholm-Larsen, B., et al., Elevated HDL cholesterol is a risk factor for ischemic heart 
disease in white women when caused by a common mutation in the cholesteryl ester transfer 
protein gene. Circulation, 2000. 101(16): p. 1907-12. 
113. Andersen, R.V., et al., Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, 
and increased risk of ischemic heart disease: the Copenhagen City Heart Study. J Am Coll 
Cardiol, 2003. 41(11): p. 1972-82. 
114. Frikke-Schmidt, R., et al., Association of loss-of-function mutations in the ABCA1 gene with 
high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA, 2008. 
299(21): p. 2524-32. 
115. Bennett, D.A. and M.V. Holmes, Mendelian randomisation in cardiovascular research: an 
introduction for clinicians. Heart, 2017. 103(18): p. 1400-1407. 
116. Teslovich, T.M., et al., Biological, clinical and population relevance of 95 loci for blood lipids. 
Nature, 2010. 466(7307): p. 707-13. 
117. Pollin, T.I., et al., A null mutation in human APOC3 confers a favorable plasma lipid profile 
and apparent cardioprotection. Science, 2008. 322(5908): p. 1702-5. 
118. Flannick, J., et al., Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat 
Genet, 2014. 46(4): p. 357-63. 
119. Pearson, E.R., et al., Variation in TCF7L2 influences therapeutic response to sulfonylureas: a 
GoDARTs study. Diabetes, 2007. 56(8): p. 2178-82. 
156 
 
120. Aslibekyan, S., et al., Variants identified in a GWAS meta-analysis for blood lipids are 
associated with the lipid response to fenofibrate. PLoS One, 2012. 7(10): p. e48663. 
121. Wheeler, E., et al., Impact of common genetic determinants of Hemoglobin A1c on type 2 
diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide 
meta-analysis. PLoS Med, 2017. 14(9): p. e1002383. 
122. Price, A.L., C.C. Spencer, and P. Donnelly, Progress and promise in understanding the genetic 
basis of common diseases. Proc Biol Sci, 2015. 282(1821). 
123. Pritchard, J.K., Are rare variants responsible for susceptibility to complex diseases? Am J Hum 
Genet, 2001. 69(1): p. 124-37. 
124. Boyle, E.A., Y.I. Li, and J.K. Pritchard, An Expanded View of Complex Traits: From Polygenic to 
Omnigenic. Cell, 2017. 169(7): p. 1177-1186. 
125. The Haplotype Reference Consortium. Available from: http://www.haplotype-reference-
consortium.org. 
126. Huang, J., et al., Improved imputation of low-frequency and rare variants using the UK10K 
haplotype reference panel. Nat Commun, 2015. 6: p. 8111. 
127. McCarthy, S., et al., A reference panel of 64,976 haplotypes for genotype imputation. Nat 
Genet, 2016. 48(10): p. 1279-83. 
128. Bustamante, C.D., et al., Natural selection on protein-coding genes in the human genome. 
Nature, 2005. 437(7062): p. 1153-7. 
129. Lim, E.T., et al., Distribution and medical impact of loss-of-function variants in the Finnish 
founder population. PLoS Genet, 2014. 10(7): p. e1004494. 
130. UK Biobank Axiom Array. Available from: http://www.ukbiobank.ac.uk/scientists-3/uk-
biobank-axiom-array/. 
131. Kotowski, I.K., et al., A spectrum of PCSK9 alleles contributes to plasma levels of low-density 
lipoprotein cholesterol. Am J Hum Genet, 2006. 78(3): p. 410-22. 
132. Cohen, J.C., et al., Multiple rare alleles contribute to low plasma levels of HDL cholesterol. 
Science, 2004. 305(5685): p. 869-72. 
133. Romeo, S., et al., Population-based resequencing of ANGPTL4 uncovers variations that 
reduce triglycerides and increase HDL. Nat Genet, 2007. 39(4): p. 513-6. 
134. Sudlow, C., et al., UK biobank: an open access resource for identifying the causes of a wide 
range of complex diseases of middle and old age. PLoS Med, 2015. 12(3): p. e1001779. 
135. Sankar, P.L. and L.S. Parker, The Precision Medicine Initiative's All of Us Research Program: 
an agenda for research on its ethical, legal, and social issues. Genet Med, 2017. 19(7): p. 
743-750. 
136. Chen, Z., et al., China Kadoorie Biobank of 0.5 million people: survey methods, baseline 
characteristics and long-term follow-up. Int J Epidemiol, 2011. 40(6): p. 1652-66. 
137. Higgins, J.P., et al., Measuring inconsistency in meta-analyses. BMJ, 2003. 327(7414): p. 557-
60. 
138. Nakaoka, H. and I. Inoue, Meta-analysis of genetic association studies: methodologies, 
between-study heterogeneity and winner's curse. J Hum Genet, 2009. 54(11): p. 615-23. 
139. Lin, D.Y. and P.F. Sullivan, Meta-analysis of genome-wide association studies with 
overlapping subjects. Am J Hum Genet, 2009. 85(6): p. 862-72. 
140. Galesloot, T.E., et al., A comparison of multivariate genome-wide association methods. PLoS 
One, 2014. 9(4): p. e95923. 
141. O'Reilly, P.F., et al., MultiPhen: joint model of multiple phenotypes can increase discovery in 
GWAS. PLoS One, 2012. 7(5): p. e34861. 
142. Furlotte, N.A. and E. Eskin, Efficient multiple-trait association and estimation of genetic 
correlation using the matrix-variate linear mixed model. Genetics, 2015. 200(1): p. 59-68. 
143. Denny, J.C., et al., Systematic comparison of phenome-wide association study of electronic 
medical record data and genome-wide association study data. Nat Biotechnol, 2013. 31(12): 
p. 1102-10. 
157 
 
144. Denny, J.C., et al., PheWAS: demonstrating the feasibility of a phenome-wide scan to discover 
gene-disease associations. Bioinformatics, 2010. 26(9): p. 1205-10. 
145. Ritchie, M.D., et al., Genome- and phenome-wide analyses of cardiac conduction identifies 
markers of arrhythmia risk. Circulation, 2013. 127(13): p. 1377-85. 
146. Tyrrell, J., et al., Gene-obesogenic environment interactions in the UK Biobank study. Int J 
Epidemiol, 2017. 46(2): p. 559-575. 
147. Moore, R., et al., A linear mixed model approach to study multivariate gene-environment 
interactions. bioRxiv, 2018. 
148. Emdin, C.A., et al., Analysis of predicted loss-of-function variants in UK Biobank identifies 
variants protective for disease. Nat Commun, 2018. 9(1): p. 1613. 
149. Dhandapany, P.S., et al., A common MYBPC3 (cardiac myosin binding protein C) variant 
associated with cardiomyopathies in South Asia. Nat Genet, 2009. 41(2): p. 187-91. 
150. Kurki, M.I., et al., High risk population isolate reveals low frequency variants predisposing to 
intracranial aneurysms. PLoS Genet, 2014. 10(1): p. e1004134. 
151. Consortium, S.T.D., et al., Association of a low-frequency variant in HNF1A with type 2 
diabetes in a Latino population. JAMA, 2014. 311(22): p. 2305-14. 
152. Genomes Project, C., et al., An integrated map of genetic variation from 1,092 human 
genomes. Nature, 2012. 491(7422): p. 56-65. 
153. Hatzikotoulas, K., A. Gilly, and E. Zeggini, Using population isolates in genetic association 
studies. Brief Funct Genomics, 2014. 13(5): p. 371-7. 
154. Asimit, J.L., et al., Trans-ethnic study design approaches for fine-mapping. Eur J Hum Genet, 
2016. 24(9): p. 1330-6. 
155. Hu, Y., et al., Discovery and fine-mapping of loci associated with MUFAs through trans-ethnic 
meta-analysis in Chinese and European populations. J Lipid Res, 2017. 58(5): p. 974-981. 
156. Kuo, J.Z., et al., Trans-ethnic fine mapping identifies a novel independent locus at the 3' end 
of CDKAL1 and novel variants of several susceptibility loci for type 2 diabetes in a Han 
Chinese population. Diabetologia, 2013. 56(12): p. 2619-28. 
157. Magi, R., et al., Trans-ethnic meta-regression of genome-wide association studies accounting 
for ancestry increases power for discovery and improves fine-mapping resolution. Hum Mol 
Genet, 2017. 26(18): p. 3639-3650. 
158. Sebat, J., et al., Strong association of de novo copy number mutations with autism. Science, 
2007. 316(5823): p. 445-9. 
159. Walsh, T., et al., Rare structural variants disrupt multiple genes in neurodevelopmental 
pathways in schizophrenia. Science, 2008. 320(5875): p. 539-43. 
160. Wheeler, E., et al., Genome-wide SNP and CNV analysis identifies common and low-
frequency variants associated with severe early-onset obesity. Nat Genet, 2013. 45(5): p. 
513-7. 
161. Glessner, J.T., et al., A genome-wide study reveals copy number variants exclusive to 
childhood obesity cases. Am J Hum Genet, 2010. 87(5): p. 661-6. 
162. Gonzalez, J.R., et al., A common 16p11.2 inversion underlies the joint susceptibility to asthma 
and obesity. Am J Hum Genet, 2014. 94(3): p. 361-72. 
163. Mace, A., et al., CNV-association meta-analysis in 191,161 European adults reveals new loci 
associated with anthropometric traits. Nat Commun, 2017. 8(1): p. 744. 
164. Dajani, R., et al., CNV Analysis Associates AKNAD1 with Type-2 Diabetes in Jordan 
Subpopulations. Sci Rep, 2015. 5: p. 13391. 
165. Hayes, J.L., et al., Diagnosis of copy number variation by Illumina next generation sequencing 
is comparable in performance to oligonucleotide array comparative genomic hybridisation. 
Genomics, 2013. 102(3): p. 174-81. 
166. Hehir-Kwa, J.Y., et al., Genome-wide copy number profiling on high-density bacterial artificial 
chromosomes, single-nucleotide polymorphisms, and oligonucleotide microarrays: a platform 
comparison based on statistical power analysis. DNA Res, 2007. 14(1): p. 1-11. 
158 
 
167. Feng, Y., et al., Improved molecular diagnosis by the detection of exonic deletions with target 
gene capture and deep sequencing. Genet Med, 2015. 17(2): p. 99-107. 
168. Russo, C.D., et al., Comparative study of aCGH and Next Generation Sequencing (NGS) for 
chromosomal microdeletion and microduplication screening. J Prenat Med, 2014. 8(3-4): p. 
57-69. 
169. Fromer, M., et al., Discovery and statistical genotyping of copy-number variation from 
whole-exome sequencing depth. Am J Hum Genet, 2012. 91(4): p. 597-607. 
170. Handsaker, R.E., et al., Discovery and genotyping of genome structural polymorphism by 
sequencing on a population scale. Nat Genet, 2011. 43(3): p. 269-76. 
171. Shin, S.Y., et al., An atlas of genetic influences on human blood metabolites. Nat Genet, 2014. 
46(6): p. 543-550. 
172. Suhre, K., et al., Human metabolic individuality in biomedical and pharmaceutical research. 
Nature, 2011. 477(7362): p. 54-60. 
173. Kettunen, J., et al., Genome-wide study for circulating metabolites identifies 62 loci and 
reveals novel systemic effects of LPA. Nat Commun, 2016. 7: p. 11122. 
174. Folkersen, L., et al., Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular 
disease. PLoS Genet, 2017. 13(4): p. e1006706. 
175. Global, B.M.I.M.C., et al., Body-mass index and all-cause mortality: individual-participant-
data meta-analysis of 239 prospective studies in four continents. Lancet, 2016. 388(10046): 
p. 776-86. 
176. Ogden, C.L., M.D. Carroll, and K.M. Flegal, Prevalence of obesity in the United States. JAMA, 
2014. 312(2): p. 189-90. 
177. Wardle, J., et al., Evidence for a strong genetic influence on childhood adiposity despite the 
force of the obesogenic environment. Am J Clin Nutr, 2008. 87(2): p. 398-404. 
178. Silventoinen, K., et al., Heritability of body size and muscle strength in young adulthood: a 
study of one million Swedish men. Genet Epidemiol, 2008. 32(4): p. 341-9. 
179. Allison, D.B., et al., The heritability of body mass index among an international sample of 
monozygotic twins reared apart. Int J Obes Relat Metab Disord, 1996. 20(6): p. 501-6. 
180. Akiyama, M., et al., Genome-wide association study identifies 112 new loci for body mass 
index in the Japanese population. Nat Genet, 2017. 49(10): p. 1458-1467. 
181. Grarup, N., et al., Loss-of-function variants in ADCY3 increase risk of obesity and type 2 
diabetes. Nat Genet, 2018. 50(2): p. 172-174. 
182. Justice, A.E., et al., Genome-wide meta-analysis of 241,258 adults accounting for smoking 
behaviour identifies novel loci for obesity traits. Nat Commun, 2017. 8: p. 14977. 
183. Minster, R.L., et al., A thrifty variant in CREBRF strongly influences body mass index in 
Samoans. Nat Genet, 2016. 48(9): p. 1049-1054. 
184. Pigeyre, M., et al., Recent progress in genetics, epigenetics and metagenomics unveils the 
pathophysiology of human obesity. Clin Sci (Lond), 2016. 130(12): p. 943-86. 
185. Ramachandrappa, S., et al., Rare variants in single-minded 1 (SIM1) are associated with 
severe obesity. J Clin Invest, 2013. 123(7): p. 3042-50. 
186. Doche, M.E., et al., Human SH2B1 mutations are associated with maladaptive behaviors and 
obesity. J Clin Invest, 2012. 122(12): p. 4732-6. 
187. O'Rahilly, S. and I.S. Farooqi, Human obesity: a heritable neurobehavioral disorder that is 
highly sensitive to environmental conditions. Diabetes, 2008. 57(11): p. 2905-10. 
188. Saeed, S., et al., Loss-of-function mutations in ADCY3 cause monogenic severe obesity. Nat 
Genet, 2018. 50(2): p. 175-179. 
189. Clement, K., et al., A mutation in the human leptin receptor gene causes obesity and pituitary 
dysfunction. Nature, 1998. 392(6674): p. 398-401. 
190. Krude, H., et al., Severe early-onset obesity, adrenal insufficiency and red hair pigmentation 
caused by POMC mutations in humans. Nat Genet, 1998. 19(2): p. 155-7. 
159 
 
191. Montague, C.T., et al., Congenital leptin deficiency is associated with severe early-onset 
obesity in humans. Nature, 1997. 387(6636): p. 903-8. 
192. Gray, J., et al., Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity 
associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) 
gene. Diabetes, 2006. 55(12): p. 3366-71. 
193. Collet, T.H., et al., Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in 
MC4R deficiency. Mol Metab, 2017. 6(10): p. 1321-1329. 
194. Yeo, G.S., et al., A frameshift mutation in MC4R associated with dominantly inherited human 
obesity. Nat Genet, 1998. 20(2): p. 111-2. 
195. Vaisse, C., et al., A frameshift mutation in human MC4R is associated with a dominant form 
of obesity. Nat Genet, 1998. 20(2): p. 113-4. 
196. Loos, R.J., et al., Common variants near MC4R are associated with fat mass, weight and risk 
of obesity. Nat Genet, 2008. 40(6): p. 768-75. 
197. Bulik, C.M. and D.B. Allison, The genetic epidemiology of thinness. Obes Rev, 2001. 2(2): p. 
107-15. 
198. Costanzo, P.R. and S.S. Schiffman, Thinness--not obesity--has a genetic component. Neurosci 
Biobehav Rev, 1989. 13(1): p. 55-8. 
199. Magnusson, P.K. and F. Rasmussen, Familial resemblance of body mass index and familial 
risk of high and low body mass index. A study of young men in Sweden. Int J Obes Relat 
Metab Disord, 2002. 26(9): p. 1225-31. 
200. Laskarzewski, P.M., et al., Familial obesity and leanness. Int J Obes, 1983. 7(6): p. 505-27. 
201. Whitaker, K.L., et al., The intergenerational transmission of thinness. Arch Pediatr Adolesc 
Med, 2011. 165(10): p. 900-5. 
202. Jacquemont, S., et al., Mirror extreme BMI phenotypes associated with gene dosage at the 
chromosome 16p11.2 locus. Nature, 2011. 478(7367): p. 97-102. 
203. Hasstedt, S.J., et al., A Copy Number Variant on Chromosome 20q13.3 Implicated in Thinness 
and Severe Obesity. J Obes, 2015. 2015: p. 623431. 
204. Hinney, A., et al., Genome wide association (GWA) study for early onset extreme obesity 
supports the role of fat mass and obesity associated gene (FTO) variants. PLoS One, 2007. 
2(12): p. e1361. 
205. Scannell Bryan, M., et al., Genome-wide association studies and heritability estimates of 
body mass index related phenotypes in Bangladeshi adults. PLoS One, 2014. 9(8): p. 
e105062. 
206. Braud, S., M. Ciufolini, and I. Harosh, 'Energy expenditure genes' or 'energy absorption 
genes': a new target for the treatment of obesity and Type II diabetes. Future Med Chem, 
2010. 2(12): p. 1777-83. 
207. Berndt, S.I., et al., Genome-wide meta-analysis identifies 11 new loci for anthropometric 
traits and provides insights into genetic architecture. Nat Genet, 2013. 45(5): p. 501-12. 
208. Speliotes, E.K., et al., Association analyses of 249,796 individuals reveal 18 new loci 
associated with body mass index. Nat Genet, 2010. 42(11): p. 937-48. 
209. Cornish, K.M., et al., Association of the dopamine transporter (DAT1) 10/10-repeat genotype 
with ADHD symptoms and response inhibition in a general population sample. Mol 
Psychiatry, 2005. 10(7): p. 686-98. 
210. Emond, M.J., et al., Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier 
of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet, 2012. 44(8): p. 
886-9. 
211. Lanktree, M.B., et al., Extremes of unexplained variation as a phenotype: an efficient 
approach for genome-wide association studies of cardiovascular disease. Circ Cardiovasc 
Genet, 2010. 3(2): p. 215-21. 
160 
 
212. Zhou, Y.J., Y. Wang, and L.L. Chen, Detecting the Common and Individual Effects of Rare 
Variants on Quantitative Traits by Using Extreme Phenotype Sampling. Genes (Basel), 2016. 
7(1). 
213. Morgan, J.F., F. Reid, and J.H. Lacey, The SCOFF questionnaire: assessment of a new 
screening tool for eating disorders. BMJ, 1999. 319(7223): p. 1467-8. 
214. Bochukova, E.G., et al., Large, rare chromosomal deletions associated with severe early-
onset obesity. Nature, 2010. 463(7281): p. 666-70. 
215. University of Essex. Institute for Social and Economic Research and NatCen Social Research, 
Understanding Society: Waves 1-5, 2009-2014 [computer file]. 7th Edition. Colchester, Essex: 
UK Data Archive [distributor] November 2015 SN: 6614. 
216. Wain, L.V., et al., Novel insights into the genetics of smoking behaviour, lung function, and 
chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK 
Biobank. Lancet Respir Med, 2015. 3(10): p. 769-81. 
217. Riveros-Mckay, F., et al., Genetic architecture of human thinness compared to severe obesity. 
PLoS Genet, 2018. [in press]. 
218. Ma, C., et al., Recommended joint and meta-analysis strategies for case-control association 
testing of single low-count variants. Genet Epidemiol, 2013. 37(6): p. 539-50. 
219. Boyd, A., et al., Cohort Profile: the 'children of the 90s'--the index offspring of the Avon 
Longitudinal Study of Parents and Children. Int J Epidemiol, 2013. 42(1): p. 111-27. 
220. Fraser, A., et al., Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC 
mothers cohort. Int J Epidemiol, 2013. 42(1): p. 97-110. 
221. Howie, B., J. Marchini, and M. Stephens, Genotype imputation with thousands of genomes. 
G3 (Bethesda), 2011. 1(6): p. 457-70. 
222. Howie, B.N., P. Donnelly, and J. Marchini, A flexible and accurate genotype imputation 
method for the next generation of genome-wide association studies. PLoS Genet, 2009. 5(6): 
p. e1000529. 
223. Purcell, S., et al., PLINK: a tool set for whole-genome association and population-based 
linkage analyses. Am J Hum Genet, 2007. 81(3): p. 559-75. 
224. Price, A.L., et al., Principal components analysis corrects for stratification in genome-wide 
association studies. Nat Genet, 2006. 38(8): p. 904-9. 
225. Manichaikul, A., et al., Robust relationship inference in genome-wide association studies. 
Bioinformatics, 2010. 26(22): p. 2867-73. 
226. Marchini, J., et al., A new multipoint method for genome-wide association studies by 
imputation of genotypes. Nat Genet, 2007. 39(7): p. 906-13. 
227. Loh, P.R., et al., Efficient Bayesian mixed-model analysis increases association power in large 
cohorts. Nat Genet, 2015. 47(3): p. 284-90. 
228. Bulik-Sullivan, B., et al., An atlas of genetic correlations across human diseases and traits. 
Nat Genet, 2015. 47(11): p. 1236-41. 
229. Measuring and interpreting BMI in Children :: Public Health England Obesity Knowledge and 
Intelligence team.  19th December 2016]; Available from: 
https://www.noo.org.uk/NOO_about_obesity/measurement/children. 
230. Denaxas, S.C., et al., Data resource profile: cardiovascular disease research using linked 
bespoke studies and electronic health records (CALIBER). Int J Epidemiol, 2012. 41(6): p. 
1625-38. 
231. Zheng, J., et al., LD Hub: a centralized database and web interface to perform LD score 
regression that maximizes the potential of summary level GWAS data for SNP heritability and 
genetic correlation analysis. Bioinformatics, 2017. 33(2): p. 272-279. 
232. Harrell, F.E., rms: R functions for biostatistical/epidemiologic modeling, testing, estimation, 
validation, graphics, prediction, and typesetting by storing enhanced model design attributes 
in the fit, 2013. Implements methods in Regression Modeling Strategies, New York:Springer, 
2001. 
161 
 
233. R Development Core Team, R: A Language and Environment for Statistical Computing. 2011, 
R Foundation for Statistical Computing: Vienna, Austria. 
234. Gauderman, W. and J. Morrison, QUANTO 1.1: A computer program for power and sample 
size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe. 2006. 
235. Canela-Xandri, O., et al., A new tool called DISSECT for analysing large genomic data sets 
using a Big Data approach. Nat Commun, 2015. 6: p. 10162. 
236. Bradfield, J.P., et al., A genome-wide association meta-analysis identifies new childhood 
obesity loci. Nat Genet, 2012. 44(5): p. 526-31. 
237. Southam, L., et al., Whole genome sequencing and imputation in isolated populations 
identify genetic associations with medically-relevant complex traits. Nat Commun, 2017. 8: 
p. 15606. 
238. Willer, C.J., Y. Li, and G.R. Abecasis, METAL: fast and efficient meta-analysis of genomewide 
association scans. Bioinformatics, 2010. 26(17): p. 2190-1. 
239. Xu, C., et al., Estimating genome-wide significance for whole-genome sequencing studies. 
Genet Epidemiol, 2014. 38(4): p. 281-90. 
240. Hinney, A., A.L. Volckmar, and N. Knoll, Melanocortin-4 receptor in energy homeostasis and 
obesity pathogenesis. Prog Mol Biol Transl Sci, 2013. 114: p. 147-91. 
241. Geller, F., et al., Melanocortin-4 receptor gene variant I103 is negatively associated with 
obesity. Am J Hum Genet, 2004. 74(3): p. 572-81. 
242. Klimentidis, Y.C., et al., Genome-wide association study of habitual physical activity in over 
377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int 
J Obes (Lond), 2018. 
243. Mitchell, J.A., et al., Obesity-susceptibility loci and the tails of the pediatric BMI distribution. 
Obesity (Silver Spring), 2013. 21(6): p. 1256-60. 
244. Beyerlein, A., et al., Genetic markers of obesity risk: stronger associations with body 
composition in overweight compared to normal-weight children. PLoS One, 2011. 6(4): p. 
e19057. 
245. Chan, Y., et al., Common variants show predicted polygenic effects on height in the tails of 
the distribution, except in extremely short individuals. PLoS Genet, 2011. 7(12): p. e1002439. 
246. Young, A.I., F. Wauthier, and P. Donnelly, Multiple novel gene-by-environment interactions 
modify the effect of FTO variants on body mass index. Nat Commun, 2016. 7: p. 12724. 
247. Winkler, T.W., et al., The Influence of Age and Sex on Genetic Associations with Adult Body 
Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genet, 2015. 11(10): p. 
e1005378. 
248. Qi, Q., et al., FTO genetic variants, dietary intake and body mass index: insights from 177,330 
individuals. Hum Mol Genet, 2014. 23(25): p. 6961-72. 
249. Bjornland, T., et al., Assessing gene-environment interaction effects of FTO, MC4R and 
lifestyle factors on obesity using an extreme phenotype sampling design: Results from the 
HUNT study. PLoS One, 2017. 12(4): p. e0175071. 
250. Shungin, D., et al., New genetic loci link adipose and insulin biology to body fat distribution. 
Nature, 2015. 518(7538): p. 187-96. 
251. Tachmazidou, I., et al., Whole-Genome Sequencing Coupled to Imputation Discovers Genetic 
Signals for Anthropometric Traits. Am J Hum Genet, 2017. 100(6): p. 865-884. 
252. Lango Allen, H., et al., Hundreds of variants clustered in genomic loci and biological pathways 
affect human height. Nature, 2010. 467(7317): p. 832-8. 
253. Wen, W., et al., Genome-wide association studies in East Asians identify new loci for waist-
hip ratio and waist circumference. Sci Rep, 2016. 6: p. 17958. 
254. Shaheen, R., et al., A founder CEP120 mutation in Jeune asphyxiating thoracic dystrophy 
expands the role of centriolar proteins in skeletal ciliopathies. Hum Mol Genet, 2015. 24(5): 
p. 1410-9. 
162 
 
255. Roosing, S., et al., Mutations in CEP120 cause Joubert syndrome as well as complex ciliopathy 
phenotypes. J Med Genet, 2016. 53(9): p. 608-15. 
256. Athersuch, T.J. and H.C. Keun, Metabolic profiling in human exposome studies. Mutagenesis, 
2015. 30(6): p. 755-62. 
257. Lydic, T.A. and Y.H. Goo, Lipidomics unveils the complexity of the lipidome in metabolic 
diseases. Clin Transl Med, 2018. 7(1): p. 4. 
258. Arsenault, B.J., S.M. Boekholdt, and J.J. Kastelein, Lipid parameters for measuring risk of 
cardiovascular disease. Nat Rev Cardiol, 2011. 8(4): p. 197-206. 
259. Nordestgaard, B.G. and A. Varbo, Triglycerides and cardiovascular disease. Lancet, 2014. 
384(9943): p. 626-635. 
260. Varbo, A., M. Benn, and B.G. Nordestgaard, Remnant cholesterol as a cause of ischemic heart 
disease: evidence, definition, measurement, atherogenicity, high risk patients, and present 
and future treatment. Pharmacol Ther, 2014. 141(3): p. 358-67. 
261. Wyler von Ballmoos, M.C., B. Haring, and F.M. Sacks, The risk of cardiovascular events with 
increased apolipoprotein CIII: A systematic review and meta-analysis. J Clin Lipidol, 2015. 
9(4): p. 498-510. 
262. Geng, P., et al., Serum mannose-binding lectin is a strong biomarker of diabetic retinopathy 
in chinese patients with diabetes. Diabetes Care, 2015. 38(5): p. 868-75. 
263. Trpkovic, A., et al., Oxidized low-density lipoprotein as a biomarker of cardiovascular 
diseases. Crit Rev Clin Lab Sci, 2015. 52(2): p. 70-85. 
264. Strategies for the prevention of coronary heart disease: a policy statement of the European 
Atherosclerosis Society. Eur Heart J, 1987. 8(1): p. 77-88. 
265. Gordon, T., et al., High density lipoprotein as a protective factor against coronary heart 
disease. The Framingham Study. Am J Med, 1977. 62(5): p. 707-14. 
266. Hokanson, J.E. and M.A. Austin, Plasma triglyceride level is a risk factor for cardiovascular 
disease independent of high-density lipoprotein cholesterol level: a meta-analysis of 
population-based prospective studies. J Cardiovasc Risk, 1996. 3(2): p. 213-9. 
267. UK, N., 'Chronic kidney disease - Diagnosis - NHS Choices', [online] Available from: 
https://www.nhs.uk/conditions/kidney-disease/diagnosis/ (Accessed 02 July 2018). . 2018. 
268. Chaussain, J.L., et al., Serum branched-chain amino acids in the diagnosis of hyperinsulinism 
in infancy. J Pediatr, 1980. 97(6): p. 923-6. 
269. Adeva, M.M., et al., Insulin resistance and the metabolism of branched-chain amino acids in 
humans. Amino Acids, 2012. 43(1): p. 171-81. 
270. Wang, Q., et al., Genetic Support for a Causal Role of Insulin Resistance on Circulating 
Branched-Chain Amino Acids and Inflammation. Diabetes Care, 2017. 40(12): p. 1779-1786. 
271. Hobbs, H.H., M.S. Brown, and J.L. Goldstein, Molecular genetics of the LDL receptor gene in 
familial hypercholesterolemia. Hum Mutat, 1992. 1(6): p. 445-66. 
272. Shichiri, M., A. Tanaka, and Y. Hirata, Intravenous gene therapy for familial 
hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL receptor gene 
complex. Gene Ther, 2003. 10(9): p. 827-31. 
273. Soria, L.F., et al., Association between a specific apolipoprotein B mutation and familial 
defective apolipoprotein B-100. Proc Natl Acad Sci U S A, 1989. 86(2): p. 587-91. 
274. Gebhard, C., et al., Apolipoprotein B antisense inhibition--update on mipomersen. Curr 
Pharm Des, 2013. 19(17): p. 3132-42. 
275. Abifadel, M., et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. 
Nat Genet, 2003. 34(2): p. 154-6. 
276. Duff, C.J. and N.M. Hooper, PCSK9: an emerging target for treatment of 
hypercholesterolemia. Expert Opin Ther Targets, 2011. 15(2): p. 157-68. 
277. Duell, P.B., et al., Long-term mipomersen treatment is associated with a reduction in 
cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol, 2016. 
10(4): p. 1011-1021. 
163 
 
278. Karatasakis, A., et al., Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With 
Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials. J Am Heart 
Assoc, 2017. 6(12). 
279. Asselbergs, F.W., et al., Large-scale gene-centric meta-analysis across 32 studies identifies 
multiple lipid loci. Am J Hum Genet, 2012. 91(5): p. 823-38. 
280. Willer, C.J., et al., Discovery and refinement of loci associated with lipid levels. Nat Genet, 
2013. 45(11): p. 1274-1283. 
281. Albrechtsen, A., et al., Exome sequencing-driven discovery of coding polymorphisms 
associated with common metabolic phenotypes. Diabetologia, 2013. 56(2): p. 298-310. 
282. Peloso, G.M., et al., Association of low-frequency and rare coding-sequence variants with 
blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet, 2014. 
94(2): p. 223-32. 
283. Surakka, I., et al., The impact of low-frequency and rare variants on lipid levels. Nat Genet, 
2015. 47(6): p. 589-97. 
284. Tang, C.S., et al., Exome-wide association analysis reveals novel coding sequence variants 
associated with lipid traits in Chinese. Nat Commun, 2015. 6: p. 10206. 
285. Natarajan, P., et al., Deep-coverage whole genome sequences and blood lipids among 16,324 
individuals. bioRxiv, 2017. 
286. White, J., et al., Plasma urate concentration and risk of coronary heart disease: a Mendelian 
randomisation analysis. Lancet Diabetes Endocrinol, 2016. 4(4): p. 327-36. 
287. Keenan, T., et al., Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases 
Through a Mendelian Randomization Study. J Am Coll Cardiol, 2016. 67(4): p. 407-416. 
288. Davis, J.P., et al., Common, low-frequency, and rare genetic variants associated with 
lipoprotein subclasses and triglyceride measures in Finnish men from the METSIM study. 
PLoS Genet, 2017. 13(10): p. e1007079. 
289. Teslovich, T.M., et al., Identification of seven novel loci associated with amino acid levels 
using single-variant and gene-based tests in 8545 Finnish men from the METSIM study. Hum 
Mol Genet, 2018. 27(9): p. 1664-1674. 
290. Dewey, F.E., et al., Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N 
Engl J Med, 2016. 374(12): p. 1123-33. 
291. Dewey, F.E., et al., Distribution and clinical impact of functional variants in 50,726 whole-
exome sequences from the DiscovEHR study. Science, 2016. 354(6319). 
292. Moore, C., et al., The INTERVAL trial to determine whether intervals between blood 
donations can be safely and acceptably decreased to optimise blood supply: study protocol 
for a randomised controlled trial. Trials, 2014. 15: p. 363. 
293. Astle, W.J., et al., The Allelic Landscape of Human Blood Cell Trait Variation and Links to 
Common Complex Disease. Cell, 2016. 167(5): p. 1415-1429 e19. 
294. Singh, T., et al., Rare loss-of-function variants in SETD1A are associated with schizophrenia 
and developmental disorders. Nat Neurosci, 2016. 19(4): p. 571-7. 
295. Li, H. and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics, 2009. 25(14): p. 1754-60. 
296. McKenna, A., et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing 
next-generation DNA sequencing data. Genome Res, 2010. 20(9): p. 1297-303. 
297. Jun, G., et al., Detecting and estimating contamination of human DNA samples in sequencing 
and array-based genotype data. Am J Hum Genet, 2012. 91(5): p. 839-48. 
298. Soininen, P., et al., High-throughput serum NMR metabonomics for cost-effective holistic 
studies on systemic metabolism. Analyst, 2009. 134(9): p. 1781-5. 
299. Pinero, J., et al., DisGeNET: a comprehensive platform integrating information on human 
disease-associated genes and variants. Nucleic Acids Res, 2017. 45(D1): p. D833-D839. 
300. Pinero, J., et al., DisGeNET: a discovery platform for the dynamical exploration of human 
diseases and their genes. Database (Oxford), 2015. 2015: p. bav028. 
164 
 
301. Kanehisa, M., et al., KEGG: new perspectives on genomes, pathways, diseases and drugs. 
Nucleic Acids Res, 2017. 45(D1): p. D353-D361. 
302. Kanehisa, M. and S. Goto, KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids 
Res, 2000. 28(1): p. 27-30. 
303. Kanehisa, M., et al., KEGG as a reference resource for gene and protein annotation. Nucleic 
Acids Res, 2016. 44(D1): p. D457-62. 
304. Fabregat, A., et al., The Reactome Pathway Knowledgebase. Nucleic Acids Res, 2018. 46(D1): 
p. D649-D655. 
305. Milacic, M., et al., Annotating cancer variants and anti-cancer therapeutics in reactome. 
Cancers (Basel), 2012. 4(4): p. 1180-211. 
306. Zaykin, D.V., Optimally weighted Z-test is a powerful method for combining probabilities in 
meta-analysis. J Evol Biol, 2011. 24(8): p. 1836-41. 
307. Dewey, M., metap: meta-analysis of significance values. 2018. 
308. Rhee, E.P., et al., An exome array study of the plasma metabolome. Nat Commun, 2016. 7: p. 
12360. 
309. Aschard, H., et al., Adjusting for heritable covariates can bias effect estimates in genome-
wide association studies. Am J Hum Genet, 2015. 96(2): p. 329-39. 
310. Aschard, H., et al., Covariate selection for association screening in multiphenotype genetic 
studies. Nat Genet, 2017. 49(12): p. 1789-1795. 
311. Drenos, F., et al., Metabolic Characterization of a Rare Genetic Variation Within APOC3 and 
Its Lipoprotein Lipase-Independent Effects. Circ Cardiovasc Genet, 2016. 9(3): p. 231-9. 
312. Grevengoed, T.J., et al., Acyl-CoA synthetase 1 deficiency alters cardiolipin species and 
impairs mitochondrial function. J Lipid Res, 2015. 56(8): p. 1572-82. 
313. Yan, S., et al., Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and 
other diseases: an update. World J Gastroenterol, 2015. 21(12): p. 3492-8. 
314. Zirath, H., et al., MYC inhibition induces metabolic changes leading to accumulation of lipid 
droplets in tumor cells. Proc Natl Acad Sci U S A, 2013. 110(25): p. 10258-63. 
315. Gopinathrao, G., Image for “Regulation of pyruvate dehydrogenase (PDH) complex”. 
Reactome, release 65, doi:10.3180/REACT_12528.1. 2007. 
316. Li, L.O., et al., Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol 
synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem, 
2009. 284(41): p. 27816-26. 
317. Scott, R.A., et al., An Expanded Genome-Wide Association Study of Type 2 Diabetes in 
Europeans. Diabetes, 2017. 66(11): p. 2888-2902. 
318. Yang, L., et al., High expression of long chain acyl-coenzyme A synthetase 1 in peripheral 
blood may be a molecular marker for assessing the risk of acute myocardial infarction. Exp 
Ther Med, 2017. 14(5): p. 4065-4072. 
319. Brodeur, G.M., et al., Amplification of N-myc in untreated human neuroblastomas correlates 
with advanced disease stage. Science, 1984. 224(4653): p. 1121-4. 
320. Emanuel, B.S., et al., N-myc amplification in multiple homogeneously staining regions in two 
human neuroblastomas. Proc Natl Acad Sci U S A, 1985. 82(11): p. 3736-40. 
321. Sato, T., et al., Molecular cloning and characterization of a novel human beta 1,4-N-
acetylgalactosaminyltransferase, beta 4GalNAc-T3, responsible for the synthesis of N,N'-
diacetyllactosediamine, galNAc beta 1-4GlcNAc. J Biol Chem, 2003. 278(48): p. 47534-44. 
322. Morgan, H., et al., EuroPhenome: a repository for high-throughput mouse phenotyping data. 
Nucleic Acids Res, 2010. 38(Database issue): p. D577-85. 
323. Wood, A.R., et al., Defining the role of common variation in the genomic and biological 
architecture of adult human height. Nat Genet, 2014. 46(11): p. 1173-86. 
324. Jin, J., et al., Systematic analysis and nomenclature of mammalian F-box proteins. Genes 
Dev, 2004. 18(21): p. 2573-80. 
165 
 
325. Zhang, S., et al., The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. 
Nutr Metab (Lond), 2014. 11(1): p. 10. 
326. Holmes, M.V., et al., Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction 
and Stroke. J Am Coll Cardiol, 2018. 71(6): p. 620-632. 
327. Dron, J.S., et al., Polygenic determinants in extremes of high-density lipoprotein cholesterol. J 
Lipid Res, 2017. 58(11): p. 2162-2170. 
328. Lange, L.A., et al., Whole-exome sequencing identifies rare and low-frequency coding 
variants associated with LDL cholesterol. Am J Hum Genet, 2014. 94(2): p. 233-45. 
329. Diabetes.co.uk. Normal and Diabetic Blood Sugar Level Ranges. 2018  [Accessed: 11-08-
2018]; Available from: https://www.diabetes.co.uk/diabetes_care/blood-sugar-level-
ranges.html. 
330. Drzewoski, J. and L. Czupryniak, Concordance between fasting and 2-h post-glucose 
challenge criteria for the diagnosis of diabetes mellitus and glucose intolerance in high risk 
individuals. Diabet Med, 2001. 18(1): p. 29-31. 
331. Faerch, K., et al., Trajectories of cardiometabolic risk factors before diagnosis of three 
subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. 
Lancet Diabetes Endocrinol, 2013. 1(1): p. 43-51. 
332. Decode Study Group, t.E.D.E.G., Glucose tolerance and cardiovascular mortality: comparison 
of fasting and 2-hour diagnostic criteria. Arch Intern Med, 2001. 161(3): p. 397-405. 
333. American Diabetes, A., Diagnosis and classification of diabetes mellitus. Diabetes Care, 2014. 
37 Suppl 1: p. S81-90. 
334. Paschou, S.A., et al., Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J 
Clin Endocrinol Metab, 2017. 102(10): p. 3621-3634. 
335. Phung, O.J., et al., Early combination therapy for the treatment of type 2 diabetes mellitus: 
systematic review and meta-analysis. Diabetes Obes Metab, 2014. 16(5): p. 410-7. 
336. Saulsberry, W.J., et al., Comparative efficacy and safety of antidiabetic drug regimens added 
to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J 
Clin Pract, 2015. 69(11): p. 1221-35. 
337. Koenig, R.J., et al., Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. 
N Engl J Med, 1976. 295(8): p. 417-20. 
338. Sidorenkov, G., et al., A longitudinal study examining adherence to guidelines in diabetes 
care according to different definitions of adequacy and timeliness. PLoS One, 2011. 6(9): p. 
e24278. 
339. Ghazanfari, Z., et al., A Comparison of HbA1c and Fasting Blood Sugar Tests in General 
Population. Int J Prev Med, 2010. 1(3): p. 187-94. 
340. Roberts, W.L., et al., Effects of hemoglobin C and S traits on glycohemoglobin measurements 
by eleven methods. Clin Chem, 2005. 51(4): p. 776-8. 
341. Son, J.I., et al., Hemoglobin a1c may be an inadequate diagnostic tool for diabetes mellitus in 
anemic subjects. Diabetes Metab J, 2013. 37(5): p. 343-8. 
342. Herman, W.H., et al., Differences in A1C by race and ethnicity among patients with impaired 
glucose tolerance in the Diabetes Prevention Program. Diabetes Care, 2007. 30(10): p. 2453-
7. 
343. Cohen, R.M., S. Haggerty, and W.H. Herman, HbA1c for the diagnosis of diabetes and 
prediabetes: is it time for a mid-course correction? J Clin Endocrinol Metab, 2010. 95(12): p. 
5203-6. 
344. Simonis-Bik, A.M., et al., The heritability of HbA1c and fasting blood glucose in different 
measurement settings. Twin Res Hum Genet, 2008. 11(6): p. 597-602. 
345. Snieder, H., et al., HbA(1c) levels are genetically determined even in type 1 diabetes: 
evidence from healthy and diabetic twins. Diabetes, 2001. 50(12): p. 2858-63. 
346. Chen, P., et al., Multiple nonglycemic genomic loci are newly associated with blood level of 
glycated hemoglobin in East Asians. Diabetes, 2014. 63(7): p. 2551-62. 
166 
 
347. Franklin, C.S., et al., The TCF7L2 diabetes risk variant is associated with HbA(1)(C) levels: a 
genome-wide association meta-analysis. Ann Hum Genet, 2010. 74(6): p. 471-8. 
348. Pare, G., et al., Novel association of HK1 with glycated hemoglobin in a non-diabetic 
population: a genome-wide evaluation of 14,618 participants in the Women's Genome 
Health Study. PLoS Genet, 2008. 4(12): p. e1000312. 
349. Ryu, J. and C. Lee, Association of glycosylated hemoglobin with the gene encoding CDKAL1 in 
the Korean Association Resource (KARE) study. Hum Mutat, 2012. 33(4): p. 655-9. 
350. Soranzo, N., et al., Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels 
via glycemic and nonglycemic pathways. Diabetes, 2010. 59(12): p. 3229-39. 
351. Danese, E., et al., Advantages and pitfalls of fructosamine and glycated albumin in the 
diagnosis and treatment of diabetes. J Diabetes Sci Technol, 2015. 9(2): p. 169-76. 
352. Armbruster, D.A., Fructosamine: structure, analysis, and clinical usefulness. Clin Chem, 1987. 
33(12): p. 2153-63. 
353. Sacks, D.B., A1C versus glucose testing: a comparison. Diabetes Care, 2011. 34(2): p. 518-23. 
354. Little, R.R., et al., Status of hemoglobin A1c measurement and goals for improvement: from 
chaos to order for improving diabetes care. Clin Chem, 2011. 57(2): p. 205-14. 
355. Juraschek, S.P., et al., Alternative markers of hyperglycemia and risk of diabetes. Diabetes 
Care, 2012. 35(11): p. 2265-70. 
356. Selvin, E., et al., Fructosamine and glycated albumin for risk stratification and prediction of 
incident diabetes and microvascular complications: a prospective cohort analysis of the 
Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol, 2014. 2(4): p. 
279-88. 
357. Hom, F.G., B. Ettinger, and M.J. Lin, Comparison of serum fructosamine vs glycohemoglobin 
as measures of glycemic control in a large diabetic population. Acta Diabetol, 1998. 35(1): p. 
48-51. 
358. Smart, L.M., et al., Comparison of fructosamine with glycosylated hemoglobin and plasma 
proteins as measures of glycemic control. Diabetes Care, 1988. 11(5): p. 433-6. 
359. Zafon, C., et al., Variables involved in the discordance between HbA1c and fructosamine: the 
glycation gap revisited. PLoS One, 2013. 8(6): p. e66696. 
360. Cohen, R.M., et al., Discordance between HbA1c and fructosamine: evidence for a 
glycosylation gap and its relation to diabetic nephropathy. Diabetes Care, 2003. 26(1): p. 
163-7. 
361. Rodriguez-Segade, S., et al., Influence of the glycation gap on the diagnosis of type 2 
diabetes. Acta Diabetol, 2015. 52(3): p. 453-9. 
362. Cohen, R.M., et al., Evidence for independent heritability of the glycation gap (glycosylation 
gap) fraction of HbA1c in nondiabetic twins. Diabetes Care, 2006. 29(8): p. 1739-43. 
363. Loomis, S.J., et al., Genome-Wide Association Study of Serum Fructosamine and Glycated 
Albumin in Adults Without Diagnosed Diabetes: Results From the Atherosclerosis Risk in 
Communities Study. Diabetes, 2018. 67(8): p. 1684-1696. 
364. O'Connell, J., et al., Haplotype estimation for biobank-scale data sets. Nat Genet, 2016. 
48(7): p. 817-20. 
365. Machiela, M.J. and S.J. Chanock, LDlink: a web-based application for exploring population-
specific haplotype structure and linking correlated alleles of possible functional variants. 
Bioinformatics, 2015. 31(21): p. 3555-7. 
366. Manning, A.K., et al., A genome-wide approach accounting for body mass index identifies 
genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet, 2012. 
44(6): p. 659-69. 
367. Scott, R.A., et al., Large-scale association analyses identify new loci influencing glycemic 
traits and provide insight into the underlying biological pathways. Nat Genet, 2012. 44(9): p. 
991-1005. 
167 
 
368. Mahajan, A., et al., Identification and functional characterization of G6PC2 coding variants 
influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS 
Genet, 2015. 11(1): p. e1004876. 
369. Strawbridge, R.J., et al., Genome-wide association identifies nine common variants 
associated with fasting proinsulin levels and provides new insights into the pathophysiology 
of type 2 diabetes. Diabetes, 2011. 60(10): p. 2624-34. 
370. Saxena, R., et al., Genetic variation in GIPR influences the glucose and insulin responses to an 
oral glucose challenge. Nat Genet, 2010. 42(2): p. 142-8. 
371. Kim, Y.J., et al., Large-scale genome-wide association studies in East Asians identify new 
genetic loci influencing metabolic traits. Nat Genet, 2011. 43(10): p. 990-5. 
372. Hwang, J.Y., et al., Genome-wide association meta-analysis identifies novel variants 
associated with fasting plasma glucose in East Asians. Diabetes, 2015. 64(1): p. 291-8. 
373. Liu, C.T., et al., Trans-ethnic Meta-analysis and Functional Annotation Illuminates the Genetic 
Architecture of Fasting Glucose and Insulin. Am J Hum Genet, 2016. 99(1): p. 56-75. 
374. Huyghe, J.R., et al., Exome array analysis identifies new loci and low-frequency variants 
influencing insulin processing and secretion. Nat Genet, 2013. 45(2): p. 197-201. 
375. Wessel, J., et al., Low-frequency and rare exome chip variants associate with fasting glucose 
and type 2 diabetes susceptibility. Nat Commun, 2015. 6: p. 5897. 
376. Go, M.J., et al., New susceptibility loci in MYL2, C12orf51 and OAS1 associated with 1-h 
plasma glucose as predisposing risk factors for type 2 diabetes in the Korean population. J 
Hum Genet, 2013. 58(6): p. 362-5. 
377. Horikoshi, M., et al., Discovery and Fine-Mapping of Glycaemic and Obesity-Related Trait Loci 
Using High-Density Imputation. PLoS Genet, 2015. 11(7): p. e1005230. 
378. Chen, G., et al., Genome-wide association study identifies novel loci association with fasting 
insulin and insulin resistance in African Americans. Hum Mol Genet, 2012. 21(20): p. 4530-6. 
379. Henny, J., et al., Detetermination of reference values for a colorimetric fructosamine assay. 
Vol. 38. 1992. 153-160. 
380. Sherwani, S.I., et al., Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic 
Patients. Biomark Insights, 2016. 11: p. 95-104. 
381. Franceschini, N., et al., Discovery and fine mapping of serum protein loci through transethnic 
meta-analysis. Am J Hum Genet, 2012. 91(4): p. 744-53. 
382. Kanai, M., et al., Genetic analysis of quantitative traits in the Japanese population links cell 
types to complex human diseases. Nat Genet, 2018. 50(3): p. 390-400. 
383. Martin, C.C., et al., Cloning and characterization of the human and rat islet-specific glucose-
6-phosphatase catalytic subunit-related protein (IGRP) genes. J Biol Chem, 2001. 276(27): p. 
25197-207. 
384. Wang, Y., et al., Deletion of the gene encoding the islet-specific glucose-6-phosphatase 
catalytic subunit-related protein autoantigen results in a mild metabolic phenotype. 
Diabetologia, 2007. 50(4): p. 774-8. 
385. Pound, L.D., et al., G6PC2: a negative regulator of basal glucose-stimulated insulin secretion. 
Diabetes, 2013. 62(5): p. 1547-56. 
386. Honore, B. and H. Vorum, The CREC family, a novel family of multiple EF-hand, low-affinity 
Ca(2+)-binding proteins localised to the secretory pathway of mammalian cells. FEBS Lett, 
2000. 466(1): p. 11-8. 
387. Consortium, G.T., The Genotype-Tissue Expression (GTEx) project. Nat Genet, 2013. 45(6): p. 
580-5. 
388. Chaudhury, C., et al., The major histocompatibility complex-related Fc receptor for IgG (FcRn) 
binds albumin and prolongs its lifespan. J Exp Med, 2003. 197(3): p. 315-22. 
389. Pyzik, M., et al., Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. 
Proc Natl Acad Sci U S A, 2017. 114(14): p. E2862-E2871. 
168 
 
390. Turley, P., et al., Multi-trait analysis of genome-wide association summary statistics using 
MTAG. Nat Genet, 2018. 50(2): p. 229-237. 
391. Dimas, A.S., et al., Impact of type 2 diabetes susceptibility variants on quantitative glycemic 
traits reveals mechanistic heterogeneity. Diabetes, 2014. 63(6): p. 2158-71. 
392. Gurdasani, D., et al., The African Genome Variation Project shapes medical genetics in Africa. 
Nature, 2015. 517(7534): p. 327-32. 
393. UK Biobank, Nightingale Health and UK Biobank announces major initiative to analyse half a 
million blood samples to facilitate global medical research. 2018, [Press Release] Retrieved 
from: http://www.ukbiobank.ac.uk/2018/06/nightingale-health-and-uk-biobank-announces-
major-initiative-to-analyse-half-a-million-blood-samples-to-facilitate-global-medical-
research/. 
394. UK Biobank, Whole genome sequencing will ‘transform the research landscape for a wide 
range of diseases’. 2018, [Prese Release] Retrieved from:: 
http://www.ukbiobank.ac.uk/2018/04/whole-genome-sequencing-will-transform-the-
research-landscape-for-a-wide-range-of-diseases/. 
395. Cross-Disorder Group of the Psychiatric Genomics, C., et al., Genetic relationship between 
five psychiatric disorders estimated from genome-wide SNPs. Nat Genet, 2013. 45(9): p. 984-
94. 
396. Andreassen, O.A., et al., Genetic pleiotropy between multiple sclerosis and schizophrenia but 
not bipolar disorder: differential involvement of immune-related gene loci. Mol Psychiatry, 
2015. 20(2): p. 207-14. 
397. Moutsianas, L., et al., The power of gene-based rare variant methods to detect disease-
associated variation and test hypotheses about complex disease. PLoS Genet, 2015. 11(4): p. 
e1005165. 
398. Fowler, D.M. and S. Fields, Deep mutational scanning: a new style of protein science. Nat 
Methods, 2014. 11(8): p. 801-7. 
399. Chen, S., et al., An interactome perturbation framework prioritizes damaging missense 
mutations for developmental disorders. Nat Genet, 2018. 50(7): p. 1032-1040. 
400. Hendricks, A.E., et al., Rare Variant Analysis of Human and Rodent Obesity Genes in 
Individuals with Severe Childhood Obesity. Sci Rep, 2017. 7(1): p. 4394. 
401. Singh, T., et al., The contribution of rare variants to risk of schizophrenia in individuals with 
and without intellectual disability. Nat Genet, 2017. 49(8): p. 1167-1173. 
402. Short, P.J., et al., De novo mutations in regulatory elements in neurodevelopmental 
disorders. Nature, 2018. 555(7698): p. 611-616. 
403. Siggens, L. and K. Ekwall, Epigenetics, chromatin and genome organization: recent advances 
from the ENCODE project. J Intern Med, 2014. 276(3): p. 201-14. 
404. Roadmap Epigenomics, C., et al., Integrative analysis of 111 reference human epigenomes. 
Nature, 2015. 518(7539): p. 317-30. 
405. Martens, J.H. and H.G. Stunnenberg, BLUEPRINT: mapping human blood cell epigenomes. 
Haematologica, 2013. 98(10): p. 1487-9. 
406. Li, X., et al., The impact of rare variation on gene expression across tissues. Nature, 2017. 
550(7675): p. 239-243. 
407. Inoue, F. and N. Ahituv, Decoding enhancers using massively parallel reporter assays. 
Genomics, 2015. 106(3): p. 159-164. 
 
 
 
Appendix A  
 
169 
 
Appendix 1 
Genetic architecture of human thinness compared to 2 
severe obesity 3 
Fernando Riveros-McKay1*, Vanisha Mistry2*, Rebecca Bounds2, Audrey Hendricks1,3, Julia M. 4 
Keogh2, Hannah Thomas2, Elana Henning2, Laura J. Corbin4,5, Understanding Society Scientific 5 
Group, Stephen O’Rahilly2, Eleftheria Zeggini1, Eleanor Wheeler1, Inês Barroso1,2, I. Sadaf Farooqi2. 6 
 7 
Affiliations 8 
1Wellcome Sanger Institute, Cambridge, UK; 2University of Cambridge Metabolic Research 9 
Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of 10 
Metabolic Science, Addenbrooke's Hospital, Cambridge, UK; 3Department of Mathematical and 11 
Statistical Sciences, University of Colorado-Denver, Denver, CO 80204, USA; 4MRC Integrative 12 
Epidemiology Unit at University of Bristol, Bristol, BS8 2BN, UK; 5Population Health Sciences, Bristol 13 
Medical School, University of Bristol, Bristol, BS8 2BN, UK. Correspondence should be addressed to: 14 
I. Sadaf Farooqi (isf20@cam.ac.uk) and Inês Barroso (ib1@sanger.ac.uk). *These authors 15 
contributed equally.  16 
 17 
18 
Appendix A  
 
170 
 
Abstract  19 
The variation in weight within a shared environment is largely attributable to genetic factors. Whilst 20 
many genes/loci confer susceptibility to obesity, little is known about the genetic architecture of 21 
healthy thinness. Here, we characterise the heritability of thinness which we found was comparable 22 
to that of severe obesity (h2=28.07 vs 32.33% respectively), although with incomplete genetic 23 
overlap (r=-0.49, 95% CI [-0.17, -0.82], p=0.003). In a genome-wide association analysis of thinness 24 
(n=1,471) vs severe obesity (n=1,456), we identified 10 loci previously associated with obesity, and 25 
demonstrate enrichment for established BMI-associated loci (pbinomial=3.05x10
-5). Simulation 26 
analyses showed that different association results between the extremes were likely in agreement 27 
with additive effects across the BMI distribution, suggesting different effects on thinness and 28 
obesity could be due to their different degrees of extremeness. In further analyses, we detected a 29 
novel obesity and BMI-associated locus at PKHD1 (rs2784243, obese vs. thin p=5.99x10-6, obese vs. 30 
controls p=2.13x10-6 pBMI=2.3x10
-13), associations at loci recently discovered with much larger 31 
sample sizes (e.g. FAM150B and PRDM6-CEP120), and novel variants driving associations at 32 
previously established signals (e.g. rs205262 at the SNRPC/C6orf106 locus and rs112446794 at the 33 
PRDM6-CEP120 locus). Our ability to  replicate loci found with much larger sample sizes 34 
demonstrates the value of clinical extremes and suggest that characterisation of the genetics of 35 
thinness may provide a more nuanced understanding of the genetic architecture of body weight 36 
regulation and may inform the identification of potential anti-obesity targets.  37 
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Author Summary 38 
Obesity-associated disorders are amongst the leading causes of morbidity and mortality 39 
worldwide. Most genome-wide association studies (GWAS) have focused on body mass index (BMI= 40 
weight in Kg divided by height squared (m2)) and obesity, but to date no genetic association study 41 
testing thin and healthy individuals has been performed. In this study, we recruited a first of its kind 42 
cohort of 1,471 clinically ascertained thin and healthy individuals and contrasted the genetic 43 
architecture of the trait with that of severe early onset obesity. We show that thinness, like obesity, 44 
is a heritable trait with a polygenic component. In a GWAS of persistent healthy thinness vs. severe 45 
obesity with a total sample size of 2,927, we are able to find evidence of association in loci that 46 
have only been recently discovered using large cohorts with >40,000 individuals. We also find a 47 
novel BMI-associated locus at PKHD1 in UK Biobank highlighted by our association study. This work 48 
illustrates the value and increased power brought upon by using clinically ascertained extremes to 49 
study complex traits and provides a valuable resource on which to study resistance to obesity in an 50 
increasingly obesogenic environment.   51 
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Introduction 52 
The rising prevalence of obesity is driven by changes in the environment including the consumption 53 
of high calorie foods and reduced levels of physical activity [1]. However, within a given 54 
environment, there is considerable variation in body weight; some people are particularly 55 
susceptible to severe obesity, whilst others remain thin [2,3]. Family, twin and adoption studies 56 
have consistently demonstrated that 40-70% of the variation in body weight can be attributed to 57 
heritable factors [4]. As a result, many studies have focused on the genetic basis of body mass index 58 
(BMI) and/or obesity. To date >250 common and low-frequency obesity-susceptibility loci have 59 
been identified [5-10]. Additionally, studies of people at one extreme of the distribution (severe 60 
obesity) have led to the identification of rare, penetrant genetic variants that affect key molecular 61 
and neural pathways involved in human energy homeostasis [11-14]. These findings have provided 62 
a rationale for targeting these pathways for therapeutic benefit. In contrast, little is known about 63 
the specific genetic characteristics of persistently thin individuals (thinness defined using WHO 64 
criteria BMI<18kg/m2). Understanding the mechanisms underlying thinness/resistance to obesity 65 
may highlight novel anti-obesity targets for future drug development. 66 
A small number of previous studies have found that thinness appears to be a trait that is at least as 67 
stable and heritable as obesity [15-18]. A large study of 7,078 UK children and adolescents, found 68 
that the strongest predictor of child/adolescent thinness was parental weight status. The 69 
prevalence of thinness was highest (16.2%) when both parents were thin and progressively lower 70 
when both parents were normal weight, overweight or obese [19].  71 
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One approach to studying thinness is to study individuals from a population-based cohort for a 72 
quantitative or continuous trait. For example, it is possible to generate a “case-control” study by 73 
taking the extremes of the population distribution for a continuous trait such as BMI, an approach 74 
used effectively by Berndt et al. 2013 [20] who analysed the top and bottom 5% in cohorts 75 
participating in the GIANT Consortium.  However, by their very definition, such population-based 76 
cohorts often contain a limited number of people at the “extremes” (i.e. severe obesity and 77 
thinness) [20]. To date, other GWAS approaches that included thin individuals have either used 78 
them exclusively as controls to contrast with extreme obesity [21], or have not ascertained for 79 
healthy thinness [22]. Here, we use a different study design, and one that has been used to 80 
increase power to detect genetic association, in particular for disorders where there is a large 81 
environmental component (e.g. asthma, type 2 diabetes and obesity), enriching our case series with 82 
affected individuals that may be more genetically loaded.  This selection is usually done by selecting 83 
individuals who may have a more extreme form of disease, are younger (less time for environment 84 
to impact their disease) and perhaps have family members also affected with the same condition. 85 
To complement this approach to the selection of cases, controls are also selected to increase the 86 
chances that they do not have the disease or are unlikely to develop the disease later in life [21]. 87 
This is normally done by selecting contrasting controls, or “super-controls”. However, the low 88 
prevalence of thinness in countries such as the UK and the fact that people who are well but 89 
constitutionally thin do not routinely come to medical attention, poses challenges to recruitment of 90 
a cohort of healthy thin individuals. We were able to take advantage of the UK National Health 91 
Service (NHS) research infrastructure to recruit from primary care (Methods) using body mass index 92 
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(BMI: weight in kg/height in metres2) criteria and personal review of individual case files to identify 93 
a cohort of approximately 2000 UK European descent thin adults (STudy Into Lean and Thin 94 
Subjects, STILTS cohort; mean BMI = 17.6 kg/m2) who are well, without medical conditions or eating 95 
disorders (Methods). 74% of the STILTS cohort have a family history of persistent thinness 96 
throughout life, suggesting we have enriched for genetically driven thinness.  97 
Here, we present a new, and the largest-to-date, GWAS focused on persistent healthy thinness and 98 
contrast the genetic architecture of this trait with that of severe early onset obesity ascertained in 99 
the clinic.  We explored whether the genetic loci influencing thinness are the same as those 100 
influencing obesity, i.e., are these two clinically ascertained traits reverse sides of the same “coin”, 101 
or whether there are important genetic differences between them.  We show that persistent 102 
thinness and severe early onset obesity are both heritable traits (h2=28.07% and h2=32.33%, 103 
respectively) that share a number of associated loci, and both are enriched for established BMI 104 
associated loci (binomial p=3.05x10-5 and 9.09x10-13, respectively).  Nonetheless, we also detected 105 
important differences, with some loci more strongly associated at the upper clinical end of the BMI 106 
distribution (e.g. FTO), some at the lower end (e.g. CADM2), whilst other loci are equivalently 107 
associated with both clinical ends of the BMI spectrum (e.g. MC4R). Simulation tests showed that 108 
these results did not significantly deviate from additive effects and most likely reflect the different 109 
degrees of extremeness present in our clinically ascertained cohorts, where severely obese 110 
individuals represent a more significant deviation from the mean than healthy thin individuals do 111 
(the same degree of thinness may not be compatible with healthy human life). These data support 112 
expansion of genetic studies of persistent thinness as an approach to gain further insights into the 113 
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biology underlying human energy homeostasis, and as an alternative approach to uncovering 114 
potential anti-obesity targets for drug development. 115 
 116 
Results 117 
Heritability of persistent thinness and severe early onset obesity 118 
To investigate the heritability of healthy thinness and contrast it with that of severe early onset 119 
childhood obesity we obtained genotype data for 1,622 persistently thin healthy individuals 120 
(STILTS), 1,985 severe childhood onset obesity cases (SCOOP; European ancestry individuals from 121 
the GOOS cohort) and 10,433 population-based individuals (UKHLS) used as a common set of 122 
controls (Methods, S1 Table). All participants were genotyped on the Illumina Core Exome array, 123 
including 551,839 markers. After sample and variant quality control, we retained 1,471 thin 124 
individuals, 1,456 obese individuals, 6,460 control individuals in the BMI range 19-30 kg/m2 (non-125 
extremes). 477,288 directly genotyped variants were included in the analysis (Methods); 54% 126 
common variants (minor allele frequency (MAF) ≥1% amongst controls) and 46% rare variants 127 
(MAF<1% amongst controls), of which most were protein-coding (96.8%). We then imputed 128 
genotypes to a combined UK10K+1000G reference panel and, using LD score regression, we 129 
estimated that a subset of 1,197,969 HapMap3 markers accounted for 32.33% (95% CI 23.75%-130 
40.91%) of the phenotypic variance on the liability scale in severe early onset obesity, and 28.07% 131 
(95% CI 13.80%-42.34%) in persistent thinness, suggesting both traits are similarly heritable 132 
(Methods). The heritability estimates reported here were used mainly to establish the fact that 133 
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thinness is a heritable trait; we expect our liability scale estimates to be mostly unbiased given the 134 
study design   [23]. However, given the low prevalence of the traits presented here, these estimates 135 
may represent upper bounds.   136 
 137 
Contribution of known BMI associated loci to thinness and severe early onset obesity  138 
To investigate the role of established common variant European BMI associated loci, we studied the 139 
97 loci from GIANT [24] in persistent thinness vs severe early onset obesity and performed three-140 
way association analyses: obese vs. thin, obese vs controls, controls vs. thin (Methods, S1 Table). 141 
After quality control, 41,266,535 variants remained for association analyses in the three cohorts: 142 
SCOOP vs STILTS, SCOOP vs UKHLS and UKHLS vs STILTS. Of the 97 established BMI associated loci 143 
from GIANT [24], we found that 40 were nominally significant (p<0.05) in SCOOP vs UKHLS and 15 in 144 
UKHLS vs STILTS (S2 Table). Direction of effect was consistent for all of these loci, which was more 145 
than expected by chance (binomial p=9.09x10-13 and binomial p=3.05x10-5, respectively). Overall, 146 
the proportion of phenotypic variance explained by the 97 established BMI associated loci was 147 
10.67% in SCOOP vs UKHLS, and 4.33% in STILTS vs UKHLS (Methods). Evaluation of association 148 
results in thin (STILTS) and obese (SCOOP) individuals, compared to the same controls (UKHLS), 149 
suggested that the results are not a mirror image of each other (Figs 1-2), however we found little 150 
evidence of non-additive effects at the loci explaining this discrepancy (see below).  We observed 151 
a striking difference in association results in the FTO locus where the lead intronic obesity risk 152 
variant, rs1558902, showed a moderate effect size and modest evidence of association in controls 153 
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compared to thin individuals from STILTS (p=0.00027, OR=1.17, 95% CI [1.08,1.28], EAF=0.39), 154 
despite having a large effect and being associated at genome-wide significance levels in SCOOP 155 
(p=1.25x10-17, OR=1.43, 95% CI [1.32,1.55], EAF=0.41), and GNAT2 also showed a larger effect and 156 
significance in the analysis of obese compared to control individuals (p=1.26x10-4, OR=1.57, 95% CI 157 
[1.25, 1.97], EAF=0.03), than in the thin analysis (p=0.52, OR=1.10, 95% CI [0.82, 1.47], EAF=0.02, 158 
Fig 1, S2 Table). This discrepancy in association strength and effect size was also seen at the 159 
opposite end of the BMI spectrum in CADM2 where the lead SNP, rs13078960, showed evidence of 160 
association in STILTS (p= 9.48x10-4, OR=1.2, 95% CI [1.08, 1.33], EAF=0.20) but no association in 161 
SCOOP (p>0.05). In contrast to results at the FTO and CADM2 loci, for MC4R the results are more 162 
comparable, with genome-wide significant association in obese individuals (rs6567160, p=7.91x10-9, 163 
OR=1.31, 95% CI [1.19, 1.43], EAF=0.25) and highly significant association results in thin individuals 164 
(p=1.38x10-5, OR=1.26, 95% CI [1.13, 1.39], EAF=0.23, S2 Table). To formally test if these results 165 
were significantly different from those expected under a model where loci act additively across the 166 
BMI distribution, we simulated 10,000 different populations of 1 million individuals with genotypes 167 
for the 97 established BMI loci using allele frequencies in the European population, and then 168 
simulated a phenotype using the effect sizes in GIANT (Methods). These simulations detected 169 
fourteen loci with nominally significant deviation from an additive model, however none remained 170 
significant after correction for the number of tests (p=0.05/97*2 = ~0.0002, S3 Table), though 171 
CADM2 was nominally significant in both SCOOP and STILTS analyses, with slightly lower OR 172 
detected in SCOOP compared to simulated data, and slightly higher OR detected in STILTS 173 
compared to simulated data (S3 Table). Recent work in mouse knockouts has shown CADM2 plays 174 
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an important role in systemic energy homeostasis [25] and variants near the gene have also been 175 
recently linked to habitual physical activity in humans [26].  Since SCOOP participants are 176 
significantly younger than UKHLS, we used summary statistics from a subset of the ALSPAC cohort 177 
[27] which consists of 4,964 children aged 13-16 to test if the observed OR differences in SCOOP vs 178 
UKHLS, compared to STILTS vs UKHLS, were due to age effects in SCOOP (Methods). For the 97 179 
GIANT loci overall there were no significant differences in the ORs when comparing SCOOP to 180 
UKHLS or SCOOP to ALSPAC (z-test, p>0.05) except for rs2245368 (PMS2L11 locus, z-test 181 
p=3.81x105, S4 Table).  In combination, these results suggest that the observed differences in ORs 182 
and p-values could have arisen because our severe obese cases are much more extreme (i.e. 183 
deviate more from the mean) than the healthy thin individuals, and that our obese and thin sample 184 
sizes gave us limited power to detect significant differences compared to the additive model.   185 
Fig 1. Odds ratio comparison for established BMI associated loci. Odds ratios for SCOOP vs UKHLS 186 
(x-axis) and UKHLS vs STILTS (y-axis) comparisons are shown for the 97 known BMI loci from GIANT 187 
[24].  Colours of data points represent nominal significance in both analyses (red), only SCOOP vs. 188 
UKHLS (green), only STILTS vs UKHLS (blue) or in neither analysis (purple). Error bars represent 95% 189 
confidence intervals for the odds ratios for SCOOP vs UKHLS (x-axis) and for UKHLS vs STILTS (y-190 
axis). A subset of data points with larger separation from the red diagonal line (x=y) are labelled. 191 
 192 
Next we investigated the association of a genetic risk score, generated from the 97 BMI associated 193 
loci from GIANT [24] on BMI category (i.e. thin, normal, obese) using an ordinal logistic regression 194 
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(Methods). As expected, the standardised BMI genetic risk score was strongly associated with BMI 195 
category (weighted score p=8.59x10-133). We found that the effect of a one standard deviation 196 
increase in the standardised BMI genetic risk score was significantly larger for obese vs. (thin & 197 
normal) than for (obese & normal) vs. thin (p=7.48x10-11, S1 Appendix) with odds ratio and 95% 198 
confidence intervals of 1.94 (1.83, 2.07) and 1.50 (1.42, 1.59) respectively.  However, using the 199 
simulations described above (Methods), we confirm that the larger OR for obese vs. (thin & normal) 200 
is not significantly different (p=0.41) than what we would expect given an additive genetic model, 201 
and the different degrees of extremeness in our thin and obese cases. Mean GRS in each BMI 202 
category was also not significantly different from that predicted via simulations (S1 Fig, Methods).  203 
 204 
Genetic Correlation between persistent thinness, severe early onset childhood obesity and BMI 205 
Given the observed differences in association results from thin and obese individuals, compared to 206 
the same set of control individuals, we next explored the genetic correlation of severe early onset 207 
obesity, persistent thinness and BMI using LD score regression (Methods). For this, we used 208 
summary statistics from the SCOOP vs UKHLS, STILTS vs UKHLS and BMI data from participants in 209 
UK Biobank (UKBB, Methods). As expected from the association results, the genetic correlation of 210 
severe early onset obesity and BMI was high (r=0.79, 95% CI [0.69, 0.89], p=1.14x10-52).  We also 211 
observed weaker negative correlation between persistent thinness and BMI (r=-0.69, 95% CI [-0.86, 212 
-0.51], p= 1.17x10-14), and between persistent thinness and severe obesity (r=-0.49, 95% CI [-0.17,     213 
-0.82], p=0.003).  As an inverse genetic correlation between BMI, obesity and anorexia nervosa (a 214 
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disorder that is characterised by thinness and complex behavioural manifestations) has recently 215 
been reported [28], we also tested for genetic correlation with anorexia nervosa, and found that 216 
neither severe early onset obesity, nor persistent thinness, were significantly correlated with 217 
anorexia nervosa (r=-0.05, 95% CI [-0.15,0.05], p=0.33 and r=0.13, 95% CI [-0.02,0.28], p=0.09,  218 
respectively; Methods).   219 
 220 
Association signals for persistent thinness and severe early onset obesity replicate established 221 
BMI associated loci 222 
Given available genome-wide directly genotyped and imputed data we sought evidence for novel 223 
signals associated with either end of the BMI distribution (persistent thinness or severe early onset 224 
obesity; Methods) but found no novel replicating loci (details below). In all three discovery 225 
analyses, in addition to loci mapping to established BMI and obesity loci, we identified PIGZ and 226 
C3orf38, two putative novel loci in the thin vs control analysis, that reached conventional genome-227 
wide significance (GWS) (p≤5x10-8) (Tables S5-S7, Fig 2).  However, an additional 125 SNPs, in 118 228 
distinct loci, reached the arbitrary threshold of p ≤10-5 in at least one analysis, for which we sought 229 
replication (Tables S5-S7).  230 
Fig 2. Miami plot of SCOOP vs. UKHLS and STILTS vs. UKHLS. Miami plot produced in EasyStrata 231 
[29], Red=SCOOP vs. UKHLS; Blue=STILTS vs. UKHLS. Red lines indicate genome-wide significance 232 
threshold at p=5x10-08. Orange lines indicate discovery significance threshold at p=1x10-05.  Black 233 
labels highlight known BMI/obesity loci that were taken forward for replication and yellow peaks 234 
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indicate those that met genome-wide significance after replication. Grey labels highlight novel loci 235 
with p<5x10-08 that did not replicate.  236 
 237 
As our obese and thin cases (SCOOP and STILTS) lie at the very extreme tails of the BMI distribution, 238 
there are few comparable replication datasets. We therefore used the UKBB dataset and selected 239 
individuals at the top (BMI>=40, N= 7,526) and bottom end of the distribution (BMI≤19, N= 3,532) 240 
to more closely match the BMI criteria of our clinically ascertained thin and obese individuals. We 241 
used 20,720 samples from the rest of the UKBB cohort as a control set (Methods, S2 Fig).  In cases 242 
where lead variants or proxies (r2>0.8) were not currently available in the full UKBB genetic release 243 
we used results from the interim release using 2,799 individuals with BMI>=40, 1,212 with BMI<=19 244 
and 8,193 controls (Methods). We noted a significant negative genetic correlation for our obese 245 
replication cohort with anorexia nervosa (r= -0.24, 95% CI [-0.37,-0.11], p=0.01) and a positive 246 
genetic correlation for our thin cohort (r=0.49, 95% CI [0.22-0.76] p=0.0003). We also observed 247 
significant genetic correlation between obesity in the discovery and replication cohorts (r=0.84, 248 
95% CI [0.65-1] p=5.05x10-17) and between thinness in the discovery and replication cohorts (r= 249 
0.62, 95% CI [0.20-1]  p=0.004). 250 
To further increase power, we took advantage of publicly available summary statistics from the 251 
GIANT Extremes obesity meta-analysis [20], the EGG childhood obesity study [30], and our own 252 
previous study on non-overlapping SCOOP participants (SCOOP 2013) [31], as additional replication 253 
datasets. For SCOOP vs. STILTS we used the GIANT BMI tails meta-analysis results [20] (up to 7,962 254 
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cases/8,106 controls from the upper/lower 5th percentiles of the BMI trait distribution). For SCOOP 255 
vs. UKHLS we used the GIANT obesity class III summary statistics [20] (up to 2,896 cases with BMI 256 
≥40kg/m2 vs 47,468 controls with BMI <25 kg/m2), the EGG childhood obesity study [30] (children 257 
with BMI ≥95th percentile of BMI vs 8,318 children with BMI <50th percentile of BMI) and SCOOP 258 
2013 [31]. Fixed effect meta-analyses yielded genome-wide significant signals at well-known BMI 259 
associated loci in both the obese vs. thin, and obese vs. control analyses, and both the PIGZ and 260 
C3orf38 loci identified at the discovery stage failed to replicate when combined with additional data 261 
(Table 1, S7 Table). However, the SNRPC locus described here (rs75398113), though not 262 
independent from the previously described SNRPC/C6orf106 locus (rs205262, r2= 0.29) [24], 263 
appears to be driving the previously reported association at this locus (rs205262 conditioned on 264 
rs75398113, pconditioned=0.7, S8 Table). Both SNPs are eQTLs for C6or106 and UHRF1BP1 in multiple 265 
tissues including brain and colon tissues on GTEx however neither of these are obvious biological 266 
candidates linked to energy homeostasis.  267 
 268 
Table 1 - GWAS results for SNPs meeting p<5x10-8 in all three analyses.  EA= Effect allele (BMI 269 
increasing allele); NEA= Non-effect allele; OR = Odds ratio; 95% CI = 95% confidence interval for the 270 
odds ratio; EAF = effect allele frequency. Positions mapped to hg19, Build 37. ars12995480 used as 271 
proxy in GIANT. brs2384054 used as proxy in GIANT. crs12641981 used as proxy in GIANT. drs663129 272 
used as proxy in GIANT, EGG and SCOOP 2013. ers13007080 used as proxy in GIANT, EGG and 273 
SCOOP 2013. frs7138803 used as proxy in SCOOP 2013. grs6722587 used as proxy in GIANT, EGG 274 
and SCOOP 2013. hrs4132288 used as proxy in GIANT, EGG and SCOOP 2013. irs1460940 used as 275 
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proxy in GIANT, EGG and SCOOP 2013. jrs1366333 used as proxy in GIANT, EGG and SCOOP 2013. 276 
kGIANT BMI tails [20]. lGIANT obesity class III [20]. 277 
 278 
Finally, we used the independent BMI dataset from UKBB (Methods) to investigate whether any of 279 
the loci meeting our arbitrary p ≤10-5 in discovery efforts, were independently associated with BMI 280 
as a continuous trait.  This identified a novel BMI-associated locus near PKHD1 (SCOOP vs. STILTS 281 
p=5.99x10-6, SCOOP vs. UKHLS p=2.13x10-6, BMI p=2.3x10-13, S9 Table).  Furthermore, we note that 282 
when comparing the signals we took for replication (based on case control analyses) with 283 
association results with BMI as a continuous trait derived from an independent set of samples from 284 
UKBB, there are more directionally consistent and nominally significant associations with BMI than 285 
expected by chance suggesting that amongst these loci, there may be additional real associations 286 
(binomial p=4.88x10-4, and binomial p=9.77x10-3, respectively, Methods, S9 Table).” 287 
Despite the smaller sample size, the obese vs thin comparison had increased power to detect some 288 
loci (S3 Fig), including a recently discovered variant near FAM150B [32] (rs62107261, MAF= ~5%), 289 
which did not meet our p<10-5 threshold to be taken forward for replication in obese vs controls 290 
analysis (p=2.36x10-4).   291 
 292 
Discussion 293 
Here we present results from the largest to-date GWAS performed on healthy individuals with 294 
persistent thinness and provide the first insights into the genetic architecture of this trait. To our 295 
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knowledge, there are only two other studies using thin individuals with comparable mean BMIs 296 
[21,22]. The study by Hinney et al. [21] (N=442), was only able to detect FTO at genome-wide 297 
significance level with rs1121980 having a similar effect to that which we report (OR=1.66 vs OR= 298 
1.69 in our data).  In the Scannell Bryan et al. [22] study, Bangladeshi individuals were reportedly 299 
thin and malnourished, and a single suggestive association was found with an intronic variant in 300 
NRXN3 (rs12882679, p=9.57x10-7) which is not significant in our study (p=0.77). 301 
Using genome-wide genotype data we show that persistent healthy thinness, similar to severe 302 
obesity (h2=32.33%), is a heritable trait (h2=28.07%). Persistent healthy thinness and severe 303 
childhood obesity are negatively correlated (r=-0.49, 95% CI [-0.17, -0.82], p=0.003), and share a 304 
number of genetic risk loci. Nonetheless, the genetic overlap between the two clinically ascertained 305 
traits appears to be incomplete, as highlighted by some loci which were more strongly associated  306 
at one end of the BMI distribution (e.g. CADM2), while others, appeared to exert effects across the 307 
entire BMI spectrum (e.g. MC4R [9,33,34]).  Further exploration by simulation demonstrated that 308 
these differences are likely to be due to the different degrees of extremeness of the two clinical 309 
cohorts (i.e. a similar degree of thinness to that of the obese cohort may not be compatible with 310 
healthy human life) and not due to a deviation from additive effects of the tested loci on BMI, with 311 
the possible exception of CADM2 which deviated from expectation with nominal significance in 312 
both the obese and the thin analysis (S3 Table). This is in contrast with earlier studies which 313 
suggested larger effects at the higher end of the BMI distribution [35,36] but in agreement with 314 
more recent observations contrasting the bottom 5% and top 5% of the BMI tails where associated 315 
loci were also consistent with additive effects [20]. This is also in contrast with a previous study on 316 
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height, where a deviation from additivity was found, but only for short individuals in the bottom 317 
1.5% of the distribution [37], which suggests that analysis focused just on the most extreme 318 
individuals may be warranted.  319 
 320 
Focusing on the 97 previously established BMI associated loci [24], we show that the percentage of 321 
phenotypic variance explained by these loci is lower in persistently thin (4.33%) compared to obese 322 
individuals (10.67%), and that the effect of an increase/decrease in the BMI genetic risk score was 323 
much larger, on average, for obese individuals than for thin individuals (one standard deviation 324 
increase in the standardised BMI genetic risk score of 1.94, 95% CI (1.83, 2.07) and 1.50, 95% CI 325 
(1.42, 1.59), respectively) which is consistent with the difference in BMI units amongst categories.  326 
And, although our analysis using age-matched controls from ALSPAC suggested that the observed 327 
differences in ORs, comparing obese vs control individuals to controls vs thin individuals, was 328 
unlikely to be due to age effects, we cannot completely exclude the possibility that different effects 329 
of age and sex in our discovery cohorts (S1 Table), and gene-by-environment interactions, could be 330 
influencing some of the results we observe.  For example, gene-by-environment interactions and 331 
age effects have been previously reported at the FTO locus [38-41] where a larger effect is detected 332 
in younger adults. It is worth noting though that non-additive effects have also been observed in 333 
the FTO locus [42]. 334 
 335 
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In studying thin individuals there are often concerns regarding the prevalence of eating disorders, 336 
notably anorexia nervosa amongst participants. We sought to carefully exclude eating disorders at 337 
two phases of recruitment (by medical history and by questionnaire). Additionally, we demonstrate 338 
that in our cohort of healthy thin individuals, anorexia nervosa is unlikely to be a confounder as the 339 
two traits are genetically only weakly correlated (r=0.13, 95% CI [-0.02,0.28], p=0.09).  This was not 340 
the case for the UKBB replication cohort where a positive genetic correlation was observed (r= 0.49 341 
95% CI [0.22-0.76] p=0.0003). The positive genetic correlation with anorexia was still observed after 342 
removing individuals with medical conditions that could explain their low BMI (r=0.62, 95% CI 343 
[0.30,0.92], p=0.0001, Methods). These results highlight the importance of the careful phenotyping 344 
performed in the recruitment phase and the utility of the STILTS cohort as a resource to study 345 
healthy and persistent thinness. 346 
In the genome-wide association analyses amongst the signals we took forward for replication, in 347 
addition to detecting established BMI-associated loci, we find a novel BMI-association at PKHD1 in 348 
the UKBB BMI dataset (rs10456655, =0.10, p=2.3x10-13, S9 Table), where a proxy for this variant 349 
(rs2579994, r2=1 in 1000G Phase 3 CEU) has been previously nominally associated with waist and 350 
hip circumference (p=5.60x10-5 and p=4.40x10-4 respectively) [43].  In addition, we found 351 
associations at loci that have only recently been established using very large sample sizes. 352 
FAM150B, was only suggestively associated at discovery stage in Tachmazidou et al. (2017) [32] 353 
(n=47,476, p=2.57×10−5) whereas it reached genome-wide significance when contrasting SCOOP vs 354 
STILTS (n=2,927, p=2.07x10-8, S5 Table). Also, PRDM6-CEP120 [5] was recently discovered in a 355 
Japanese study with a sample size of 173,430 and has not been previously reported in a European 356 
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population. In our study, a signal near the locus (rs112446794, r2=0.36) showed suggestive evidence 357 
of association in SCOOP vs UKHLS (p=2.08x10-6, S6 Table) with a significantly smaller sample size. 358 
Conditional analysis reveals the lead SNP in this study drives the association of the previously 359 
established signal (S8 Table).  CEP120 codes for centrosomal protein 120. Variants near this locus 360 
have been previously associated with height [44] and waist circumference in East Asians [45]. 361 
Missense variants in the gene itself have been associated with rare ciliopathies [46,47].  Lastly, 362 
amongst the signals we took for replication, and after removing known and newly established loci, 363 
we still observe an enrichment of directionally consistent and nominal associations in the analysis 364 
of BMI as a continuous trait, suggesting that some of these results may warrant additional 365 
investigation, in particular in similarly ascertained thin and obese cohorts. One such example is 366 
rs4447506, near PIK3C3, which was not only nominally significant and consistent in the 367 
independent UKBB BMI analysis (p=1.5x10-6, S9 Table), but also in the Locke et al. (2015) [24] BMI 368 
results (p= 0.01), and in the GIANT BMI tails analysis we used as replication (S5 Table).  We also 369 
note, that despite not reaching genome-wide significance in our discovery cohorts, we observe 370 
directionally consistent suggestive associations at a number of loci previously associated with BMI 371 
tails and with different obesity classes [20] (S10 Table). Altogether, these results highlight some 372 
power advantages of using clinically ascertained extremes of the phenotype distribution to detect 373 
associations and suggest that healthy thinness falls at the lower end of the polygenic BMI spectrum. 374 
It is worth noting though that these clinically ascertained extremes display evidence of incomplete 375 
genetic correlation with BMI, in contrast to previously described obesity classes (S4 Fig), so it is 376 
plausible that additional loci might be uncovered by focusing on clinical extremes. 377 
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As our results were based on clinically ascertained participants which met very specific criteria, it is 378 
worth noting these conclusions cannot be straightforwardly extrapolated to the general population. 379 
Experiments in animals have identified loci/genes associated with thinness/decreased body weight 380 
due to reduced food intake/increased energy expenditure/resistance to high fat diet-induced 381 
obesity [48,49], mechanisms that we hypothesise may contribute to human thinness. The STILTS 382 
cohort, being uncorrelated to anorexia nervosa, is an excellent resource in which to conduct such 383 
additional genetic exploration. Further genetic and phenotypic studies focused on persistently thin 384 
individuals may provide new insights into the mechanisms regulating human energy balance and 385 
may uncover potential anti-obesity drug targets.  386 
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Methods 387 
ETHICS STATEMENT 388 
The study was reviewed and approved by the South Cambridgeshire Research Ethics Committee 389 
(12/EE/0172). All participants provided written informed consent prior to inclusion. 390 
COHORTS 391 
SCOOP, STILTS and UKHLS cohorts were used for the heritability, genetic correlation, genetic risk 392 
score and association analyses with established BMI loci, as well as, used as a discovery cohort in 393 
the genome-wide association study (GWAS) and gene-based tests. UK Biobank samples were used 394 
for genetic correlation analysis and in the replication stages of the GWAS and gene-based tests. 395 
ALSPAC was used as an additional control dataset to UKHLS for comparison against SCOOP in the 396 
established BMI loci analysis. 397 
 398 
STILTS  399 
The aim was to recruit a new cohort of UK European people who are thin (defined as a body mass 400 
index < 18kg/m2) and well. After ethical committee approval (12/EE/0172), we worked with the 401 
NIHR Primary Care Research Network (PCRN) to collaborate with 601 GP practices in England. Each 402 
practice searched their electronic health records using our inclusion criteria (age 18-65 years, 403 
BMI<18 kg/m2) and exclusion criteria (medical conditions that could potentially affect weight 404 
(chronic renal, liver, gastrointestinal problems, metabolic and psychiatric disease, known eating 405 
disorders). A small number of individuals (n=43) with a BMI of 19.0 kg/m2 were included as they 406 
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had a strong family history of thinness. The case notes of each potential participant were reviewed 407 
by the GP or a senior nurse with clinical knowledge of the participant to exclude other potential 408 
causes of low body weight in discussion with the study team. Through this approach we identified 409 
25,000 individuals who fitted our criteria for inclusion in the study. These individuals were invited 410 
to participate in the study; approximately 12% (2,900) replied consenting to take part. We obtained 411 
a detailed medical and medication history, screened for eating disorders using a questionnaire 412 
(SCOFF) that has been validated against more formal clinical assessment [50]. We excluded all 413 
participants who stated that they exercised every day/more than 3 times a week/whose reported 414 
activity exceeded 6 metabolic equivalents (METs) for any duration or frequency 415 
(http://www.who.int/dietphysicalactivity/physical_activity_intensity/en/). With these rather strict 416 
criteria for exercise, we sought to limit the contribution of exercise as a contributor to the thinness 417 
of participants in the STILTS cohort. We excluded people who were thin only at a certain point in 418 
their lives (often as young adults) to focus on those who were persistently thin/always thin 419 
throughout life as we hypothesised that this group would be enriched for genetic factors 420 
contributing to their thinness. We asked a specific question to identify these individuals: “have you 421 
always been thin?” Only those who answered positively were included. Questionnaires were 422 
manually checked by senior clinical staff for these parameters and for reported ethnicity (non-423 
European ancestry excluded). DNA was extracted from salivary samples obtained from these 424 
individuals using the Oragene 500 kit according to manufacturer’s instructions (S1 Table).   425 
 426 
SCOOP 427 
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With ethical committee approval (MREC 97/5/21), we have recruited 7,000 individuals with severe 428 
early-onset obesity (BMI standard deviation score (SDS) > 3; onset of obesity before the age of 10 429 
years) to the Genetics of Obesity Study (GOOS) [51]. The Severe Childhood Onset Obesity Project 430 
(SCOOP) cohort [31] is a sub-cohort of GOOS comprised of ~4,800 British individuals of European 431 
ancestry; S1 Table). SCOOP individuals likely to have congenital leptin deficiency, a treatable cause 432 
of severe obesity, were excluded by measurement of serum leptin, and individuals with mutations 433 
in the melanocortin 4 receptor gene (MC4R) (the most common genetic form of penetrant obesity) 434 
were excluded by prior Sanger sequencing.  435 
 436 
UKHLS 437 
Understanding Society (UKHLS) is a longitudinal household study designed to capture economic, 438 
social and health information from UK individuals[52]. A subset of 10,484 individuals was selected 439 
for genome-wide array genotyping. This cohort was used as a control dataset with SCOOP and 440 
STILTS cases (S1 Table). 441 
 442 
UK BIOBANK (UKBB) 443 
This study includes approximately 487,411 participants with genetic data released (including 444 
~50,000 from the UKBiLEVE cohort [53]) of the total 502,648 individuals from UK BioBank (UKBB).  445 
UKBB samples were genotyped on the UK Biobank Axiom array at the Affymetrix Research Services 446 
Laboratory in Santa Clara, California, USA and imputed to the Haplotype Reference Consortium 447 
(HRC) panel [54].  UKBiLEVE samples were genotyped on the UK BiLEVE array which is a previous 448 
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version of the UK Biobank Axiom array sharing over 95% of the markers. To date, 487,411 samples 449 
with directly genotyped and imputed data are available and data was downloaded using tools 450 
provided by UK Biobank. Extensive data from health and lifestyle questionnaires is currently 451 
available as well as linked clinical records. BMI, as well as other physical measurements were taken 452 
on attendance of recruitment centre. Severely obese participants in the available data were defined 453 
as those with BMI ≥ 40 kg/m2 (N=9,706) and thin individuals were defined as those with BMI ≤ 19 454 
kg/m2 (N=4,538).  Given that it has been previously shown that type I error rate for variants with a 455 
low minor allele count (MAC) is inadequately controlled for in very unbalanced case-control 456 
scenarios[55], we randomly subsampled 35,000 individuals from the original 487,411 genotyped 457 
individuals and removed those with BMI≤19 or BMI ≥30, to generate an independent control set. 458 
The 25,856 participants remaining after BMI exclusions from the tails, generated a non-extreme set 459 
of individuals kept as putative controls (S2 Fig). The other 452,411 genotyped samples were kept as 460 
the BMI dataset for downstream analyses (S11 Table, S2 Fig). An interim release consisting of a 461 
subset 152,249 individuals from UKBB was released in May 2015. This interim release was imputed 462 
to a combined UK10K and 1000G Phase 3 reference panel and contains several variants which are 463 
not currently present in the HRC panel, as such it was used in some of the analyses described.  464 
 465 
ALSPAC 466 
The Avon Longitudinal Study of Parents and Children (ALSPAC) [27,56], also known as Children of 467 
the 90s, is a prospective population-based British birth cohort study.  Ethical approval for the study 468 
was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics 469 
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Committees. Please note that the study website contains details of all the data that is available 470 
through a fully searchable data dictionary (http://www.bris.ac.uk/alspac/researchers/data-471 
access/data-dictionary/). Further information about this cohort, including details of the genotyping 472 
and imputation procedures, can be found in S2 Appendix.  This analysis was restricted to a subset 473 
of unrelated (identity-by-state < 0.05 [57]) children with genetic data and BMI measured between 474 
the age of 12 and 17 years (n=4,964, 48.5% male).  The mean age of the children was 14 years and 475 
the mean BMI 20.5. 476 
 477 
GENOTYPING AND QUALITY CONTROL 478 
SCOOP, STILTS and UKHLS 479 
For the SCOOP cohort, DNA was extracted from whole blood as previously described [31]. For the 480 
STILTS cohort, DNA was extracted from saliva using the Oragene saliva DNA kits (online protocol) 481 
and quantified using Qubit. All samples from SCOOP, STILTS and UKHLS were typed across 30 SNPs 482 
on the Sequenom platform (Sequenom Inc. California, USA) for sample quality control. Of the 3,607 483 
SCOOP and STILTS samples submitted for Sequenom genotyping, 3,280 passed quality controls 484 
filters (90.9% pass rate).  Of the 10,433 UKHLS samples, 9,965 passed Sequenom sample quality 485 
control (95.5% pass rate). Subsequently, UKHLS controls were genotyped on the Illumina 486 
HumanCoreExome-12v1-0 Beadchip. The 3,280 SCOOP and STILTS samples, and 48 overlapping 487 
UKHLS samples (to test for possible array version effects) were genotyped on the Illumina 488 
HumanCoreExome-12v1-1 Beadchip by the Genotyping Facility at the Wellcome Sanger Institute 489 
(WSI).  Genotype calling was performed centrally for all batches at the WSI using GenCall. Criteria 490 
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for excluding samples were as follows: i) concordance against Sequenom genotypes <90%; ii) for 491 
each pair of sample duplicates, exclude one with highest missingness; iii) sex inferred from genetic 492 
data different from stated sex ; iv) sample call rate <95%; v) sample autosome heterozygosity rate 493 
>3 SDS from mean done separately for low (<1%) and high MAF(>1%) bins; vi) magnitude of 494 
intensity signal in both channels <90%; and vii) for each pair of related individuals (proportion of 495 
IBD (PI_HAT) >0.05), the individual with the lowest call rate was excluded.  We performed SNP QC 496 
using PLINK v1.07[58]. Criteria for excluding SNPs was: i) Hardy-Weinberg equilibrium (HWE) 497 
p<1x10-6; ii) Call rate <95% for MAF≥5%, call rate <97% for 1% ≤MAF<5%, and call rate <99% for 498 
MAF <1%.  SMARTPCA v10210 [59] was used for principal component analysis (PCA). To verify the 499 
absence of array version effects we used PCA on the subset of shared controls genotyped on both 500 
versions of the array. Cut-offs for samples that diverged from the European cluster were chosen 501 
manually after inspecting the PCA plot. SNPs with discordant MAFs in the different versions of the 502 
array were excluded. After removal of non-European samples and 13 samples due to cryptic 503 
relatedness, 1,456 SCOOP and 1,471 STILTS samples remained for analysis. For UKHLS, 82 samples 504 
were removed after applying a strict European filter and 680 related samples were removed after 505 
applying a “3rd degree” kinship filter in KING[60]. A total of 9,203 samples remained, of which 6,460 506 
had a BMI >19 and <30 (“controls”).  507 
 508 
UK BIOBANK  509 
Sample QC was performed using all 487,411 samples. Criteria for excluding samples were as 510 
follows: i) supplied and genetically inferred sex mismatches; ii) heterozygosity and missingness 511 
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outliers according to centrally provided sample QC files; iii) samples not used in kinship estimation 512 
by UKBB; iv) individuals that did not identify as “white british” or did not cluster with other “white 513 
british” in PCA analysis ;  v) samples that withdrew consent and vi) for each pair of related 514 
individuals (KING kinship estimate>0.0442), we randomly selected an individual preferentially 515 
keeping cases if one related individual is a control.  After sample QC, thirteen individuals with 516 
underlying health conditions that could influence their BMI were also removed, twelve had BMI<14, 517 
and one had BMI>74.  In the end, 7,526 obese, 3,532 thin and 20,720 non-extreme controls 518 
remained for case-control analyses. In addition, 387,164 samples remained for analysis of BMI as a 519 
continuous trait. There is an overlap of 10, 282 samples (~2.6% of the BMI dataset) with obese and 520 
thin cases (S2 Fig). The same procedure was performed on the interim release of 152,249 UKBB 521 
samples to produce a set of 2,799 obese, 1,212 thin, 8,193 controls and 127,672 individuals for the 522 
independent BMI dataset. All subsequent analyses on UKBB were also performed on this subset to 523 
query variants that are not currently available in the full UKBB release.  524 
 525 
IMPUTATION AND GENOME-WIDE ASSOCIATION ANALYSES 526 
SCOOP, STILTS and UKHLS single-variant association analysis 527 
Genotypes from SCOOP, STILTS and UKHLS controls were phased together with SHAPEITv2 [61], and 528 
subsequently imputed with IMPUTE2 [62,63] to the merged UK10K and 1000G Phase 3 reference 529 
panel [64], containing ~91.3 million autosomal and chromosome X sites, from 6,285 samples. More 530 
than 98% of variants with MAF ≥0.5% had an imputation quality score of r2≥0.4, however variants 531 
with MAF <0.1% had a poor imputation quality with only 27% variants with r2≥0.4 (S5 Fig). First-532 
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pass single-variant association tests were done for all variants irrespective of MAF, or imputation 533 
quality score (see below).  Analyses of 1,456 SCOOP, 1,471 STILTS and 6,460 controls (BMI range 534 
19-30) of European ancestry were based on the frequentist association test, using the EM 535 
algorithm, as implemented in SNPTEST v2.5 [65], under an additive model and adjusting for six PCs 536 
and sex as covariates.  537 
 538 
UKBB BMI dataset single-variant association analysis 539 
For the BMI dataset, we used BOLT-LMM [66] to perform an association analysis with BMI using 540 
sex, age, 10 PCs and UKBB genotyping array as covariates.  541 
 542 
Heritability estimates and genetic correlation 543 
Summary statistics from the SCOOP vs. UKHLS, STILTS vs. UKHLS, UKBB obese vs controls, UKBB thin 544 
vs controls and UKBB BMI analyses were filtered and a subset of 1,197,969 HapMap3 SNPs was 545 
kept in each dataset. Using LD score regression [67] we first calculated the heritability of severe 546 
childhood obesity (SCOOP vs UKHLS) and persistent thinness (STILTS vs UKHLS). For severe 547 
childhood obesity, we estimated a prevalence of 0.15% using the BMI centile equivalent to 3SDS in 548 
children [68]. In the case of persistent thinness (BMI<=19), we used a GP based cohort for our 549 
prevalence estimates: CALIBER [69].  The CALIBER database consists of 1,173,863 records derived 550 
from GP practices.  For the heritability analysis, we used a prevalence estimate of 2.8% for BMI<=19 551 
(Claudia Langenberg and Harry Hemingway, personal communication). We also used LD score 552 
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regression to calculate the genetic correlation of SCOOP with STILTS, SCOOP with UKBB obese, 553 
SCOOP with BMI, STILTS with UKBB thin and STILTS with BMI. The genetic correlation between 554 
obesity and persistent thinness with anorexia was estimated using the summary statistics from 555 
SCOOP vs UKHLS and STILTS vs. UKHLS, and summary statistics available from the Genetic 556 
Consortium for Anorexia Nervosa (GCAN) in LD Hub [70]. The same analysis was repeated for UKBB 557 
obese vs controls and UKBB thin vs controls. Genetic correlation estimates for BMI vs Overweight, 558 
Obesity Class 1, Obesity Class 2 and Obesity Class 3 were also extracted from LD Hub (S4 Fig).   559 
 560 
Comparison with established GIANT BMI associated loci 561 
We obtained the list of 97 established BMI associated loci from the publicly available data from the 562 
GIANT consortium [24]. We used this list as we wanted to focus on established common variation in 563 
Europeans with accurate effect sizes for simulations. In order to test whether there is evidence of 564 
enrichment of nominally significant signals with consistent direction of effect, we performed a 565 
binomial test using the subset of signals with nominal significance in the SCOOP vs UKHLS, and 566 
STILTS vs UKHLS analyses.  Variance explained was calculated using the rms package [71] v4.5.0 in R 567 
[72] and Nagelkerke’s R2 is reported. Power calculations were performed using  Quanto [73]. To 568 
calculate ORs and SE from the ALSPAC BMI summary statistics we used genotype counts from 569 
SNPTEST output. We then used a z-test to test for significant differences between the OR calculated 570 
using genotype counts of SCOOP and ALSPAC against the SCOOP vs. UKHLS OR.  571 
 572 
Simulations under an additive model 573 
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We created 10,000 simulations of 1 million individuals for the 97 GIANT BMI loci randomly sampling 574 
alleles based on the allele frequency from the sex-combined European dataset reported in Locke et 575 
al. [24] using an R script. For each simulated genotype, we simulated phenotypes with DISSECT [74] 576 
using the effect size in GIANT and then removed all samples from the lower tail where the 577 
phenotype was <3SDs to better reproduce the actual BMI distribution. Afterwards we randomly 578 
sampled 1,471 individuals from the bottom 2.8% and 1,456 from top 0.15% and compared against a 579 
random set of 6,460 controls from the equivalent percentiles to BMI 19-30.  Finally, for each of 580 
these loci, we calculated the absolute difference between our observed OR and the mean OR from 581 
the simulations and counted how many times we saw an equal or larger absolute difference in the 582 
simulated data and assigned a p-value. This was done separately for SCOOP vs UKHLS and STILTS vs 583 
UKHLS.  584 
 585 
Genetic Risk Score 586 
The R package GTX ( https://cran.r-project.org/web/packages/gtx/index.html) was used to 587 
transpose genotype probabilities into dosages, and a combined dosage score, weighted by the 588 
effect size from GIANT, for 97 BMI SNPs [24] was calculated and standardised. We checked whether 589 
there was an ordinal relationship between the genetic risk score and BMI category (i.e. thin, 590 
normal, or obese) using ordinal logistic regression with the clm function in the ordinal R package. 591 
While the assumption of equal variance appears to hold (S6 Fig), the proportional odds assumption 592 
indicating equal odds between thin, normal, and obese groups is violated for the BMI genetic risk 593 
score and some of the principal component covariates (i.e., PC2, PC3, and PC6). As our primary 594 
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model, we ran a partial proportional odds model adjusting for PC1, PC4, and PC5 and allowing the 595 
BMI genetic score, PC2, PC3, and PC6 to vary between BMI category. To check for consistency, we 596 
ran a partial proportional odds model adjusting for the first six PCs and allowing only the BMI 597 
genetic score to vary between BMI group and a full proportional odds model allowing all six PCs and 598 
the BMI genetic score to vary between BMI group (S1 Appendix). Using ANOVA, we formally tested 599 
the proportional odds assumption for the BMI genetic risk score. A genetic risk score was created 600 
and an ordinal logistic regression was run for each of the 10,000 simulations. We compared the 601 
observed test statistic testing whether the odds were the same by BMI category to the 10,000 602 
simulation test statistics. We calculated the p-value as the number of simulations with a test 603 
statistic larger than that observed in the real data. A mean genetic risk score was also calculated for 604 
each BMI category (obese, thin and controls) across the 10,000 simulations. A t-test was used to 605 
test whether the mean observed GRS score in each category was significantly different from the 606 
one estimated using the simulations.  607 
 608 
Discovery stage GWAS 609 
First pass single-variant association analyses results were used as discovery datasets for the GWAS. 610 
After association analysis, we removed variants with MAF<0.5%, an INFO score <0.4, and HWE 611 
p<1x10-6, as these highlighted regions of the genome that were problematic, including CNV regions 612 
with poor imputation quality. Quantile-quantile plots indicated that the genomic inflation was well 613 
controlled for in SCOOP-UKHLS (λ=1.06) and STILTS-UKHLS (λ =1.04), and slightly higher for SCOOP-614 
STILTS (λ =1.08, S7 Fig). We used LD score regression [67] to correct for inflation not due to 615 
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polygenicity. To identify distinct loci, we performed clumping as implemented in PLINK [58] using 616 
summary statistics from the association tests and LD information from the imputed data, clumping 617 
variants 250kb away from an index variant and with an r2>0.1.  In order to further identify a set of 618 
likely independent signals we performed conditional analysis of the lead SNPs in SNPTEST to take 619 
into account long-range LD. A total of 135 autosomal variants with p<1x10-5 in any of the three 620 
case-control analyses were taken forward for replication in UKBB. All case-control results are 621 
reported with the lower BMI group as reference.  622 
 623 
UKBB association analysis 624 
We tested 1,208,692 SNPs for association under an additive model in SNPTEST using sex, age, 10 625 
PCs and UKBB genotyping array as covariates. Three comparisons were done: obese vs thin, obese 626 
vs controls and controls vs thin. Variants with an INFO score <0.4, HWE p<1x10-6 were filtered out 627 
from the results. Inflation factors were calculated using HapMap markers. The LD score regression 628 
intercepts were 1.0074 in obese vs thin, 1.0057 in obese vs controls and 1.009 in thin vs controls.  629 
We used all thin individuals, regardless of health status, as our replication cohort to maximize 630 
power. However, using ICD10 codes and self-reported illness data (Tables S12 and S13) to remove 631 
individuals who had a relevant medical diagnosis before date of attendance at UKBB recruitment 632 
centre, yielded 2,518 thin individuals and materially equivalent results (S8 Fig). 633 
 634 
GIANT, EGG and SCOOP 2013 summary statistics 635 
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We obtained summary statistics for the GIANT Extremes obesity meta-analysis [20] from 636 
http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files. 637 
Summary statistics for EGG [30] were obtained from http://egg-consortium.org/childhood-638 
obesity.html. We used summary statistics from our previous study of 1,509 early-onset obesity 639 
SCOOP cases compared to 5,380 publicly available WTCCC2 controls (SCOOP 2013) [31]. Data for 640 
the SCOOP cases is available to download from the European Genome-Phenome Archive (EGA) 641 
using accession number EGAD00010000594. The control samples are available to download using 642 
accession numbers EGAD00000000021 and EGAD00000000023. These replication studies are 643 
largely non-overlapping with our discovery datasets and each-other. When a lead variant was not 644 
available in a replication cohort, a proxy (r2≥ 0.8) was used in the meta-analysis. 645 
 646 
Replication meta-analysis 647 
We meta-analysed summary statistics for the 135 variants reaching p<1x10-5 in 648 
SCOOP/STILTS/UKHLS with the corresponding results from UKBB and study specific replication 649 
cohorts (Tables S5-S7). For obese vs. thin and obese vs. controls comparisons we used fixed-effects 650 
meta-analysis correcting for unknown sample overlap in replication cohorts using METACARPA [75]. 651 
For thin vs. controls we used a fixed-effects meta-analysis in METAL [76].  Heterogeneity was 652 
assessed using Cochran’s Q-test heterogeneity p-value in METAL. A signal was considered to 653 
replicate if it met all the following criteria: i) consistent direction of effect; ii) p<0.05 in at least one 654 
replication cohort; and iii) the meta-analysis p-value reached standard genome-wide significance 655 
(p<5x10-8). Given that we are querying additional variants on the lower allele frequency spectrum, 656 
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one could also use a more strict genome-wide significance threshold taking into account the 657 
increased number of tests (p≤1.17x10-8) [77]. In practice, this only affected one previously 658 
established signal (SULT1A1, rs3760091) in our obese vs. controls analysis that fell just below this 659 
threshold (S6 Table).  rs4440960 was later removed from final results (SCOOP vs UKHLS and STILTS 660 
vs UKHLS) after close examination revealed it was present in a CNV region with poor imputation 661 
quality. 662 
 663 
Comparison of newly established candidate loci and UKBB independent BMI dataset 664 
We identified eleven signals in SCOOP vs STILTS, nine in SCOOP vs UKHLS and two in UKHLS vs 665 
STILTS that were nominally significant in the UKBB BMI dataset GWAS, and directionally consistent. 666 
A binomial test was used to check for enrichment of signals with consistent direction of effect (S9 667 
Table).  668 
 669 
Lookup of previously identified obesity-related signals in our discovery datasets 670 
We took all signals reaching genome-wide significance, or identified for the first time in the GIANT 671 
Extremes obesity meta-analysis [20], with either the tails of BMI or obesity classes, and in childhood 672 
obesity studies [30,31] and performed look-up of those signals in all three of our discovery analyses 673 
(SCOOP vs STILTS, SCOOP vs UKHLS and UKHLS vs STILTS).  ORs and p-values from the previous 674 
studies and look-up results from our discovery datasets are reported in S10 Table. 675 
 676 
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Data availability  677 
Summary statistics for the discovery analyses will be available to download from EGA 678 
(EGAS00001002624). UKHLS data is available for download in EGA with accession code 679 
EGAS00001001232.  680 
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Table 1 
Obese vs. thin           Discovery cohort Replication cohorts Combined analysis 
rsID Nearest gene Chr. Position (bp) EA NEA OR  (95% CI) P value EAF Ob EAF Th Cohort OR  (95% CI) P value EAF Ob EAF Th OR  (95% CI) P value HetPVal 
rs9930333 FTO 16 53799977 G T 1.70(1.52,1.90) 2.30E-20 49.59% 37.46% UKBB  1.46(1.38,1.55) 3.60E-36 48.26% 38.93% 1.48(1.42,1.54) 8.52E-76 3.34E-02 
  
    
  
   
  GIANTk 1.43(1.34,1.54) 8.10E-25 
 
  
  
  
rs2168711 MC4R 18 57848531 C T 1.66(1.45,1.89) 8.29E-14 28.90% 19.95% UKBB  1.23(1.15,1.32) 2.19E-09 26.75% 22.90% 1.27(1.21,1.33) 2.02E-21 1.12E-04 
  
    
  
   
  GIANTk 1.20(1.10,1.30) 1.80E-05 
 
  
  
  
rs6748821 TMEM18a 2 629601 G A 1.65(1.42,1.91) 9.45E-11 86.69% 79.84% UKBB 1.27(1.18,1.37) 1.31E-09 85.00% 81.69% 1.32(1.24,1.39) 7.76E-21 2.81E-03 
  
    
  
   
  GIANTk 1.26(1.14,1.39) 9.90E-06 
 
  
  
  
rs506589 SEC16B 1 177894287 C T 1.46(1.27,1.67) 5.42E-08 23.98% 18.07% UKBB 1.25(1.17,1.35) 5.44E-10 23.11% 19.16% 1.28(1.21,1.35) 3.14E-20 1.21E-01 
  
    
  
   
  GIANTk 1.25(1.14,1.37) 2.70E-06 
 
  
  
  
rs6738433 ADCY3-DNAJC27b 2 25159501 C G 1.43(1.28,1.60) 1.71E-10 47.31% 43.92% UKBB 1.21(1.14,1.28) 2.74E-10 50.70% 45.96% 1.19(1.14,1.24) 3.19E-17 6.25E-03 
  
    
  
   
  GIANTk 1.10(1.03,1.17) 5.70E-03 
 
  
  
  
rs7132908 FAIM2 12 50263148 A G 1.31(1.17,1.47) 2.26E-06 42.45% 36.27% UKBB 1.18(1.11,1.25) 5.43E-08 41.11% 37.39% 1.20(1.15,1.26) 1.93E-16 2.52E-01 
  
    
  
   
  GIANTk 1.20(1.10,1.30) 6.60E-06 
 
  
  
  
rs62107261 FAM150B 2 422144 T C 2.37(1.75,3.20) 2.07E-08 96.37% 93.38% UKBB 1.54(1.35,1.76) 3.57E-10 96.28% 94.36% 1.65(1.46,1.87) 1.15E-15 1.07E-02 
rs12507026 GNPDA2c 4 45181334 T A 1.30(1.17,1.46) 
 
3.69E-06 47.29% 40.92% UKBB 1.14(1.08,1.21) 8.76E-06 45.30% 41.98% 1.18(1.13,1.23) 5.53E-15 4.06E-02 
  
    
  
   
  GIANTk 1.20(1.12,1.28) 3.10E-07 
 
  
  
  
rs75398113 SNRPC 6 34728071 C A  1.53(1.27,1.85) 8.91E-06 11.95% 8.04% UKBB  1.24(1.12,1.37)  2.07E-05 10.47% 8.52%  1.30(1.19,1.42) 5.19E-09 5.56E-02 
rs13135092 SLC39A8 4 103198082 G A  1.58(1.30,1.93) 4.70E-06 10.50% 7.24% UKBB  1.25(1.12,1.39) 5.57E-05 9.24% 7.52% 1.32(1.20,1.45) 1.06E-08 3.59E-02 
                  
Obese vs. controls 
    
  
   
  
    
  
  
  
rsID Nearest gene Chr. Position (bp) EA NEA OR  (95% CI) P value EAF Ob EAF Co Cohort OR  (95% CI) P value EAF Ob EAF Co OR  (95% CI) P value HetPVal 
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rs9928094 FTO 16 53799905 G A 1.44(1.33,1.57) 1.42E-18 49.50% 41.32% UKBB 1.30(1.25,1.35) 2.74E-41 48.34% 41.91% 1.32(1.29,1.36)  5.94E-101 4.41E-05 
  
    
  
   
  SCOOP 2013 1.46(1.34,1.60) 4.88E-17 
 
  
  
  
  
    
  
   
  EGG 1.21(1.15,1.28) 7.20E-13 
 
  
  
  
  
    
  
   
  GIANTl 1.43(1.34,1.54) 6.60E-25 
 
  
  
  
rs35614134 MC4Rd 18 57832856 AC A 1.31(1.20,1.44) 6.27E-09 29.01% 23.69% UKBB 1.22(1.16,1.27) 1.25E-18 26.72% 23.15%  1.23(1.20,1.27)  1.57E-43 3.55E-01 
  
    
  
   
  SCOOP 2013 1.32(1.19,1.46) 1.22E-07 
 
  
  
  
  
    
  
   
  EGG 1.22(1.15,1.30) 1.27E-10 
 
  
  
  
  
    
  
   
  GIANTl 1.20(1.10,1.30) 1.70E-05 
 
  
  
  
rs66906321 TMEM18e 2 630070 C T 1.40(1.24,1.57) 2.35E-08 85.78% 81.35% UKBB 1.17(1.11,1.24)  3.44E-09 84.44% 82.20%  1.25(1.21,1.29)  9.72E-35 1.33E-02 
  
    
  
   
  SCOOP 2013 1.39(1.24,1.57) 6.65E-08 
 
  
  
  
  
    
  
   
  EGG 1.28(1.19,1.37) 5.15E-12 
 
  
  
  
  
    
  
   
  GIANTl 1.27(1.15,1.40) 3.40E-06 
 
  
  
  
rs7132908 FAIM2f 12 50263148 A G 1.22(1.12,1.32) 3.27E-06 42.45% 37.82% UKBB 1.15(1.10,1.19)  5.37E-12 41.11% 37.71%  1.17(1.14,1.21)  2.38E-31 4.86E-01 
  
    
  
   
  SCOOP 2013 1.23(1.12,1.35) 8.89E-06 
 
  
  
  
  
    
  
   
  EGG 1.18(1.11,1.25) 1.24E-08 
 
  
  
  
  
    
  
   
  GIANTl 1.20(1.10,1.30) 6.60E-06 
 
  
  
  
rs2384060 ADCY3-DNAJC27g 2 25135438 G A 1.23(1.13,1.34) 1.53E-06 43.52% 38.90% UKBB 1.11(1.07,1.15)  4.89E-08 47.67% 44.93%  1.14(1.11,1.17)  9.39E-23 1.13E-01 
  
    
  
   
  SCOOP 2013 1.09(1.00,1.19) 5.01XE-02 
 
  
  
  
  
    
  
   
  EGG 1.18(1.12,1.24) 1.02E-09 
 
  
  
  
  
    
  
   
  GIANTl 1.12(1.04,1.19) 1.60E-03 
 
  
  
  
rs11209947 NEGR1h 1 72808551 A T 1.30(1.17,1.44) 8.51E-07 76.58% 72.18% UKBB 1.11(1.05,1.16) 4.53E-05 81.18% 79.76% 1.17(1.13,1.21) 5.17E-20 7.26E-05 
  
    
  
   
  SCOOP 2013 1.46(1.30,1.63) 2.21E-10 
 
  
  
  
  
    
  
   
  EGG 1.13(1.06,1.22) 4.60E-04 
 
  
  
  
  
    
  
   
  GIANTl 1.22(1.11,1.35) 5.60E-05 
 
  
  
  
rs12735657 SEC16Bi 1 177809133 C T 1.24(1.13,1.37) 9.72E-06 24.26% 20.46% UKBB 1.12(1.07,1.17) 1.48E-06 22.87% 20.94% 1.15(1.12,1.19)  7.26E-19 1.79E-01 
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  SCOOP 2013 1.20(1.07,1.33) 1.18E-03 
 
  
  
  
  
    
  
   
  EGG 1.14(1.06,1.21) 1.52E-04 
 
  
  
  
  
    
  
   
  GIANTl 1.22(1.11,1.34) 1.80E-05 
 
  
  
  
                  
                  
                  
                  
rs13104545 GNPDA2 4 45184907 A G 1.27(1.15,1.40) 1.61E-06 27.41% 23.45% UKBB 1.07(1.02,1.11) 5.35E-03 24.36% 23.26%  1.13(1.09,1.17)  1.47E-11 9.39E-05 
  
    
  
   
  EGG 1.13(1.04,1.22) 3.39E-03 
 
  
  
  
  
    
  
   
  GIANTl 1.34(1.20,1.49) 1.20E-07 
 
  
  
  
rs112446794 CEP120j 5 122665465 T C 1.23(1.13,1.35) 2.08E-06 33.15% 28.69% UKBB 1.07(1.02,1.11) 2.55E-03 29.47% 28.21%  1.09(1.06,1.13)  3.45E-10 3.33E-02 
  
    
  
   
  SCOOP 2013 1.08(0.98,1.19) 1.38E-01 
 
  
  
  
  
    
  
   
  EGG 1.12(1.06,1.18) 1.22E-04 
 
  
  
  
                    GIANTl 1.05(0.97,1.13) 2.40E-01           
rs3760091 SULT1A1 16 28620800 C G 1.24(1.14,1.35) 1.56E-06 64.89% 60.23% UKBB  1.09(1.04,1.14) 1.19E-04 63.49% 61.44% 1.12(1.07,1.16) 2.65E-08 8.49E-03 
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Supporting information captions 
 
S1 Appendix. Assessing equal vs. unequal effects for the genetic risk score. 
 
S2 Appendix. The Avon Longitudinal Study of Parents and Children. 
 
S1 Fig. Mean GRS for SCOOP and STILTS compared to simulations. Histogram represents mean GRS 
scores for each BMI category across 10,000 simulations. Vertical red line highlights the observed 
value in real data. p=p-value of difference. 
 
S2 Fig. Summary of the UKBB sample sets after QC. Venn Diagram showing sample numbers and 
overlap between UKBB sample sets used in genetic correlation (BMI dataset) and GWAS replication 
(obese, controls, thin) analyses. 
 
S3 Fig. Manhattan plot of SCOOP vs STILTS. Manhattan plot produced in EasyStrata, red line 
indicates genome-wide significance threshold at p=5x10-08. Orange line indicates discovery 
significance threshold at p=1x10-05.  Black labels highlight known BMI/obesity loci that were taken 
forward for replication and yellow peaks indicate those that met genome-wide significance after 
replication. 
 
S4 Fig. Genetic correlation of traits and BMI. Genetic correlation estimates and 95% CI for severe 
early-onset childhood obesity (SCOOP), healthy persistent thinness (STILTS), Obesity Class 3, 
Obesity Class 2, Obesity Class 1 and Overweight.  Dotted lines represent complete genetic 
correlation.  
 
S5 Fig. Quality of UK10K+1000G imputed genotypes. Percentage of variants with INFO score 
(r2)>0.4, as derived from the IMPUTE2 imputation algorithm, stratified by minor allele frequency 
across all samples (SCOOP, STILTS and UKHLS). 
 
S6 Fig. Box and density plots of risk score weighted by effect size for 97 BMI associated SNPs from 
GIANT. A weighted genetic risk score for each individual was obtained by summing genotype 
dosages multiplied by the effect (beta) estimates from GIANT for each of the 97 SNPs. To check the 
equal variance assumption, we used a box plot (left) and density plot (right). Density plot: Green = 
STILTS; Blue = UKHLS; Red = SCOOP. 
 
S7 Fig. Quantile-quantile plots of three discovery analysis cohorts. Q-Q plots of LD Score 
Regression-corrected p-values for the three analysis cohorts used for the discovery analysis, 
produced in EasyStrata. Red=SCOOP vs. STILTS; Black=SCOOP vs. UKHLS, Blue=STILTS vs. UKHLS. 
Variants passing QC and with MAF >=0.5% are shown. LD Score regression intercept (λLD) values 
before correction are shown for each analysis. 
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S8 Fig. Quantile-quantile plots for UKBB case-control analysis with different exclusion criteria for 
thin individuals. Q-Q plot using all thin individuals as cases (Full UKBB) and removing individuals 
based on ICD10 and self-reported data (ICD10+self-reported filter). Correlation for –log10 p-values 
is shown (r=0.7462). 
 
S1 Table. Summary of discovery sample sets. 
 
S2 Table. 97 BMI SNPs from the GIANT consortium study and their summary statistics in our three 
analysis cohorts. 
 
S3 Table. Nominally significant loci for non-additive effect in extremes. 
 
S4 Table. Difference in SCOOP OR when using ALSPAC as control dataset vs. UKHLS. 
 
S5 Table. Discovery, replication and meta-analysis results for 32 SNPs meeting P<10-5 in 
discovery association results of SCOOP vs STILTS analysis. 
 
S6 Table. Discovery, replication and meta-analysis results for 66 SNPs meeting P<10-5 in 
discovery association results of SCOOP vs UKHLS analysis. 
 
S7 Table. Discovery, replication and meta-analysis results for 37 SNPs meeting P<10-5 in 
discovery association results of UKHLS vs STILTS analysis. 
 
S8 Table:  Reciprocal analysis of previously established signals and lead signals in this study.  
 
S9 Table. Consistency of the direction of effect in candidate loci meeting p<1x10-5 in the 
discovery stages with BMI dataset GWAS. 
 
S10 Table. Published loci from GIANT, EGG and SCOOP 2013 not reaching genome-wide 
significance in our study 
 
S11 Table. Summary of UKBB sample sets. 
 
S12 Table. ICD10 codes used to exclude thin individuals in UKBB 
 
S13 Table. Self-reported illness codes used to exclude thin individuals in UKBB 
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Effect Other EAF Beta SE P value Effect Other EAF OR 95% CI P value Direction Effect Other EAF OR 95% CI P value Direction Effect Other EAF OR 95% CI P value Direction
rs1558902 16 53803574 FTO A T 0.415 0.082 0.003 7.51E-153 A T 0.419 1.689 (1.509,1.89) 7.31E-20 + A T 0.410 1.429 (1.317,1.55) 1.25E-17 + A T 0.387 1.174 (1.077,1.28) 2.78E-04 +
rs6567160 18 57829135 MC4R C T 0.236 0.056 0.004 3.93E-53 C T 0.244 1.643 (1.44,1.875) 1.77E-13 + C T 0.246 1.308 (1.194,1.433) 7.91E-09 + C T 0.229 1.257 (1.134,1.394) 1.38E-05 +
rs13021737 2 632348 TMEM18 G A 0.828 0.060 0.004 1.113E-50 G A 0.832 1.586 (1.365,1.844) 1.81E-09 + G A 0.832 1.356 (1.206,1.526) 3.89E-07 + G A 0.820 1.211 (1.088,1.347) 4.44E-04 +
rs10938397 4 45182527 GNPDA2 G A 0.434 0.040 0.003 3.205E-38 G A 0.442 1.302 (1.164,1.457) 4.19E-06 + G A 0.440 1.186 (1.093,1.287) 4.50E-05 + G A 0.429 1.084 (0.996,1.179) 6.24E-02 +
rs543874 1 177889480 SEC16B G A 0.193 0.048 0.004 2.618E-35 G A 0.210 1.452 (1.267,1.664) 8.57E-08 + G A 0.213 1.201 (1.09,1.324) 2.22E-04 + G A 0.202 1.177 (1.056,1.311) 3.11E-03 +
rs2207139 6 50845490 TFAP2B G A 0.177 0.045 0.004 4.126E-29 G A 0.171 1.292 (1.116,1.496) 5.91E-04 + G A 0.170 1.175 (1.057,1.306) 2.70E-03 + G A 0.163 1.116 (0.994,1.253) 6.21E-02 +
rs11030104 11 27684517 BDNF A G 0.792 0.041 0.004 5.557E-28 A G 0.796 1.320 (1.151,1.513) 7.31E-05 + A G 0.799 1.143 (1.029,1.269) 1.27E-02 + A G 0.792 1.122 (1.015,1.24) 2.43E-02 +
rs3101336 1 72751185 NEGR1 C T 0.613 0.033 0.003 2.661E-26 C T 0.613 1.245 (1.111,1.395) 1.58E-04 + C T 0.605 1.195 (1.098,1.3) 3.66E-05 + C T 0.595 1.056 (0.97,1.15) 2.07E-01 +
rs7138803 12 50247468 BCDIN3D A G 0.384 0.032 0.003 8.153E-24 A G 0.379 1.286 (1.149,1.441) 1.31E-05 + A G 0.371 1.216 (1.118,1.322) 4.68E-06 + A G 0.360 1.035 (0.948,1.13) 4.47E-01 +
rs10182181 2 25150296 ADCY3 G A 0.462 0.031 0.003 8.777E-24 G A 0.490 1.415 (1.268,1.58) 6.34E-10 + G A 0.496 1.202 (1.108,1.304) 9.30E-06 + G A 0.480 1.186 (1.09,1.29) 6.81E-05 +
rs3888190 16 28889486 ATP2A1 A C 0.403 0.031 0.003 3.14E-23 A C 0.407 1.136 (1.017,1.271) 2.46E-02 + A C 0.401 1.129 (1.04,1.226) 3.87E-03 + A C 0.395 1.035 (0.95,1.126) 4.34E-01 +
rs1516725 3 185824004 ETV5 C T 0.872 0.045 0.005 1.886E-22 C T 0.859 1.303 (1.112,1.526) 1.05E-03 + C T 0.863 1.158 (1.024,1.309) 1.89E-02 + C T 0.856 1.180 (1.051,1.325) 5.03E-03 +
rs12446632 16 19935389 GPRC5B G A 0.865 0.040 0.005 1.477E-18 G A 0.849 1.279 (1.094,1.495) 2.03E-03 + G A 0.856 1.097 (0.975,1.235) 1.24E-01 + G A 0.850 1.194 (1.066,1.337) 2.20E-03 +
rs2287019 19 46202172 QPCTL C T 0.804 0.036 0.004 4.585E-18 C T 0.814 1.038 (0.898,1.2) 6.14E-01 + C T 0.816 1.024 (0.919,1.142) 6.61E-01 + C T 0.814 1.047 (0.939,1.168) 4.06E-01 +
rs16951275 15 68077168 MAP2K5 T C 0.784 0.031 0.004 1.911E-17 T C 0.779 1.173 (1.028,1.339) 1.79E-02 + T C 0.776 1.133 (1.025,1.251) 1.43E-02 + T C 0.770 1.056 (0.957,1.164) 2.80E-01 +
rs3817334 11 47650993 MTCH2 T C 0.407 0.026 0.003 5.145E-17 T C 0.408 1.202 (1.073,1.347) 1.46E-03 + T C 0.414 1.093 (1.006,1.187) 3.52E-02 + T C 0.405 1.098 (1.008,1.196) 3.29E-02 +
rs2112347 5 75015242 POC5 T G 0.629 0.026 0.003 6.191E-17 T G 0.633 1.087 (0.969,1.219) 1.55E-01 + T G 0.637 1.032 (0.949,1.124) 4.60E-01 + T G 0.634 1.065 (0.977,1.16) 1.51E-01 +
rs12566985 1 75002193 FPGT-TNNI3K G A 0.446 0.024 0.003 3.282E-15 G A 0.448 1.273 (1.138,1.424) 2.48E-05 + G A 0.439 1.206 (1.11,1.311) 1.04E-05 + G A 0.429 1.038 (0.952,1.132) 3.96E-01 +
rs3810291 19 47569003 ZC3H4 A G 0.666 0.028 0.004 4.812E-15 A G 0.670 1.198 (1.067,1.345) 2.19E-03 + A G 0.671 1.134 (1.039,1.237) 4.69E-03 + A G 0.663 1.072 (0.983,1.17) 1.15E-01 +
rs7141420 14 79899454 NRXN3 T C 0.527 0.024 0.003 1.23E-14 T C 0.518 1.151 (1.03,1.287) 1.33E-02 + T C 0.513 1.112 (1.025,1.208) 1.11E-02 + T C 0.507 1.003 (0.922,1.091) 9.48E-01 +
rs13078960 3 85807590 CADM2 G T 0.196 0.030 0.004 1.737E-14 G T 0.192 1.170 (1.018,1.344) 2.74E-02 + G T 0.206 0.994 (0.899,1.099) 9.08E-01 - G T 0.201 1.198 (1.076,1.334) 9.49E-04 +
rs10968576 9 28414339 LINGO2 G A 0.320 0.025 0.003 6.607E-14 G A 0.322 1.026 (0.91,1.155) 6.78E-01 + G A 0.316 1.049 (0.96,1.145) 2.88E-01 + G A 0.316 0.964 (0.881,1.055) 4.22E-01 -
rs17024393 1 110154688 GNAT2 C T 0.040 0.066 0.009 7.029E-14 C T 0.029 1.802 (1.284,2.529) 6.58E-04 + C T 0.026 1.568 (1.246,1.973) 1.26E-04 + C T 0.023 1.099 (0.824,1.465) 5.20E-01 +
rs657452 1 49589847 AGBL4 A G 0.394 0.023 0.003 5.482E-13 A G 0.381 1.103 (0.981,1.24) 1.01E-01 + A G 0.384 1.035 (0.95,1.126) 4.31E-01 + A G 0.380 1.037 (0.95,1.132) 4.14E-01 +
rs12429545 13 54102206 OLFM4 A G 0.133 0.033 0.005 1.094E-12 A G 0.134 1.076 (0.916,1.264) 3.72E-01 + A G 0.130 1.119 (0.992,1.261) 6.73E-02 + A G 0.127 0.982 (0.866,1.115) 7.82E-01 -
rs12286929 11 115022404 CADM1 G A 0.523 0.022 0.003 1.31E-12 G A 0.529 1.143 (1.024,1.276) 1.74E-02 + G A 0.530 1.069 (0.985,1.16) 1.11E-01 + G A 0.524 1.063 (0.978,1.155) 1.49E-01 +
rs13107325 4 103188709 SLC39A8 T C 0.072 0.048 0.007 1.825E-12 T C 0.081 1.605 (1.309,1.967) 5.14E-06 + T C 0.081 1.284 (1.116,1.477) 4.84E-04 + T C 0.075 1.203 (1.019,1.42) 2.89E-02 +
rs11165643 1 96924097 PTBP2 T C 0.583 0.022 0.003 2.07E-12 T C 0.588 1.022 (0.913,1.144) 7.03E-01 + T C 0.591 1.017 (0.936,1.105) 6.97E-01 + T C 0.589 1.030 (0.947,1.12) 4.94E-01 +
rs7903146 10 114758349 TCF7L2 C T 0.713 0.023 0.003 1.112E-11 C T 0.717 1.015 (0.899,1.147) 8.07E-01 + C T 0.712 1.049 (0.959,1.149) 2.94E-01 + C T 0.711 0.956 (0.872,1.048) 3.34E-01 -
rs10132280 14 25928179 STXBP6 C A 0.682 0.023 0.003 1.141E-11 C A 0.704 0.968 (0.855,1.095) 6.02E-01 - C A 0.703 0.991 (0.906,1.084) 8.48E-01 - C A 0.704 0.984 (0.897,1.079) 7.25E-01 -
rs17405819 8 76806584 HNF4G T C 0.700 0.022 0.003 2.07E-11 T C 0.705 1.269 (1.125,1.433) 1.09E-04 + T C 0.706 1.124 (1.026,1.23) 1.19E-02 + T C 0.699 1.089 (0.995,1.191) 6.30E-02 +
rs6091540 20 51087862 ZFP64 C T 0.723 0.019 0.004 2.154E-11 C T 0.711 1.145 (1.015,1.292) 2.76E-02 + C T 0.711 1.067 (0.975,1.168) 1.60E-01 + C T 0.707 1.035 (0.945,1.133) 4.62E-01 +
rs1016287 2 59305625 LINC01122 T C 0.287 0.023 0.003 2.253E-11 T C 0.311 1.007 (0.895,1.131) 9.13E-01 + T C 0.298 1.070 (0.98,1.168) 1.29E-01 + T C 0.298 0.928 (0.849,1.016) 1.05E-01 -
rs4256980 11 8673939 TRIM66 G C 0.646 0.021 0.003 2.9E-11 G C 0.650 1.031 (0.919,1.157) 6.04E-01 + G C 0.654 1.013 (0.93,1.104) 7.68E-01 + G C 0.652 1.039 (0.952,1.134) 3.94E-01 +
rs17094222 10 102395440 HIF1AN C T 0.211 0.025 0.004 5.942E-11 C T 0.210 1.133 (0.985,1.303) 8.06E-02 + C T 0.212 1.043 (0.942,1.155) 4.15E-01 + C T 0.209 1.045 (0.939,1.163) 4.25E-01 +
rs12401738 1 78446761 FUBP1 A G 0.352 0.021 0.003 1.145E-10 A G 0.378 0.988 (0.881,1.106) 8.30E-01 - A G 0.377 1.007 (0.925,1.096) 8.75E-01 + A G 0.377 0.998 (0.916,1.089) 9.71E-01 -
rs7599312 2 213413231 ERBB4 G A 0.724 0.022 0.003 1.173E-10 G A 0.732 1.083 (0.957,1.225) 2.08E-01 + G A 0.731 1.047 (0.955,1.148) 3.32E-01 + G A 0.729 0.985 (0.897,1.081) 7.45E-01 -
rs2365389 3 61236462 FHIT C T 0.582 0.020 0.003 1.629E-10 C T 0.595 1.185 (1.058,1.328) 3.43E-03 + C T 0.594 1.092 (1.004,1.187) 3.94E-02 + C T 0.589 1.060 (0.973,1.154) 1.80E-01 +
rs205262 6 34563164 C6orf106 G A 0.273 0.022 0.004 1.753E-10 G A 0.275 1.186 (1.049,1.341) 6.38E-03 + G A 0.269 1.163 (1.062,1.274) 1.14E-03 + G A 0.262 1.051 (0.955,1.156) 3.12E-01 +
rs2820292 1 201784287 NAV1 C A 0.555 0.020 0.003 1.834E-10 C A 0.562 1.084 (0.969,1.212) 1.57E-01 + C A 0.567 1.031 (0.949,1.119) 4.74E-01 + C A 0.563 1.095 (1.007,1.191) 3.47E-02 +
rs12885454 14 29736838 PRKD1 C A 0.642 0.021 0.003 1.943E-10 C A 0.631 1.084 (0.967,1.214) 1.65E-01 + C A 0.633 1.034 (0.95,1.126) 4.35E-01 + C A 0.630 1.033 (0.948,1.125) 4.61E-01 +
rs9641123 7 93197732 CALCR C G 0.429 0.019 0.004 2.077E-10 C G 0.411 1.161 (1.036,1.302) 1.03E-02 + C G 0.410 1.096 (1.008,1.193) 3.19E-02 + C G 0.404 1.037 (0.951,1.131) 4.09E-01 +
rs12016871 13 28017782 MTIF3 T C 0.203 0.030 0.005 2.291E-10 T C 0.188 1.089 (0.947,1.252) 2.32E-01 + T C 0.179 1.152 (1.039,1.278) 7.09E-03 + T C 0.176 0.962 (0.862,1.073) 4.84E-01 -
rs16851483 3 141275436 RASA2 T G 0.066 0.048 0.008 3.548E-10 T G 0.066 1.428 (1.137,1.795) 2.23E-03 + T G 0.067 1.202 (1.027,1.406) 2.17E-02 + T G 0.064 1.170 (0.977,1.403) 8.83E-02 +
rs1167827 7 75163169 HIP1 G A 0.553 0.020 0.003 6.333E-10 G A 0.569 1.167 (1.046,1.302) 5.65E-03 + G A 0.572 1.075 (0.99,1.167) 8.67E-02 + G A 0.566 1.075 (0.989,1.169) 8.89E-02 +
rs758747 16 3627358 NLRC3 T C 0.265 0.023 0.004 7.473E-10 T C 0.270 1.138 (1.007,1.287) 3.88E-02 + T C 0.280 1.010 (0.923,1.106) 8.29E-01 + T C 0.275 1.089 (0.991,1.197) 7.65E-02 +
rs1928295 9 120378483 TLR4 T C 0.548 0.019 0.003 7.91E-10 T C 0.576 1.116 (0.998,1.249) 5.38E-02 + T C 0.568 1.103 (1.015,1.197) 2.00E-02 + T C 0.563 0.990 (0.911,1.076) 8.13E-01 -
rs9925964 16 31129895 KAT8 A G 0.620 0.019 0.003 8.108E-10 A G 0.642 1.036 (0.924,1.161) 5.47E-01 + A G 0.646 1.010 (0.927,1.1) 8.27E-01 + A G 0.644 1.025 (0.939,1.119) 5.77E-01 +
rs11126666 2 26928811 KCNK3 A G 0.283 0.021 0.003 1.332E-09 A G 0.255 1.001 (0.883,1.134) 9.89E-01 + A G 0.254 0.992 (0.903,1.089) 8.60E-01 - A G 0.255 1.004 (0.913,1.104) 9.33E-01 +
rs2650492 16 28333411 SBK1 A G 0.303 0.021 0.004 1.915E-09 A G 0.306 1.211 (1.076,1.363) 1.48E-03 + A G 0.299 1.175 (1.077,1.281) 2.93E-04 + A G 0.292 1.056 (0.964,1.158) 2.42E-01 +
rs6804842 3 25106437 RARB G A 0.575 0.019 0.003 2.476E-09 G A 0.580 1.118 (1,1.25) 4.99E-02 + G A 0.580 1.083 (0.996,1.177) 6.17E-02 + G A 0.574 1.037 (0.953,1.128) 3.96E-01 +
rs12940622 17 78615571 RPTOR G A 0.575 0.018 0.003 2.494E-09 G A 0.560 1.185 (1.061,1.324) 2.62E-03 + G A 0.559 1.121 (1.031,1.218) 7.20E-03 + G A 0.551 1.068 (0.981,1.161) 1.28E-01 +
rs7164727 15 73093991 LOC100287559 T C 0.686 0.018 0.003 3.915E-09 T C 0.676 0.940 (0.835,1.058) 3.04E-01 - T C 0.669 0.992 (0.909,1.082) 8.56E-01 - T C 0.672 0.949 (0.867,1.04) 2.61E-01 -
rs11847697 14 30515112 PRKD1 T C 0.042 0.049 0.008 3.99E-09 T C 0.045 1.420 (1.093,1.846) 8.68E-03 + T C 0.045 1.252 (1.041,1.507) 1.72E-02 + T C 0.042 1.244 (1,1.548) 5.05E-02 +
rs4740619 9 15634326 C9orf93 T C 0.542 0.018 0.003 4.564E-09 T C 0.537 1.183 (1.059,1.321) 2.94E-03 + T C 0.548 1.054 (0.971,1.143) 2.10E-01 + T C 0.540 1.124 (1.034,1.221) 5.88E-03 +
rs492400 2 219349752 USP37 C T 0.423 0.016 0.003 6.784E-09 C T 0.426 1.097 (0.983,1.225) 9.79E-02 + C T 0.431 1.033 (0.951,1.121) 4.42E-01 + C T 0.426 1.063 (0.976,1.158) 1.58E-01 +
rs13191362 6 163033350 PARK2 A G 0.879 0.028 0.005 7.339E-09 A G 0.878 1.164 (0.981,1.38) 8.18E-02 + A G 0.878 1.073 (0.945,1.219) 2.78E-01 + A G 0.876 1.069 (0.943,1.211) 2.98E-01 +
rs3736485 15 51748610 DMXL2 A G 0.454 0.018 0.003 7.412E-09 A G 0.472 1.021 (0.914,1.14) 7.18E-01 + A G 0.460 1.084 (0.998,1.177) 5.48E-02 + A G 0.458 0.961 (0.884,1.045) 3.54E-01 -
rs17001654 4 77129568 SCARB2 G C 0.153 0.031 0.005 7.76E-09 G C 0.153 0.991 (0.849,1.158) 9.12E-01 - G C 0.149 1.012 (0.901,1.137) 8.37E-01 + G C 0.150 0.950 (0.844,1.069) 3.94E-01 -
rs11191560 10 104869038 NT5C2 C T 0.089 0.031 0.005 8.446E-09 C T 0.082 1.255 (1.025,1.538) 2.83E-02 + C T 0.076 1.236 (1.069,1.429) 4.23E-03 + C T 0.073 1.000 (0.852,1.174) 9.98E-01 +
rs2080454 16 49062590 CBLN1 C A 0.405 0.017 0.003 8.604E-09 C A 0.385 1.011 (0.903,1.131) 8.50E-01 + C A 0.386 0.989 (0.91,1.075) 7.96E-01 - C A 0.387 0.998 (0.917,1.087) 9.70E-01 -
rs7715256 5 153537893 GALNT10 G T 0.421 0.016 0.003 8.851E-09 G T 0.423 1.180 (1.055,1.318) 3.60E-03 + G T 0.428 1.067 (0.982,1.158) 1.26E-01 + G T 0.421 1.087 (0.998,1.185) 5.56E-02 +
rs2176040 2 227092802 LOC646736 A G 0.365 0.014 0.003 9.989E-09 A G 0.364 1.025 (0.913,1.151) 6.75E-01 + A G 0.350 1.080 (0.993,1.175) 7.37E-02 + A G 0.350 0.930 (0.853,1.013) 9.77E-02 -
rs1528435 2 181550962 UBE2E3 T C 0.631 0.018 0.003 1.196E-08 T C 0.636 1.013 (0.904,1.136) 8.21E-01 + T C 0.624 1.087 (0.999,1.183) 5.27E-02 + T C 0.622 0.944 (0.866,1.029) 1.90E-01 -
rs2075650 19 45395619 TOMM40 A G 0.848 0.026 0.005 1.247E-08 G A 0.147 0.968 (0.828,1.131) 6.82E-01 - A G 0.853 1.002 (0.893,1.123) 9.77E-01 + A G 0.853 1.007 (0.896,1.132) 9.04E-01 +
rs1000940 17 5283252 RABEP1 G A 0.320 0.019 0.003 1.284E-08 G A 0.307 1.155 (1.026,1.302) 1.75E-02 + G A 0.304 1.115 (1.022,1.218) 1.47E-02 + G A 0.298 1.061 (0.968,1.164) 2.04E-01 +
rs11583200 1 50559820 ELAVL4 C T 0.396 0.018 0.003 1.479E-08 C T 0.376 1.083 (0.965,1.214) 1.75E-01 + C T 0.381 1.024 (0.943,1.113) 5.70E-01 + C T 0.377 1.058 (0.971,1.153) 2.01E-01 +
rs7239883 18 40147671 LOC284260 G A 0.393 0.016 0.003 1.511E-08 G A 0.380 1.029 (0.917,1.154) 6.25E-01 + G A 0.377 1.029 (0.946,1.119) 5.08E-01 + G A 0.376 1.004 (0.921,1.093) 9.33E-01 +
rs2836754 21 40291740 ETS2 C T 0.612 0.016 0.003 1.605E-08 C T 0.643 1.134 (1.011,1.272) 3.22E-02 + C T 0.651 1.053 (0.966,1.147) 2.42E-01 + C T 0.645 1.120 (1.027,1.221) 1.03E-02 +
rs9400239 6 108977663 FOXO3 C T 0.688 0.019 0.003 1.613E-08 C T 0.706 1.214 (1.074,1.371) 1.85E-03 + C T 0.709 1.118 (1.019,1.226) 1.84E-02 + C T 0.702 1.099 (1.003,1.205) 4.31E-02 +
rs10733682 9 129460914 LMX1B A G 0.478 0.017 0.003 1.83E-08 A G 0.479 1.084 (0.968,1.212) 1.61E-01 + A G 0.475 1.071 (0.986,1.165) 1.06E-01 + A G 0.471 1.014 (0.93,1.105) 7.55E-01 +
rs11688816 2 63053048 EHBP1 G A 0.525 0.017 0.003 1.893E-08 G A 0.542 1.033 (0.924,1.154) 5.69E-01 + G A 0.544 0.988 (0.91,1.074) 7.83E-01 - G A 0.544 1.001 (0.92,1.09) 9.76E-01 +
rs11057405 12 122781897 CLIP1 G A 0.901 0.031 0.006 2.019E-08 G A 0.898 1.070 (0.892,1.284) 4.67E-01 + G A 0.891 1.129 (0.985,1.293) 8.09E-02 + G A 0.890 0.929 (0.81,1.065) 2.89E-01 -
rs9914578 17 2005136 SMG6 G C 0.211 0.020 0.004 2.072E-08 G C 0.208 1.044 (0.91,1.197) 5.39E-01 + G C 0.207 1.042 (0.943,1.152) 4.17E-01 + G C 0.205 1.030 (0.929,1.143) 5.74E-01 +
rs977747 1 47684677 TAL1 T G 0.391 0.017 0.003 2.182E-08 T G 0.412 1.099 (0.983,1.23) 9.84E-02 + T G 0.416 1.043 (0.961,1.133) 3.13E-01 + T G 0.411 1.050 (0.965,1.143) 2.54E-01 +
S2 Table. 97 BMI SNPs from the GIANT consortium study and their summary statistics in our three analysis cohorts.
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rs2121279 2 143043285 LRP1B T C 0.152 0.025 0.004 2.313E-08 T C 0.133 1.063 (0.904,1.252) 4.59E-01 + T C 0.127 1.118 (0.991,1.26) 6.99E-02 + T C 0.126 0.958 (0.845,1.085) 4.99E-01 -
rs29941 19 34309532 KCTD15 G A 0.669 0.018 0.003 2.407E-08 G A 0.677 1.187 (1.055,1.336) 4.37E-03 + G A 0.671 1.132 (1.037,1.236) 5.77E-03 + G A 0.665 1.027 (0.94,1.123) 5.56E-01 +
rs11727676 4 145659064 HHIP T C 0.910 0.036 0.006 2.55E-08 C T 0.092 0.999 (0.813,1.228) 9.94E-01 - T C 0.904 1.056 (0.907,1.23) 4.80E-01 + T C 0.905 0.899 (0.766,1.054) 1.90E-01 -
rs3849570 3 81792112 GBE1 A C 0.359 0.019 0.003 2.601E-08 A C 0.348 1.040 (0.926,1.169) 5.05E-01 + A C 0.346 1.021 (0.937,1.113) 6.37E-01 + A C 0.346 0.988 (0.905,1.078) 7.80E-01 -
rs9374842 6 120185665 LOC285762 T C 0.748 0.019 0.004 2.673E-08 T C 0.775 1.222 (1.073,1.393) 2.54E-03 + T C 0.772 1.160 (1.05,1.281) 3.41E-03 + T C 0.766 1.058 (0.96,1.166) 2.53E-01 +
rs6477694 9 111932342 EPB41L4B C T 0.365 0.017 0.003 2.673E-08 C T 0.356 1.161 (1.035,1.303) 1.07E-02 + C T 0.353 1.101 (1.011,1.198) 2.73E-02 + C T 0.347 1.043 (0.955,1.139) 3.53E-01 +
rs4787491 16 30015337 INO80E G A 0.509 0.016 0.003 2.696E-08 G A 0.538 1.014 (0.908,1.132) 8.08E-01 + G A 0.536 1.006 (0.927,1.092) 8.87E-01 + G A 0.537 0.981 (0.902,1.067) 6.56E-01 -
rs1441264 13 79580919 MIR548A2 A G 0.609 0.018 0.003 2.959E-08 A G 0.590 1.082 (0.963,1.215) 1.86E-01 + A G 0.590 1.051 (0.963,1.146) 2.68E-01 + A G 0.587 1.049 (0.961,1.146) 2.86E-01 +
rs7899106 10 87410904 GRID1 G A 0.052 0.040 0.007 2.96E-08 G A 0.056 1.269 (0.998,1.613) 5.17E-02 + G A 0.051 1.240 (1.043,1.475) 1.48E-02 + G A 0.050 0.949 (0.786,1.147) 5.90E-01 -
rs2176598 11 43864278 HSD17B12 T C 0.251 0.020 0.004 2.971E-08 T C 0.237 1.055 (0.926,1.201) 4.19E-01 + T C 0.247 0.957 (0.871,1.053) 3.68E-01 - T C 0.246 1.076 (0.976,1.187) 1.41E-01 +
rs2245368 7 76608143 PMS2L11 C T 0.180 0.032 0.006 3.187E-08 C T 0.178 1.190 (1.025,1.382) 2.27E-02 + C T 0.167 1.225 (1.098,1.366) 2.73E-04 + C T 0.162 0.984 (0.875,1.105) 7.82E-01 -
rs17203016 2 208255518 CREB1 G A 0.197 0.021 0.004 3.406E-08 G A 0.213 1.128 (0.987,1.289) 7.77E-02 + G A 0.206 1.133 (1.026,1.25) 1.32E-02 + G A 0.202 0.982 (0.886,1.088) 7.28E-01 -
rs17724992 19 18454825 PGPEP1 A G 0.746 0.019 0.004 3.415E-08 A G 0.744 1.196 (1.055,1.356) 5.09E-03 + A G 0.741 1.155 (1.05,1.271) 2.99E-03 + A G 0.734 1.042 (0.949,1.144) 3.90E-01 +
rs7243357 18 56883319 GRP T G 0.812 0.022 0.004 3.857E-08 T G 0.825 1.182 (1.02,1.368) 2.56E-02 + T G 0.826 1.106 (0.989,1.236) 7.66E-02 + T G 0.821 1.090 (0.978,1.214) 1.19E-01 +
rs16907751 8 81375457 ZBTB10 C T 0.916 0.035 0.007 3.888E-08 C T 0.906 0.966 (0.797,1.171) 7.28E-01 - C T 0.908 0.953 (0.828,1.097) 5.01E-01 - C T 0.909 1.013 (0.876,1.171) 8.63E-01 +
rs1808579 18 21104888 C18orf8 C T 0.534 0.017 0.003 4.169E-08 C T 0.522 1.096 (0.981,1.224) 1.05E-01 + C T 0.517 1.079 (0.994,1.172) 6.90E-02 + C T 0.513 1.026 (0.943,1.115) 5.53E-01 +
rs13201877 6 137675541 IFNGR1 G A 0.142 0.023 0.005 4.285E-08 G A 0.141 1.181 (1.006,1.385) 4.18E-02 + G A 0.141 1.091 (0.971,1.225) 1.43E-01 + G A 0.138 1.056 (0.932,1.196) 3.95E-01 +
rs2033732 8 85079709 RALYL C T 0.747 0.019 0.004 4.889E-08 C T 0.743 1.008 (0.89,1.142) 8.95E-01 + C T 0.744 0.982 (0.895,1.078) 7.08E-01 - C T 0.744 1.015 (0.923,1.117) 7.62E-01 +
rs9540493 13 66205704 MIR548X2 A G 0.456 0.017 0.003 4.971E-08 A G 0.460 1.130 (1.005,1.27) 4.13E-02 + A G 0.454 1.120 (1.028,1.222) 9.92E-03 + A G 0.449 1.004 (0.92,1.096) 9.28E-01 +
rs1460676 2 164567689 FIGN C T 0.173 0.020 0.004 4.978E-08 C T 0.158 1.022 (0.879,1.187) 7.81E-01 + C T 0.155 1.044 (0.934,1.168) 4.46E-01 + C T 0.154 0.983 (0.876,1.103) 7.66E-01 -
rs6465468 7 95169514 ASB4 T G 0.304 0.017 0.004 4.98E-08 T G 0.308 1.005 (0.887,1.139) 9.36E-01 + T G 0.301 1.047 (0.955,1.149) 3.24E-01 + T G 0.301 0.955 (0.868,1.049) 3.36E-01 -
rs751414** 6 40350030 TDRG1 T G 0.258 0.018 0.004 1.58E-05 T G 0.283 1.16813 (1.033,1.32) 1.29E-02 + T G 0.287 1.04676 (0.957,1.145) 3.18E-01 + T G 0.283 1.08231 (0.986,1.188) 9.67E-02 +
*GRCh37/hg19 coordinates
**Proxy for rs2033529
Effect = Effect allele (BMI increasing allele); Other = Other allele; EAF = Effect allele frequency
Appendix A
S4 Table. Difference in SCOOP OR when using ALSPAC as control dataset vs. UKHLS 
SNP Locus OR.UKHLS OR.ALSPAC P.Diff
rs1558902 FTO 1.4287329 1.3427721 2.94E-01
rs6567160 MC4R 1.3080991 1.3604779 5.52E-01
rs13021737 TMEM18 1.3563998 1.2974696 6.00E-01
rs10938397 GNPDA2 1.1857281 1.1860919 9.96E-01
rs543874 SEC16B 1.2010834 1.2045657 9.67E-01
rs2207139 TFAP2B 1.1750903 1.1546588 8.18E-01
rs11030104 BDNF 1.1428476 1.1088972 6.90E-01
rs3101336 NEGR1 1.1948946 1.2385984 5.57E-01
rs7138803 BCDIN3D 1.215858 1.2146898 9.87E-01
rs10182181 ADCY3 1.2020002 1.2265576 7.31E-01
rs3888190 ATP2A1 1.1293237 1.0144525 7.22E-02
rs1516725 ETV5 1.158149 1.026153 1.74E-01
rs12446632 GPRC5B 1.0971063 1.0185721 3.86E-01
rs2287019 QPCTL 1.0244956 1.0421619 8.25E-01
rs16951275 MAP2K5 1.1325514 1.092782 6.20E-01
rs3817334 MTCH2 1.0927407 1.1358904 5.16E-01
rs2112347 POC5 1.0324305 1.004322 6.53E-01
rs12566985 FPGT-TNNI3K 1.2061603 1.1713434 6.23E-01
rs3810291 ZC3H4 1.1339907 1.0873902 5.08E-01
rs7141420 NRXN3 1.1124525 1.1058898 9.20E-01
rs13078960 CADM2 0.99411 1.031164 6.16E-01
rs10968576 LINGO2 1.048838 1.0523973 9.57E-01
rs17024393 GNAT2 1.5681554 1.5545372 9.58E-01
rs657452 AGBL4 1.0346724 1.0741845 5.39E-01
rs12429545 OLFM4 1.1186482 1.1316867 8.93E-01
rs12286929 CADM1 1.0687761 1.0658373 9.63E-01
rs13107325 SLC39A8 1.2837186 1.3563332 5.90E-01
rs11165643 PTBP2 1.0166116 1.0013239 8.01E-01
rs7903146 TCF7L2 1.049512 1.1068024 4.16E-01
rs10132280 STXBP6 0.9912485 0.9586591 6.05E-01
rs17405819 HNF4G 1.1236114 1.0863413 6.08E-01
rs6091540 ZFP64 1.067074 1.1034806 6.08E-01
rs1016287 LINC01122 1.0702148 1.0895905 7.78E-01
rs4256980 TRIM66 1.0129686 0.9606069 3.92E-01
rs17094222 HIF1AN 1.0431979 1.0554176 8.73E-01
rs12401738 FUBP1 1.0068534 0.9709964 5.52E-01
rs7599312 ERBB4 1.0466985 0.9901823 4.06E-01
rs2365389 FHIT 1.0918292 1.1451163 4.30E-01
rs205262 C6orf106 1.1634375 1.0784589 2.46E-01
rs2820292 NAV1 1.0305774 0.9731171 3.36E-01
rs12885454 PRKD1 1.0343118 0.9851811 4.27E-01
rs9641123 CALCR 1.0963951 1.0743197 7.35E-01
rs9581854 MTIF3 1.1523104 1.0643572 2.87E-01
rs16851483 RASA2 1.2018139 1.2290979 8.43E-01
rs1167827 HIP1 1.0745054 1.0968666 7.30E-01
rs758747 NLRC3 1.0100159 1.0528825 5.26E-01
rs1928295 TLR4 1.1026364 1.0470854 3.86E-01
rs9925964 KAT8 1.009594 1.0531275 4.94E-01
rs11126666 KCNK3 0.9916191 1.0011154 8.88E-01
rs2650492 SBK1 1.1745464 1.1002881 3.00E-01
rs6804842 RARB 1.0826074 1.0744722 9.00E-01
rs12940622 RPTOR 1.1210032 1.0859058 5.96E-01
rs7164727 LOC100287559 0.9919261 0.9667406 6.83E-01
rs11847697 PRKD1 1.2522288 1.1977594 7.40E-01
rs4740619 C9orf93 1.053687 1.0122709 4.98E-01
rs492400 USP37 1.0326143 1.0502736 7.75E-01
rs13191362 PARK2 1.0730103 1.1335706 5.49E-01
rs3736485 DMXL2 1.0839278 1.0843441 9.95E-01
rs17001654 SCARB2 1.0123387 0.9533294 4.70E-01
rs11191560 NT5C2 1.2358896 1.1978983 7.66E-01
rs2080454 CBLN1 0.9890632 0.9957939 9.11E-01
rs7715256 GALNT10 1.0667076 1.0659983 9.91E-01
rs2176040 LOC646736 1.0800962 1.0561891 7.15E-01
rs1528435 UBE2E3 1.0871075 1.0592421 6.71E-01
rs2075650 TOMM40 1.0017207 0.9436388 4.72E-01
rs1000940 RABEP1 1.1155025 1.1561709 5.73E-01
rs11583200 ELAVL4 1.0244068 1.0473277 7.14E-01
rs7239883 LOC284260 1.0288501 0.9941999 5.73E-01
rs2836754 ETS2 1.0526894 1.0507287 9.76E-01
rs9400239 FOXO3 1.1176888 1.0694002 5.06E-01
rs10733682 LMX1B 1.0712934 1.0545872 7.92E-01
rs11688816 EHBP1 0.988461 0.9758464 8.29E-01
rs11057405 CLIP1 1.1285696 1.0499994 4.62E-01
rs9914578 SMG6 1.0423268 1.0775537 6.46E-01
rs977747 TAL1 1.0432587 1.0166069 6.64E-01
rs2121279 LRP1B 1.1174631 1.0960597 8.23E-01
rs29941 KCTD15 1.1320951 1.0502216 2.39E-01
rs11727676 HHIP 1.0563982 1.0477135 9.38E-01
rs3849570 GBE1 1.0208987 0.9989013 7.25E-01
rs9374842 LOC285762 1.159775 1.1754326 8.52E-01
rs6477694 EPB41L4B 1.100504 1.0672617 6.17E-01
rs4787491 INO80E 1.0059218 1.0361099 6.17E-01
rs1441264 MIR548A2 1.0505803 1.0275484 7.19E-01
rs7899106 GRID1 1.240441 1.3269198 5.94E-01
rs2176598 HSD17B12 0.9573421 0.9531657 9.49E-01
rs2245368 PMS2L11 1.2247062 0.8928163 3.81E-05
rs17203016 CREB1 1.1327383 1.1718323 6.35E-01
rs17724992 PGPEP1 1.1553103 1.156706 9.86E-01
rs7243357 GRP 1.1056075 1.0651079 6.41E-01
rs16907751 ZBTB10 0.9527799 1.0182715 5.11E-01
rs1808579 C18orf8 1.0793057 1.0641407 8.11E-01
rs13201877 IFNGR1 1.0907763 1.0761121 8.71E-01
rs2033732 RALYL 0.9823586 0.9258369 3.80E-01
rs9540493 MIR548X2 1.1204384 1.0826008 5.72E-01
rs1460676 FIGN 1.0443083 1.0803401 6.74E-01
rs6465468 ASB4 1.0475326 0.949917 1.33E-01
rs2033529 TDRG1 0.9553109 0.9790073 7.05E-01
OR.UKHLS= OR when using UKHLS as control group
OR.ALSPAC= OR when using age-matched ALSPAC as control group
P.Diff=p value for difference
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rsID Nearest gene Chr. Position (bp) EA NEA OR  (95% CI) P value EAF Obese EAF Thin proxy rsID OR  (95% CI) P value EAF Obese EAF Thin proxy rsID r2 OR  (95% CI) P value OR  (95% CI) P value HetPVal
rs9930333 FTO 16 53799977 G T 1.70(1.52,1.90) 2.30E-20 49.59% 37.46% 1.46(1.38,1.55) 3.60E-36 48.26% 38.93% 1.43(1.34,1.54) 8.10E-25 1.48(1.42,1.54) 8.52E-76 3.34E-02
rs2168711 MC4R 18 57848531 C T 1.66(1.45,1.89) 8.29E-14 28.90% 19.95% 1.23(1.15,1.32) 2.19E-09 26.75% 22.90% 1.20(1.10,1.30) 1.80E-05 1.27(1.21,1.33) 2.02E-21 1.12E-04
rs6748821 TMEM18 2 629601 G A 1.65(1.42,1.91) 9.45E-11 86.69% 79.84% 1.27(1.18,1.37) 1.31E-09 85.00% 81.69% rs12995480 0.998 1.26(1.14,1.39) 9.90E-06 1.32(1.24,1.39) 7.76E-21 2.81E-03
rs506589 SEC16B 1 177894287 C T 1.46(1.27,1.67) 5.42E-08 23.98% 18.07% 1.25(1.17,1.35) 5.44E-10 23.11% 19.16% 1.25(1.14,1.37) 2.70E-06 1.28(1.21,1.35) 3.14E-20 1.21E-01
rs6738433 ADCY3-DNAJC27 2 25159501 C G 1.43(1.28,1.60) 1.71E-10 47.31% 43.92% 1.21(1.14,1.28) 2.74E-10 50.70% 45.96% rs2384054 0.968 1.10(1.03,1.17) 5.70E-03 1.19(1.14,1.24) 3.19E-17 6.25E-03
rs7132908 FAIM2 12 50263148 A G 1.31(1.17,1.47) 2.26E-06 42.45% 36.27% 1.18(1.11,1.25) 5.43E-08 41.11% 37.39% 1.20(1.10,1.30) 6.60E-06 1.20(1.15,1.26) 1.93E-16 2.52E-01
rs62107261 FAM150B 2 422144 T C 2.37(1.75,3.20) 2.07E-08 96.37% 93.38% 1.54(1.35,1.76) 3.57E-10 96.28% 94.36% NA NA NA NA 1.65(1.46,1.87) 1.15E-15 1.07E-02
rs12507026 GNPDA2 4 45181334 T A 1.30(1.17,1.46) 3.69E-06 47.29% 40.92% 1.14(1.08,1.21) 8.76E-06 45.30% 41.98% rs12641981 0.998 1.20(1.12,1.28) 3.10E-07 1.18(1.13,1.23) 5.53E-15 4.06E-02
rs75398113 SNRPC 6 34728071 C G 1.53(1.27,1.85) 8.91E-06 11.95% 8.04% 1.24(1.12,1.37) 2.07E-05 10.47% 8.52% NA NA NA NA 1.30(1.19,1.42) 5.19E-09 5.56E-02
rs13135092 SLC39A8 4 103198082 G A 1.58(1.30,1.93) 4.70E-06 10.50% 7.24% 1.25(1.12,1.39) 5.57E-05 9.24% 7.52% NA NA NA NA 1.32(1.20,1.45) 1.06E-08 3.59E-02
rs57988840 TFAP2B 6 50817748 T A 1.69(1.39,2.05) 1.27E-07 92.53% 88.81% 1.13(1.02,1.24) 1.65E-02 91.05% 90.04% rs7769978 1 1.20(1.03,1.39) 1.90E-02 1.22(1.13,1.31) 3.86E-07 2.87E-04
rs4447506 PIK3C3 18 39510074 G A 1.32(1.17,1.48) 4.21E-06 41.83% 36.39% 1.07(1.01,1.14) 2.60E-02 39.34% 37.71% 1.10(1.02,1.18) 7.80E-03 1.11(1.06,1.16) 1.46E-06 7.85E-03
rs375252497* SEMA3B 3 50310286 AAATAATAATAAT A 1.35(1.20,1.53) 1.74E-06 37.22% 31.78% 1.13(1.02,1.26) 2.50E-02 34.30% 31.95% NA NA NA NA 1.22(1.13,1.32) 1.49E-06 3.05E-02
rs7927262 HIPK3 11 33384447 C T 1.41(1.24,1.60) 1.81E-07 41.78% 35.78% 1.08(0.89,1.32) 4.43E-01 97.52% 97.37% NA NA NA NA 1.31(1.17,1.45) 1.58E-06 2.87E-02
rs654240 CCND1 11 69448373 T C 1.35(1.21,1.52) 2.99E-07 43.85% 37.39% 1.05(0.99,1.12) 9.25E-02 41.43% 40.23% 1.08(1.00,1.16) 5.30E-02 1.10(1.05,1.15) 2.10E-05 6.81E-04
rs35403928* PRDM6 5 122416569 GT G 1.39(1.23,1.56) 6.79E-08 39.85% 32.94% 1.05(0.95,1.16) 3.61E-01 37.64% 36.49% NA NA NA NA 1.18(1.09,1.28) 2.46E-05 4.77E-04
rs516579 MTCL1 18 8801634 G T 1.40(1.22,1.61) 2.07E-06 82.14% 77.25% 1.03(0.96,1.11) 4.52E-01 80.35% 80.05% rs518561 0.998 1.15(1.04,1.27) 6.40E-03 1.11(1.05,1.18) 9.70E-05 1.11E-04
rs397859802* FLJ26850 19 50556007 C CA 1.92(1.45,2.53) 4.49E-06 6.02% 3.44% 1.11(0.86,1.44) 4.28E-01 4.25% 3.78% NA NA NA NA 1.43(1.18,1.73) 2.12E-04 4.77E-03
rs2784243 PKHD1 6 51454640 T C 1.30(1.16,1.45) 5.99E-06 61.89% 56.06% 1.07(1.01,1.13) 2.90E-02 58.99% 57.34% rs2784187 0.988 1.02(0.95,1.10) 5.40E-01 1.08(1.04,1.13) 3.14E-04 2.55E-03
rs11792928 LMX1B 9 129401550 T C 1.36(1.20,1.53) 1.32E-06 32.13% 26.91% 1.05(0.99,1.12) 1.17E-01 29.94% 29.01% 1.03(0.95,1.11) 5.00E-01 1.08(1.03,1.13) 8.05E-04 5.19E-04
rs6711131* BAZ2B 2 160407777 A G 1.31(1.17,1.47) 4.30E-06 65.12% 58.62% 1.02(0.92,1.13) 6.81E-01 63.33% 63.04% NA NA NA NA 1.14(1.05,1.23) 8.90E-04 1.33E-03
rs73145387 ABI3BP 3 100813661 C G 2.48(1.67,3.69) 7.36E-06 98.00% 96.42% 1.15(0.96,1.37) 1.29E-01 97.55% 97.19% NA NA NA NA 1.31(1.11,1.54) 1.29E-03 5.19E-04
rs599291 SLC44A5 1 75691616 T C 1.31(1.17,1.47) 2.35E-06 47.71% 41.63% 1.02(0.96,1.08) 4.95E-01 44.55% 44.01% 1.04(0.97,1.11) 2.20E-01 1.06(1.02,1.11) 3.44E-03 4.01E-04
rs11185396 LOC100129138 1 104754536 C T 1.50(1.26,1.80) 8.13E-06 12.78% 9.21% 1.06(0.97,1.17) 2.13E-01 10.37% 9.65% 1.01(0.89,1.14) 9.20E-01 1.10(1.03,1.18) 6.95E-03 8.13E-04
rs2836760 LOC400867 21 40300052 T G 1.65(1.33,2.03) 3.28E-06 10.33% 7.12% 1.03(0.93,1.14) 5.92E-01 9.14% 8.91% 1.07(0.93,1.23) 3.50E-01 1.11(1.03,1.20) 9.44E-03 3.30E-04
rs11159277 SPTLC2 14 78032957 A T 1.35(1.20,1.53) 1.56E-06 71.04% 66.32% 1.01(0.95,1.08) 6.53E-01 68.83% 68.55% NA NA NA NA 1.08(1.02,1.14) 9.74E-03 4.58E-05
rs10546790 CDH22 20 44910100 C CAT 1.34(1.19,1.52) 1.91E-06 72.94% 66.87% rs2425853 1.03(0.97,1.10) 3.42E-01 70.11% 69.59% rs2425853 0.998 1.00(0.93,1.08) 9.90E-01 1.06(1.01,1.11) 1.35E-02 1.57E-04
rs11319985* CNTN6 3 1377810 T TA 1.29(1.15,1.45) 9.85E-06 61.56% 56.63% 0.97(0.88,1.07) 5.75E-01 57.91% 58.39% NA NA NA NA 1.10(1.02,1.18) 1.38E-02 2.03E-04
rs4790399 RAP1GAP2 17 2883199 C T 1.33(1.18,1.51) 6.95E-06 74.28% 69.50% 1.02(0.96,1.09) 5.43E-01 71.22% 70.85% 0.99(0.91,1.08) 8.30E-01 1.05(1.00,1.10) 4.40E-02 2.50E-04
rs536093 PDE10A 6 165945641 T C 1.38(1.22,1.58) 1.01E-06 27.05% 21.65% 0.97(0.90,1.03) 3.17E-01 24.39% 25.03% 1.06(0.97,1.15) 2.00E-01 1.05(1.00,1.10) 6.84E-02 9.29E-06
rs936249 CACNA1B 9 140971315 T C 2.41(1.66,3.49) 3.81E-06 6.31% 4.63% 1.01(0.88,1.15) 9.30E-01 4.78% 4.77% NA NA NA NA 1.11(0.98,1.27) 9.53E-02 1.62E-05
rs1692144 GJA5 1 147281349 C T 1.37(1.19,1.57) 8.19E-06 81.52% 77.06% 1.04(0.97,1.12) 2.90E-01 79.54% 79.06% 0.92(0.84,1.01) 7.00E-02 1.04(0.99,1.10) 1.29E-01 1.68E-05
*Interim release used in UKBB for these signals. Nobese=2,799. Nthin=1,212
EA= Effect allele (BMI increasing allele); NEA= Non-effect allele; OR = Odds ratio; 95% CI = 95% confidence interval for the odds ratio; EAF = effect allele frequency. HetPVal= Heterozygosity p-value
Positions mapped to hg19
 Blue line: Conventional genome-wide significant threshold (p<5E-08) in combined analysis.
SCOOP UKBB GIANT BMI Tails Combined analysis
S5 Table. Discovery, replication and meta-analysis results for 32 SNPs meeting P<10-5 in discovery association results of SCOOP vs STILTS analysis.
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rsID Nearest gene Chr. Position (bp) EA NEA OR  (95% CI) P value EAF Obese EAF Non-extremes proxy rsID OR  (95% CI) P value EAF Obese EAF Non-extremes proxy rsID r2 OR  (95% CI) P value proxy rsID r2 OR  (95% CI) P value proxy rsID r2 OR  (95% CI) P value OR  (95% CI) P value HetPVal
rs9928094 FTO 16 53799905 G A 1.44(1.33,1.57) 1.42E-18 49.50% 41.32% 1.30(1.25,1.35) 2.74E-41 48.34% 41.91% 1.46(1.34,1.60) 4.88E-17 1.21(1.15,1.28) 7.20E-13 1.43(1.34,1.54) 6.60E-25 1.32(1.29,1.36) 5.94E-101 4.41E-05
rs35614134 MC4R 18 57832856 AC A 1.31(1.20,1.44) 6.27E-09 29.01% 23.69% rs663129 1.22(1.16,1.27) 1.25E-18 26.72% 23.15% rs663129 0.99814 1.32(1.19,1.46) 1.22E-07 rs663129 0.99814 1.22(1.15,1.30) 1.27E-10 rs663129 0.99814 1.20(1.10,1.30) 1.70E-05 1.23(1.20,1.27) 1.57E-43 3.55E-01
rs66906321 TMEM18 2 630070 C T 1.40(1.24,1.57) 2.35E-08 85.78% 81.35% 1.17(1.11,1.24) 3.44E-09 84.44% 82.20% rs13007080 0.95655 1.39(1.24,1.57) 6.65E-08 rs13007080 0.956548 1.28(1.19,1.37) 5.15E-12 rs13007080 0.956548 1.27(1.15,1.40) 3.40E-06 1.25(1.21,1.29) 9.72E-35 1.33E-02
rs7132908 FAIM2 12 50263148 A G 1.22(1.12,1.32) 3.27E-06 42.45% 37.82% 1.15(1.10,1.19) 5.37E-12 41.11% 37.71% rs7138803 0.90165 1.23(1.12,1.35) 8.89E-06 1.18(1.11,1.25) 1.24E-08 1.20(1.10,1.30) 6.60E-06 1.17(1.14,1.21) 2.38E-31 4.86E-01
rs2384060 ADCY3-DNAJC27 2 25135438 G A 1.23(1.13,1.34) 1.53E-06 43.52% 38.90% rs6722587 1.11(1.07,1.15) 4.89E-08 47.67% 44.93% rs6722587 0.90829 1.09(1.00,1.19) 5.01E-02 rs6722587 0.908287 1.18(1.12,1.24) 1.02E-09 rs6722587 0.908287 1.12(1.04,1.19) 1.60E-03 1.14(1.11,1.17) 9.39E-23 1.13E-01
rs11209947 NEGR1 1 72808551 A T 1.30(1.17,1.44) 8.51E-07 76.58% 72.18% rs1460940 1.11(1.05,1.16) 4.53E-05 81.18% 79.76% rs1460940 0.80203 1.46(1.30,1.63) 2.21E-10 rs1460940 0.802029 1.13(1.06,1.22) 4.60E-04 rs1460940 0.802029 1.22(1.11,1.35) 5.60E-05 1.17(1.13,1.21) 5.17E-20 7.26E-05
rs12735657 SEC16B 1 177809133 C T 1.24(1.13,1.37) 9.72E-06 24.26% 20.46% 1.12(1.07,1.17) 1.48E-06 22.87% 20.94% rs4132288 0.9914 1.20(1.07,1.33) 1.18E-03 rs4132288 0.991399 1.14(1.06,1.21) 1.52E-04 rs4132288 0.991399 1.22(1.11,1.34) 1.80E-05 1.15(1.12,1.19) 7.26E-19 1.79E-01
rs13104545 GNPDA2 4 45184907 A G 1.27(1.15,1.40) 1.61E-06 27.41% 23.45% 1.07(1.02,1.11) 5.35E-03 24.36% 23.26% NA NA NA NA 1.13(1.04,1.22) 3.39E-03 1.34(1.20,1.49) 1.20E-07 1.13(1.09,1.17) 1.47E-11 9.39E-05
rs112446794 CEP120 5 122665465 T C 1.23(1.13,1.35) 2.08E-06 33.15% 28.69% 1.07(1.02,1.11) 2.55E-03 29.47% 28.21% rs1366333 0.95876 1.08(0.98,1.19) 1.38E-01 rs1366333 0.958762 1.12(1.06,1.18) 1.22E-04 rs1366333 0.958762 1.05(0.97,1.13) 2.40E-01 1.09(1.06,1.13) 3.45E-10 3.33E-02
rs3760091 SULT1A1 16 28620800 C G 1.24(1.14,1.35) 1.56E-06 64.89% 60.23% 1.09(1.04,1.14) 1.19E-04 63.49% 61.44% NA NA NA NA NA NA NA NA NA NA NA NA 1.12(1.07,1.16) 2.65E-08 8.49E-03
rs115474151 SLC7A14 3 170272967 A T 1.36(1.20,1.55) 2.63E-06 12.44% 9.53% 1.27(0.86,1.87) 2.36E-01 0.26% 0.20% NA NA NA NA NA NA NA NA NA NA NA NA 1.35(1.20,1.53) 1.40E-06 7.24E-01
rs8096590 LINC01541 18 69231235 A G 1.24(1.14,1.35) 1.26E-06 34.39% 29.80% 1.03(0.99,1.07) 1.68E-01 31.28% 30.75% rs7228473 0.98094 1.08(0.99,1.19) 9.70E-02 rs7228473 0.980939 1.02(0.97,1.08) 4.30E-01 rs7228473 0.980939 1.14(1.05,1.23) 1.40E-03 1.07(1.04,1.10) 7.38E-06 7.32E-04
rs201388971* CDKAL1 6 20514945 T TTG 1.33(1.17,1.50) 7.17E-06 85.90% 82.52% 1.10(1.01,1.20) 3.58E-02 84.15% 82.90% NA NA NA NA NA NA NA NA NA NA NA NA 1.17(1.09,1.25) 1.77E-05 1.36E-02
rs141442356 FAT1 4 187723286 T TG 1.23(1.13,1.35) 6.26E-06 42.33% 38.18% 0.97(0.76,1.24) 8.27E-01 99.39% 99.42% NA NA NA NA NA NA NA NA NA NA NA NA 1.20(1.10,1.31) 2.98E-05 7.57E-02
rs10456655 PKHD1 6 51817204 G C 1.30(1.16,1.44) 2.13E-06 20.35% 16.84% 1.06(1.01,1.12) 2.00E-02 17.45% 16.53% NA NA NA NA NA NA NA NA NA NA NA NA 1.10(1.05,1.16) 3.34E-05 1.10E-03
rs7752955 TFAP2D 6 50402660 T C 1.28(1.16,1.40) 6.46E-07 76.66% 72.16% 1.04(1.00,1.09) 6.33E-02 73.38% 72.61% 1.07(0.97,1.18) 1.89E-01 1.06(1.00,1.12) 6.05E-02 1.00(0.92,1.09) 9.50E-01 1.06(1.03,1.10) 3.90E-05 2.37E-03
rs898708 PNOC 8 28119194 C T 1.26(1.15,1.38) 9.94E-07 73.10% 68.50% 1.02(0.98,1.07) 2.77E-01 69.52% 69.11% 1.06(0.96,1.17) 2.51E-01 1.04(0.98,1.10) 1.53E-01 1.08(0.99,1.16) 7.10E-02 1.06(1.03,1.09) 9.27E-05 2.38E-03
rs34208875 CASC17 17 69195603 C T 2.95(1.90,4.59) 1.55E-06 1.33% 0.59% 1.18(0.90,1.55) 2.29E-01 0.52% 0.43% NA NA NA NA NA NA NA NA NA NA NA NA 1.53(1.21,1.93) 3.78E-04 5.57E-04
rs540249707 METTL7B 12 56072632 G A 3.60(2.13,6.08) 1.77E-06 1.03% 0.41% 1.17(0.78,1.75) 4.46E-01 0.23% 0.21% NA NA NA NA NA NA NA NA NA NA NA NA 1.78(1.29,2.46) 4.25E-04 9.06E-04
rs10944524 MIR4643 6 91898609 T C 1.28(1.15,1.43) 5.88E-06 18.12% 14.73% 1.05(0.99,1.10) 9.69E-02 15.62% 15.13% NA NA NA NA NA NA NA NA NA NA NA NA 1.09(1.04,1.14) 4.94E-04 8.25E-04
rs60581051 ANKS1B 12 100147984 T C 1.30(1.16,1.45) 7.81E-06 16.53% 13.40% 1.05(0.99,1.11) 8.71E-02 14.04% 13.55% NA NA NA NA NA NA NA NA NA NA NA NA 1.09(1.04,1.15) 5.02E-04 1.01E-03
rs147725108 LINC00354 13 112579895 C G 1.89(1.44,2.48) 4.66E-06 3.10% 1.92% 1.11(0.93,1.32) 2.61E-01 1.20% 1.07% NA NA NA NA NA NA NA NA NA NA NA NA 1.30(1.12,1.51) 5.74E-04 1.27E-03
rs142450848 CARD18 11 105111566 C T 2.34(1.69,3.25) 3.54E-07 2.08% 0.97% 1.10(0.92,1.33) 3.00E-01 1.07% 0.96% NA NA NA NA NA NA NA NA NA NA NA NA 1.33(1.13,1.57) 5.89E-04 9.62E-05
rs5873242* RANBP17 5 170321490 A T 1.25(1.14,1.38) 2.73E-06 72.23% 67.87% 1.03(0.96,1.10) 4.25E-01 68.78% 68.25% NA NA NA NA NA NA NA NA NA NA NA NA 1.10(1.04,1.17) 6.63E-04 8.90E-04
rs67529790* LINC00977 8 130055514 AT A 1.26(1.14,1.39) 2.78E-06 42.00% 37.87% 1.02(0.95,1.10) 5.13E-01 38.60% 38.10% NA NA NA NA NA NA NA NA NA NA NA NA 1.10(1.04,1.17) 8.05E-04 8.21E-04
rs138019013 ALS2CL 3 46737713 T G 3.92(2.29,6.69) 5.75E-07 1.01% 0.40% 0.97(0.58,1.60) 8.90E-01 0.14% 0.14% NA NA NA NA NA NA NA NA NA NA NA NA 1.87(1.29,2.70) 8.55E-04 1.86E-04
rs28581396* SLC38A11 2 165876796 C T 2.14(1.54,2.98) 6.32E-06 2.01% 1.06% 1.07(0.80,1.42) 6.50E-01 1.42% 1.34% NA NA NA NA NA NA NA NA NA NA NA NA 1.44(1.16,1.79) 9.60E-04 1.84E-03
rs144209184 SCD5 4 83646583 C T 2.40(1.64,3.51) 7.09E-06 1.70% 0.88% 1.14(0.90,1.44) 2.74E-01 0.68% 0.59% NA NA NA NA NA NA NA NA NA NA NA NA 1.40(1.15,1.71) 1.01E-03 1.15E-03
rs116931808* CSMD1 8 4035481 C G 2.29(1.59,3.29) 7.45E-06 1.60% 0.73% 1.01(0.70,1.47) 9.45E-01 0.72% 0.72% NA NA NA NA NA NA NA NA NA NA NA NA 1.54(1.19,2.00) 1.10E-03 2.13E-03
rs11563327 HOXA1 7 27071888 C T 1.24(1.13,1.36) 9.41E-06 74.64% 70.42% 1.03(0.99,1.08) 1.16E-01 71.80% 71.12% NA NA NA NA 1.03(0.97,1.09) 3.30E-01 1.03(0.95,1.11) 5.30E-01 1.05(1.02,1.08) 1.21E-03 4.77E-03
rs540119135 PTPRR 12 71094332 G A 3.17(2.03,4.95) 4.21E-07 1.24% 0.45% 1.05(0.75,1.46) 7.90E-01 0.33% 0.33% NA NA NA NA NA NA NA NA NA NA NA NA 1.55(1.19,2.03) 1.22E-03 9.42E-05
rs66671632 ARC 8 143680772 T C 1.31(1.17,1.47) 2.62E-06 16.48% 13.14% 1.04(0.98,1.10) 2.32E-01 12.61% 12.26% NA NA NA NA NA NA NA NA NA NA NA NA 1.09(1.03,1.15) 1.35E-03 2.70E-04
rs141214244* RAB11FIP2 10 119652851 T TTGTGTGTG1.32(1.18,1.49) 3.45E-06 21.01% 17.88% 1.02(0.94,1.12) 5.92E-01 19.37% 18.93% NA NA NA NA NA NA NA NA NA NA NA NA 1.12(1.04,1.20) 1.51E-03 5.94E-04
rs2237402 POU6F2 7 39449768 G A 1.23(1.12,1.34) 6.31E-06 69.78% 65.38% 1.04(1.00,1.08) 7.72E-02 66.68% 65.95% rs2237403 0.99506 1.02(0.93,1.12) 7.31E-01 rs2237403 0.995062 1.01(0.95,1.06) 7.75E-01 rs2237403 0.995062 1.04(0.96,1.11) 3.30E-01 1.04(1.02,1.07) 1.78E-03 5.14E-03
rs147345620 GPC6 13 94017255 G A 3.02(1.89,4.82) 3.46E-06 1.25% 0.60% 1.12(0.85,1.47) 4.20E-01 0.51% 0.45% NA NA NA NA NA NA NA NA NA NA NA NA 1.44(1.14,1.83) 2.37E-03 3.17E-04
rs11589523 FAM46C 1 118270980 T C 1.22(1.12,1.32) 6.46E-06 36.66% 32.31% 1.02(0.98,1.07) 2.64E-01 33.42% 32.89% NA NA NA NA NA NA NA NA NA NA NA NA 1.06(1.02,1.10) 3.26E-03 3.27E-04
rs556954774* LOC100130992 10 22549699 C CT 1.33(1.17,1.51) 9.52E-06 16.87% 14.13% 1.01(0.91,1.12) 8.35E-01 14.57% 14.53% NA NA NA NA NA NA NA NA NA NA NA NA 1.12(1.04,1.22) 3.54E-03 8.29E-04
rs34515326* MIR99AHG 21 17987843 CA C 1.95(1.46,2.60) 6.33E-06 3.12% 2.02% 1.00(0.79,1.26) 9.72E-01 2.17% 2.16% NA NA NA NA NA NA NA NA NA NA NA NA 1.30(1.09,1.57) 4.58E-03 4.39E-04
rs139198909 ZFHX3 16 72929809 C A 2.50(1.68,3.73) 7.18E-06 1.50% 0.74% 1.08(0.85,1.36) 5.37E-01 0.68% 0.64% NA NA NA NA NA NA NA NA NA NA NA NA 1.34(1.09,1.64) 5.10E-03 3.66E-04
rs191312158* CCNY 10 35871176 C T 2.76(1.80,4.23) 3.30E-06 1.42% 0.74% 0.96(0.69,1.35) 8.27E-01 0.98% 1.04% NA NA NA NA NA NA NA NA NA NA NA NA 1.44(1.11,1.88) 6.68E-03 1.54E-04
6:153400217_AT_A RGS17 6 153400217 AT A 1.24(1.13,1.36) 6.04E-06 62.00% 57.94% 1.02(0.97,1.07) 4.13E-01 74.18% 73.83% NA NA NA NA NA NA NA NA NA NA NA NA 1.06(1.02,1.10) 6.69E-03 1.98E-04
rs191634319 SOS1 2 39318135 C G 3.54(2.13,5.88) 1.09E-06 1.04% 0.41% 1.05(0.78,1.40) 7.66E-01 0.43% 0.43% NA NA NA NA NA NA NA NA NA NA NA NA 1.42(1.10,1.83) 7.11E-03 4.52E-05
rs62179502 SPATS2L 2 201146942 G A 2.03(1.51,2.73) 2.31E-06 98.06% 96.28% 1.06(0.95,1.19) 3.12E-01 97.12% 96.98% NA NA NA NA NA NA NA NA NA NA NA NA 1.15(1.04,1.28) 8.37E-03 5.18E-05
rs543354609 MDS2 1 23930694 C T 2.79(1.78,4.37) 7.11E-06 1.20% 0.52% 1.04(0.80,1.36) 7.73E-01 0.51% 0.50% NA NA NA NA NA NA NA NA NA NA NA NA 1.35(1.07,1.70) 1.04E-02 2.15E-04
rs144759478 PTH2R 2 209323283 T C 1.64(1.34,2.02) 2.06E-06 5.13% 3.42% 1.02(0.92,1.14) 7.04E-01 3.29% 3.23% NA NA NA NA NA NA NA NA NA NA NA NA 1.13(1.03,1.25) 1.10E-02 5.66E-05
rs6496033 LOC440311 15 95245915 A C 1.47(1.25,1.73) 4.82E-06 8.81% 6.65% 1.00(0.93,1.08) 9.73E-01 7.37% 7.35% NA NA NA NA 1.07(0.96,1.19) 2.48E-01 1.19(0.96,1.47) 1.10E-01 1.07(1.02,1.13) 1.16E-02 3.80E-04
rs1571570 PBX3 9 128748249 C G 1.41(1.22,1.63) 3.08E-06 9.45% 6.91% 1.08(1.00,1.16) 4.00E-02 7.33% 6.82% NA NA NA NA 0.97(0.89,1.06) 5.17E-01 0.96(0.83,1.12) 6.30E-01 1.07(1.01,1.12) 1.28E-02 1.40E-04
rs28700201* TP53TG3D 16 32275881 A G 1.33(1.18,1.50) 2.04E-06 49.33% 45.88% 0.96(0.88,1.06) 4.72E-01 54.34% 54.74% NA NA NA NA NA NA NA NA NA NA NA NA 1.10(1.02,1.18) 1.36E-02 3.76E-05
rs571984391* LMX1B 9 129414279 TG T 1.22(1.12,1.33) 6.58E-06 44.94% 40.48% 0.99(0.93,1.06) 7.89E-01 42.42% 42.68% NA NA NA NA NA NA NA NA NA NA NA NA 1.07(1.01,1.12) 1.54E-02 1.39E-04
rs524349 UNC13C 15 54689366 A G 1.29(1.17,1.41) 8.01E-08 73.26% 67.99% 1.01(0.97,1.05) 7.10E-01 69.42% 69.20% rs563881 0.9026 1.00(0.91,1.11) 9.41E-01 rs563881 0.902595 1.02(0.96,1.08) 5.48E-01 rs563881 0.902595 1.02(0.95,1.11) 5.80E-01 1.04(1.01,1.07) 1.64E-02 8.42E-05
rs144435735 LINC00682 4 41881253 A G 1.98(1.49,2.61) 1.96E-06 3.26% 2.06% 0.95(0.80,1.13) 5.51E-01 1.25% 1.33% NA NA NA NA NA NA NA NA NA NA NA NA 1.16(1.00,1.34) 4.81E-02 1.23E-05
rs73676140 NXPH1 7 8729124 G A 1.59(1.29,1.95) 9.74E-06 4.75% 3.16% 0.99(0.88,1.10) 7.95E-01 3.07% 3.12% NA NA NA NA NA NA NA NA NA NA NA NA 1.10(1.00,1.21) 6.06E-02 5.89E-05
rs139813768 SNX5 20 17828396 A G 2.47(1.66,3.67) 8.32E-06 1.57% 0.83% 0.94(0.75,1.19) 6.21E-01 0.65% 0.68% NA NA NA NA NA NA NA NA NA NA NA NA 1.21(0.99,1.48) 6.46E-02 4.32E-05
rs6806545 LOC647323 3 193660056 T C 1.21(1.11,1.32) 9.08E-06 41.15% 36.68% 0.99(0.95,1.03) 6.64E-01 37.72% 37.84% NA NA NA NA 1.03(0.98,1.09) 2.74E-01 1.00(0.94,1.07) 9.20E-01 1.02(1.00,1.05) 8.16E-02 4.24E-04
rs146883791 DCHS2 4 155121474 A ATAAG 1.74(1.37,2.21) 5.48E-06 3.42% 2.02% rs7680244 0.94(0.83,1.07) 3.43E-01 2.26% 2.41% rs7680244 0.99439 1.43(1.04,1.96) 2.95E-02 rs7680244 0.994386 0.99(0.80,1.23) 9.25E-01 NA NA NA NA 1.09(0.99,1.20) 8.79E-02 3.30E-05
rs9863931 ADAMTS9-AS2 3 65014778 T C 1.31(1.17,1.47) 3.89E-06 15.79% 12.47% 1.01(0.96,1.07) 6.52E-01 12.40% 12.17% NA NA NA NA 0.98(0.91,1.06) 6.73E-01 0.99(0.88,1.12) 9.20E-01 1.04(0.99,1.08) 9.31E-02 2.84E-04
rs7069309 CAMK1D 10 12351089 T C 1.20(1.11,1.30) 5.59E-06 49.24% 45.94% 1.01(0.97,1.05) 5.94E-01 50.11% 49.66% NA NA NA NA 0.99(0.94,1.05) 7.17E-01 0.99(0.92,1.07) 8.10E-01 1.02(1.00,1.05) 9.91E-02 3.72E-04
rs79325679 LARGE 22 33929898 T C 2.07(1.55,2.76) 7.71E-07 2.50% 1.26% 0.93(0.80,1.09) 3.70E-01 1.47% 1.59% NA NA NA NA NA NA NA NA NA NA NA NA 1.12(0.97,1.28) 1.16E-01 1.79E-06
rs11872477 18 2037477 T C 1.26(1.14,1.39) 5.92E-06 37.93% 34.04% 0.99(0.94,1.03) 6.07E-01 32.52% 32.80% NA NA NA NA NA NA NA NA NA NA NA NA 1.03(0.99,1.08) 1.44E-01 1.55E-05
rs190999252 CCSER1 4 92847036 A G 2.07(1.51,2.84) 7.12E-06 2.25% 1.27% 0.93(0.79,1.11) 4.34E-01 1.26% 1.34% NA NA NA NA NA NA NA NA NA NA NA NA 1.12(0.96,1.30) 1.52E-01 1.49E-05
rs75809547 PTBP2 1 97331151 C T 2.61(1.74,3.93) 3.85E-06 1.46% 0.65% 0.86(0.68,1.09) 2.21E-01 0.62% 0.72% NA NA NA NA NA NA NA NA NA NA NA NA 1.14(0.93,1.41) 2.00E-01 4.10E-06
rs147842378 AGO4 1 36276202 C G 2.01(1.49,2.71) 5.08E-06 3.16% 2.10% 0.91(0.78,1.07) 2.67E-01 1.48% 1.63% NA NA NA NA NA NA NA NA NA NA NA NA 1.08(0.94,1.25) 2.54E-01 5.19E-06
11:23234822_ATGG_A MIR8054 11 23234822 ATGG A 1.22(1.13,1.33) 2.68E-06 43.06% 38.46% rs2403819 0.99(0.96,1.03) 7.41E-01 39.17% 39.33% rs2403819 0.97568 1.01(0.92,1.11) 8.49E-01 rs2403819 0.975677 0.96(0.91,1.01) 1.04E-01 rs2403819 0.975677 1.03(0.96,1.10) 4.00E-01 1.01(0.98,1.04) 4.19E-01 5.19E-05
rs12261064 GPR26 10 125429706 A G 1.55(1.30,1.86) 1.48E-06 6.21% 4.14% 0.90(0.82,0.99) 2.71E-02 4.32% 4.72% 0.86(0.69,1.05) 1.44E-01 0.92(0.82,1.04) 2.00E-01 1.05(0.86,1.28) 6.20E-01 1.02(0.96,1.09) 4.68E-01 2.40E-06
rs1188854 ECT2L 6 139196524 G A 1.39(1.21,1.61) 6.57E-06 10.13% 7.69% 0.97(0.90,1.03) 3.14E-01 8.20% 8.43% NA NA NA NA 1.00(0.91,1.10) 9.58E-01 0.94(0.81,1.11) 4.80E-01 1.02(0.97,1.07) 5.48E-01 8.42E-05
rs3104056 COL13A1 10 71510039 A G 1.53(1.27,1.84) 6.31E-06 5.64% 3.78% 0.85(0.76,0.94) 1.16E-03 3.55% 4.09% 1.05(0.83,1.32) 6.83E-01 0.98(0.84,1.14) 8.09E-01 1.20(0.93,1.54) 1.60E-01 1.00(0.94,1.08) 9.08E-01 1.17E-06
*Interim release used in UKBB for these signals. Nobese=2,799. Ncontrols=8,193
EA= Effect allele (BMI increasing allele); NEA= Non-effect allele; OR = Odds ratio; 95% CI = 95% confidence interval for the odds ratio; EAF = effect allele frequency. HetPVal= Heterozygosity p-value
Positions mapped to hg19
Combined analysis
S6 Table. Discovery, replication and meta-analysis results for 66 SNPs meeting P<10-5 in discovery association results of SCOOP vs UKHLS analysis.
UKBB SCOOP 2013 EGG GIANT obesity class IIISCOOP 
Appendix A
rsID Nearest gene Chr. Position (bp) EA NEA OR  (95% CI) P value EAF Non-extremes EAF Thin OR  (95% CI) P value EAF Non-extremes EAF Thin OR  (95% CI) P value HetPVal
rs13262703 PI15 8 75819902 A T 4.15 (2.42,7.11) 2.32E-07 99.62% 98.88% 1.69(0.98,2.91) 5.68E-02 99.84% 99.74% 2.66(1.81,3.89) 5.46E-07 2.15E-02
rs558258836* LOC102724874 8 78716821 T A 4.04 (2.25,7.26) 3.07E-06 99.60% 99.04% 1.69 (0.89,3.2) 1.07E-01 99.50% 99.28% 2.71 (1.76,4.18) 5.99E-06 4.90E-02
rs2123163 CADM2 3 85243797 T G 1.68 (1.35,2.1) 4.90E-06 6.40% 4.20% 1.14(1.00,1.29) 4.22E-02 5.12% 4.60% 1.25(1.12,1.39) 6.18E-05 2.76E-03
rs150756788 SLC2A7 1 9050295 G T 2.09 (1.52,2.87) 4.96E-06 98.21% 97.25% 1.20(0.91,1.60) 2.00E-01 99.26% 99.11% 1.54(1.25,1.90) 6.41E-05 1.07E-02
rs545797179* FOXN2 2 48546924 AT A 2.79 (1.8,4.32) 4.31E-06 99.24% 98.48% 1.15 (0.65,2.05) 6.23E-01 99.18% 99.07% 2.02 (1.42,2.86) 7.77E-05 1.65E-02
rs117638949* PIGZ 3 196692722 T A 3.5 (2.27,5.4) 1.50E-08 99.50% 98.55% 0.54 (0.27,1.09) 8.60E-02 99.30% 99.62% 2.09 (1.44,3.02) 9.25E-05 8.97E-06
rs576762972* CACNA1C 12 2244717 T C 2.17 (1.55,3.05) 7.23E-06 98.99% 98.03% 1.16 (0.78,1.72) 4.69E-01 98.87% 98.73% 1.66 (1.29,2.15) 1.05E-04 1.79E-02
rs138454709* COL8A2 1 36592131 A G 2.58 (1.72,3.88) 5.29E-06 99.03% 98.33% 1.11 (0.65,1.9) 7.04E-01 99.04% 99.00% 1.89 (1.37,2.62) 1.17E-04 1.41E-02
rs75937976 C3orf38 3 88321976 G C 2.95 (2.02,4.32) 2.43E-08 99.20% 98.25% 1.10(0.84,1.44) 4.96E-01 99.13% 99.05% 1.53(1.23,1.91) 1.52E-04 3.33E-05
rs190051670 PHF2 9 96460947 C T 2.55 (1.73,3.76) 2.11E-06 99.25% 98.35% 1.19(0.91,1.56) 2.00E-01 99.18% 99.05% 1.53(1.23,1.91) 1.68E-04 1.59E-03
rs56152157 EDIL3 5 83171742 G A 1.21 (1.11,1.31) 6.91E-06 47.95% 42.99% 1.04(0.99,1.10) 1.21E-01 47.37% 46.44% 1.09(1.04,1.14) 2.11E-04 2.85E-03
rs139226692* ASAH1 8 17928720 C CA 2.82 (1.78,4.46) 9.46E-06 99.56% 98.81% 1.11 (0.63,1.92) 7.24E-01 99.37% 99.34% 1.93 (1.35,2.75) 2.73E-04 1.08E-02
rs112958625* KNDC1 10 134969737 G A 2.8 (1.81,4.33) 3.61E-06 99.00% 98.39% 1.01 (0.59,1.72) 9.73E-01 98.93% 98.94% 1.86 (1.33,2.62) 3.02E-04 3.75E-03
rs68090520* ZMAT3 3 178717361 C A 1.24 (1.13,1.36) 4.04E-06 54.37% 50.43% 1.02 (0.93,1.11) 7.45E-01 53.49% 53.13% 1.12 (1.05,1.2) 4.39E-04 2.72E-03
rs17544568 ONECUT1 15 53321119 G A 2.04 (1.54,2.7) 6.53E-07 97.94% 96.67% 1.09(0.93,1.29) 2.78E-01 97.58% 97.40% 1.28(1.11,1.47) 5.80E-04 1.74E-04
rs143866745* LOC101927495 11 61356693 C T 1.31 (1.17,1.46) 1.26E-06 60.23% 56.57% 0.89 (0.51,1.55) 6.88E-01 99.16% 99.21% 1.84 (1.29,2.61) 6.65E-04 9.33E-04
rs184273748* PTPRU 1 29562801 G A 2.53 (1.71,3.73) 3.04E-06 99.12% 98.24% 0.65 (0.33,1.26) 2.00E-01 99.17% 99.35% 1.79 (1.28,2.5) 7.11E-04 5.41E-04
rs115861768 MIR4426 16 60885992 C T 3.27 (1.93,5.52) 9.57E-06 99.53% 98.98% 1.14(0.73,1.76) 5.68E-01 99.65% 99.64% 1.76(1.25,2.46) 1.04E-03 2.46E-03
rs191980904* UQCRC2 16 21946517 C T 2.98 (1.85,4.79) 6.69E-06 99.56% 98.93% 0.84 (0.46,1.55) 5.84E-01 99.36% 99.44% 1.85 (1.27,2.7) 1.28E-03 1.39E-03
rs11665052 MC4R 18 57908675 G A 1.31 (1.18,1.44) 1.40E-07 27.11% 22.61% 1.02(0.96,1.08) 5.63E-01 26.22% 25.78% 1.09(1.03,1.14) 1.48E-03 2.22E-05
2:25411587_C_CT** POMC 2 25411587 C CT 1.36 (1.21,1.51) 6.52E-08 83.75% 79.76% 1.01(0.95,1.08) 7.22E-01 82.18% 82.10% 1.10(1.04,1.16) 1.76E-03 9.91E-06
rs137887309 CDH23 10 73211425 G A 2.66 (1.74,4.07) 6.24E-06 99.48% 98.66% 1.03(0.71,1.50) 8.67E-01 99.54% 99.50% 1.56(1.18,2.06) 1.94E-03 9.94E-04
rs11757467 EYA4 6 133808153 A T 1.71 (1.35,2.17) 8.55E-06 97.57% 96.11% 1.05(0.90,1.24) 5.26E-01 97.48% 97.33% 1.23(1.08,1.40) 2.43E-03 9.08E-04
rs148209625 ZNF664-FAM101A 12 124681051 C T 2.2 (1.58,3.07) 2.97E-06 99.02% 97.95% 1.04(0.82,1.32) 7.63E-01 98.89% 98.85% 1.35(1.11,1.64) 2.74E-03 3.19E-04
rs71515311* TMEM72-AS1 10 45116672 A ATAT 1.25 (1.13,1.38) 8.55E-06 70.65% 66.71% 0.99 (0.89,1.09) 7.72E-01 69.59% 70.05% 1.11 (1.04,1.19) 2.84E-03 9.00E-04
rs11557769 ACTN1 14 69341653 T A 1.95 (1.5,2.55) 8.61E-07 98.33% 96.94% 0.91(0.70,1.17) 4.48E-01 98.83% 98.98% 1.31(1.09,1.57) 4.41E-03 4.45E-05
rs142441937 KLF15 3 126030681 G A 2.53 (1.69,3.79) 6.78E-06 99.16% 98.44% 1.02(0.78,1.34) 8.75E-01 99.08% 99.11% 1.36(1.08,1.70) 8.09E-03 2.71E-04
rs117944743 ZNF93 19 20060211 C G 2.06 (1.5,2.82) 7.33E-06 98.81% 97.84% 1.01(0.82,1.25) 9.34E-01 98.49% 98.47% 1.26(1.05,1.50) 1.06E-02 2.28E-04
rs142425331 CHCHD3 7 132583478 G A 1.6 (1.31,1.96) 4.36E-06 96.58% 94.82% 0.98(0.84,1.13) 7.44E-01 96.61% 96.71% 1.16(1.03,1.30) 1.59E-02 8.80E-05
rs138251346 LOC101929452 2 7279064 A G 2.99 (1.9,4.7) 2.23E-06 99.27% 98.62% 0.77(0.50,1.19) 2.42E-01 99.53% 99.64% 1.46(1.07,2.00) 1.66E-02 2.20E-05
rs1435711 ADAMTS20 12 43429113 G A 1.32 (1.18,1.49) 2.11E-06 86.34% 83.30% 0.99(0.92,1.07) 8.17E-01 85.74% 85.93% 1.08(1.01,1.15) 1.76E-02 3.92E-05
rs553440779 KCNJ3 2 155835504 T C 2.67 (1.74,4.09) 6.98E-06 99.27% 98.53% 0.72(0.45,1.15) 1.66E-01 99.61% 99.70% 1.46(1.07,2.00) 1.78E-02 4.88E-05
rs77709566 INTU 4 128466995 A G 2 (1.5,2.66) 2.01E-06 98.42% 97.20% 0.97(0.81,1.17) 7.51E-01 97.98% 98.03% 1.20(1.03,1.40) 2.02E-02 3.20E-05
rs514529 LRP5 11 68090836 T A 1.23 (1.13,1.34) 1.09E-06 53.61% 51.60% 0.99(0.94,1.05) 7.62E-01 52.12% 52.27% 1.05(1.01,1.10) 2.04E-02 1.68E-05
rs200275909* ADAMTS20 12 43954570 A AT 3.21 (1.93,5.35) 7.29E-06 99.42% 98.76% 0.88 (0.78,1) 5.84E-02 85.23% 86.54% 1.1 (1.01,1.2) 2.38E-02 4.69E-06
rs73085383 ZNF343 20 2503465 C T 2.13 (1.56,2.92) 2.05E-06 98.63% 97.60% 0.85(0.66,1.10) 2.28E-01 98.79% 98.97% 1.23(1.01,1.50) 3.92E-02 8.79E-06
rs527595266 ADAMTS16 5 5341419 C G 2.91 (1.81,4.68) 9.95E-06 99.42% 98.79% 0.93(0.68,1.27) 6.52E-01 99.30% 99.30% 1.31(1.01,1.71) 4.00E-02 8.21E-05
*Interim release used in UKBB for these signals.  Nthin=1,212. Ncontrols=8,193
**rs4665779 was used as a proxy in UKBB
EA= Effect allele (BMI increasing allele); NEA= Non-effect allele; OR = Odds ratio; 95% CI = 95% confidence interval for the odds ratio; EAF = effect allele frequency. HetPVal= Heterozygosity p-value
Positions mapped to hg19
Red line: Strict genome-wide significant threshold (p<1.17E-08) in combined analysis. Blue line: Conventional genome-wide significant threshold (p<5E-08) in combined analysis.
STILTS UKBB
S7 Table. Discovery, replication and meta-analysis results for 37 SNPs meeting P<10-5 in discovery association results of UKHLS vs STILTS analysis.
Combined analysis
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S10 Table. Published loci from GIANT, EGG and SCOOP 2013 not reaching genome-wide significance in our study
rsID Gene OR GIANT BMI tails Stage 1 P GIANT BMI tails Stage 1 OR SCOOP/STILTS P SCOOP/STILTS OR SCOOP/UKHLS P SCOOP/UKHLS OR UKHLS/STILTS P UKHLS/STILTS
rs2568958 NEGR1 1.17 (1.12,1.23) 6.80E-10 1.25 (1.11,1.39) 1.00E-04 1.19(1.09,1.29) 5.65E-05 1.06(0.97,1.16) 1.73E-01
rs987237 TFAP2B 1.20 (1.12,1.28) 4.30E-07 1.31 (1.14,1.50) 2.00E-04 1.17(1.05,1.29) 3.25E-03 1.14(1.01,1.27) 2.72E-02
rs2030323 BDNF 1.21 (1.13,1.30) 5.20E-08 1.31 (1.13,1.50) 7.46E-05 1.15(1.03,1.27) 1.03E-02 1.10(1.00,1.22) 4.92E-02
rs1516725 ETV5 1.30 (1.19, 1.42) 2.10E-08 1.30 (1.11,1.52) 8.00E-04 1.16(1.02,1.31) 1.89E-02 1.18(1.05,1.33) 5.03E-03
rsID Gene OR GIANT Stage 1 P GIANT Stage 1 OR SCOOP/STILTS P SCOOP/STILTS OR SCOOP/UKHLS P SCOOP/UKHLS OR UKHLS/STILTS P UKHLS/STILTS Reported Trait
rs7989336 HS6ST3 1.12 5.88E-09 1.13(1.01,1.26) 3.17E-02 1.03(0.95,1.12) 4.42E-01 1.09(1.00,1.19) 4.15E-02 Obesity class 2
rs17381664 ZZZ3 1.11 7.61E-08 1.00(0.89,1.12) 9.86E-01 0.98(0.91,1.07) 6.99E-01 1.03(0.95,1.12) 4.82E-01 Obesity class 2
rs17024258 GNAT2 1.23 1.41E-06 1.80(1.29,2.53) 6.27E-04 1.57(1.25,1.97) 1.18E-04 1.10(0.82,1.46) 5.32E-01 Obesity class 1
rs4735692 HNF4G 1.07 5.03E-08 1.08(0.97,1.21) 1.57E-01 1.00(0.92,1.09) 9.87E-01 1.07(0.98,1.16) 1.27E-01 Obesity class 1
rs13041126 MRPS33P4 1.07 3.05E-07 1.14(1.01,1.28) 3.88E-02 1.07(0.97,1.17) 1.71E-01 1.03(0.94,1.13) 5.43E-01 Obesity class 1
rs2531995 ADCY9 1.06 3.17E-06 1.14(1.01,1.28) 3.22E-02 1.06(0.97,1.16) 2.06E-01 1.08(0.98,1.18) 1.04E-01 Obesity class 1
rs4735692 HNF4G 1.05 6.13E-09 1.08(0.97,1.21) 1.57E-01 1.00(0.92,1.09) 9.87E-01 1.07(0.98,1.16) 1.27E-01 Overweight
rs7503807 RPTOR 1.04 4.20E-06 1.18(1.06,1.32) 2.90E-03 1.11(1.03,1.21) 1.04E-02 1.07(0.98,1.16) 1.24E-01 Overweight
rsID Gene OR EGG Stage 1 P EGG Stage 1 OR SCOOP/STILTS P SCOOP/STILTS OR SCOOP/UKHLS P SCOOP/UKHLS OR UKHLS/STILTS P UKHLS/STILTS
rs9568856 OLFM4 1.21 6.58E−7 1.09(0.93,1.28) 2.71E-01 1.14(1.01,1.28) 2.99E-02 0.97(0.86,1.10) 6.41E-01
rs9299 HOXB5 1.14 9.12E−7 1.18(1.05,1.32) 6.46E-03 1.03(0.94,1.12) 5.68E-01 1.09(1.00,1.19) 5.34E-02
rsID Gene OR SCOOP 2013 Stage 1 P SCOOP 2013 Stage 1 OR SCOOP/STILTS P SCOOP/STILTS OR SCOOP/UKHLS P SCOOP/UKHLS OR UKHLS/STILTS P UKHLS/STILTS
rs1993709 NEGR1 1.46 1.98E-12 1.30(1.13,1.50) 2.54E-04 1.29(1.16,1.44) 4.45E-06 1.03(0.93,1.14) 6.16E-01
rs1957894 PRKCH 1.64 1.01E-08 1.25(1.03,1.51) 2.61E-02 1.17(1.02,1.35) 2.40E-02 1.01(0.87,1.18) 8.79E-01
rs11208659 LEPR 1.63 1.16E-10 1.22(1.01,1.48) 4.33E-02 1.28(1.12,1.48) 4.35E-04 0.95(0.81,1.10) 4.90E-01
rs564343 PACS1 1.25 5.81E-08 1.01(0.90,1.13) 9.18E-01 1.04(0.95,1.13) 4.12E-01 0.96(0.89,1.05) 4.12E-01
rs11109072 RMST 1.79 1.48E-07 0.87(0.63,1.20) 3.83E-01 0.95(0.74,1.21) 6.74E-01 0.97(0.76,1.24) 8.13E-01
Loci identified in E. Wheeler, et al. (2013)
Known BMI loci with meta p <5E-8 in GIANT BMI tails study but not in this study (obese vs thin)
Loci identified in S.I. Berndt, et al. (2013)
Loci indentified in J.P. Bradfield, H.R. Taal, et al. (2012)
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S12 Table. ICD10 codes used to exclude thin individuals in UKBB
Code Description
A071 A07.1 Giardiasis [lambliasis]
A150 A15.0 Tuberculosis of lung, confirmed by sputum microscopy with or without culture
A151 A15.1 Tuberculosis of lung, confirmed by culture only
A152 A15.2 Tuberculosis of lung, confirmed histologically
A159 A15.9 Respiratory tuberculosis unspecified, confirmed bacteriologically and histologically
A162 A16.2 Tuberculosis of lung, without mention of bacteriological or histological confirmation
A169 A16.9 Respiratory tuberculosis unspecified, without mention of bacteriological or histological confirmation
B181 B18.1 Chronic viral hepatitis B without delta-agent
B182 B18.2 Chronic viral hepatitis C
B203 B20.3 HIV disease resulting in other viral infections
B204 B20.4 HIV disease resulting in candidiasis
B238 B23.8 HIV disease resulting in other specified conditions
B24 B24 Unspecified human immunodeficiency virus [HIV] disease
C01 C01 Malignant neoplasm of base of tongue
C099 C09.9 Tonsil, unspecified
C108 C10.8 Overlapping lesion of oropharynx
C109 C10.9 Oropharynx, unspecified
C155 C15.5 Lower third of oesophagus
C159 C15.9 Oesophagus, unspecified
C169 C16.9 Stomach, unspecified
C172 C17.2 Ileum
C180 C18.0 Caecum
C182 C18.2 Ascending colon
C184 C18.4 Transverse colon
C187 C18.7 Sigmoid colon
C189 C18.9 Colon, unspecified
C20 C20 Malignant neoplasm of rectum
C210 C21.0 Anus, unspecified
C211 C21.1 Anal canal
C220 C22.0 Liver cell carcinoma
C221 C22.1 Intrahepatic bile duct carcinoma
C250 C25.0 Head of pancreas
C258 C25.8 Overlapping lesion of pancreas
C259 C25.9 Pancreas, unspecified
C341 C34.1 Upper lobe, bronchus or lung
C342 C34.2 Middle lobe, bronchus or lung
C343 C34.3 Lower lobe, bronchus or lung
C349 C34.9 Bronchus or lung, unspecified
C411 C41.1 Mandible
C435 C43.5 Malignant melanoma of trunk
C436 C43.6 Malignant melanoma of upper limb, including shoulder
C437 C43.7 Malignant melanoma of lower limb, including hip
C439 C43.9 Malignant melanoma of skin, unspecified
C441 C44.1 Skin of eyelid, including canthus
C442 C44.2 Skin of ear and external auricular canal
C443 C44.3 Skin of other and unspecified parts of face
C444 C44.4 Skin of scalp and neck
C445 C44.5 Skin of trunk
C446 C44.6 Skin of upper limb, including shoulder
C447 C44.7 Skin of lower limb, including hip
C482 C48.2 Peritoneum, unspecified
C503 C50.3 Lower-inner quadrant of breast
C504 C50.4 Upper-outer quadrant of breast
C505 C50.5 Lower-outer quadrant of breast
C509 C50.9 Breast, unspecified
C541 C54.1 Endometrium
C56 C56 Malignant neoplasm of ovary
C61 C61 Malignant neoplasm of prostate
C64 C64 Malignant neoplasm of kidney, except renal pelvis
C66 C66 Malignant neoplasm of ureter
C679 C67.9 Bladder, unspecified
C719 C71.9 Brain, unspecified
C73 C73 Malignant neoplasm of thyroid gland
C770 C77.0 Lymph nodes of head, face and neck
C771 C77.1 Intrathoracic lymph nodes
C772 C77.2 Intra-abdominal lymph nodes
C773 C77.3 Axillary and upper limb lymph nodes
C779 C77.9 Lymph node, unspecified
C780 C78.0 Secondary malignant neoplasm of lung
C786 C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum
C787 C78.7 Secondary malignant neoplasm of liver
C788 C78.8 Secondary malignant neoplasm of other and unspecified digestive organs
C793 C79.3 Secondary malignant neoplasm of brain and cerebral meninges
C795 C79.5 Secondary malignant neoplasm of bone and bone marrow
C80 C80 Malignant neoplasm without specification of site
C829 C82.9 Follicular non-Hodgkin's lymphoma, unspecified
C844 C84.4 Peripheral T-cell lymphoma
C859 C85.9 Non-Hodgkin's lymphoma, unspecified type
C880 C88.0 Waldenstr¸m's macroglobulinaemia
C910 C91.0 Acute lymphoblastic leukaemia
C920 C92.0 Acute myeloid leukaemia
D001 D00.1 Oesophagus
D013 D01.3 Anus and anal canal
D033 D03.3 Melanoma in situ of other and unspecified parts of face
D371 D37.1 Stomach
D374 D37.4 Colon
D375 D37.5 Rectum
D377 D37.7 Other digestive organs
D381 D38.1 Trachea, bronchus and lung
D391 D39.1 Ovary
D400 D40.0 Prostate
D430 D43.0 Brain, supratentorial
D432 D43.2 Brain, unspecified
D443 D44.3 Pituitary gland
D45 D45 Polycythaemia vera
D469 D46.9 Myelodysplastic syndrome, unspecified
D471 D47.1 Chronic myeloproliferative disease
D477 D47.7 Other specified neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue
D481 D48.1 Connective and other soft tissue
D485 D48.5 Skin
D486 D48.6 Breast
D500 D50.0 Iron deficiency anaemia secondary to blood loss (chronic)
D508 D50.8 Other iron deficiency anaemias
D509 D50.9 Iron deficiency anaemia, unspecified
D510 D51.0 Vitamin B12 deficiency anaemia due to intrinsic factor deficiency
D519 D51.9 Vitamin B12 deficiency anaemia, unspecified
D529 D52.9 Folate deficiency anaemia, unspecified
D539 D53.9 Nutritional anaemia, unspecified
E039 E03.9 Hypothyroidism, unspecified
E041 E04.1 Non-toxic single thyroid nodule
E042 E04.2 Non-toxic multinodular goitre
E049 E04.9 Non-toxic goitre, unspecified
E050 E05.0 Thyrotoxicosis with diffuse goitre
E052 E05.2 Thyrotoxicosis with toxic multinodular goitre
E059 E05.9 Thyrotoxicosis, unspecified
E063 E06.3 Autoimmune thyroiditis
E079 E07.9 Disorder of thyroid, unspecified
E101 E10.1 With ketoacidosis
E103 E10.3 With ophthalmic complications
E104 E10.4 With neurological complications
E105 E10.5 With peripheral circulatory complications
E109 E10.9 Without complications
E110 E11.0 With coma
E112 E11.2 With renal complications
E113 E11.3 With ophthalmic complications
E114 E11.4 With neurological complications
E115 E11.5 With peripheral circulatory complications
E118 E11.8 With unspecified complications
E162 E16.2 Hypoglycaemia, unspecified
E210 E21.0 Primary hyperparathyroidism
E211 E21.1 Secondary hyperparathyroidism, not elsewhere classified
E212 E21.2 Other hyperparathyroidism
E213 E21.3 Hyperparathyroidism, unspecified
E222 E22.2 Syndrome of inappropriate secretion of antidiuretic hormone
E229 E22.9 Hyperfunction of pituitary gland, unspecified
E230 E23.0 Hypopituitarism
E232 E23.2 Diabetes insipidus
E236 E23.6 Other disorders of pituitary gland
E237 E23.7 Disorder of pituitary gland, unspecified
E271 E27.1 Primary adrenocortical insufficiency
E272 E27.2 Addisonian crisis
E274 E27.4 Other and unspecified adrenocortical insufficiency
E279 E27.9 Disorder of adrenal gland, unspecified
E348 E34.8 Other specified endocrine disorders
E349 E34.9 Endocrine disorder, unspecified
E46 E46 Unspecified protein-energy malnutrition
E538 E53.8 Deficiency of other specified B group vitamins
E559 E55.9 Vitamin D deficiency, unspecified
E804 E80.4 Gilbert's syndrome
E831 E83.1 Disorders of iron metabolism
E833 E83.3 Disorders of phosphorus metabolism
E834 E83.4 Disorders of magnesium metabolism
E835 E83.5 Disorders of calcium metabolism
E853 E85.3 Secondary systemic amyloidosis
E854 E85.4 Organ-limited amyloidosis
E859 E85.9 Amyloidosis, unspecified
E86 E86 Volume depletion
E870 E87.0 Hyperosmolality and hypernatraemia
E871 E87.1 Hypo-osmolality and hyponatraemia
E872 E87.2 Acidosis
E873 E87.3 Alkalosis
E875 E87.5 Hyperkalaemia
E876 E87.6 Hypokalaemia
E878 E87.8 Other disorders of electrolyte and fluid balance, not elsewhere classified
E880 E88.0 Disorders of plasma-protein metabolism, not elsewhere classified
E881 E88.1 Lipodystrophy, not elsewhere classified
E890 E89.0 Postprocedural hypothyroidism
E891 E89.1 Postprocedural hypoinsulinaemia
F009 F00.9 Dementia in Alzheimer's disease, unspecified
F019 F01.9 Vascular dementia, unspecified
F03 F03 Unspecified dementia
F059 F05.9 Delirium, unspecified
F067 F06.7 Mild cognitive disorder
F069 F06.9 Unspecified mental disorder due to brain damage and dysfunction and to physical disease
F072 F07.2 Postconcussional syndrome
F09 F09 Unspecified organic or symptomatic mental disorder
F100 F10.0 Acute intoxication
F101 F10.1 Harmful use
F102 F10.2 Dependence syndrome
F103 F10.3 Withdrawal state
F104 F10.4 Withdrawal state with delirium
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F105 F10.5 Psychotic disorder
F106 F10.6 Amnesic syndrome
F109 F10.9 Unspecified mental and behavioural disorder
F110 F11.0 Acute intoxication
F111 F11.1 Harmful use
F112 F11.2 Dependence syndrome
F115 F11.5 Psychotic disorder
F121 F12.1 Harmful use
F122 F12.2 Dependence syndrome
F170 F17.0 Acute intoxication
F171 F17.1 Harmful use
F172 F17.2 Dependence syndrome
F173 F17.3 Withdrawal state
F191 F19.1 Harmful use
F193 F19.3 Withdrawal state
F200 F20.0 Paranoid schizophrenia
F206 F20.6 Simple schizophrenia
F208 F20.8 Other schizophrenia
F209 F20.9 Schizophrenia, unspecified
F220 F22.0 Delusional disorder
F230 F23.0 Acute polymorphic psychotic disorder without symptoms of schizophrenia
F231 F23.1 Acute polymorphic psychotic disorder with symptoms of schizophrenia
F239 F23.9 Acute and transient psychotic disorder, unspecified
F258 F25.8 Other schizoaffective disorders
F29 F29 Unspecified nonorganic psychosis
F300 F30.0 Hypomania
F309 F30.9 Manic episode, unspecified
F310 F31.0 Bipolar affective disorder, current episode hypomanic
F312 F31.2 Bipolar affective disorder, current episode manic with psychotic symptoms
F315 F31.5 Bipolar affective disorder, current episode severe depression with psychotic symptoms
F317 F31.7 Bipolar affective disorder, currently in remission
F319 F31.9 Bipolar affective disorder, unspecified
F320 F32.0 Mild depressive episode
F321 F32.1 Moderate depressive episode
F322 F32.2 Severe depressive episode without psychotic symptoms
F323 F32.3 Severe depressive episode with psychotic symptoms
F328 F32.8 Other depressive episodes
F329 F32.9 Depressive episode, unspecified
F330 F33.0 Recurrent depressive disorder, current episode mild
F331 F33.1 Recurrent depressive disorder, current episode moderate
F332 F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms
F333 F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms
F334 F33.4 Recurrent depressive disorder, currently in remission
F339 F33.9 Recurrent depressive disorder, unspecified
F341 F34.1 Dysthymia
F380 F38.0 Other single mood [affective] disorders
F402 F40.2 Specific (isolated) phobias
F410 F41.0 Panic disorder [episodic paroxysmal anxiety]
F411 F41.1 Generalised anxiety disorder
F412 F41.2 Mixed anxiety and depressive disorder
F419 F41.9 Anxiety disorder, unspecified
F420 F42.0 Predominantly obsessional thoughts or ruminations
F428 F42.8 Other obsessive-compulsive disorders
F429 F42.9 Obsessive-compulsive disorder, unspecified
F430 F43.0 Acute stress reaction
F431 F43.1 Posttraumatic stress disorder
F432 F43.2 Adjustment disorders
F439 F43.9 Reaction to severe stress, unspecified
F458 F45.8 Other somatoform disorders
F500 F50.0 Anorexia nervosa
F501 F50.1 Atypical anorexia nervosa
F502 F50.2 Bulimia nervosa
F508 F50.8 Other eating disorders
F509 F50.9 Eating disorder, unspecified
F522 F52.2 Failure of genital response
F530 F53.0 Mild mental and behavioural disorders associated with the puerperium, not elsewhere classified
F55 F55 Abuse of non-dependence-producing substances
F603 F60.3 Emotionally unstable personality disorder
F605 F60.5 Anankastic personality disorder
F606 F60.6 Anxious [avoidant] personality disorder
F607 F60.7 Dependent personality disorder
F609 F60.9 Personality disorder, unspecified
F633 F63.3 Trichotillomania
F640 F64.0 Transsexualism
F801 F80.1 Expressive language disorder
F819 F81.9 Developmental disorder of scholastic skills, unspecified
F911 F91.1 Unsocialised conduct disorder
F99 F99 Mental disorder, not otherwise specified
G309 G30.9 Alzheimer's disease, unspecified
G35 G35 Multiple sclerosis
J440 J44.0 Chronic obstructive pulmonary disease with acute lower respiratory infection
J441 J44.1 Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J448 J44.8 Other specified chronic obstructive pulmonary disease
J449 J44.9 Chronic obstructive pulmonary disease, unspecified
K500 K50.0 Crohn's disease of small intestine
K501 K50.1 Crohn's disease of large intestine
K508 K50.8 Other Crohn's disease
K509 K50.9 Crohn's disease, unspecified
K510 K51.0 Ulcerative (chronic) enterocolitis
K512 K51.2 Ulcerative (chronic) proctitis
K513 K51.3 Ulcerative (chronic) rectosigmoiditis
K518 K51.8 Other ulcerative colitis
K519 K51.9 Ulcerative colitis, unspecified
K521 K52.1 Toxic gastro-enteritis and colitis
K528 K52.8 Other specified non-infective gastro-enteritis and colitis
K529 K52.9 Non-infective gastro-enteritis and colitis, unspecified
K580 K58.0 Irritable bowel syndrome with diarrhoea
K589 K58.9 Irritable bowel syndrome without diarrhoea
K700 K70.0 Alcoholic fatty liver
K703 K70.3 Alcoholic cirrhosis of liver
K709 K70.9 Alcoholic liver disease, unspecified
K720 K72.0 Acute and subacute hepatic failure
K729 K72.9 Hepatic failure, unspecified
K740 K74.0 Hepatic fibrosis
K743 K74.3 Primary biliary cirrhosis
K744 K74.4 Secondary biliary cirrhosis
K745 K74.5 Biliary cirrhosis, unspecified
K746 K74.6 Other and unspecified cirrhosis of liver
K750 K75.0 Abscess of liver
K760 K76.0 Fatty (change of) liver, not elsewhere classified
K766 K76.6 Portal hypertension
K767 K76.7 Hepatorenal syndrome
K768 K76.8 Other specified diseases of liver
K769 K76.9 Liver disease, unspecified
K770 K77.0 Liver disorders in infectious and parasitic diseases classified elsewhere
K900 K90.0 Coeliac disease
K904 K90.4 Malabsorption due to intolerance, not elsewhere classified
K909 K90.9 Intestinal malabsorption, unspecified
K910 K91.0 Vomiting following gastro-intestinal surgery
K911 K91.1 Postgastric surgery syndromes
K912 K91.2 Postsurgical malabsorption, not elsewhere classified
K913 K91.3 Postoperative intestinal obstruction
K914 K91.4 Colostomy and enterostomy malfunction
K918 K91.8 Other postprocedural disorders of digestive system, not elsewhere classified
K920 K92.0 Haematemesis
K921 K92.1 Melaena
K922 K92.2 Gastro-intestinal haemorrhage, unspecified
K928 K92.8 Other specified diseases of digestive system
K929 K92.9 Disease of digestive system, unspecified
N180 N18.0 End-stage renal disease
N185 N18.5 Chronic kidney disease, stage 5
N188 N18.8 Other chronic renal failure
N189 N18.9 Chronic renal failure, unspecified
N19 N19 Unspecified renal failure
Q02 Q02 Microcephaly
Q874 Q87.4 Marfan's syndrome
R630 R63.0 Anorexia
R633 R63.3 Feeding difficulties and mismanagement
R634 R63.4 Abnormal weight loss
R64 R64 Cachexia
Y835 Y83.5 Amputation of limb(s)
Z511 Z51.1 Chemotherapy session for neoplasm
Z512 Z51.2 Other chemotherapy
Z800 Z80.0 Family history of malignant neoplasm of digestive organs
Z850 Z85.0 Personal history of malignant neoplasm of digestive organs
Z851 Z85.1 Personal history of malignant neoplasm of trachea, bronchus and lung
Z853 Z85.3 Personal history of malignant neoplasm of breast
Z854 Z85.4 Personal history of malignant neoplasm of genital organs
Z855 Z85.5 Personal history of malignant neoplasm of urinary tract
Z856 Z85.6 Personal history of leukaemia
Z857 Z85.7 Personal history of other malignant neoplasms of lymphoid, haematopoietic and related tissues
Z858 Z85.8 Personal history of malignant neoplasms of other organs and systems
Z860 Z86.0 Personal history of other neoplasms
Z864 Z86.4 Personal history of psychoactive substance abuse
Z865 Z86.5 Personal history of other mental and behavioural disorders
Z895 Z89.5 Acquired absence of leg at or below knee
Z896 Z89.6 Acquired absence of leg above knee
Z899 Z89.9 Acquired absence of limb, unspecified
Z901 Z90.1 Acquired absence of breast(s)
Z902 Z90.2 Acquired absence of lung [part of]
Z903 Z90.3 Acquired absence of part of stomach
Z904 Z90.4 Acquired absence of other parts of digestive tract
Z905 Z90.5 Acquired absence of kidney
Z906 Z90.6 Acquired absence of other parts of urinary tract
Z907 Z90.7 Acquired absence of genital organ(s)
Z992 Z99.2 Dependence on renal dialysis
Z993 Z99.3 Dependence on wheelchair
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S13 Table. Self-reported illness codes used to exclude thin individuals in UKBB
Psychiatric
1286 depression
1287 anxiety/panic attacks
1288 nervous breakdown
1289 schizophrenia
1290 deliberate self-harm/suicide attempt
1291 mania/bipolar disorder/manic depression
1469 post-traumatic stress disorder
1470 anorexia/bulimia/other eating disorder
1614 stress
1615 obsessive compulsive disorder (ocd)
1616 insomnia
1408 alcohol dependency
1409 opioid dependency
1410 other substance abuse/dependency
1531  post-natal depression
Liver
1136 liver/biliary/pancreas problem
1155 hepatitis
1158 liver failure/cirrhosis
1159 bile duct disease
1161 gall bladder disease
1164 pancreatic disease
1507 haemochromatosis
1508 jaundice (unknown cause)
1156 infective/viral hepatitis
1157 non-infective hepatitis
1578 hepatitis a
1579 hepatitis b
1580 hepatitis c
1581 hepatitis d
1582 hepatitis e
1506 primary biliary cirrhosis
1604 alcoholic liver disease / alcoholic cirrhosis
1160 bile duct obstruction/ascending cholangitis
1475 sclerosing cholangitis
1165 pancreatitis
Cardiac
1076 heart failure/pulmonary odema
Renal
1192 renal/kidney failure
1193 renal failure requiring dialysis
1194 renal failure not requiring dialysis
1405 other renal/kidney problem
1196 urinary tract infection/kidney infection
1515 pyelonephritis
1427 polycystic kidney
1519 kidney nephropathy
1608 nephritis 
1520 iga nephropathy
1607 diabetic nephropathy
1609 glomerulnephritis
Gut
1154 irritable bowel syndrome
1456 malabsorption/coeliac disease
1457 duodenal ulcer
1459 colitis/not chrons or ulcerative colitis
1461 inflammatory bowel disease
1502 appendicitis
1503 anal problem
1599 constipation
1600 bowel / intestinal perforation
1601 bowel / intestinal infarction
1602 bowel / intestinal obstruction
1603 rectal prolapse
1462 crohns disease
1463 ulcerative colitis
Abdominal
1400 peptic ulcer
Endocrine
1224 thyroid problem (not cancer)
1229 parathyroid gland problem (not cancer)
1232 disorder of adrenal gland
1237 disorder of pituitary gland
1239 cushings syndrome
1432 carcinoid syndrome
1682 benign insulinoma
1221 gestational diabetes
1222 type 1 diabetes
1225 hyperthyroidism/thyrotoxicosis
1226 hypothyroidism/myxoedema
1228 thyroid radioablation therapy
1428 thyroiditis
1522 grave's disease
1610 thyroid goitre
1230 parathyroid hyperplasia/adenoma
1611 hyperparathyroidism
1233 adrenal tumour
1234 adrenocortical insufficiency/addison's disease
1235 hyperaldosteronism/conn's syndrome
1236 phaeochromocytoma
1238 pituitary adenoma/tumour
1429 acromegaly
1430 hypopituitarism
1431 hyperprolactinaemia
COPD
1112 COPD
Infections
1439 hiv/aids
1567 infectious mononucleosis / glandular fever / epstein barr virus (ebv)
1440 tuberculosis (tb)
1575 herpes simplex
Cancer (responded yes to "Have you ever been diagnosed with cancer?")
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Supplementary Table 4: Gene set analyses results
Gene set id Trait Meta-p Meta-p (no APO) WES p N WES WGS p N WGS Description Source
C0020445 lhdlfc_ 2.31E-10 0.02813214 1.01E-05 35 7.62E-06 21 Hypercholesterolemia Familial DisGeneNet
C0020476 lhdlfc_ 1.58E-11 0.000932652 2.39E-06 14 7.77E-07 7 Hyperlipoproteinemias DisGeneNet
C0020476 hdld 1.81E-10 0.000279994 0.000496 14 1.80E-08 7 Hyperlipoproteinemias DisGeneNet
C0020476 lhdlc_ 2.90E-08 0.00385449 2.23E-05 14 0.000201 7 Hyperlipoproteinemias DisGeneNet
C0020476 lhdlpl_ 2.15E-06 0.002200132 0.000977 14 0.000793 7 Hyperlipoproteinemias DisGeneNet
C0342881 idltg 2.02E-11 0.015485781 2.03E-09 11 0.002838 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 xsvldlp 3.79E-10 0.014275635 4.03E-07 11 0.00085 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 ldltg 7.64E-10 0.006844523 9.76E-09 11 0.004302 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 xsvldltg 1.08E-09 0.023413237 1.84E-07 11 0.006007 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 lldltg 3.58E-09 0.005062039 8.20E-08 11 0.003857 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 apob 7.72E-09 0.005089742 2.38E-07 11 0.002934 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 svldlfc 3.18E-08 0.012250296 2.71E-05 11 0.002389 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 mldltg 7.07E-08 0.013478956 5.24E-08 11 0.029378 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 sldltg 8.59E-08 0.016697804 5.88E-08 11 0.026173 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 mufa 1.10E-07 0.018070242 0.00013 11 0.007047 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 idll 1.75E-07 0.010999563 3.69E-06 11 0.003782 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 apobapoa1 2.15E-07 0.004237918 1.04E-06 11 0.00795 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 lldlp 2.43E-07 0.009922028 4.65E-07 11 0.012224 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 svldlpl 2.48E-07 0.0089107 4.13E-05 11 0.002879 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 lldll 2.84E-07 0.010485712 8.43E-07 11 0.013297 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 xsvldlpl 3.71E-07 0.03201298 1.63E-07 11 0.004467 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 idlp 3.89E-07 0.009724476 1.56E-06 11 0.002886 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 idlpl 4.91E-07 0.012464279 3.13E-06 11 0.008312 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 ldlc 6.95E-07 0.013848465 1.34E-06 11 0.026768 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 lldlpl 7.04E-07 0.013332371 3.51E-06 11 0.018528 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 lldlce 7.20E-07 0.01120345 2.29E-06 11 0.018631 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 mldlpl 7.91E-07 0.012623335 1.12E-06 11 0.030335 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 totfa 9.12E-07 0.020070097 2.66E-05 11 0.006704 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 lldlc 9.44E-07 0.01233823 3.16E-06 11 0.018568 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 mldlp 9.49E-07 0.012045521 2.99E-07 11 0.043184 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 mldll 1.10E-06 0.011701482 4.54E-07 11 0.047026 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342881 mldlfc 1.64E-06 0.03871723 2.76E-06 11 0.044593 8 Familial hypercholesterolemia - homozygous DisGeneNet
C0342883 lhdlfc_ 9.97E-14 0.001782186 6.12E-07 9 1.04E-09 4 Cholesteryl Ester Transfer Protein Deficiency DisGeneNet
C0342883 tgpg 9.85E-10 0.016207152 5.21E-05 9 2.13E-06 4 Cholesteryl Ester Transfer Protein Deficiency DisGeneNet
C0542037 lhdlfc_ 3.57E-13 0.003632137 6.12E-07 9 1.74E-09 3 Hypotriglyceridaemia DisGeneNet
C0542037 tgpg 3.23E-09 0.01845352 5.21E-05 9 2.21E-06 3 Hypotriglyceridaemia DisGeneNet
C0745103 idltg 1.90E-10 0.008406138 1.83E-08 21 0.010046 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 xsvldltg 2.03E-10 0.001916666 3.13E-07 21 0.008834 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 svldlfc 1.22E-09 0.001385636 3.49E-05 21 0.001432 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 xsvldlp 3.75E-09 0.014609129 3.02E-06 21 0.00142 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 svldlpl 4.15E-09 0.000606073 3.76E-05 21 0.001927 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 svldll 1.06E-08 0.001568385 7.76E-05 21 0.002428 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 svldlp 1.49E-08 0.001319162 8.22E-05 21 0.003239 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 mufa 1.26E-07 0.00369098 0.000211 21 0.003996 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 ldltg 2.00E-07 0.020495788 2.63E-07 21 0.013265 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 lldltg 4.58E-07 0.020209296 1.50E-06 21 0.01609 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 sldltg 5.19E-07 0.01743014 2.02E-06 21 0.032317 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 apob 1.19E-06 0.006937804 2.87E-06 21 0.001865 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 apobapoa1 1.34E-06 0.004883344 1.88E-05 21 0.010105 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 mvldlfc 1.68E-06 0.000836725 0.000477 21 0.019124 17 Hyperlipoproteinemia Type IIa DisGeneNet
C0745103 totfa 1.71E-06 0.006830084 6.15E-05 21 0.006047 17 Hyperlipoproteinemia Type IIa DisGeneNet
C1848486 xsvldlpl 5.53E-08 0.004265067 6.53E-07 11 0.005985 9 Premature arteriosclerosis DisGeneNet
C1848486 sldltg 2.10E-07 0.026356402 9.08E-08 11 0.036179 9 Premature arteriosclerosis DisGeneNet
C1848486 mldltg 8.28E-07 0.02980488 2.03E-07 11 0.044683 9 Premature arteriosclerosis DisGeneNet
C4280503 xsvldlpl 5.53E-08 0.004265067 6.53E-07 11 0.005985 9 Premature hardening of arteries DisGeneNet
C4280503 sldltg 2.10E-07 0.026356402 9.08E-08 11 0.036179 9 Premature hardening of arteries DisGeneNet
C4280503 mldltg 8.28E-07 0.02980488 2.03E-07 11 0.044683 9 Premature hardening of arteries DisGeneNet
R-HSA-204174 idlpl 7.85E-07 7.85E-07 0.005939 12 0.000503 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 mldlpl 1.01E-06 1.01E-06 0.002671 12 0.000594 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 estc 1.09E-06 1.09E-06 0.004754 12 0.001175 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 idlp 1.17E-06 1.17E-06 0.003992 12 0.000593 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 lldlp 1.20E-06 1.20E-06 0.004822 12 0.000258 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 lldlpl 1.21E-06 1.21E-06 0.004853 12 0.000423 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 idll 1.21E-06 1.21E-06 0.004313 12 0.000574 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 serumc 1.24E-06 1.24E-06 0.005999 12 0.001071 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 lldll 1.35E-06 1.35E-06 0.005082 12 0.000275 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 idlc 1.40E-06 1.40E-06 0.00475 12 0.001019 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 lldlfc 1.46E-06 1.46E-06 0.00681 12 0.0003 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 lldlc 1.87E-06 1.87E-06 0.006489 12 0.000275 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 mldlp 1.96E-06 1.96E-06 0.006409 12 0.000132 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 lldlce 2.01E-06 2.01E-06 0.006486 12 0.000277 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 sldll 2.13E-06 2.13E-06 0.006413 12 0.000115 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 sldlp 2.13E-06 2.13E-06 0.005994 12 0.000113 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 mldll 2.13E-06 2.13E-06 0.006416 12 0.000164 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 ldlc 2.17E-06 2.17E-06 0.007809 12 0.000177 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 apob 2.20E-06 2.20E-06 0.00504 12 0.000803 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-204174 idlfc 2.22E-06 2.22E-06 0.009798 12 0.000399 4 Regulation of pyruvate dehydrogenase (PDH) complex Reactome
R-HSA-8866423 xsvldlp 1.49E-12 0.027026999 2.06E-09 8 0.000246 7 VLDL assembly Reactome
R-HSA-8866423 xsvldll 6.57E-12 0.029658511 3.13E-09 8 0.000254 7 VLDL assembly Reactome
R-HSA-8866423 xsvldlpl 3.27E-10 0.047296943 4.87E-10 8 0.000529 7 VLDL assembly Reactome
R-HSA-8866423 idlp 5.94E-10 0.012821521 2.79E-09 8 0.000385 7 VLDL assembly Reactome
R-HSA-8866423 apob 9.00E-10 0.035805827 1.23E-09 8 0.001105 7 VLDL assembly Reactome
R-HSA-8866423 lldlpl_ 1.21E-09 0.003361758 2.31E-11 8 0.006697 7 VLDL assembly Reactome
R-HSA-8866423 idll 2.82E-09 0.014169646 1.95E-08 8 0.000547 7 VLDL assembly Reactome
R-HSA-8866423 ldlc 2.02E-08 0.015814492 6.36E-09 8 0.003754 7 VLDL assembly Reactome
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R-HSA-8866423 lldlp 2.09E-08 0.010925413 1.78E-09 8 0.001674 7 VLDL assembly Reactome
R-HSA-8866423 remnantc 6.95E-08 0.005468158 4.44E-09 8 0.00083 7 VLDL assembly Reactome
R-HSA-8866423 lldlfc 1.75E-07 0.012845409 7.16E-08 8 0.002439 7 VLDL assembly Reactome
R-HSA-8866423 idlpl 1.84E-07 0.011330913 2.70E-08 8 0.000806 7 VLDL assembly Reactome
R-HSA-8866423 xsvldlfc 1.96E-07 0.037068974 1.64E-07 8 0.002008 7 VLDL assembly Reactome
R-HSA-8866423 lldlpl 2.05E-07 0.009682997 1.12E-08 8 0.00295 7 VLDL assembly Reactome
R-HSA-8866423 lldlce 2.22E-07 0.012777309 8.81E-09 8 0.002613 7 VLDL assembly Reactome
R-HSA-8866423 lldlc 2.28E-07 0.012348304 1.40E-08 8 0.002473 7 VLDL assembly Reactome
R-HSA-8866423 lldll 2.53E-07 0.010991255 3.93E-09 8 0.00178 7 VLDL assembly Reactome
R-HSA-8866423 idlfc 2.64E-07 0.020705061 2.07E-07 8 0.001976 7 VLDL assembly Reactome
R-HSA-8866423 xsvldlc 2.81E-07 0.010931813 7.53E-06 8 0.000766 7 VLDL assembly Reactome
R-HSA-8866423 idlc 3.52E-07 0.018406604 6.83E-07 8 0.001729 7 VLDL assembly Reactome
R-HSA-8866423 serumc 4.74E-07 0.023383675 6.02E-07 8 0.008607 7 VLDL assembly Reactome
R-HSA-8866423 idlce 5.22E-07 0.00201215 1.58E-06 8 0.001804 7 VLDL assembly Reactome
R-HSA-8866423 mldlp 5.32E-07 0.019315992 6.25E-09 8 0.008059 7 VLDL assembly Reactome
R-HSA-8866423 mldll 5.50E-07 0.017018952 9.19E-09 8 0.008598 7 VLDL assembly Reactome
R-HSA-8866423 estc 5.80E-07 0.024024992 4.43E-07 8 0.012954 7 VLDL assembly Reactome
R-HSA-8866423 freec 6.04E-07 0.027416347 6.56E-06 8 0.004008 7 VLDL assembly Reactome
R-HSA-8866423 idlpl_ 6.58E-07 0.039687097 7.17E-07 8 0.01239 7 VLDL assembly Reactome
R-HSA-8866423 mldlpl 7.13E-07 0.015426761 1.99E-08 8 0.010748 7 VLDL assembly Reactome
R-HSA-8866423 xsvldlce 7.44E-07 0.009844208 4.89E-05 8 0.000835 7 VLDL assembly Reactome
R-HSA-8866423 sldlc 7.51E-07 0.024307244 4.84E-09 8 0.017042 7 VLDL assembly Reactome
R-HSA-8866423 sldlp 7.67E-07 0.027289638 2.54E-09 8 0.015185 7 VLDL assembly Reactome
R-HSA-8866423 pufa 7.71E-07 0.08454695 1.50E-06 8 0.008925 7 VLDL assembly Reactome
R-HSA-8866423 vldlc 8.93E-07 0.052364901 1.41E-05 8 0.002975 7 VLDL assembly Reactome
R-HSA-8866423 sldlce 9.02E-07 0.007812149 2.95E-09 8 0.01715 7 VLDL assembly Reactome
R-HSA-8866423 sldll 9.22E-07 0.027649486 1.60E-09 8 0.015745 7 VLDL assembly Reactome
R-HSA-8866423 mldlc 1.18E-06 0.019562719 3.67E-08 8 0.012777 7 VLDL assembly Reactome
R-HSA-8866423 mldlce 1.27E-06 0.021261762 4.76E-08 8 0.012747 7 VLDL assembly Reactome
R-HSA-8866423 svldlce 1.44E-06 0.024795814 8.30E-05 8 0.001773 7 VLDL assembly Reactome
R-HSA-8866423 mldlfc 2.02E-06 0.005231542 3.73E-08 8 0.016205 7 VLDL assembly Reactome
R-HSA-8866423 sldlfc 2.14E-06 0.015190169 6.26E-09 8 0.027399 7 VLDL assembly Reactome
R-HSA-8963888 xsvldlp 2.49E-14 0.206996778 2.15E-10 10 2.02E-05 11 Chylomicron assembly Reactome
R-HSA-8963888 svldlc 3.38E-14 0.378917505 1.71E-09 10 2.65E-05 11 Chylomicron assembly Reactome
R-HSA-8963888 xsvldll 2.89E-13 0.204758667 3.87E-10 10 5.27E-05 11 Chylomicron assembly Reactome
R-HSA-8963888 apobapoa1 8.43E-13 0.167387417 1.72E-09 10 3.83E-06 11 Chylomicron assembly Reactome
R-HSA-8963888 vldlc 2.12E-11 0.280931433 3.23E-09 10 4.19E-05 11 Chylomicron assembly Reactome
R-HSA-8963888 lldlfc_ 7.49E-11 0.195504351 2.15E-10 10 0.000573 11 Chylomicron assembly Reactome
R-HSA-8963888 svldlce 2.15E-10 0.147784098 1.40E-08 10 0.000173 11 Chylomicron assembly Reactome
R-HSA-8963888 mvldlce 2.15E-10 0.281624878 1.40E-07 10 0.000117 11 Chylomicron assembly Reactome
R-HSA-8963888 remnantc 5.86E-10 0.085210798 2.92E-08 10 0.000799 11 Chylomicron assembly Reactome
R-HSA-8963888 ldltg 9.59E-10 0.396710914 6.92E-08 10 0.000441 11 Chylomicron assembly Reactome
R-HSA-8963888 lldltg 3.23E-09 0.294471306 3.09E-07 10 0.000602 11 Chylomicron assembly Reactome
R-HSA-8963888 xsvldlfc 3.29E-09 0.081395683 2.97E-08 10 0.002742 11 Chylomicron assembly Reactome
R-HSA-8963888 mufa 2.93E-08 0.388099899 7.78E-06 10 0.002762 11 Chylomicron assembly Reactome
R-HSA-8963888 xsvldlce 2.94E-08 0.069144815 2.02E-06 10 0.001391 11 Chylomicron assembly Reactome
R-HSA-8963888 xsvldlc 3.01E-08 0.06186095 4.02E-07 10 0.001125 11 Chylomicron assembly Reactome
R-HSA-8963888 idlpl_ 3.01E-08 0.098183672 7.18E-08 10 0.005842 11 Chylomicron assembly Reactome
R-HSA-8963888 apob 6.39E-08 0.24090487 6.48E-09 10 0.001438 11 Chylomicron assembly Reactome
R-HSA-8963888 xsvldlpl 6.41E-08 0.303509995 6.64E-09 10 0.000858 11 Chylomicron assembly Reactome
R-HSA-8963888 lhdltg_ 2.38E-07 0.248013219 6.88E-05 10 0.000773 11 Chylomicron assembly Reactome
R-HSA-8963888 lldlpl_ 4.25E-07 0.046875529 2.37E-07 10 0.02747 11 Chylomicron assembly Reactome
R-HSA-8963888 xlvldlpl 6.11E-07 0.195788822 0.000226 10 0.001796 11 Chylomicron assembly Reactome
R-HSA-8963888 xlvldll 6.12E-07 0.215946625 0.000218 10 0.001764 11 Chylomicron assembly Reactome
R-HSA-8963888 xlvldlp 6.27E-07 0.336990987 0.000219 10 0.001784 11 Chylomicron assembly Reactome
R-HSA-8963888 xsvldltg_ 6.28E-07 0.089073028 0.00775 10 1.70E-05 11 Chylomicron assembly Reactome
R-HSA-8963888 xlvldlce 1.14E-06 0.309746179 0.000159 10 0.001166 11 Chylomicron assembly Reactome
R-HSA-8963888 xxlvldltg 1.16E-06 0.176848043 0.000474 10 0.002696 11 Chylomicron assembly Reactome
R-HSA-8963888 xlvldltg 1.18E-06 0.321278515 0.000222 10 0.002044 11 Chylomicron assembly Reactome
R-HSA-8963888 xlvldlc 1.20E-06 0.309130119 0.000172 10 0.001447 11 Chylomicron assembly Reactome
R-HSA-8963888 xxlvldlce 1.21E-06 0.210451215 0.000326 10 0.001414 11 Chylomicron assembly Reactome
R-HSA-8963888 xxlvldll 1.29E-06 0.192140471 0.000347 10 0.002374 11 Chylomicron assembly Reactome
R-HSA-8963888 lvldlpl_ 1.43E-06 0.551285259 8.06E-06 9 0.014211 11 Chylomicron assembly Reactome
R-HSA-8963888 xxlvldlp 2.07E-06 0.186176084 0.000354 10 0.00242 11 Chylomicron assembly Reactome
R-HSA-8963888 totfa 2.11E-06 0.511678701 8.44E-07 10 0.045133 11 Chylomicron assembly Reactome
R-HSA-8963888 xxlvldlc 2.14E-06 0.219048098 0.000325 10 0.001807 11 Chylomicron assembly Reactome
R-HSA-8963888 xlvldlfc 2.19E-06 0.314011612 0.000228 10 0.002124 11 Chylomicron assembly Reactome
R-HSA-8963898 xsvldltg 9.97E-10 0.237293907 2.89E-08 23 0.003889 19 Plasma lipoprotein assembly Reactome
R-HSA-8963898 svldlpl 6.28E-07 0.819781918 1.17E-06 23 0.002978 19 Plasma lipoprotein assembly Reactome
R-HSA-8963898 svldlfc 6.79E-07 1 1.11E-06 23 0.004052 19 Plasma lipoprotein assembly Reactome
R-HSA-8963898 svldlp 1.19E-06 1 1.35E-06 23 0.004011 19 Plasma lipoprotein assembly Reactome
R-HSA-8963898 svldll 1.25E-06 1 1.13E-06 23 0.004472 19 Plasma lipoprotein assembly Reactome
R-HSA-8963901 hdld 9.72E-10 0.001414545 0.000108 12 8.68E-06 12 Chylomicron remodeling Reactome
R-HSA-8963901 xlhdlfc 3.04E-09 0.004188796 0.000336 12 6.07E-05 12 Chylomicron remodeling Reactome
R-HSA-8963901 lhdlc_ 1.01E-08 0.003841981 4.60E-05 12 0.000594 12 Chylomicron remodeling Reactome
R-HSA-8963901 xlhdlpl 1.13E-08 0.007480561 0.000162 12 4.45E-05 12 Chylomicron remodeling Reactome
R-HSA-8963901 xlhdlc 1.76E-07 0.011331821 0.002411 12 0.000666 12 Chylomicron remodeling Reactome
R-HSA-8964058 tgpg 5.88E-10 0.006630914 1.81E-05 17 2.46E-06 8 HDL remodeling Reactome
Meta-p= Meta-analysis p-value
Meta-p (no APO) = Meta-analysis p-value after removing APO genes from gene sets (APOB and APOC3)
WES p = p-value in WES dataset
N WES = number of variants tested in WES dataset
WGS p = p-value in WGS dataset
N WGS = number of variants tested in WGS dataset
Appendix B
Supplementary Table 9: Detailed results for gene sets with enriched rare variation in tails of lipoprotein traits
S-VLDL-C lower tail outliers. Hyperlipidemia gene set.
gene snp dataset MAC residuals in all carriers
AGL rs200459772 WES 5 2.36762834154852,-0.334045067074641,0.431527558983269,-0.838811852821138,-3.05000388882286
APOB 2:21236148 WES 1 -2.661258903
APC rs150973053 WES 1 -3.089584993
APC rs201830995 WES 3 -2.87066740721444,-0.787318922230483,0.420463200843388
CYP19A1 rs141305220 WES 2 -3.49405574671022,-1.2437172570647
CYP19A1 rs200111039 WES 9 -2.97590453300663,0.253051068847167,0.795701074251656,1.01065228811834,-0.403431340606028,-0.144560598282279,-3.08958499345356,0.741693060794646,-0.4324749949308
NPHS1 rs368988883 WES 1 -3.374778926
GCG 2:163003928 WGS 1 -3.123944186
APC 5:112173509 WGS 2 -3.54394449881421,-0.121786221385006
APC 5:112174919 WGS 2 -3.54394449881421,-0.121786221385006
APC 5:112178070 WGS 2 -3.54394449881421,-0.121786221385006
APC 5:112179437 WGS 2 -3.54394449881421,-0.121786221385006
NOS3 7:150698995 WGS 2 -0.18836307152566,-2.7037021818663
NOS3 7:150706632 WGS 5 -0.304682642445497,-0.26183599116571,-0.48084454181164,-2.83884053615798,-0.759193154129386
CETP rs150236668 WGS 2 -1.08925353711354,-3.54394449881421
NPHS1 19:36342715 WGS 3 0.920578019402659,-0.398163133632229,-2.93246487402699
XS-VLDL-P lower tail outliers. Hyperlipidemia gene set.
gene snp dataset MAC effects
APOB 2:21236148 WES 1 -3.436640493
APC rs150973053 WES 1 -3.202863174
APC rs201830995 WES 3 -2.86524374013287,-0.168052075323293,0.077312983454771
NOS3 rs141170595 WES 7 -1.18611115166881,-2.95589825540599,-0.246085238062439,1.13215214546922,0.154253491587311,-0.217108986788457,-1.74689283105004
CYP19A1 rs141305220 WES 2 -3.20538984720828,-0.876451886676179
CYP19A1 rs200111039 WES 9 -2.64098645212551,0.545406135777777,1.01054251354388,0.76392757891617,-0.245365417517183,-0.682701582154253,-3.20286317422441,0.569449665319146,-0.251861115970539
NPHS1 rs368988883 WES 1 -3.318749511
NPHS2 1:179520511 WGS 2 0.213855282424323,-2.73710673267041
NPHS2 1:179530462 WGS 6 -2.85736273031488,0.500033274189366,0.129175297645043,0.476908535573381,-0.94191940828643,0.175183524144263
APOB 2:21255263 WGS 1 -2.965806851
GCG 2:163003928 WGS 1 -3.430062283
APC 5:112173509 WGS 2 -2.94907099537461,-0.259525678305062
APC 5:112174919 WGS 2 -2.94907099537461,-0.259525678305062
APC 5:112178070 WGS 2 -2.94907099537461,-0.259525678305062
APC 5:112179437 WGS 2 -2.94907099537461,-0.259525678305062
NOS3 7:150698995 WGS 2 -0.466020371752611,-2.83066719904639
CETP rs150236668 WGS 2 -0.633213631434203,-2.94907099537461
S-VLDL-CE lower tail outliers. Hyperlipidemia gene set.
gene snp dataset MAC effects
AGL rs200459772 WES 5 2.36762834154852,-0.334045067074641,0.431527558983269,-0.838811852821138,-3.05000388882286
APOB 2:21236148 WES 1 -2.661258903
APC rs150973053 WES 1 -3.089584993
APC rs201830995 WES 3 -2.87066740721444,-0.787318922230483,0.420463200843388
CYP19A1 rs141305220 WES 2 -3.49405574671022,-1.2437172570647
CYP19A1 rs200111039 WES 9 -2.97590453300663,0.253051068847167,0.795701074251656,1.01065228811834,-0.403431340606028,-0.144560598282279,-3.08958499345356,0.741693060794646,-0.4324749949308
NPHS1 rs368988883 WES 1 -3.374778926
GCG 2:163003928 WGS 1 -3.123944186
APC 5:112173509 WGS 2 -3.54394449881421,-0.121786221385006
APC 5:112174919 WGS 2 -3.54394449881421,-0.121786221385006
APC 5:112178070 WGS 2 -3.54394449881421,-0.121786221385006
APC 5:112179437 WGS 2 -3.54394449881421,-0.121786221385006
NOS3 7:150698995 WGS 2 -0.18836307152566,-2.7037021818663
NOS3 7:150706632 WGS 5 -0.304682642445497,-0.26183599116571,-0.48084454181164,-2.83884053615798,-0.759193154129386
CETP rs150236668 WGS 2 -1.08925353711354,-3.54394449881421
NPHS1 19:36342715 WGS 3 0.920578019402659,-0.398163133632229,-2.93246487402699
S-HDL-P lower tail outliers. HDL remodeling gene set
gene snp dataset MAC effects
CETP rs140547417 WES 10 0.578651608406939,0.610798008574449,0.292679415486239,0.395395459347943,-1.11386853475629,-2.93263937740899,-0.0998285578608295,-0.0864903418646204,-0.318903381965163,0.775064146714445
LIPG 18:47107925 WES 1 -3.234598237
APOE rs199768005 WES 7 -0.540244700238687,1.92520088605348,0.92978260411206,-3.02709326825206,-0.789305787720864,0.121976706457689,-1.34111543948004
ABCG1 rs148226451 WES 1 -2.932639377
APOA1 11:116706867WGS 1 -3.003505735
APOA1 rs199759119 WGS 7 -1.00536349532665,-2.86126280384725,-0.582922966059555,-0.693164051709012,1.64763326906752,-2.39922951075938,-1.79280325835833
CETP rs142750310 WGS 1 -3.046409293
Appendix B
Supplementary Table 10: Sensitity analyses for rare variant enrichment in tails analysis using different percentile cutoffs to define tails of the phenotypic distribution
.5% Percentile upper tails
trait p.wes p.wgs meta-p Gene set
lldlc 0.00432 0.03209 0.0007737 LDL_clearance
vldld 0.02887 0.00607 0.0009188 VLDL_clearance
.5% Percentile lower tails
trait p.wes p.wgs meta-p Gene set
svldlce 0.02992 0.01634 0.0022477 Hyperlipidemia
svldlfc 0.01287 0.00676 0.0004448 Hyperlipidemia
xsvldlp 0.02992 0.0024 0.0004422 Hyperlipidemia
idltg 0.00032 0.01528 4.02E-05 LDL_remodeling
idltg 1.00E-05 0.01621 2.97E-06 VLDL_assembly
1 Percentile lower tails
trait p.wes p.wgs meta-p Gene set
mhdltg 0.04487 0.00976 0.0021777 Hyperlipidemia
p.wes: permutation p-value in WES
p.wgs: permutation p-value in WGS
meta-p: p-value after meta-analysis using Stouffer's method
Highlighted in yellow are gene sets that are significant after meta-analysis using Stouffer’s method and after adjusting for multiple traits (p<=0.00037). 
